Science.gov

Sample records for i-131 dosimetria especifica

  1. Recurrent thyrotoxicosis after I-131 induced hypothyroidism

    SciTech Connect

    Liu, L.; Borowski, G.D.; Shtasel, P.; Rose, L.I.

    1984-01-01

    The first clinically and biochemically documented case of recurrent thyrotoxicosis after I-131 induced hypothyroidism in a patient with Graves' disease is reported. Two months after the administration of 9.2 mCi of I-131, the subject developed hypothyroidism. One month later, the patient became euthyroid. Then, nine months following ablation, the patient again developed thyrotoxicosis. A second dose of I-131 of 12.5 mCi was required to finally produce permanent hypothyroidism. This case illustrates the recurrence of hypothyroidism after what had seemed to have been adequate I-131 radiation.

  2. Radioactive Iodine (I-131) Therapy for Hyperthyroidism

    MedlinePlus

    ... Iodine (I-131) Therapy Radioiodine therapy is a nuclear medicine treatment for an overactive thyroid, a condition ... locally overactive in producing too much thyroid hormone. Nuclear medicine is a branch of medical imaging that ...

  3. Tositumomab and Iodine I 131 Tositumomab

    Cancer.gov

    This page contains brief information about tositumomab and iodine I 131 tositumomab and a collection of links to more information about the use of this drug combination, research results, and ongoing clinical trials.

  4. Unusual patterns of I-131 contamination.

    PubMed

    Ozguven, Mehmet; Ilgan, Seyfettin; Arslan, Nuri; Karacalioglu, A Ozgur; Yuksel, Dogangun; Dundar, Sabri

    2004-05-01

    Whole body imaging with radioiodine can detect functioning metastases, which can often be effectively treated with appropriate amounts of radioiodine. Non-physiologic I-131 uptake detected on images is usually interpreted as suggesting functioning thyroid metastases. However, extra-thyroidal I-131 accumulation does not always imply thyroid cancer metastases and has been reported on many occasions, including various non-thyroidal neoplasms, and contamination by body secretions. In order to avoid unnecessary therapeutic interventions it is extremely important to properly distinguish false-positive sites of I-131 localization. Three patients with unusual radioiodine contamination patterns, either presented for the first time or rarely presented in the existing literature, were reported. Reported cases consist of contamination in hair (due to styling hair with sputum), contamination in neck (due to drooling during sleep) and, contaminated chewing gum. False positive contamination sources were clarified by careful examination of patients and further images when necessary. PMID:15233290

  5. Scintigraphic imaging of neuroblastoma with I-131-meta-iodobenzylguanidine (I-131-MIBG)

    SciTech Connect

    Feine, U.; Treuner, J.; Schauenburg, W.M.; Niethammer, D.; Meinke, J.; Elbach, E.; Dopfer, R.; Klingebiel, T.

    1984-01-01

    I-131MIBG is commonly used for the scintigraphic localization of phaeochromocytoma. The authors present data which indicate that the neuroblastoma may show a similar or even higher accumulation of I-131-MIBG. Four children were examined quantitatively by 8'' crystal dual head whole body scanner interfaced to a computer. Scans were performed 4 h, to 21 dp.i. of 1-4 MBq (25-100 ..mu..Ci) I-131-MIBG. Three of the four children aged 2 months to 2.8 years had large tumor masses in the abdomen or diffuse infiltration of the enlarged liver and high catecholamine levels in 24 h urine samples. They showed high tumor uptake of the tracer already in the 4 h scans. The uptake level correlated well with the catecholamine excretion. The biological half live was in all three cases for about 4 days. In the following days contrast between tumor and non tumor tissues became excellent. The fourth child was clinically free of tumor one year after cytostatic treatment and had normal catecholamine levels. The MIBG-scans did not show any tumor uptake but the myocardium and the salivary glands show pronounced tracer uptake according to the results of a previous study. The authors conclude that MIBG may not be only a diagnostic-tracer for neuroblastoma but may perhaps permit therapy.

  6. Scintigraphic depiction of an insulinoma by I-131 metaiodobenzylguanidine

    SciTech Connect

    Geatti, O.; Shapiro, B.; Barillari, B. )

    1989-12-01

    Scintigraphy with I-131 metaiodobenzylguanidine (MIBG) was effective in depicting a pancreatic insulinoma in a patient suffering from intermittent hypoglycemia. This observation widens the range of neuroendocrine tumors that take up to I-131 MIBG and supports the concept that many tumors of the amine precursor uptake and decarboxylation system may be imaged in this way.

  7. Uptake of I-131 MIBG by medullary thyroid cancer

    SciTech Connect

    Endo, K.; Koizumi, M.; Sakahara, H.; Nakashima, T.; Ohta, H.; Kasagi, K.; Konishi, J.; Miyauchi, A.; Kuma, K.; Torizuka, K.

    1985-05-01

    I-131 MIBG scans are useful for the localization of pheochromocytoma and neuroblastoma with high catecholamine levels. Recently the authors have found that medullary thyroid cancer also showed an uptake of I-131 MIBG in both primary neck tumors and metastatic sites. Up to now scintigraphic studies were performed in 5 patients with medullary thyroid cancer. Scintigraphy was done at 24 and 48 hours after the administration of 0.5 mCi of I-131 MIBG, thyroid uptake of dissociated I-131 being prevented by Lugol's solution. Four out of 5 cases were familial type and uptake of I-131 MIBG was similarly observed in medullary thyroid cancer as well as in pheochromocytoma. Bone metastasis of medullary thyroid cancer was also detected with I-131 MIBG. However, one case of sporadic form was negative with I-131 MIBG, whereas there was a high uptake of Tc(V)-99m dimercaptosuccinic acid: a newly developed radiopharmaceutical for medullary thyroid cancer, visualizing a different uptake mechanism of both reagents (J Nucl Med 25: 323-325, 1984). After adrenalectomy high uptake of I-131 MIBG was still observed in medullary thyroid cancer, in spite of normal catecholamine levels. The tumor to blood ratio was estimated in vivo to be about several hundreds at 24 hours after the administration. These cells are of neural crest origin and the mechanism of uptake of I-131 MIBG may not be related to the catechamine uptake mechanism. This paper concludes that I-131 MIBG is useful not only for the localization but also for the treatment of medullary thyroid cancer, as preliminary performed in pheochromocytoma and neuroblastoma.

  8. The progressive and diffuse nature of neuroblastoma: Treatment with I-131 metaiodobenzylguanidine (I-131 MIBG). S-W

    SciTech Connect

    Shen; Sisson, J.C.; Hutchinson, R.; Shapiro, B.; Shulkin, B.; Geatti, O.; Mallett, S.; Eyre, P.; Mangner, T.; Beierwaltes, W.H.

    1985-05-01

    Neuroblastoma is a lethal and not uncommon cancer. In advanced disease, external beam radiation and chemotherapy bring no more than temporary remissions. Most neuroblastomas concentrate I-131 MIBG which then has therapeutic potential for these tumors. The authors treated the neuroblastomas of 7 patients, 20 mos-24 yrs of age, with I-131 MIBG. Factors were examined to explain the results. All but the oldest patient had extensive disease. Scintigraphy portrayed tumor infiltrations of the skeleton not otherwise detectable; in long bones, and, for 2 patients, in hands or feet. Hematopoiesis was precarious from the effects of both tumor and prior chemotherapy. Some tumors produce dopamine, but blockade of receptors was not required prior to I-131 MIBG. I-131 MIBG doses, 60-200 mCi, were scaled for body size. Because of the infiltrative nature of the tumor, rad doses could not be measured. Three had subjective (less pain, more ambulatory) improvement but 1 had enlarging tumors and 1 died; the oldest has not been reevaluated. Four patients died, all of progressive disease. No harmful effects of I-131 MIBG were seen but 1 patient had leukopenia. This paper concludes; I-131 MIBG has the potential to produce benefits in patients with neuroblastoma. But certain factors must be taken into account. Diffuse involvement of marrow will require new approaches to dosimetry, for tumor and for marrow; and the cancer is usually rapidly lethal, and early treatment is necessary.

  9. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine

    SciTech Connect

    Kimmig, B.; Brandeis, W.E.; Eisenhut, M.; Bubeck, B.; Hermann, H.J.; Zum Winkel, K.

    1984-07-01

    Radioiodinated m-iodobenzylguanidine has been applied mainly for the diagnosis of pheochromocytoma and blastoma. In this paper the authors show that an ontogenetically related tumor, the neuroblastoma, is also scintigraphically visualized by its high uptake of I-131 MIBG. Because of the kinetic findings and the high uptake of more than 30% of the injected activity, it is likely that the neuroblastoma, by analogy with pheochromocytoma, is susceptible to specific radionuclide therapy.

  10. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine

    SciTech Connect

    Kimmig, B.; Brandeis, W.E.; Eisenhut, M.; Bubeck, B.; Hermann, H.J.; zum Winkel, K.

    1984-07-01

    Radioiodinated m-iodobenzylguanidine has been applied mainly for the diagnosis of pheochromocytoma and blastoma. In this paper the author shows that an ontogenetically related tumor, the neuroblastoma, is also scintigraphically visualized by its high uptake of I-131 MIBG. Because of the kinetic findings and the high uptake of more than 30% of the injected activity, it is likely that the neuroblastoma, by analogy with pheochromocytoma, is susceptible to specific radionuclide therapy.

  11. Vocal cord paralysis following I-131 ablation of a postthyroidectomy remnant

    SciTech Connect

    Lee, T.C.; Harbert, J.C.; Dejter, S.W.; Mariner, D.R.; VanDam, J.

    1985-01-01

    Vocal cord paralysis has been reported following I-131 therapy of thyrotoxicosis and following ablation of the whole thryoid. However, this rare complication has not previously been described following I-131 ablation of a postthyroidectomy remnant. The authors report a patient who required tracheostomy for bilateral vocal cord paralysis following I-131 ablation after near-total thyroidectomy for papillary thyroid carcinoma.

  12. Post-laryngectomy localization of I-131 at tracheostomy site on a total body scan

    SciTech Connect

    Kirk, G.A.; Schulz, E.E.

    1984-07-01

    A post-thyroidectomy, post-I-131-therapy patient had a laryngectomy and neck dissection for recurrent papillary thyroid carcinoma. A subsequent I-131 total body scan revealed persistent anterior neck activity, which disappeared upon removal of the tracheostomy tube and dressings.

  13. 76 FR 81517 - Agency Information Collection Activities: Form I-131, Revision of an Existing Information...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2011-12-28

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services Agency Information Collection Activities: Form I-131, Revision of an Existing Information Collection; Comment Request ACTION: 60-Day Notice of Information Collection Under Review: Form I- 131,...

  14. Transient radiation effects following high dose I-131 therapy for differentiated thyroid cancer (DTC)

    SciTech Connect

    Khan, S.; Waxman, A.; Ramanna, L.

    1994-05-01

    There is limited information regarding the incidence of post-I-131 therapeutic side effects in pts. undergoing high-dose I-131 therapy for DTC. The purpose of the current study is to characterize side effects experienced by patients following 150 mCi.

  15. Pregnancy Outcome After I-131 Therapy for Patients With Thyroid Cancer

    PubMed Central

    Ko, Kuan-Yin; Yen, Ruoh-Fang; Lin, Cheng-Li; Cheng, Mei-Fang; Huang, Wen-Sheng; Kao, Chia-Hung

    2016-01-01

    Abstract The aim of this study was to evaluate the influence of I-131 therapy on pregnancy outcome in patients that received therapeutic I-131 doses for thyroid cancer in Taiwan. This nationwide population-based cohort study was based on data from 1998 to 2010 obtained from the Taiwanese National Health Insurance Research Database. We identified 11,708 women with thyroid cancer (≥15 and ≤50 years of age) by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Patients were divided into 2 cohorts: I-131 therapy cohort and non-I-131 therapy cohort. The mean follow-up period was 6.08 years for the I-131 cohort and 6.87 years for the non-I-131 cohort. The case cohort and the control cohort comprised 775 and 716 pregnant patients, respectively. The overall incidence of pregnancy was significantly lower in the I-131 cohort (adjusted HR = 0.77, 95% CI = 0.70–0.86) and it was also observed when the patients were stratified according to age (HR = 0.73, 95% CI = 0.64–0.83 in 25–34 years; HR = 0.63, 95% CI = 0.49–0.82 in 35–44 years). Patients in the I-131 cohort had a lower successful delivery rate, particularly among patients in 25 to 34 years (OR = 0.60, 95% CI = 0.45–0.80). No significant difference was observed for adverse pregnancy conditions between 2 cohorts. I-131 therapy is associated with decreased pregnancy and successful delivery rates. The underlying mechanism likely involves physician recommendation, patient's psychological issue, and potential impact of I-131 treatment on reproductive health. Further investigation is needed. PMID:26844507

  16. Impact of reconstruction parameters on quantitative I-131 SPECT.

    PubMed

    van Gils, C A J; Beijst, C; van Rooij, R; de Jong, H W A M

    2016-07-21

    Radioiodine therapy using I-131 is widely used for treatment of thyroid disease or neuroendocrine tumors. Monitoring treatment by accurate dosimetry requires quantitative imaging. The high energy photons however render quantitative SPECT reconstruction challenging, potentially requiring accurate correction for scatter and collimator effects. The goal of this work is to assess the effectiveness of various correction methods on these effects using phantom studies. A SPECT/CT acquisition of the NEMA IEC body phantom was performed. Images were reconstructed using the following parameters: (1) without scatter correction, (2) with triple energy window (TEW) scatter correction and (3) with Monte Carlo-based scatter correction. For modelling the collimator-detector response (CDR), both (a) geometric Gaussian CDRs as well as (b) Monte Carlo simulated CDRs were compared. Quantitative accuracy, contrast to noise ratios and recovery coefficients were calculated, as well as the background variability and the residual count error in the lung insert. The Monte Carlo scatter corrected reconstruction method was shown to be intrinsically quantitative, requiring no experimentally acquired calibration factor. It resulted in a more accurate quantification of the background compartment activity density compared with TEW or no scatter correction. The quantification error relative to a dose calibrator derived measurement was found to be  <1%,-26% and 33%, respectively. The adverse effects of partial volume were significantly smaller with the Monte Carlo simulated CDR correction compared with geometric Gaussian or no CDR modelling. Scatter correction showed a small effect on quantification of small volumes. When using a weighting factor, TEW correction was comparable to Monte Carlo reconstruction in all measured parameters, although this approach is clinically impractical since this factor may be patient dependent. Monte Carlo based scatter correction including accurately simulated CDR

  17. Impact of reconstruction parameters on quantitative I-131 SPECT

    NASA Astrophysics Data System (ADS)

    van Gils, C. A. J.; Beijst, C.; van Rooij, R.; de Jong, H. W. A. M.

    2016-07-01

    Radioiodine therapy using I-131 is widely used for treatment of thyroid disease or neuroendocrine tumors. Monitoring treatment by accurate dosimetry requires quantitative imaging. The high energy photons however render quantitative SPECT reconstruction challenging, potentially requiring accurate correction for scatter and collimator effects. The goal of this work is to assess the effectiveness of various correction methods on these effects using phantom studies. A SPECT/CT acquisition of the NEMA IEC body phantom was performed. Images were reconstructed using the following parameters: (1) without scatter correction, (2) with triple energy window (TEW) scatter correction and (3) with Monte Carlo-based scatter correction. For modelling the collimator-detector response (CDR), both (a) geometric Gaussian CDRs as well as (b) Monte Carlo simulated CDRs were compared. Quantitative accuracy, contrast to noise ratios and recovery coefficients were calculated, as well as the background variability and the residual count error in the lung insert. The Monte Carlo scatter corrected reconstruction method was shown to be intrinsically quantitative, requiring no experimentally acquired calibration factor. It resulted in a more accurate quantification of the background compartment activity density compared with TEW or no scatter correction. The quantification error relative to a dose calibrator derived measurement was found to be  <1%,‑26% and 33%, respectively. The adverse effects of partial volume were significantly smaller with the Monte Carlo simulated CDR correction compared with geometric Gaussian or no CDR modelling. Scatter correction showed a small effect on quantification of small volumes. When using a weighting factor, TEW correction was comparable to Monte Carlo reconstruction in all measured parameters, although this approach is clinically impractical since this factor may be patient dependent. Monte Carlo based scatter correction including accurately simulated

  18. Normal and abnormal distribution of the adrenomedullary imaging agent m-(I-131)iodobenzylguanidine (I-131 MIBG) in man; evaluation by scintigraphy

    SciTech Connect

    Nakajo, M.; Shapiro, B.; Copp, J.; Kalff, V.; Gross, M.D.; Sisson, J.C.; Beierwaltes, W.H.

    1983-08-01

    The scintigraphic distribution of m-(/sup 131/I)iodobenzylguanidine (I-131 MIBG), an adrenal medullary imaging agent, was studied to determine the patterns of uptake of this agent in man. The normal distribution of I-131 MIBG includes clear portrayal of the salivary glands, liver, spleen, and urinary bladder. The heart, middle and lower lung zones, and colon were less frequently or less clearly seen. The upper lung zones and kidneys were seldom visualized. The thyroid appeared only in cases of inadequate thyroidal blockade. The normal adrenal glands were seldom seen and faintly imaged in 2% at 24 h after injection and in 16% at 48 h, in patients shown not to have pheochromocytomas, whereas intra-adrenal, extra-adrenal, and malignant pheochromocytomas usually appeared as intense focal areas of I-131 MIBG uptake at 24 through 72 h.

  19. Effect of doxorubicin on (at-I-131) heptadecanoic acid myocardial scintigraphy and echocardiography in dogs

    SciTech Connect

    Styles, C.B.; Noujaim, A.A.; Jugdutt, B.I.; Sykes, T.R.; Bain, G.O.; Shnitka, T.L.; Hooper, H.R.

    1983-11-01

    The effects of serial treatment with doxorubicin on dynamic myocardidal scintigraphy with (at-I-131) heptadecanoic acid (I-131 HA), and on global left-ventricular function determined echocardiographically, were studied in a group of nine mongrel dogs. Total extractable myocaridal lipid was compared postmortem between a group of control dogs and doxorubicin-treated dogs. A significant and then progressive fall in global LV function was observed at a cumulative doxorubicin dose of 4 mg/kg. A significant increase in the myocaridal t/sub 1/2/ of the I-131 HA was observed only at a higher cumulative dose, 10 mg/kg. No significant alteration in total extractable myocardial lipids was observed between control dogs and those treated with doxorubicin. The findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I-131 HA are not the initiating factor in doxorubicin cardiotoxicity.

  20. Late presentation of metastatic pheochromocytoma: A problem case solved by I-131 MIBG scintigraphy

    SciTech Connect

    Geatti, O.; Shapiro, B.; Virgolini, L. )

    1990-02-01

    A patient presented with recurrent pheochromocytoma 10 years following the apparently successful surgical cure of a right adrenal pheochromocytoma. Conventional medical imaging techniques, (chest radiograph, abdominal ultrasound, and abdominal CT) suggested local recurrence for which surgery was planned. I-131 MIBG scintigraphy revealed disseminated metastatic disease that rendered attempts at surgical cure futile. The patient was treated with three therapeutic doses of I-131 MIBG with good symptomatic palliation and improvement of some biochemical parameters.

  1. A case report of hyperfunctioning metastatic thyroid cancer and rare I-131 avid liver metastasis

    PubMed Central

    Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Chotipanich, Chanisa

    2016-01-01

    Thyroid cancer is usually, relatively hypofunctional; most patients with thyroid cancer are clinically euthyroid. The combination of thyroid cancer and thyrotoxicosis is not common. We herein, report a case of follicular thyroid cancer with hyperfunctioning metastasis in a 43-year-old woman who presented with thyrotoxicosis, a cold right thyroid nodule, and low I-131 uptake at the thyroid bed. An additional total body scan with I-131 revealed a large radioiodine avid osteolytic bone metastasis with soft tissue masses and liver metastasis. The patient received treatment with total thyroidectomy, methimazole, and I-131 at a cumulative dose of 600 mCi along with recombinant human thyroid-stimulating hormone before the first I-131 treatment and palliative radiation. The patient had normal liver function test and experienced a mild degree of bone marrow suppression after I-131. At the 2-year follow-up, the patient was still alive with the progression of bone metastases but was doing well with less severe thyrotoxicosis, good ambulation, and an Eastern Cooperative Oncology Group performance status of 2. Clinicians should be aware of the unusual concurrent presentation of thyrotoxicosis and thyroid cancer, a differential diagnosis in patients with thyrotoxicosis and low or normal radioiodine uptake over the neck and also potential pitfalls during radionuclide treatment. PMID:27385894

  2. I-131 labelled peanut lectin renal kinetics in cis-platin induced tubular toxicity in dogs

    SciTech Connect

    Boniface, G.R.; Willans, D.J.; Noujaim, A.A.

    1985-05-01

    Quantitative I-131 labelled Peanut lectin (I-131-PNA) renal clearance was determined in dogs before and after a 5 day single cycle cis-platinum chemotherapy regimen (0.5mg/Kg/day). Results were statistically compared with E.R.P.F. (I-131-Hippuran), G.F.R. (Tc-99m-DTPA), and serum biochemistry and correlated with histopathology. I-131-PNA clearance was significantly reduced in all dogs 5 days after cessation of cis-platinum treatment (mean ..delta..S% = 71.3%) and similar reductions in the gamma camera derived renogram peak were demonstrated (mean ..delta..S% = 65.8%). E.R.P.F. was noted to drop by a minor degree (mean ..delta..S% = 20.9%) post treatment. G.F.R. was diminished (mean ..delta..S% = 46.6%) and serum creatinine elevated (mean ..delta..S% = 42.7%) in all dogs compared to their pretreatment values. Histopathology demonstrated variable degrees of tubular toxicity ranging from mild to severe. The degree of change of the I-131-PNA values was significantly greater than that predicted by indicators of glomerular function. These results suggest that quantitative renal tubular imaging may be useful in the determination of tubular toxicity.

  3. A case report of hyperfunctioning metastatic thyroid cancer and rare I-131 avid liver metastasis.

    PubMed

    Kunawudhi, Anchisa; Promteangtrong, Chetsadaporn; Chotipanich, Chanisa

    2016-01-01

    Thyroid cancer is usually, relatively hypofunctional; most patients with thyroid cancer are clinically euthyroid. The combination of thyroid cancer and thyrotoxicosis is not common. We herein, report a case of follicular thyroid cancer with hyperfunctioning metastasis in a 43-year-old woman who presented with thyrotoxicosis, a cold right thyroid nodule, and low I-131 uptake at the thyroid bed. An additional total body scan with I-131 revealed a large radioiodine avid osteolytic bone metastasis with soft tissue masses and liver metastasis. The patient received treatment with total thyroidectomy, methimazole, and I-131 at a cumulative dose of 600 mCi along with recombinant human thyroid-stimulating hormone before the first I-131 treatment and palliative radiation. The patient had normal liver function test and experienced a mild degree of bone marrow suppression after I-131. At the 2-year follow-up, the patient was still alive with the progression of bone metastases but was doing well with less severe thyrotoxicosis, good ambulation, and an Eastern Cooperative Oncology Group performance status of 2. Clinicians should be aware of the unusual concurrent presentation of thyrotoxicosis and thyroid cancer, a differential diagnosis in patients with thyrotoxicosis and low or normal radioiodine uptake over the neck and also potential pitfalls during radionuclide treatment. PMID:27385894

  4. Estimation of foetal brain dose from I-131 in the foetal thyroid

    NASA Astrophysics Data System (ADS)

    O'Hare, N. J.; Gilligan, P.; Murphy, D.; Malone, J. F.

    1997-09-01

    The ingestion of I-131 by pregnant women can have consequences for the developing foetus, in particular brain function. As the foetal thyroid accumulates iodine from the twelfth week of gestation onwards, the determination of foetal brain dose resulting from such I-131 accumulation is essential. Normal dosimetric methods fail to treat the case of the foetus. Using an approximation method based on the MIRD approach, a foetal dose estimation scheme is developed to allow the determination of foetal brain dose from foetal thyroid irradiation. Dose values are obtained for the foetus based on the maternal intake of I-131. It was found that the choice of biokinetic model for the mother/foetus has a large impact on the determined dose estimate.

  5. Is thyroid scintigraphy necessary before I-131 therapy for hyperthyroidism. Concise Communication

    SciTech Connect

    Ripley, S.D.; Freitas, J.E.; Nagle, C.E.

    1984-06-01

    To assess the value of routine thyroid scintigraphy in the differential diagnosis of hyperthyroidism and as a guide to I-131 therapy, the authors prospectively examined 100 consecutive hyperthyroid patients referred for a 24-hr radioiodine uptake and I-131 therapy. The nuclear medicine physician recorded his preimaging diagnostic impression and therapeutic plan for each patient. After the (/sup 99m/Tc) pertechnetate image, the patient was reassessed to determine whether the image induced any change in the diagnosis or therapeutic plan. Seventy-nine of 80 patients with diffuse goiter to palpation, had scintigrams demonstrating no discrete focal defects and were diagnosed as Graves' disease; thus the scintigram did not contribute useful information. In 17 of 20 patients with uninodular or multinodular goiters, the image was necessary to clarify the final diagnosis and therapeutic plan. Thus, selective use of thyroid scintigraphy should decrease the number of scintigrams performed before I-131 therapy for hyperthyroidism, without compromising diagnostic accuracy or therapeutic success.

  6. Ovarian teratoma mimicking metastasis on I-131 scan : a case report.

    PubMed

    Yoon, Sohee; Soo Hong, In

    2013-03-01

    The whole body I-131 scan is routinely performed in the postoperative treatment of patients with well-differentiated thyroid cancer. Accurate interpretation of whole body I-131 scan after thyroidectomy is critical to appropriate management of patients with thyroid cancer, to prevent unnecessary surgical removal or exposure to radioiodine. Unfortunately, false-positive uptakes in several other organs and their associated disease processes have been reported. We report a case of false-positive iodine uptake in the pelvic region with incidentally diagnosed mature cystic teratoma. PMID:24895508

  7. 77 FR 71432 - Agency Information Collection Activities: Application for Travel Document, Form Number I-131...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2012-11-30

    ... notice on December 28, 2011 published at 76 FR 81517, allowing for a 60-day public comment period; and, a notice on March 16, 2012 published at 77 FR 15787, allowing for a 30-day public comment period. USCIS did... for Travel Document, Form Number I-131; Revision of a Currently Approved Collection ACTION:...

  8. Pheochromocytoma in the organ of Zukerkandl: I-131 MIBG scintigraphic localization

    SciTech Connect

    el-Desouki, M.; al-Nuaim, A.; Mofti, A.; Shanna, A.

    1989-06-01

    Scintigraphic localization of an extra-adrenal pheochromocytoma in a 27 year-old female with clinical and biochemical evidence of the disease is presented. While both ultrasonography and computed tomography were negative, I-131 MIBG scintigraphy successfully localized the extra-adrenal lesion in the organ of Zukerkandl.

  9. The therapeutic efficacy of I131-PSCA-mAb in orthotopic mouse models of prostate cancer

    PubMed Central

    2013-01-01

    Background Prostate stem cell antigen (PSCA) is upregulated in prostate cancer tissues. Here we aimed to study the therapeutic efficacy of a monoclonal antibody of PSCA-labeled I131 (I131-PSCA-mAb) in orthotopic mouse models of prostate cancer. Methods The proliferation, apoptosis and invasion abilities of PC-3 and LNCaP cells treated with I131-PSCA-mAb were measured by methyl thiazolyl tetrazolium assay, flow cytometry and transwell culture, respectively. The human prostate cancer models were established by orthotopic implantation of PC-3 and LNCaP cells in nude mice. I131-PSCA-mAb distribution and tumor cell apoptosis in the tumor-bearing nude mice were measured. Results The inhibitory and apoptosis rates of PC-3 and LNCaP cells treated with I131-PSCA-mAb reached a maximum of 84%, 80% and 50%, 46%, respectively, which were obviously higher than in the cells treated with I131-IgG or PSCA-mAb. The invaded number of PC-3 and LNCaP cells treated with I131-PSCA-mAbe was significantly reduced (P < 0.01) compared with the control group. The ratios of I131-PSCA-mAb in tumor to intramuscular I131-PSCA-mAb (T/NT) in tumor-bearing nude mice were increased with time and reached the highest level after 8 h. T/NT stayed above 3.0 after 12 h, and the tumor could still be developed after 24 h. The number of apoptotic cells in tumor tissue of nude mice treated with I131-PSCA-mAb was larger than that in the control group. Conclusion I131-PSCA-mAb has the potential to become a new targeted therapy drug for the treatment of prostate cancer. PMID:24330823

  10. Rapid thyroidal iodine turnover in hyperthyroid patients: Incidence and impact on outcome of I-131 therapy (Rx)

    SciTech Connect

    Aktay, R.; Rezai, K.; Kirchner, P.T.

    1995-05-01

    It has been suggested that rapid thyroidal iodine turnover (RTIT) may be frequent in hyperthyroid patients and that it could cause not only I-131 therapy failures but also high radiation doses to the blood from circulating protein bound I-131 (JNM 73;14:379A). We investigated the incidence and importance of this phenomenon by comparing 4 hr to 24 hr uptake ratios with the success of I-131 therapy (3.7-5.5 MBq/gm of thyroid). Of 525 hyperthyroid patients treated at our institution between 1980 and 1993, 460 had both 4 and 24 hr uptake measurements: 370 were female, 90 male, mean age 42 years. Clinical diagnosis was Graves` disease in 402, non-Graves` disease in 58. Of the 460, 27 patients were lost to follow-up after the first I-131 Rx, 6 after the second Rx. Defining rapid turnover as early uptake {ge} late uptake, we found 71 of 460 hyperthyroids (15%) to have rapid thyroidal I-131 turnover with all but 2 in patients with Graves` disease. Of 22 patients with RTIT who failed 1st I-131 Rx, 18 (82%) were successfully treated with 2nd I-131 Rx; and of 29 with nonrapid turnover, 27 (93%) had a successful 2nd I-131 Rx. 17 of 24 (71%) patients were converted to nonrapid after the 1st I-131 Rx. The results (a) confirm a relatively high incidence of rapid thyroidal iodine turnover in hyperthyroid patients, (b) reveal a near 50% failure rate for first I-131 Rx in such patients vs. 11% for non-RTIT, (c) demonstrate a reversion to non-RTIT for most RTIT patients after first I-131 Rx, (d) show the 4 to 24 hour uptake ratios to be a guide for treatment outcome.

  11. Development of gamma-photon/Cerenkov-light hybrid system for simultaneous imaging of I-131 radionuclide

    NASA Astrophysics Data System (ADS)

    Yamamoto, Seiichi; Suzuki, Mayumi; Kato, Katsuhiko; Watabe, Tadashi; Ikeda, Hayato; Kanai, Yasukazu; Ogata, Yoshimune; Hatazawa, Jun

    2016-09-01

    Although iodine 131 (I-131) is used for radionuclide therapy, high resolution images are difficult to obtain with conventional gamma cameras because of the high energy of I-131 gamma photons (364 keV). Cerenkov-light imaging is a possible method for beta emitting radionuclides, and I-131 (606 MeV maximum beta energy) is a candidate to obtain high resolution images. We developed a high energy gamma camera system for I-131 radionuclide and combined it with a Cerenkov-light imaging system to form a gamma-photon/Cerenkov-light hybrid imaging system to compare the simultaneously measured images of these two modalities. The high energy gamma imaging detector used 0.85-mm×0.85-mm×10-mm thick GAGG scintillator pixels arranged in a 44×44 matrix with a 0.1-mm thick reflector and optical coupled to a Hamamatsu 2 in. square position sensitive photomultiplier tube (PSPMT: H12700 MOD). The gamma imaging detector was encased in a 2 cm thick tungsten shield, and a pinhole collimator was mounted on its top to form a gamma camera system. The Cerenkov-light imaging system was made of a high sensitivity cooled CCD camera. The Cerenkov-light imaging system was combined with the gamma camera using optical mirrors to image the same area of the subject. With this configuration, we simultaneously imaged the gamma photons and the Cerenkov-light from I-131 in the subjects. The spatial resolution and sensitivity of the gamma camera system for I-131 were respectively ~3 mm FWHM and ~10 cps/MBq for the high sensitivity collimator at 10 cm from the collimator surface. The spatial resolution of the Cerenkov-light imaging system was 0.64 mm FWHM at 10 cm from the system surface. Thyroid phantom and rat images were successfully obtained with the developed gamma-photon/Cerenkov-light hybrid imaging system, allowing direct comparison of these two modalities. Our developed gamma-photon/Cerenkov-light hybrid imaging system will be useful to evaluate the advantages and disadvantages of these two

  12. Radioimmunoimaging of human lymphomas with I-131 tumor-specific monoclonal antibody

    SciTech Connect

    Zimmer, A.M.; Epstein, A.L.; Spies, S.M.

    1984-01-01

    The purpose of this study was to radiolabel an IgG2a monoclonal antibody (Lym-1) and fragments (Fab and F(ab')2) directed against human lymphomas (Raji) and to determine the biodistribution and feasibility of radioimmunoimaging. Radiolabeling with I-131 was achieved using Iodogen to which the monoclonal antibody (MA) and NaI-131 were added. Radioimmunoreactivity was performed utilizing a live cell assay of lymphoma cells (Raji). Athymic nude mice, each bearing a right thigh human lymphoma (Raji), were injected with 150-300 ..mu..Ci of I-131 labeled Ma, including Fab and F(ab')2 fragments, imaged up to 7 days after injection, sacrificed, and organ biodistribution performed. Results of the study demonstrated significant loss of immunoreactivity with the radioiodinated Fab fragments (11% binding) as opposed to F(ab')2 fragments (61% binding) or the whole antibody (65% binding). Highest tumor uptake was observed for the whole I-131 labeled antibody (8.2%) followed by F(ab')2 fragments (4.4%) and Fab fragments (0.9%). The most rapid whole body excretion was observed for radioiodinated Fab fragments followed by F(ab')2 fragments and whole antibody. Optimum tumor visualization for the radioiodinated F(ab')2 fragments and whole antibody was observed at 3 and 7 days after injection, with tumor/whole body ratios of 0.65 and 0.60 for F(ab')2 fragments and whole antibody, respectively. Biodistribution data obtained 7 days after injection confirmed high tumor uptake and low soft tissue distribution with tumor/liver ratios of 20.3 and 30.1 for the radioiodinated whole antibody and F(ab')2 fragments, respectively.

  13. 3-D Monte Carlo-Based Scatter Compensation in Quantitative I-131 SPECT Reconstruction

    PubMed Central

    Dewaraja, Yuni K.; Ljungberg, Michael; Fessler, Jeffrey A.

    2010-01-01

    We have implemented highly accurate Monte Carlo based scatter modeling (MCS) with 3-D ordered subsets expectation maximization (OSEM) reconstruction for I-131 single photon emission computed tomography (SPECT). The scatter is included in the statistical model as an additive term and attenuation and detector response are included in the forward/backprojector. In the present implementation of MCS, a simple multiple window-based estimate is used for the initial iterations and in the later iterations the Monte Carlo estimate is used for several iterations before it is updated. For I-131, MCS was evaluated and compared with triple energy window (TEW) scatter compensation using simulation studies of a mathematical phantom and a clinically realistic voxel-phantom. Even after just two Monte Carlo updates, excellent agreement was found between the MCS estimate and the true scatter distribution. Accuracy and noise of the reconstructed images were superior with MCS compared to TEW. However, the improvement was not large, and in some cases may not justify the large computational requirements of MCS. Furthermore, it was shown that the TEW correction could be improved for most of the targets investigated here by applying a suitably chosen scaling factor to the scatter estimate. Finally clinical application of MCS was demonstrated by applying the method to an I-131 radioimmunotherapy (RIT) patient study. PMID:20104252

  14. Dosimetry study of [I-131] and [I-125]- meta-iodobenz guanidine in a simulating model for neuroblastoma metastasis.

    PubMed

    Roa, W H; Yaremko, B; McEwan, A; Amanie, J; Yee, D; Cho, J; McQuarrie, S; Riauka, T; Sloboda, R; Wiebe, L; Loebenberg, R; Janicki, C

    2013-02-01

    The physical properties of I-131 may be suboptimal for the delivery of therapeutic radiation to bone marrow metastases, which are common in the natural history of neuroblastoma. In vitro and preliminary clinical studies have implied improved efficacy of I-125 relative to I-131 in certain clinical situations, although areas of uncertainty remain regarding intratumoral dosimetry. This prompted our study using human neuroblastoma multicellular spheroids as a model of metastasis. 3D dose calculations were made using voxel-based Medical Internal Radiation Dosimetry (MIRD) and dose-point-kernel (DPK) techniques. Dose distributions for I-131 and I-125 labeled mIBG were calculated for spheroids (metastases) of various sizes from 0.01 cm to 3 cm diameter, and the relative dose delivered to the tumors was compared for the same limiting dose to the bone marrow. Based on the same data, arguments were advanced based upon the principles of tumor control probability (TCP) to emphasize the potential theoretical utility of I-125 over I-131 in specific clinical situations. I-125-mIBG can deliver a higher and more uniform dose to tumors compared to I-131 mIBG without increasing the dose to the bone marrow. Depending on the tumor size and biological half-life, the relative dose to tumors of less than 1 mm diameter can increase several-fold. TCP calculations indicate that tumor control increases with increasing administered activity, and that I-125 is more effective than I-131 for tumor diameters of 0.01 cm or less. This study suggests that I-125-mIBG is dosimetrically superior to I-131-mIBG therapy for small bone marrow metastases from neuroblastoma. It is logical to consider adding I-125-mIBG to I-131-mIBG in multi-modality therapy as these two isotopes could be complementary in terms of their cumulative dosimetry. PMID:22974332

  15. Influence of various scanning doses on subsequent I-131 ablation of thyroid remnants

    SciTech Connect

    Kim, C.K.; Tse, K.; San Pedro, E. |

    1994-05-01

    In postsurgical patients with thyroid cancer, there is no universal agreement on the I-131 dose for total body scanning as well as on the dose for ablation (ABL) of the thyroid remnant. The objective of this study was to determine (1) whether or not using a higher scanning dose results in a lower success rate on subsequent ABL of thyroid remnant, and (2) whether or not ABL with 100 mCi is more effective than ABL with 30 mCi regardless of the scanning dose.

  16. Calibration of the Accuscan II In Vivo System for I-131 Thyroid Counting

    SciTech Connect

    Orval R. Perry; David L. Georgeson

    2011-07-01

    This report describes the March 2011 calibration of the Accuscan II HpGe In Vivo system for I-131 thyroid counting. The source used for the calibration was an Analytics mixed gamma source 82834-121 distributed in an epoxy matrix in a Wheaton Liquid Scintillation Vial with energies from 88.0 keV to 1836.1 keV. The center of the detectors was position 64-feet from the vault floor. This position places the approximate center line of the detectors at the center line of the source in the thyroid tube. The calibration was performed using an RMC II phantom (Appendix J). Validation testing was performed using a Ba-133 source and an ANSI N44.3 Phantom (Appendix I). This report includes an overview introduction and records for the energy/FWHM and efficiency calibrations including verification counting. The Accuscan II system was successfully calibrated for counting the thyroid for I-131 and verified in accordance with ANSI/HPS N13.30-1996 criteria.

  17. Analysis of elevated I-131 samples observed in 2011 over Europe

    NASA Astrophysics Data System (ADS)

    Hofman, Radek; Tichý, Ondřej; Šindelářová, Kateřina

    2016-04-01

    We are concerned with analysis of elevated I-131 samples observed in October and November 2011 across Europe. Later on these samples were connected with I-131 emissions from the Hungarian Institute of Isotopes in Budapest. Using the data from multiple European countries we attempt to estimate the source term using two methods. Firstly, we use a standard source inversion approach based on minimization of an objective function. This function has two quadratic terms: mismatch between model and measurements weighted by an observation error covariance matrix and the deviation of the solution from a first guess weighted by the first-guess error covariance matrix. For simplicity, both error covariance matrices are approximated as diagonal. Analytical minimization of the cost function leads to a liner system of equations. Secondly, we use a more advanced method based on Variational Bayes approximation. Here, all uncertainties are formulated as a prior probabilistic model which is capable of introducing some additional assumptions on the solution like sparsity or smoothness. Since the inference of the model is intractable, we follow Variational Bayes approximation yielding an iterative algorithm for estimation of all model parameters. Thus, the source term and elements of covariance matrices are estimated from the data automatically. Flexpart forced with GFS meteorological fields is used as an atmospheric transport model in both experiments. This research is supported by EEA/Norwegian Financial Mechanism under project MSMT-28477/2014 Source-Term Determination of Radionuclide Releases by Inverse Atmospheric Dispersion Modelling (STRADI).

  18. Neuroblastoma: Imaging evaluation by sequential Tc-99m MDP, I-131 MIBG, and Ga-67 citrate studies

    SciTech Connect

    Garty, I.; Friedman, A.; Sandler, M.P.; Kedar, A. )

    1989-07-01

    Fourteen children with histopathologically confirmed neuroblastoma underwent sequential correlative imaging studies using I-131 MIBG, Tc-99m MDP, and Ga-67 citrate during various stages of the disease. Of the patients 86% showed I-131 MIBG accumulation in the primary tumoral site, whereas 71% showed Tc-99m MDP and 79% Ga-67 citrate uptake. In 86% at least one of the two latter radiopharmaceuticals concentrated in the primary tumor. The use of all three radiopharmaceuticals raised the detection rate to 93%. Of the osseous or extraosseous metastases 100% were detected by Tc-99m MDP studies. The I-131 MIBG studies were positive in 71% of the osseous metastases and in 70% of the extraosseous metastases. No Ga-67 citrate uptake was demonstrated in osseous metastases, although one extraosseous lung metastasis concentrated this radiopharmaceutical. Tc-99m MDP bone imaging was the best method for diagnosing metastatic spread of the disease and for monitoring the results of treatment. Primary tumor uptake was best indicated by I-131 MIBG. Both Ga-67 citrate and I-131 MIBG were superior to Tc-99m MDP with regard to accurately demonstrating the extent of primary tumors. Only Tc-99m MDP indicated the relationship of these tumors to the kidneys and neighboring osseous structures, providing early screening of kidney compression. Ga-67 citrate study was mainly indicated in tumors with catecholamine depletion, which failed to concentrate the other two radiopharmaceuticals. I-131 MIBG proved especially useful in detecting neuroblastoma with negative Tc-99m MDP and Ga-67 citrate studies and also proved to be helpful with those cases in which I-131 MIBG was planned for therapy. The following strategy is suggested for evaluating neuroblastoma.

  19. Palliative therapy with I-131 labeled bezylidenediphosphonic acid: In vivo kinetics and response to pain induced by bone metastases

    SciTech Connect

    Eisenhut, M.; Berberich, R.; Kimmig, B.; Oberhausen, E.; Georgi, P.; Zum Winkel, K.

    1985-05-01

    I-131 labeled ..cap alpha..-amino-(4-hydroxybenzylidene)diphosphonic acid (BDP3) was recently suggested as a palliative acting radiopharmaceutical against pain syndromes associated with disseminated bone metastases. Such an application was supported by the in vivo kinetics of I-131-BDP3 in rats. The authors investigated the palliative effectiveness of I-131-BDP3 in 18 patients with typical pain symptoms induced by bone metastases of various primary carcinoma. The blood clearance was rapid. More than 90% disappeared from the blood pool at 4 hr after injection. The excretion of the activity occured solely through the kidneys and the median total body retention at 48 hr was 51% (range 30-64%). The thyroid activity decreased during therapy indicating no cleavage reactions as long as I-131-BDP3 is bound to the bone tissue. The binding of I-131-BDP3 to bone is very long since the effective half life was in the order of magnitude of the physical half life. Additionally the effective half lifes in the metastatic ares (median 182 hr; range 177-205 hr) proved to be longer than in unaffected areas (145 hr; 140-165 hr). The palliative therapies were performed with doses of 6 - 48 mCi. The response amounted to 44% complete pain relief, 6% substantial pain relief, 22% minimal improvement and 28% no change. The duration of response ranged between 1 and 8 weeks.

  20. Fetal radiation dose estimates for I-131 sodium iodide in cases where conception occurs after administration

    SciTech Connect

    Sparks, R.B.; Stabin, M.G.

    1999-01-01

    After administration of I-131 to the female patient, the possibility of radiation exposure of the embryo/fetus exists if the patient becomes pregnant while radioiodine remains in the body. Fetal radiation dose estimates for such cases were calculated. Doses were calculated for various maternal thyroid uptakes and time intervals between administration and conception, including euthyroid and hyperthyroid cases. The maximum fetal dose calculating was about 9.8E-03 mGy/MBq, which occurred with 100% maternal thyroid uptake and a 1 week interval between administration and conception. Placental crossover of the small amount of radioiodine remaining 90 days after conception was also considered. Such crossover could result in an additional fetal dose of 9.8E-05 mGy/MBq and a maximum fetal thyroid self dose of 3.5E-04 mGy/MBq.

  1. Medically-derived I-131: a potential tool for understanding the fate of wastewater nitrogen in aquatic systems

    NASA Astrophysics Data System (ADS)

    Rose, P. S.; Smith, J. P.; Aller, R. C.; Cochran, J. K.; Swanson, R. L.; Murthy, S. N.; Coffin, R. B.

    2010-12-01

    Iodine-131(t1/2 = 8 days) has been measured in Potomac River water and sediments in the vicinity of the Blue Plains Water Pollution Control Plant (WPCP), Washington, DC. The source of I-131 is medical, where it is commonly used to treat thyroid cancer and hyperthyroidism. Iodine is metabolized by patients and eliminated primarily in urine. While other medical radioisotopes may enter the environment via sewage effluent, the nature and quantity of treatments using I-131 cause it to account for much of the radioactivity in sewage effluent. Natural iodine in aquatic systems is biologically cycled similar to other nutrients, such as nitrogen. Iodine-131 concentrations measured in sewage effluent from Blue Plains WPCP and in the Potomac River suggest a relatively continuous discharge of this isotope. Dissolved I-131 shows a strong, positive correlation with δ15N values of nitrate in the river. The range of I-131 concentrations detected in surface waters is 0.18 ± 0.01 to 0.68 ± 0.02 Bq/L. Surface water δ15NO3 values ranged from 8.7 ± 0.3 to 33.4 ± 7.3 ‰ with NO3+NO2 concentrations between 0.38 ± 0.02 and 2.79 ± 0.13 mgN/L. Sediment profiles of particulate I-131 and δ15N indicate rapid mixing or sedimentation and in many cases remineralization of a heavy nitrogen source consistent with wastewater nitrogen. Iodine-131 concentrations in sediments ranged from 1.31 ± 0.8 to 117 ± 2 Bq/kg dry weight. Values of δ15N in sediments ranged from 4.7 ± 0.1 ‰ to 9.3 ± 0.1 ‰. We propose that I-131 coupled with δ15N can be an excellent tracer for the short-term fate of wastewater nitrogen in this system. However, the utility of I-131 as a tracer is not limited to use in the Potomac River. Other studies have documented the presence of I-131 in several aquatic systems and continuous discharges of this radioisotope in sewage effluent are likely to be widespread in urban environments.

  2. Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone - thyrotropin alfa)

    PubMed Central

    Gonzalez, Marta E; Muttikkal, Thomas Jose Eluvathingal; Rehm, Patrice K

    2015-01-01

    Salivary dysfunction and sialadenitis are well known complications of radioiodine treatment for thyroid cancer. The parotid gland is more frequently affected and the salivary gland injury is dose related. The symptoms may develop shortly after therapeutic Iodine 131(I-131) administration or months later and progress with time. The development of unilateral parotiditis following a low dose, diagnostic I-131 scan performed following Thyrogen stimulation in a patient without prior history of sialadenitis is rare in our experience, and has not been reported in the medical literature. PMID:26622936

  3. Implementation of iodine biokinetic model for interpreting I-131 contamination in breast milk after the Fukushima nuclear disaster.

    PubMed

    Tani, Kotaro; Kurihara, Osamu; Kim, Eunjoo; Yoshida, Satoshi; Sakai, Kazuo; Akashi, Makoto

    2015-01-01

    After the accident at the Fukushima Daiichi Nuclear Power Plant run by Tokyo Electric Power Company in 2011, breast milk samples obtained from volunteers living in Fukushima and neighboring prefectures were examined and small amounts of I-131 (2.2-36.3 Bq/kg) were detected in some samples. In this work, the I-131 concentrations in breast milk from nursing mothers in Ibaraki prefecture were calculated based on the iodine biokinetic model during lactation together with time-variable intake scenarios by inhalation of ambient air and ingestion of tap water, using the authors' code. The calculated I-131 concentrations in breast milk generally agreed with those measured for the volunteers. Based on the results, thyroid equivalent doses to breast-fed infants were estimated for each place of residence of the volunteers on the assumption that these infants consumed 800 ml of breast milk every day, resulting in 10-11 mSv for Mito and Kasama cities and 1.1-1.8 mSv for Tsukuba and Moriya cities. It was suggested that breast milk consumption could be a major contributor to internal dose of breast-fed infants in areas with mild I-131 pollution; however, further studies considering personal behavior surveys would be necessary to estimate individual doses. PMID:26198990

  4. Implementation of iodine biokinetic model for interpreting I-131 contamination in breast milk after the Fukushima nuclear disaster

    NASA Astrophysics Data System (ADS)

    Tani, Kotaro; Kurihara, Osamu; Kim, Eunjoo; Yoshida, Satoshi; Sakai, Kazuo; Akashi, Makoto

    2015-07-01

    After the accident at the Fukushima Daiichi Nuclear Power Plant run by Tokyo Electric Power Company in 2011, breast milk samples obtained from volunteers living in Fukushima and neighboring prefectures were examined and small amounts of I-131 (2.2-36.3 Bq/kg) were detected in some samples. In this work, the I-131 concentrations in breast milk from nursing mothers in Ibaraki prefecture were calculated based on the iodine biokinetic model during lactation together with time-variable intake scenarios by inhalation of ambient air and ingestion of tap water, using the authors’ code. The calculated I-131 concentrations in breast milk generally agreed with those measured for the volunteers. Based on the results, thyroid equivalent doses to breast-fed infants were estimated for each place of residence of the volunteers on the assumption that these infants consumed 800 ml of breast milk every day, resulting in 10-11 mSv for Mito and Kasama cities and 1.1-1.8 mSv for Tsukuba and Moriya cities. It was suggested that breast milk consumption could be a major contributor to internal dose of breast-fed infants in areas with mild I-131 pollution; however, further studies considering personal behavior surveys would be necessary to estimate individual doses.

  5. 10 CFR 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 1 2011-01-01 2011-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries). 35.394 Section 35.394 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written Directive Required...

  6. 10 CFR 35.392 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 1 2013-01-01 2013-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries). 35.392 Section 35.392 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written...

  7. 10 CFR 35.392 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 1 2010-01-01 2010-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries). 35.392 Section 35.392 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written...

  8. 10 CFR 35.392 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... 10 Energy 1 2011-01-01 2011-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries). 35.392 Section 35.392 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written...

  9. 10 CFR 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 1 2014-01-01 2014-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries). 35.394 Section 35.394 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written Directive Required...

  10. 10 CFR 35.392 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... 10 Energy 1 2014-01-01 2014-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries). 35.392 Section 35.392 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written...

  11. 10 CFR 35.392 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 1 2012-01-01 2012-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities less than or equal to 1.22 gigabecquerels (33 millicuries). 35.392 Section 35.392 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written...

  12. 10 CFR 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... 10 Energy 1 2010-01-01 2010-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries). 35.394 Section 35.394 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written Directive Required...

  13. 10 CFR 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... 10 Energy 1 2012-01-01 2012-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries). 35.394 Section 35.394 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written Directive Required...

  14. 10 CFR 35.394 - Training for the oral administration of sodium iodide I-131 requiring a written directive in...

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... 10 Energy 1 2013-01-01 2013-01-01 false Training for the oral administration of sodium iodide I-131 requiring a written directive in quantities greater than 1.22 gigabecquerels (33 millicuries). 35.394 Section 35.394 Energy NUCLEAR REGULATORY COMMISSION MEDICAL USE OF BYPRODUCT MATERIAL Unsealed Byproduct Material-Written Directive Required...

  15. Implementation of iodine biokinetic model for interpreting I-131 contamination in breast milk after the Fukushima nuclear disaster

    PubMed Central

    Tani, Kotaro; Kurihara, Osamu; Kim, Eunjoo; Yoshida, Satoshi; Sakai, Kazuo; Akashi, Makoto

    2015-01-01

    After the accident at the Fukushima Daiichi Nuclear Power Plant run by Tokyo Electric Power Company in 2011, breast milk samples obtained from volunteers living in Fukushima and neighboring prefectures were examined and small amounts of I-131 (2.2–36.3 Bq/kg) were detected in some samples. In this work, the I-131 concentrations in breast milk from nursing mothers in Ibaraki prefecture were calculated based on the iodine biokinetic model during lactation together with time-variable intake scenarios by inhalation of ambient air and ingestion of tap water, using the authors’ code. The calculated I-131 concentrations in breast milk generally agreed with those measured for the volunteers. Based on the results, thyroid equivalent doses to breast-fed infants were estimated for each place of residence of the volunteers on the assumption that these infants consumed 800 ml of breast milk every day, resulting in 10–11 mSv for Mito and Kasama cities and 1.1–1.8 mSv for Tsukuba and Moriya cities. It was suggested that breast milk consumption could be a major contributor to internal dose of breast-fed infants in areas with mild I-131 pollution; however, further studies considering personal behavior surveys would be necessary to estimate individual doses. PMID:26198990

  16. Determination of energy windows for the triple energy window scatter correction method in I-131 on a Siemens SYMBIA gamma camera: a GATE simulation study

    NASA Astrophysics Data System (ADS)

    Lee, Young Sub; Kim, Jin Su; Kim, Kyeong Min; Moo Lim, Sang; Kim, Hee-Joung

    2015-01-01

    Image correction for scattered photons is important for the quantification of gamma-camera imaging using I-131. Many previous studies have addressed this issue but none have compared scattered photon fractions of I-131 with varying energy windows, to determine optimal main- and sub-energy windows for the implementation of TEW correction in I-131 imaging. We assessed the scattered photon fractions and determined the optimal main- and sub- energy windows for TEW in I-131 using a Siemens SYMBIA T2 SPECT/CT using a Monte Carlo method (GATE simulation). To validate the GATE simulation code, we compared the spatial resolutions obtained experimentally and from GATE simulation, for I-123 and Tc-99m. A high-energy general purpose (HE) collimator was used to assess the scattered photon fractions measured with the I-131 radioisotope placed at eight different field-of-view locations in a water phantom (diameter 16 cm, length 32 cm), and at the center in air. To implement the TEW (triple energy window) method, two different main-energy window widths (15 and 20%) and two different sub-energy window widths (3 and 5 keV) were used. The experimental measurement and simulation results exhibited a similar pattern with < 15% difference in spatial resolution with increasing distance. The I-131 scatter fraction with 15% of the main-energy window and 5 keV sub-energy windows was similar to the ``goldstandard'' scatter fraction. Main- and sub-energy window selection for the TEW correction in I-131 is important to avoid over- or under-correction in the scatter fraction. A 15% of main energy window with 5 keV sub-energy windows were found to be optimal for implementation of the TEW method in I-131. This result provides the optimal energy window for I-131 scintigraphy data and will aid the quantification of I-131 imaging.

  17. The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma

    NASA Astrophysics Data System (ADS)

    Hänscheid, H.; Lassmann, M.; Buck, A. K.; Reiners, C.; Verburg, F. A.

    2014-05-01

    Radioiodine scintigraphy influences staging and treatment in patients with differentiated thyroid carcinoma. The limit of detection for fractional uptake in an iodine avid focus in a scintigraphic image was determined from the number of lesion net counts and the count density of the tissue background. The count statistics were used to calculate the diagnostic activity required to elevate the signal from a lesion with a given uptake significantly above a homogeneous background with randomly distributed counts per area. The dependences of the minimal uptake and the minimal size of lesions visible in a scan on several parameters of influence were determined by linking the typical biokinetics observed in iodine avid tissue to the lesion mass and to the absorbed dose received in a radioiodine therapy. The detection limits for fractional uptake in a neck lesion of a typical patient are about 0.001% after therapy with 7000 MBq, 0.01% for activities typically administered in diagnostic assessments (74-185 MBq), and 0.1% after the administration of 10 MBq I-131. Lesions at the limit of detection in a diagnostic scan with biokinetics eligible for radioiodine therapy are small with diameters of a few millimeters. Increasing the diagnostic activity by a factor of 4 reduces the diameter of visible lesions by 25% or about 1 mm. Several other determinants have a comparable or higher influence on the limit of detection than the administered activity; most important are the biokinetics in both blood pool and target tissue and the time of measurement. A generally valid recommendation for the timing of the scan is impossible as the time of the highest probability to detect iodine avid tissue depends on the administered activity as well as on the biokinetics in the lesion and background in the individual patient.

  18. Development of departmental standard for traceability of measured activity for I-131 therapy capsules used in nuclear medicine.

    PubMed

    Ravichandran, Ramamoorthy; Binukumar, Jp

    2011-01-01

    International Basic Safety Standards (International Atomic Energy Agency, IAEA) provide guidance levels for diagnostic procedures in nuclear medicine indicating the maximum usual activity for various diagnostic tests in terms of activities of injected radioactive formulations. An accuracy of ± 10% in the activities of administered radio-pharmaceuticals is being recommended, for expected outcome in diagnostic and therapeutic nuclear medicine procedures. It is recommended that the long-term stability of isotope calibrators used in nuclear medicine is to be checked periodically for their performance using a long-lived check source, such as Cs-137, of suitable activity. In view of the un-availability of such a radioactive source, we tried to develop methods to maintain traceability of these instruments, for certifying measured activities for human use. Two re-entrant chambers [(HDR 1000 and Selectron Source Dosimetry System (SSDS)] with I-125 and Ir-192 calibration factors in the Department of Radiotherapy were used to measure Iodine-131 (I-131) therapy capsules to establish traceability to Mark V isotope calibrator of the Department of Nuclear Medicine. Special nylon jigs were fabricated to keep I-131 capsule holder in position. Measured activities in all the chambers showed good agreement. The accuracy of SSDS chamber in measuring Ir-192 activities in the last 5 years was within 0.5%, validating its role as departmental standard for measuring activity. The above method is adopted because mean energies of I-131 and Ir-192 are comparable. PMID:21430859

  19. A Quantitative Evaluation of Hepatic Uptake on I-131 Whole-Body Scintigraphy for Postablative Therapy of Thyroid Carcinoma

    PubMed Central

    Nakayama, Michihiro; Okizaki, Atsutaka; Sakaguchi, Miki; Ishitoya, Shunta; Uno, Takahiro; Sato, Junichi; Takahashi, Koji

    2015-01-01

    Abstract This study aimed to determine clinical association between quantitative hepatic uptake on postablative whole-body scan (WBS) with differentiated thyroid cancer (DTC) prognosis. We analyzed 541 scans of 216 DTC patients who were divided into 3 groups based on radioactive iodine (I-131) WBS uptake and clinical follow-up: group 1 (completion of ablation), group 2 (abnormal uptake in the cervical region), and group 3 (abnormal uptake with distant metastases). For each group, we calculated the ratio of I-131 WBS hepatic uptake (H) to cranial uptake as background (B); this ratio was defined as H/B. Furthermore, we made a distinction between group 1, as having completed radioactive iodine therapy (RIT) (CR), and group 2 and 3, as requiring subsequent RIT (RR). The average H/B scores were 1.34 (median, 1.36; range 1.00–2.1) for group1; 1.89 (median, 1.75; range 1.41–4.20) for group 2; and 2.09 (median, 1.90; range 1.50–4.32) for group 3. Bonferroni multiple comparisons revealed significant differences in H/B among these groups. The H/B of group 1 was significantly smaller than that of other 2 groups (P < 0.0001). The precise cutoff value of H/B for therapeutic effect was ≤1.5. Moreover, 159 of 160 scans in the CR and 375 of 381 patients in the RR were correctly diagnosed using this cutoff value in the final outcome of RIT, yielding a sensitivity, specificity, positive predictive value, and negative predictive value of 99.4%, 98.4%, 99.7%, and 96.3%, respectively. Increased hepatic uptake of I-131 on WBS may predict disease-related progression. PMID:26181567

  20. A Quantitative Evaluation of Hepatic Uptake on I-131 Whole-Body Scintigraphy for Postablative Therapy of Thyroid Carcinoma.

    PubMed

    Nakayama, Michihiro; Okizaki, Atsutaka; Sakaguchi, Miki; Ishitoya, Shunta; Uno, Takahiro; Sato, Junichi; Takahashi, Koji

    2015-07-01

    This study aimed to determine clinical association between quantitative hepatic uptake on postablative whole-body scan (WBS) with differentiated thyroid cancer (DTC) prognosis. We analyzed 541 scans of 216 DTC patients who were divided into 3 groups based on radioactive iodine (I-131) WBS uptake and clinical follow-up: group 1 (completion of ablation), group 2 (abnormal uptake in the cervical region), and group 3 (abnormal uptake with distant metastases). For each group, we calculated the ratio of I-131 WBS hepatic uptake (H) to cranial uptake as background (B); this ratio was defined as H/B. Furthermore, we made a distinction between group 1, as having completed radioactive iodine therapy (RIT) (CR), and group 2 and 3, as requiring subsequent RIT (RR). The average H/B scores were 1.34 (median, 1.36; range 1.00-2.1) for group 1; 1.89 (median, 1.75; range 1.41-4.20) for group 2; and 2.09 (median, 1.90; range 1.50-4.32) for group 3. Bonferroni multiple comparisons revealed significant differences in H/B among these groups. The H/B of group 1 was significantly smaller than that of other 2 groups (P < 0.0001). The precise cutoff value of H/B for therapeutic effect was ≤1.5. Moreover, 159 of 160 scans in the CR and 375 of 381 patients in the RR were correctly diagnosed using this cutoff value in the final outcome of RIT, yielding a sensitivity, specificity, positive predictive value, and negative predictive value of 99.4%, 98.4%, 99.7%, and 96.3%, respectively. Increased hepatic uptake of I-131 on WBS may predict disease-related progression. PMID:26181567

  1. Three-dimensional cellular dosimetry of I-131 mIBG in neuroblastoma with EGS4 Monte Carlo code

    SciTech Connect

    Gouriou, J.; Ricard, M.; Lumbroso, J.; Aubert, B. |

    1995-05-01

    The adequate distribution of radiation dose to tumor cells is the most important factor for the outcome of internal (metabolic) radiotherapy. This study investigates the dosimetry of I-131 meta-iodobenzyl-guanidine at the cellular level in neuroblastoma. We developed a program based on the EGS4 Monte Carlo code allowing the computation of basic dosimetric parameters such as absorbed and cumulated fractions, scaled dose point kernels and dose rates, especially for radionuclides with therapeutic potential. It can be applied to various types of 3-D radionuclide tumor distributions. Geometrical parameters and mIBG uptake in xenografted tumors (nude mice, SK-N-SH) were obtained from micro-autoradiographies and SIMS microscopy images. The tumor could be simulated by a spheroid (500 {mu}m in radius) made up of spherical cells (9 {mu}m in radius) with a 1 {mu}m cytoplasm. Among this cell population, only 3% bound mIBG with local maximal rates of up to 16%. The radiation doses were calculated for I-131, since this radionuclide is the most widely used for labelling mIBG for a therapeutic potential. It can be applied to various types of 3-D radionuclide tumor distributions. Geometrical parameters and mIBG uptake in xenografted tumors (nude mice, SK-N-SH) were obtained from micro-autoradiographies and SIMS microscopy images.

  2. Marrow Ablative and Immunosuppressive Effects of I-131-anti-CD45 Antibody in Congenic and H2-Mismatched Murine Transplant Models

    SciTech Connect

    Matthews, D. C.; Martin, P J.; Nourigat, C.; Appelbaum, F. R.; Fisher, Darrell R. ); Bernstein, I. D.

    1998-12-01

    Targeted hematopoietic irradiation delivered by I-131-anti-CD45 antibody has been combined with conventional marrow transplant preparative regimens in an effort to decrease relapse. Before increasing the proportion of therapy delivered by radiolabeled antibody, the myeloablative and immunosuppressive effects of such low dose rate irradiation must be quantitated. We have examined the ability of I-131-anti-CD45 antibody to facilitate engraftment in Ly5-congenic and H2-mismatched murine marrow transplant models. Recipient B6-Ly5-a mice were treated with 30F11 antibody labeled with 0.1 to 1.5 mCi I-131 and/or total body irradiation (TBI), followed by T-cell-depleted marrow from Ly5-b-congenic (C57BL/6) or H2-mismatched (BALB/c) donors. Engraftment was achieved readily in the Ly5-congenic setting, with greater than 80% donor granulocytes and T cells after 0.5 mCi I-131 (estimated 17 Gy to marrow) or 8 Gy TBI. A higher TBI dose (14 Gy) was required to achieve engraftment of H2-mismatched mar row, and engraftment occurred in only 3 of 11 mice receiving 1.5 mCi I-131 delivered by anti-CD45 antibody. Engraftment of H2-mismatched marrow was achieved in 22 of 23 animals receiving 0.75 mCi I-131 delivered by anti-CD45 antibody combined with 8 Gy TBI. Thus, targeted radiation delivered via I-131-anti-CD45 antibody can enable engraftment of congenic marrow and can partially replace TBI when transplanting T-cell-depleted H2-mismatched marrow.

  3. Synthesis and biodistribution studies of (I-131,125)-iodo- and (Se-75) seleno-ergoline derivatives

    SciTech Connect

    Sadek, S.A.; Basmadjian, G.P.

    1984-01-01

    Pergolide, a new synthetic ergoline, has been shown to be a very potent dopamine agonist and to bind specifically to dopamine receptor sites in the brain. Two pergolide analogs labeled with I-125/I-131 and Se-75 were prepared. The radioactive iodoergoline derivative (Ia/Ib) was synthesized in a 100% yield by refluxing the mesyl derivative with NaI(125/131) in acetone. The (Se-75)-Selenopergolide derivative (II) was prepared in 80% radiochemical yield starting with (Se-75) selenious acid. Biodistribution studies of Ia and II in mature male rats showed relatively high uptake by the adrenals and brain (%dose/gm, range of 3 rats). Sequential images of dogs with Ib and II showed fast brain uptake with good retention for at least 20 min. Studies are in progress to evaluate the mechanism of uptake of Ib and II in rat and dog brains.

  4. Second malignancies in patients with differentiated thyroid carcinoma treated with low and medium activities of radioactive I-131

    PubMed Central

    PICIU, DOINA; PESTEAN, CLAUDIU; BARBUS, ELENA; LARG, MARIA IULIA; PICIU, ANDRA

    2016-01-01

    Background and aim This study aimed at determining whether there is a risk regarding the development of second primary malignancies after patient exposure to the low and medium radioiodine activity used during the treatment of differentiated thyroid cancers (DTC). Methods Second primary malignancies that occurred after DTC were detected in 1,990 patients treated between 1970 and 2003. The mean long-term follow-up period was 182 months. Results Radioiodine I-131was administrated at a mean dose of 63.2 mCi. There were 93 patients with at least one second primary malignancy. The relative risk of development of second malignancy in DTC patients was increased (p<0.0001) for breast, uterine and ovarian cancers compared with the general population. Conclusions The overall risk concerning the development of second primary malignancies was related to the presence of DTC, but not to exposure to the low and medium activities of radioiodine administered as adjuvant therapy. PMID:27547058

  5. Comparison of internal dosimetry factors for three classes of adult computational phantoms with emphasis on I-131 in the thyroid

    NASA Astrophysics Data System (ADS)

    Lamart, Stephanie; Bouville, Andre; Simon, Steven L.; Eckerman, Keith F.; Melo, Dunstana; Lee, Choonsik

    2011-11-01

    The S values for 11 major target organs for I-131 in the thyroid were compared for three classes of adult computational human phantoms: stylized, voxel and hybrid phantoms. In addition, we compared specific absorbed fractions (SAFs) with the thyroid as a source region over a broader photon energy range than the x- and gamma-rays of I-131. The S and SAF values were calculated for the International Commission on Radiological Protection (ICRP) reference voxel phantoms and the University of Florida (UF) hybrid phantoms by using the Monte Carlo transport method, while the S and SAF values for the Oak Ridge National Laboratory (ORNL) stylized phantoms were obtained from earlier publications. Phantoms in our calculations were for adults of both genders. The 11 target organs and tissues that were selected for the comparison of S values are brain, breast, stomach wall, small intestine wall, colon wall, heart wall, pancreas, salivary glands, thyroid, lungs and active marrow for I-131 and thyroid as a source region. The comparisons showed, in general, an underestimation of S values reported for the stylized phantoms compared to the values based on the ICRP voxel and UF hybrid phantoms and relatively good agreement between the S values obtained for the ICRP and UF phantoms. Substantial differences were observed for some organs between the three types of phantoms. For example, the small intestine wall of ICRP male phantom and heart wall of ICRP female phantom showed up to eightfold and fourfold greater S values, respectively, compared to the reported values for the ORNL phantoms. UF male and female phantoms also showed significant differences compared to the ORNL phantom, 4.0-fold greater for the small intestine wall and 3.3-fold greater for the heart wall. In our method, we directly calculated the S values without using the SAFs as commonly done. Hence, we sought to confirm the differences observed in our S values by comparing the SAFs among the phantoms with the thyroid as a

  6. COMPARISON OF INTERNAL DOSIMETRY FACTORS FOR THREE CLASSES OF ADULT COMPUTATIONAL PHANTOMS WITH EMPHASIS ON I-131 IN THE THYROID

    PubMed Central

    Lamart, Stephanie; Bouville, Andre; Simon, Steven L.; Eckerman, Keith F.; Melo, Dunstana; Lee, Choonsik

    2012-01-01

    S values for 11 major target organs for I-131 in the thyroid were compared for three classes of adult computational human phantoms: stylized, voxel and hybrid phantoms. In addition, we compared Specific Absorbed Fractions (SAFs) with the thyroid as a source region over a broader photon energy range than the x- and gamma-rays of I-131. S and SAF values were calculated for the International Commission on Radiological Protection (ICRP) reference voxel phantoms and the University of Florida (UF) hybrid phantoms by using Monte Carlo transport method, while the S and SAF values for the Oak Ridge National Laboratory (ORNL) stylized phantoms were obtained from earlier publications. Phantoms in our calculations were for adults of both genders. The 11 target organs and tissues that were selected for the comparison of S values are: brain, breast, stomach wall, small intestine wall, colon wall, heart wall, pancreas, salivary glands, thyroid, lungs, and active marrow for I-131 and thyroid as a source region. The comparisons showed, in general, an underestimation of S values reported for the stylized phantoms compared to the values based on the ICRP voxel and UF hybrid phantoms and a relatively good agreement between the S values obtained for the ICRP and UF phantoms. Substantial differences were observed for some organs between the 3 types of phantoms. For example, the small intestine wall of ICRP male phantom and heart wall of ICRP female phantom showed up to 8-fold and 4-fold greater S values, respectively, compared to the reported values for the ORNL phantoms. UF male and female phantoms also showed significant differences compared to the ORNL phantom, 4.0-fold greater for small intestine wall and 3.3-fold greater for heart wall. In our method, we directly calculated the S values without using the SAFs as commonly done. Hence, we sought to confirm the differences observed in our S values by comparing SAFs among the phantoms with the thyroid as a source region for selected

  7. Optimization of post ablative I-131 scintigraphy: Comparison of 2 day vs. 7 day post therapy study in patients with differentiated thyroid cancer (DTC)

    SciTech Connect

    Khfan, S.; Waxman, A.; Nagaraj, N.

    1994-05-01

    Whole body scintigraphy is recommended following ablative I-131 therapy to assess residual iodine-avid tissue, including metastasis in patients with DTC. Some controversy exists regarding the optimum time for performing the post-ablative study. A study performed as early as 2 days post-therapy would be desirable since patients could be scanned prior to discharge from the hospital.

  8. Quantitation of imaging with I-131-F(ab')/sub 2/ fragments of monoclonal antibody in patients

    SciTech Connect

    Moldofsky, P.J.; Hammond, N.D.; Mulhern, C.B. Jr.

    1984-01-01

    Iodine-131 labeled F(ab')/sub 2/ fragments of monoclonal antibody (IgG/sub 2a/ immunoglobulin with specificity for a cell surface antigen of colon carcinoma) have been used for quantitative imaging of tumor in 27 patients. Activity of I-131 F(ab')/sub 2/ fragments localized in tumor and in liver was quantitated using a modification of the method of Thomas SR, employing computer-acquired conjugate views (i.e. 180 opposed) to eliminate need for tumor or organ depth and tissue attenuation. The method was validated with an abdominal imaging phantom showing accuracy of +/- 10%. Quantitation indicates that activity reaches a peak in tumor at 48-72 hours and the ratio of activity in hepatic metastases to activity in liver peaks at approximately 72 hours. Mean activity in tumor was less than 0.01% of the administered dose per gram of tumor at any imaging time from 24 to 168 hours, while mean activity in surrounding liver was less than .002% of administered dose per gram of liver at any imaging time. Liver activity decreased monotonically with time, showing no peak activity. This non-invasive method of quantitating the distribution of F(ab')/sub 2/ fragments of monoclonal antibody in patients has proven accurate by comparison with phantom simulation. This type of quantitation is necessary for evaluating optimal imaging time, comparing relative utility of various antibodies and has use for therapeutic applications of monoclonal antibody fragments.

  9. Comparison of I-131 Radioimmunotherapy Tumor Dosimetry: Unit Density Sphere Model Versus Patient-Specific Monte Carlo Calculations

    PubMed Central

    Howard, David M.; Kearfott, Kimberlee J.; Wilderman, Scott J.

    2011-01-01

    Abstract High computational requirements restrict the use of Monte Carlo algorithms for dose estimation in a clinical setting, despite the fact that they are considered more accurate than traditional methods. The goal of this study was to compare mean tumor absorbed dose estimates using the unit density sphere model incorporated in OLINDA with previously reported dose estimates from Monte Carlo simulations using the dose planning method (DPMMC) particle transport algorithm. The dataset (57 tumors, 19 lymphoma patients who underwent SPECT/CT imaging during I-131 radioimmunotherapy) included tumors of varying size, shape, and contrast. OLINDA calculations were first carried out using the baseline tumor volume and residence time from SPECT/CT imaging during 6 days post-tracer and 8 days post-therapy. Next, the OLINDA calculation was split over multiple time periods and summed to get the total dose, which accounted for the changes in tumor size. Results from the second calculation were compared with results determined by coupling SPECT/CT images with DPM Monte Carlo algorithms. Results from the OLINDA calculation accounting for changes in tumor size were almost always higher (median 22%, range −1%–68%) than the results from OLINDA using the baseline tumor volume because of tumor shrinkage. There was good agreement (median −5%, range −13%–2%) between the OLINDA results and the self-dose component from Monte Carlo calculations, indicating that tumor shape effects are a minor source of error when using the sphere model. However, because the sphere model ignores cross-irradiation, the OLINDA calculation significantly underestimated (median 14%, range 2%–31%) the total tumor absorbed dose compared with Monte Carlo. These results show that when the quantity of interest is the mean tumor absorbed dose, the unit density sphere model is a practical alternative to Monte Carlo for some applications. For applications requiring higher accuracy, computer-intensive Monte

  10. Comparison of the physical characteristics of I-131 and I-123, with respect to differentiating the relative activity in the kidneys

    SciTech Connect

    Clarke, L.P.; Qadir, F.; Al-Sheikh, W.; Sfakianakis, G.; Serafini, A.N.

    1983-08-01

    Iodine-123 (159 keV, T/sub 1/2/ = 13.3 h) has been proposed for renal investigations, as opposed to I-131 (364 keV, T/sub 1/2/ = 8.06 days), because of its more practical photon energy and lower radiation dose to the patient. The cyclotron production method /sup 124/Te (p,2n) /sup 123/I for I-123 results in contamination with I-124 (T/sub 1/2/ = 4.5 days). The latter emits high-energy photons whole relative abundance increases with time after end of bombardment (EOB). This paper is an evaluation of the effects of photon penetration, scatter, and attenuation on the phantom calibration measurements required for determining relative renal uptake using I-123. Measurments using I-131 were performed for comparison. Phantom results obtained for I-123 suggest that this radionuclide will allow a better measurement of the activity in individual kidneys.

  11. Tumor dosimetry for I-131 trastuzumab therapy in a Her2+ NCI N87 xenograft mouse model using the Siemens SYMBIA E gamma camera with a pinhole collimator

    NASA Astrophysics Data System (ADS)

    Lee, Young Sub; Kim, Jin Su; Deuk Cho, Kyung; Kang, Joo Hyun; Moo Lim, Sang

    2015-07-01

    We performed imaging and therapy using I-131 trastuzumab and a pinhole collimator attached to a conventional gamma camera for human use in a mouse model. The conventional clinical gamma camera with a 2-mm radius-sized pinhole collimator was used for monitoring the animal model after administration of I-131 trastuzumab The highest and lowest radiation-received organs were osteogenic cells (0.349 mSv/MBq) and skin (0.137 mSv/MBq), respectively. The mean coefficients of variation (%CV) of the effective dose equivalent and effective dose were 0.091 and 0.093 mSv/MBq respectively. We showed the feasibility of the pinholeattached conventional gamma camera for human use for the assessment of dosimetry. Mouse dosimetry and prediction of human dosimetry could be used to provide data for the safety and efficacy of newly developed therapeutic schemes.

  12. A simple low-cost of liquid I-131 dispenser for routine radiopharmaceutical dispensing at nuclear medicine department, Institut Kanser Negara

    NASA Astrophysics Data System (ADS)

    Said, M. A.; Ashhar, Z. N.; Suhaimi, N. E. F.; Zainon, R.

    2016-01-01

    In routine radiopharmaceutical Iodine-131 (131I) dispensing, the amount of radiation dose received by the personnel depends on the distance between the personnel and the source, the time spent manipulating the source and the amount of shielding used to reduce the dose rate from the source. The novel iRAD-I131 dispenser using recycle 131I liquid lead pot will lead into low cost production, less maintenance and low dose received by the personnel that prepared the 131I. The new fabricated of low cost 131I dispenser was tested and the dose received by personnel were evaluated. The body of lead material is made from 2.5 cm lead shielded coated with epoxy paint to absorb the radiation dose up to 7.4 GBq of 131 I. The lead pot was supported with two stainless steel rod. The Optically Stimulated Luminescence (OSL) nanodot was used in this study to measure the dose rate at both extremities for every personnel who prepared the 131I. Each OSL nanodot was attached at the fingertip. Three different personnel (experienced between one to ten years above in preparing the radiopharmaceuticals) were participated in this study. The average equivalent dose at right and left hand were 122.694 ± 121.637 µSv/GBq and 77.281 ± 62.146 µSv/GBq respectively. This study found that the dose exposure received using iRAD-I131 was less up to seven times compared to the conventional method. The comparison of experimental data using iRAD-I131 and established radiopharmaceutical dispenser was also discussed. The innovation of 131I dispenser is highly recommended in a small radiopharmaceutical facility with limited budget. The novel iRAD-I131 enables implementation of higher output liquid dispensing with low radiation dose to the personnel.

  13. In Thyroidectomized Thyroid Cancer Patients, False-Positive I-131 Whole Body Scans Are Often Caused by Inflammation Rather Than Thyroid Cancer

    PubMed Central

    Garger, Yana Basis; Winfeld, Mathew; Friedman, Kent; Blum, Manfred

    2016-01-01

    Objective. To show that I-131 false-positive results on whole-body scans (WBSs) after thyroidectomy for thyroid cancer may be a result of inflammation unassociated with the cancer. Methods. We performed a retrospective image analysis of our database of thyroid cancer patients who underwent WBS from January 2008 to January 2012 to identify and stratify false positives. Results. A total of 564 patients underwent WBS during the study period; 96 patients were referred for 99 I-131 single-photon emission computed tomography (SPECT/CT) scans to better interpret cryptic findings. Among them, 73 scans were shown to be falsely positive; 40/73 or 54.7% of false-positive findings were a result of inflammation. Of the findings, 17 were in the head, 1 in the neck, 4 in the chest, 3 in the abdomen, and 14 in the pelvis; 1 had a knee abscess. Conclusions. In our series, inflammation caused the majority of false-positive WBSs. I-131 SPECT/CT is powerful in the differentiation of inflammation from thyroid cancer. By excluding metastatic disease, one can properly prognosticate outcome and avoid unnecessary, potentially harmful treatment of patients with thyroid cancer. PMID:26977418

  14. I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence.

    PubMed

    Shengguang, Yan; Ji-Eun, Choi; Lijuan, He Li

    2016-01-01

    BACKGROUND The aim of this study was to compare the success rate of various levels of I-131 activity for use in remnant ablation in low-risk differentiated thyroid cancer. MATERIAL AND METHODS We identified eligible studies in 5 electronic databases up to December 2014 and the reference lists of original studies and review articles were hand searched for additional articles on this topic. Summary relative risks with their 95% confidence intervals were calculated with a random-effects model. Heterogeneity was assessed using I2 statistics. RESULTS Fourteen randomized clinical trials met the eligibility criteria. The data suggest that the pooled successful ablation rate is 5% lower (95% CI, 1-9% lower) when using 30 mCi compared with 100 mCi (test for heterogeneity, p=0.468, I2=0.0%). In stratified analysis, ablation success rates using 30 mCi are similar to 100 mCi in Asia (SRRs=0.91; 95%CI=0.72-1.14). However, the results favor 100 mCi in Europe (SRRs=0.95; 95%CI=0.91-0.99). Ablation success rates using 30 mCi are similar to 100 mCi in patients who underwent TT/NTT (total thyroidectomy/near total thyroidectomy) (SRRs=0.96; 95%CI=0.92-1.00) and TT/STT (SRRs=0.98; 95%CI=0.73-1.31). However, the result favor 100 mCi in patients who underwent ST/HT (subtotal thyroidectomy/ hemithyroidectomy) (SRRs=0.80; 95%CI=0.65-0.99). There was no publication bias in the present meta-analysis. CONCLUSIONS High radioiodine activity is better than low activity in terms of successful ablation rate in low-risk differentiated thyroid cancer, but the advantage of high activity seems to only exist in patients who underwent hemithyroidectomy/subtotal thyroidectomy, but not lymph node involvement, preparation before ablation, and definition of successful ablation. PMID:27406262

  15. I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence

    PubMed Central

    Shengguang, Yan; Ji-Eun, Choi; Lijuan, He

    2016-01-01

    Background The aim of this study was to compare the success rate of various levels of I-131 activity for use in remnant ablation in low-risk differentiated thyroid cancer. Material/Methods We identified eligible studies in 5 electronic databases up to December 2014 and the reference lists of original studies and review articles were hand searched for additional articles on this topic. Summary relative risks with their 95% confidence intervals were calculated with a random-effects model. Heterogeneity was assessed using I2 statistics. Results Fourteen randomized clinical trials met the eligibility criteria. The data suggest that the pooled successful ablation rate is 5% lower (95% CI, 1–9% lower) when using 30 mCi compared with 100 mCi (test for heterogeneity, p=0.468, I2=0.0%). In stratified analysis, ablation success rates using 30 mCi are similar to 100 mCi in Asia (SRRs=0.91; 95%CI=0.72–1.14). However, the results favor 100 mCi in Europe (SRRs=0.95; 95%CI=0.91–0.99). Ablation success rates using 30 mCi are similar to 100 mCi in patients who underwent TT/NTT (total thyroidectomy/near total thyroidectomy) (SRRs=0.96; 95%CI=0.92–1.00) and TT/STT (SRRs=0.98; 95%CI=0.73–1.31). However, the result favor 100 mCi in patients who underwent ST/HT (subtotal thyroidectomy/ hemithyroidectomy) (SRRs=0.80; 95%CI=0.65–0.99). There was no publication bias in the present meta-analysis. Conclusions High radioiodine activity is better than low activity in terms of successful ablation rate in low-risk differentiated thyroid cancer, but the advantage of high activity seems to only exist in patients who underwent hemithyroidectomy/subtotal thyroidectomy, but not lymph node involvement, preparation before ablation, and definition of successful ablation. PMID:27406262

  16. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I(131) during Adolescence and Young Adulthood.

    PubMed

    Metallo, Melanie; Groza, Lelia; Brunaud, Laurent; Klein, Marc; Weryha, Georges; Feigerlova, Eva

    2016-01-01

    Introduction. Differentiated thyroid cancer (DTC) is rare and confers good prognosis. Long-term health related quality of life (HRQoL) and pregnancy outcomes are not well known in subjects treated during adolescence and young adulthood. Methods. Cross-sectional analysis of HRQoL and global self-esteem, using SF-36 and ISP-25 surveys, and of pregnancy outcomes in female survivors of DTC treated by total thyroidectomy and I(131) before age of 25 years. Results. Forty-five of 61 patients (74%) responded to the survey. Cumulative I(131) activity was ≤3.85 GBq in 18 subjects and >3.85 GBq in 27 subjects. Mean time from diagnosis was 7.6 ± 5.2 years for the group ≤ 3.85 GBq versus 16.9 ± 11.6 years for the group > 3.85 GBq (P < 0.05). No significant alteration in long-term HRQoL and global self-esteem was observed. Thirty pregnancies after I(131) were noted in patients from the group > 3.85 GBq and 10 in patients from the group ≤ 3.85 GBq. Frequency of miscarriages was of 17% (group > 3.85 GBq) and 10% (group ≤ 3.85 GBq) with 9 and 24 live births, respectively. No congenital malformations or first year mortality was noted. Conclusion. Long-term HRQoL, global self-esteem, and pregnancy outcomes are not affected in young female survivors of DTC. PMID:26977147

  17. Doses to the hand during the administration of radiolabeled antibodies containing Y-90, Tc-99m, I-131, and Lu-177

    SciTech Connect

    Barber, D.E.; Carsten, A.L.; Kaurin, D.G.L.; Baum, J.W.

    1997-02-01

    Exposure of the hands of medical personnel administering radiolabeled antibodies (RABs) was evaluated on the basis of (a) observing and photo-documenting administration techniques, and (b) experimental data on doses to thermoluminescent dosimeters (TLDs) on fingers of phantom hands holding syringes, and on syringes, with radionuclides in the syringes in each case. Actual exposure data for I-131 and Lu-177 were obtained in field studies. Variations in handling and administration techniques were identified. Dose rates measured using TLDs on the surface of loaded syringes were adjusted for differences in electronic stopping power, absorption coefficients, and attenuation between dosimeters and tissue to estimate dose-to-skin averaged over 1 cm{sup 2} at 7 mg cm{sup {minus}2} depth for Y-90, Tc-99m, I-131, and Lu-177. Dose rate coefficients to the skin, if in contact with the syringe wall, were 89, 1.9, 3.8, and 0.41 {micro}Sv s{sup {minus}1} per 37 MBq (1 mCi) for Y-90, Tc-99m, I-131, and Lu-177, respectively. For dose reduction, when using Y-90 the importance was clearly indicated of (a) avoiding direct contact with syringes containing RABs, if practical, and (b) using a beta-particle shield on the syringe. In using a syringe for injection, doses can best be approximated for the geometry studied by (a) wearing a finger dosimeter on the middle finger, toward the outside of the hand, on the hand operating the plunger, and (b) wearing finger dosimeters on the inner (palm) side of the finger on the hand that supports the syringe for energetic beta-particle emitters, such as Y-90 and Re-188.

  18. Long-Term Quality of Life and Pregnancy Outcomes of Differentiated Thyroid Cancer Survivors Treated by Total Thyroidectomy and I131 during Adolescence and Young Adulthood

    PubMed Central

    Metallo, Melanie; Groza, Lelia; Brunaud, Laurent; Klein, Marc; Weryha, Georges; Feigerlova, Eva

    2016-01-01

    Introduction. Differentiated thyroid cancer (DTC) is rare and confers good prognosis. Long-term health related quality of life (HRQoL) and pregnancy outcomes are not well known in subjects treated during adolescence and young adulthood. Methods. Cross-sectional analysis of HRQoL and global self-esteem, using SF-36 and ISP-25 surveys, and of pregnancy outcomes in female survivors of DTC treated by total thyroidectomy and I131 before age of 25 years. Results. Forty-five of 61 patients (74%) responded to the survey. Cumulative I131 activity was ≤3.85 GBq in 18 subjects and >3.85 GBq in 27 subjects. Mean time from diagnosis was 7.6 ± 5.2 years for the group ≤ 3.85 GBq versus 16.9 ± 11.6 years for the group > 3.85 GBq (P < 0.05). No significant alteration in long-term HRQoL and global self-esteem was observed. Thirty pregnancies after I131 were noted in patients from the group > 3.85 GBq and 10 in patients from the group ≤ 3.85 GBq. Frequency of miscarriages was of 17% (group > 3.85 GBq) and 10% (group ≤ 3.85 GBq) with 9 and 24 live births, respectively. No congenital malformations or first year mortality was noted. Conclusion. Long-term HRQoL, global self-esteem, and pregnancy outcomes are not affected in young female survivors of DTC. PMID:26977147

  19. Re-ablation I-131 activity does not predict treatment success in low- and intermediate-risk patients with differentiated thyroid carcinoma.

    PubMed

    Prpic, Marin; Kruljac, Ivan; Kust, Davor; Kirigin, Lora S; Jukic, Tomislav; Dabelic, Nina; Bolanca, Ante; Kusic, Zvonko

    2016-06-01

    The aim of this study was to evaluate the efficacy of different radioactive iodine (I-131) activities used for re-ablation, to compare various combinations of treatment activities, and to identify predictors of re-ablation failure in low- and intermediate-risk differentiated thyroid carcinoma (DTC) patients. The study included 128 consecutive low- and intermediate-risk patients with DTC with ablation failure after total thyroidectomy. Patient characteristics, T status, tumor size, lymph node involvement, postoperative remnant size on whole-body scintigraphy, serum thyroglobulin (Tg), thyroid-stimulating hormone (TSH), anti-Tg antibody (TgAb), and Tg/TSH ratio were analyzed as potential predictors of the re-ablation success. Re-ablation was successful in 113 out of 128 patients (88.3 %). Mean first I-131 activity was 2868 ± 914 MBq (77.5 ± 24.7 mCi) and mean second I-131 activity 3004 ± 699 MBq (81.2 ± 18.9 mCi). There was no association between the first, second, and cumulative activity with re-ablation treatment outcome. Treatment failure was associated with higher Tg levels prior to re-ablation (Tg2) (OR 1.16, 95 % CI 1.05-1.29, P = 0.003) and N1a status (OR 3.89, 95 % CI 1.13-13.41, P = 0.032). After excluding patients with positive-to-negative TgAb conversion, Tg2 level of 3.7 ng/mL predicted treatment failure with a sensitivity of 75.0 %, specificity of 80.5 %, and a negative predictive value of 97.1 %. Patients with positive-to-negative TgAb conversion had higher failure rates (OR 2.96, 95 % CI 0.94-9.29). Re-ablation success was high in all subgroups of patients and I-131 activity did not influence treatment outcome. Tg may serve as a good predictor of re-ablation failure. Patients with positive-to-negative TgAb conversion represent a specific group, in whom Tg level should not be used as a predictive marker of treatment outcome. PMID:26732041

  20. The standardization methods of radioactive sources (125I, 131I, 99mTc, and 18F) for calibrating nuclear medicine equipment in Indonesia

    NASA Astrophysics Data System (ADS)

    Wurdiyanto, G.; Candra, H.

    2016-03-01

    The standardization of radioactive sources (125I, 131I, 99mTc and 18F) to calibrate the nuclear medicine equipment had been carried out in PTKMR-BATAN. This is necessary because the radioactive sources used in the field of nuclear medicine has a very short half-life in other that to obtain a quality measurement results require special treatment. Besides that, the use of nuclear medicine techniques in Indonesia develop rapidly. All the radioactive sources were prepared by gravimetric methods. Standardization of 125I has been carried out by photon- photon coincidence methods, while the others have been carried out by gamma spectrometry methods. The standar sources are used to calibrate a Capintec CRC-7BT radionuclide calibrator. The results shows that calibration factor for Capintec CRC-7BT dose calibrator is 1,03; 1,02; 1,06; and 1,04 for 125I, 131I, 99mTc and 18F respectively, by about 5 to 6% of the expanded uncertainties.

  1. Estimation of 24-hour thyroid uptake of I-131 sodium iodide using a 5-minute uptake of technetium-99m pertechnetate

    SciTech Connect

    Smith, J.J.; Croft, B.Y.; Brookeman, V.A.; Teates, C.D. )

    1990-02-01

    The authors have developed a method to estimate the 24-hour sodium iodide thyroid uptake based on a 5-minute Tc-99m pertechnetate thyroid uptake using the equation: Estimated Iodide Uptake = 17.72*In(Pertechnetate Uptake) + 30.40. This estimation has a correlation coefficient of 0.90. It is based on a data pool of 44 patients who underwent I-131 and Tc-99m studies within 2 weeks of each other from 1978-1988, with established diagnoses as follows: 12 euthyroid, 6 hyperthyroid with multinodular goiters, 15 hyperthyroid with diffuse goiters, 4 with subacute thyroiditis, and 7 unknown. The population consisted of 30 women and 14 men with a mean age of 52.0 +/- 17.5 years; this sample was screened for use of thyroid hormone, propylthiouracil, and radiographic contrast. The authors believe this estimation method is of value whenever a 24-hour iodide uptake is desired, and where speed and minimizing radiation dose are factors. This method is strongly recommended for thyroid uptake evaluation before I-131 therapy.

  2. Long-Term Results of Fixed High-Dose I-131 Treatment for Toxic Nodular Goiter: Higher Euthyroidism Rates in Geriatric Patients

    PubMed Central

    Aktaş, Gül Ege; Turoğlu, Halil Turgut; Erdil, Tanju Yusuf; İnanır, Sabahat; Dede, Fuat

    2015-01-01

    Objective: Geriatric patient population has special importance due to particular challenges. In addition to the increase in incidence of toxic nodular goiter (TNG) with age, it has a high incidence in the regions of low-medium iodine intake such as in our country. The aim of this study was to evaluate the overall outcome of high fixed dose radioiodine (RAI) therapy, and investigate the particular differences in the geriatric patient population. Methods: One hundred and three TNG patients treated with high dose I-131 (370-740 MBq) were retrospectively reviewed. The baseline characteristics; age, gender, scintigraphic patterns and thyroid function tests before and after treatment, as well as follow-up, duration of antithyroid drug (ATD) medication and achievement of euthyroid or hypothyroid state were evaluated. The patient population was divided into two groups as those=>65 years and those who were younger, in order to assess the effect of age. Results: Treatment success was 90% with single dose RAI therapy. Hyperthyroidism was treated in 7±7, 2 months after RAI administration. At the end of the first year, overall hypothyroidism rate was 30% and euthyroid state was achieved in 70% of patients. Age was found to be the only statistically significant variable effecting outcome. A higher ratio of euthyroidism was achieved in the geriatric patient population. Conclusion: High fixed dose I-131 treatment should be preferred in geriatric TNG patients in order to treat persistent hyperthyroidism rapidly. The result of this study suggests that high fixed dose RAI therapy is a successful modality in treating TNG, and high rates of euthyroidism can be achieved in geriatric patients.

  3. Both F-18 FDG-avidity and Malignant Shape of Cervical Lymph Nodes on PET/CT after Total Thyroidectomy Predict Resistance to High-dose I-131 Therapy in Patients with Papillary Thyroid Cancer

    PubMed Central

    Byun, Byung Hyun; Kwon, Seong Young; Chong, Ari; Kim, Jahae; Yoo, Su Woong; Min, Jung-Joon; Song, Ho-Chun; Bom, Henry Hee-Seung

    2013-01-01

    Objective: Resistance of metastatic lymph nodes (LNs) to high dose I-131 therapy is associated with high morbidity in patients with differentiated thyroid cancer. We evaluated the role of F-18 FDG PET/CT in the prediction of resistance to high dose I-131 therapy in patients with papillary thyroid cancer. Methods: The subjects were 307 patients who underwent total or near total thyroidectomy followed by high dose (5.55-6.66 GBq) I-131 therapy. We divided the patients into three subgroups by visual assessment of regional LNs: FDG-avid LNs with a malignant shape on CT (PET/CT-positive group), FDG-avid LNs with a benign shape on CT (PET/CT-intermediate group) and no FDG-avid lesion (PET/CT-negative group). We measured the maximum SUV (SUVmax) of FDG-avid LNs in each patient. The presence or absence of focal increased uptake of I-131 was evaluated by whole body scan (WBS), and was denoted as WBS-positive group or WBS-negative group, respectively. Resistance to therapy was defined as presence of thyroglobulin (Tg) in serum (Tg ≥1.0 ng/ml) 3-6 months after I-131 therapy. Univariate and multivariate analyses were performed to determine the relationship between resistance to I-131 therapy and various clinico-pathologic variables. Results: PET/CT-positive, intermediate, and negative groups included 20 (6.5%), 44 (14.3%) and 243 (79.2%) patients, respectively. The mean SUVmax was significantly higher in the PET/CT-positive group than that of the PET/CT-intermediate group (4.6 vs. 2.7, P <0.001). Univariate analysis revealed that the PET/CT-positive group (P <0.001), T2-4 stage (P <0.001), N1b stage (P = 0.001), lower dose (5.55 GBq) of I-131 (P <0.001), and the WBS-positive group (P = 0.029) were associated with resistance to therapy. In multivariate analysis, the PET/CT-positive group, lower dose of I-131, N1b stage, and T2-4 stage remained significant with odds ratios of 10.07 (P <0.001), 3.82 (P <0.001), 3.58 (P = 0.001), and 2.53 (P = 0.009), respectively. Conclusion

  4. Diagnostic Value of I-131 NP-59 SPECT/CT Scintigraphy in Patients with Subclinical or Atypical Features of Primary Aldosteronism

    PubMed Central

    Chen, Yi-Chun; Su, Yu-Chieh; Wei, Chang-Kuo; Chiu, Jainn-Shiun; Tseng, Chih-En; Chen, Shao-Jer; Wang, Yuh-Feng

    2011-01-01

    Accumulating evidence has shown the adverse effect of long-term hyperaldosteronism on cardiovascular morbidity that is independent of blood pressure. However, the diagnosis of primary aldosteronism (PA) remains a challenge for patients who present with subtle or atypical features or have chronic kidney disease (CKD). SPECT/CT has proven valuable in the diagnosis of a number of conditions. The aim of this study was to determine the usefulness of I-131 NP-59 SPECT/CT in patients with atypical presentations of PA and in those with CKD. The records of 15 patients with PA were retrospectively analyzed. NP-59 SPECT/CT was able to identify adrenal lesion(s) in CKD patients with suspected PA. Patients using NP-59 SPECT/CT imaging, compared with those not performing this procedure, significantly featured nearly normal serum potassium levels, normal aldosterone-renin ratio, and smaller adrenal size on CT and pathological examination and tended to feature stage 1 hypertension and non-suppressed plasma renin activity. These findings show that noninvasive NP-59 SPECT/CT is a useful tool for diagnosis in patients with subclinical or atypical features of PA and those with CKD. PMID:21541242

  5. Prediction of Therapy Tumor-Absorbed Dose Estimates in I-131 Radioimmunotherapy Using Tracer Data Via a Mixed-Model Fit to Time Activity

    PubMed Central

    Koral, Kenneth F.; Avram, Anca M.; Kaminski, Mark S.; Dewaraja, Yuni K.

    2012-01-01

    Abstract Background For individualized treatment planning in radioimmunotherapy (RIT), correlations must be established between tracer-predicted and therapy-delivered absorbed doses. The focus of this work was to investigate this correlation for tumors. Methods The study analyzed 57 tumors in 19 follicular lymphoma patients treated with I-131 tositumomab and imaged with SPECT/CT multiple times after tracer and therapy administrations. Instead of the typical least-squares fit to a single tumor's measured time-activity data, estimation was accomplished via a biexponential mixed model in which the curves from multiple subjects were jointly estimated. The tumor-absorbed dose estimates were determined by patient-specific Monte Carlo calculation. Results The mixed model gave realistic tumor time-activity fits that showed the expected uptake and clearance phases even with noisy data or missing time points. Correlation between tracer and therapy tumor-residence times (r=0.98; p<0.0001) and correlation between tracer-predicted and therapy-delivered mean tumor-absorbed doses (r=0.86; p<0.0001) were very high. The predicted and delivered absorbed doses were within±25% (or within±75 cGy) for 80% of tumors. Conclusions The mixed-model approach is feasible for fitting tumor time-activity data in RIT treatment planning when individual least-squares fitting is not possible due to inadequate sampling points. The good correlation between predicted and delivered tumor doses demonstrates the potential of using a pretherapy tracer study for tumor dosimetry-based treatment planning in RIT. PMID:22947086

  6. Organ S values and effective doses for family members exposed to adult patients following I-131 treatment: A Monte Carlo simulation study

    SciTech Connect

    Han, Eun Young; Lee, Choonsik; Mcguire, Lynn; Brown, Tracy L. Y.; Bolch, Wesley E.

    2013-08-15

    Purpose: To calculate organ S values (mGy/Bq-s) and effective doses per time-integrated activity (mSv/Bq-s) for pediatric and adult family members exposed to an adult male or female patient treated with I-131 using a series of hybrid computational phantoms coupled with a Monte Carlo radiation transport technique.Methods: A series of pediatric and adult hybrid computational phantoms were employed in the study. Three different exposure scenarios were considered: (1) standing face-to-face exposures between an adult patient and pediatric or adult family phantoms at five different separation distances; (2) an adult female patient holding her newborn child, and (3) a 1-yr-old child standing on the lap of an adult female patient. For the adult patient model, two different thyroid-related diseases were considered: hyperthyroidism and differentiated thyroid cancer (DTC) with corresponding internal distributions of {sup 131}I. A general purpose Monte Carlo code, MCNPX v2.7, was used to perform the Monte Carlo radiation transport.Results: The S values show a strong dependency on age and organ location within the family phantoms at short distances. The S values and effective dose per time-integrated activity from the adult female patient phantom are relatively high at shorter distances and to younger family phantoms. At a distance of 1 m, effective doses per time-integrated activity are lower than those values based on the NRC (Nuclear Regulatory Commission) by a factor of 2 for both adult male and female patient phantoms. The S values to target organs from the hyperthyroid-patient source distribution strongly depend on the height of the exposed family phantom, so that their values rapidly decrease with decreasing height of the family phantom. Active marrow of the 10-yr-old phantom shows the highest S values among family phantoms for the DTC-patient source distribution. In the exposure scenario of mother and baby, S values and effective doses per time-integrated activity to

  7. Optimization of preparation of Rh-105 labeled (B72.3) MOAB using an amine oxime ligand and comparison of its biodistribution with I-131 labeled B72.3 MOAB

    SciTech Connect

    Venkatesh, M.; Kilcoin, T.T.; Schlemper, E.O.

    1994-05-01

    Propyleneamineoxime ligands with the four N donor atoms form stable complexes with Rh(III). The p-aminobenzylpropyleneamineoxime ligand (L) was made to act as a bifunctional chelating agent to label proteins with Rh-105. This study encompasses the optimization of formation of the Rh-105 complex of L, its purification, activation with thiophosgene, conjugation the B72.3 MOAB, purification by gel filtration, determination of its stability in physiological buffers and in human serum and comparison of the biodistribution Rh-105 labeled antibody with I-131 labeled antibody in normal healthy mice. Rh-105 was complexed with the ligand L by refluxing at pH 5-6 for 45 min. CuCl, was added to form a charged complex and the neutral activated Rh-105 complex extracted into chloroform. Following evaporation of CHC1{sub 3}, the complex was dissolved in 20 {mu}1 of DMF and reconstituted with 0.5 ml of saline. This was then reacted with the B72.3 MOAB in 0.05 M bicarbonate buffer at pH 9 and incubated for 3 h at 37{degrees}C. The complexation yields were generally 95% and the conjugation yields {approximately}60%. The Rh-105 conjugate was stable at room temperature in phosphate buffer saline (pH 7.4), bicarbonate buffer saline (pH 8.5) and human serum at 37{degrees}C for 4 days. >95% of the conjugate remained immunoreactive using mucin-bound to sepharose as the antigen. I-131 labeled antibody was prepared by using iodogen as the oxidizing agent. The two labeled antibodies were co-injected into healthy mice and the biodistribution studied at different time intervals. The biodistribution studies show good correlation between I-131 and Rh-105 labeled B72.3 MOAB preparations over 20 h demonstrating good in vivo stability. This ligand may be useful as a bifunctional chelating agent for Rh-105 labeled antibody.

  8. Allogeneic hematopoietic cell transplantation after conditioning with I-131-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.

    SciTech Connect

    Pagel, John M.; Gooley, T. A.; Rajendran, Joseph G.; Fisher, Darrell R.; Wilson, Wendy A.; Sandmaier, B. M.; Matthews, D. C.; Deeg, H. Joachim; Gopal, Ajay K.; Martin, P. J.; Storb, R.; Press, Oliver W.; Appelbaum, Frederick R.

    2009-12-24

    We conducted a study to estimate the maximum tolerated dose (MTD) of I-131-anti-CD45 antibody (Ab; BC8) that can be combined with a standard reduced-intensity conditioning regimen before allogeneic hematopoietic cell transplantation. Fifty-eight patients older than 50 years with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) were treated with (131)I-BC8 Ab and fludarabine plus 2 Gy total body irradiation. Eighty-six percent of patients had AML or MDS with greater than 5% marrow blasts at the time of transplantation. Treatment produced a complete remission in all patients, and all had 100% donor-derived CD3(+) and CD33(+) cells in the blood by day 28 after the transplantation. The MTD of I-131-BC8 Ab delivered to liver was estimated to be 24 Gy. Seven patients (12%) died of nonrelapse causes by day 100. The estimated probability of recurrent malignancy at 1 year is 40%, and the 1-year survival estimate is 41%. These results show that CD45-targeted radiotherapy can be safely combined with a reduced-intensity conditioning regimen to yield encouraging overall survival for older, high-risk patients with AML or MDS. This study was registered at www.clinicaltrials.gov as #NCT00008177.

  9. Randomised Phase I/II trial assessing the safety and efficacy of radiolabelled anti-carcinoembryonic antigen I131 KAb201 antibodies given intra-arterially or intravenously in patients with unresectable pancreatic adenocarcinoma

    PubMed Central

    2009-01-01

    Background Advanced pancreatic cancer has a poor prognosis, and the current standard of care (gemcitabine based chemotherapy) provides a small survival advantage. However the drawback is the accompanying systemic toxicity, which targeted treatments may overcome. This study aimed to evaluate the safety and tolerability of KAb201, an anti-carcinoembryonic antigen monoclonal antibody, labelled with I131 in pancreatic cancer (ISRCTN 16857581). Methods Patients with histological/cytological proven inoperable adenocarcinoma of the head of pancreas were randomised to receive KAb 201 via either the intra-arterial or intravenous delivery route. The dose limiting toxicities within each group were determined. Patients were assessed for safety and efficacy and followed up until death. Results Between February 2003 and July 2005, 25 patients were enrolled. Nineteen patients were randomised, 9 to the intravenous and 10 to the intra-arterial arms. In the intra-arterial arm, dose limiting toxicity was seen in 2/6 (33%) patients at 50 mCi whereas in the intravenous arm, dose limiting toxicity was noted in 1/6 patients at 50 mCi, but did not occur at 75 mCi (0/3). The overall response rate was 6% (1/18). Median overall survival was 5.2 months (95% confidence interval = 3.3 to 9 months), with no significant difference between the intravenous and intra-arterial arms (log rank test p = 0.79). One patient was still alive at the time of this analysis. Conclusion Dose limiting toxicity for KAb201 with I131 by the intra-arterial route was 50 mCi, while dose limiting toxicity was not reached in the intravenous arm. PMID:19243606

  10. Get the Facts About Exposure to I-131 Radiation

    MedlinePlus

    ... Resources NCI Grants Management Legal Requirements NCI Grant Policies Grants Management Contacts Training Cancer Training at NCI Funding for ... Closeout NCI Grants Management Legal Requirements NCI Grant Policies Grant Management Contacts Other Funding Find NCI funding for small ...

  11. I-131 metaiodobenzylguanidine: diagnostic use in neuroblastoma patients in relapse

    SciTech Connect

    Heyman, S.; Evans, A.E.; D'Angio, G.J.

    1988-01-01

    Metaiodobenzylguanidine (MIBG) has been used for the detection and treatment of neuroectodermal tumors, including neuroblastoma. We report our experience with /sup 131/I-MIBG used diagnostically in neuroblastoma patients with relapse. Thirty-eight studies were performed in 26 patients. There were 24 children (range 3 months-14 years) and two adults. While the study was found to be both sensitive and specific for the presence of disease, there are instances of discordance. False-negative studies were found with a markedly anaplastic tumor and with two mature ganglioneuromas. A bone lesion was negative with /sup 131/I-MIBG, but positive on bone scan. A biopsy confirmed the presence of neuroblastoma. Caution should be exercised when scanning pretreated patients, and perhaps with newly diagnosed patients as well.

  12. Treatment of advanced neuroblastoma with I-131 meta-iodobenzylguanidine

    SciTech Connect

    Garaventa, A.; Guerra, P.; Arrighini, A.; Bertolazzi, L.; Bestagno, M.; De Bernardi, B.; Lanino, E.; Villavecchia, G.P.; Claudiani, F. )

    1991-02-15

    From February 1986 to December 1988, 31 children with advanced pretreated neuroblastoma were treated with 131-I meta-Iodobenzylguanidine (131-MIBG). Thirteen children had been resistant to first-line therapy, three had suffered a local relapse, and fourteen had suffered a disseminated relapse without over bone marrow infiltration. One child was treated initially because of resistance to first-line therapy, and subsequently for a local relapse. A total of 72 courses of 131-MIBG was administered, with doses ranging from 2.8 to 6.0 GBq (median, 3.7 GBq). One child received five courses, two four courses, 13 three courses, four two courses, and 12 one course of 131-MIBG. The most common toxic effect was thrombocytopenia, with a platelet level of less than 50,000/cmm occurring after 19 of 60 evaluable courses. A leukocyte count less than 1000/cmm was seen only once. There were six major responses (two complete) lasting 4 to 9 months, and two minor responses lasting longer than 38 and 44 months. Responses were seen more commonly in children whose only lesion was a residual primary tumor and in children who had not been pretreated who experienced disseminated relapse. Further studies of the role of 131-I meta-Iodobenzylguanidine in treatment of neuroblastoma are needed.

  13. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

    ClinicalTrials.gov

    2016-07-12

    Poorly Differentiated Thyroid Gland Carcinoma; Recurrent Thyroid Gland Carcinoma; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma

  14. Feasibility study for production of I-131 radioisotope using MNSR research reactor.

    PubMed

    Elom Achoribo, A S; Akaho, Edward H K; Nyarko, Benjamin J B; Osae Shiloh, K D; Odame Duodu, Godfred; Gibrilla, Abass

    2012-01-01

    A feasibility study for (131)I production using a Low Power Research Reactor was conducted to predict the yield of (131)I by cyclic activation technique. A maximum activity of 5.1GBq was achieved through simulation using FORTRAN 90, for an irradiation of 6h. But experimentally only 4h irradiation could be done, which resulted in an activity of 4.0×10(5)Bq. The discrepancy in the activities was due to the fact that beta decays released during the process could not be considered. PMID:21900016

  15. I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma.

    PubMed

    Sato, Yuya; Kurosawa, Hidemitsu; Fukushima, Keitaro; Okuya, Mayuko; Hagisawa, Susumu; Sugita, Kenichi; Arisaka, Osamu; Inaki, Anri; Wakabayashi, Hiroshi; Nakamura, Ayane; Fukuoka, Makoto; Kayano, Daiki; Kinuya, Seigo

    2012-01-01

    Iodine-131-metaiodiobenzylguanidine (131I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. Although 131I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. Based on our findings, we suggest that 131I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible. PMID:23067429

  16. Development and evaluation of a model-based downscatter compensation method for quantitative I-131 SPECT

    PubMed Central

    Song, Na; Du, Yong; He, Bin; Frey, Eric C.

    2011-01-01

    Purpose: The radionuclide 131I has found widespread use in targeted radionuclide therapy (TRT), partly due to the fact that it emits photons that can be imaged to perform treatment planning or posttherapy dose verification as well as beta rays that are suitable for therapy. In both the treatment planning and dose verification applications, it is necessary to estimate the activity distribution in organs or tumors at several time points. In vivo estimates of the 131I activity distribution at each time point can be obtained from quantitative single-photon emission computed tomography (QSPECT) images and organ activity estimates can be obtained either from QSPECT images or quantification of planar projection data. However, in addition to the photon used for imaging, 131I decay results in emission of a number of other higher-energy photons with significant abundances. These higher-energy photons can scatter in the body, collimator, or detector and be counted in the 364 keV photopeak energy window, resulting in reduced image contrast and degraded quantitative accuracy; these photons are referred to as downscatter. The goal of this study was to develop and evaluate a model-based downscatter compensation method specifically designed for the compensation of high-energy photons emitted by 131I and detected in the imaging energy window. Methods: In the evaluation study, we used a Monte Carlo simulation (MCS) code that had previously been validated for other radionuclides. Thus, in preparation for the evaluation study, we first validated the code for 131I imaging simulation by comparison with experimental data. Next, we assessed the accuracy of the downscatter model by comparing downscatter estimates with MCS results. Finally, we combined the downscatter model with iterative reconstruction-based compensation for attenuation (A) and scatter (S) and the full (D) collimator-detector response of the 364 keV photons to form a comprehensive compensation method. We evaluated this combined method in terms of quantitative accuracy using the realistic 3D NCAT phantom and an activity distribution obtained from patient studies. We compared the accuracy of organ activity estimates in images reconstructed with and without addition of downscatter compensation from projections with and without downscatter contamination. Results: We observed that the proposed method provided substantial improvements in accuracy compared to no downscatter compensation and had accuracies comparable to reconstructions from projections without downscatter contamination. Conclusions: The results demonstrate that the proposed model-based downscatter compensation method is effective and may have a role in quantitative 131I imaging. PMID:21815394

  17. Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

    ClinicalTrials.gov

    2015-11-04

    Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer

  18. [Reconstruction of I-131 in milk and exposure doses to the thyroid gland of cattle after the Chernobyl AES].

    PubMed

    Spirin, E V

    2002-01-01

    Suggestions are made concerning the restoration of 131I content in cow milk of six districts in the Gomel region based on radiometric measurements of the overall activity of milk samples in the iodine period of the Chernobyl NPP accident, reconstruction of doses to thyroid of cattle and calculation of dose distribution among the live-stock by separation the function of activity changes in milk samples in time into the basic components formed by the contribution of 131I, 134Cs and 137Cs. The best approximation to the description of the function of milk activity variations was found to be achieved by the representation of forage activity changes as a sum of exponents with the half-life periods of 5 and 30 day with a partial contribution of 0.8 and 0.2. The calculations showed, that the average absorbed doses to the thyroid varied between 10 and 40 Gy. PMID:12449827

  19. Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

    ClinicalTrials.gov

    2014-08-20

    Recurrent Thyroid Cancer; Stage IVA Follicular Thyroid Cancer; Stage IVA Papillary Thyroid Cancer; Stage IVB Follicular Thyroid Cancer; Stage IVB Papillary Thyroid Cancer; Stage IVC Follicular Thyroid Cancer; Stage IVC Papillary Thyroid Cancer

  20. Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

    ClinicalTrials.gov

    2015-08-04

    Lymphoid Leukemia in Remission; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma

  1. Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

    ClinicalTrials.gov

    2016-06-10

    Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Hodgkin Lymphoma; Refractory T-Cell Non-Hodgkin Lymphoma

  2. Unusual case of hepatic metastasis in follicular thyroid carcinoma detected using I-131 whole body scintigraphy and single-photon emission computerized tomography/computerized tomography

    PubMed Central

    Kamaleshwaran, Koramadai Karuppusamy; Natarajan, Sudhakar; Mohanan, Vyshak; Shinto, Ajit Sugunan

    2015-01-01

    Papillary and follicular thyroid carcinomas, together known as differentiated thyroid carcinomas (DTC), are among the most curable of cancers. Distant metastases are rare events at the onset of DTC. Among these presentations, metastasis to the liver is even more unusual. Only 11 cases of DTC with liver metastasis were previously reported in the literature. We present a 55-year-old male on Iodine-131 whole body scintigraphy showed intense uptake in thyroid bed, metastasis in both lungs and right lobe of the liver. Radioiodine concentration in liver metastases made him amenable to high-dose radioiodine therapy patient. PMID:26430327

  3. Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    ClinicalTrials.gov

    2014-08-04

    Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia

  4. SU-E-CAMPUS-I-03: Dosimetric Comparison of the Hypoxia Agent Iodoazomycin Arabinoside (IAZA) Labeled with the Radioisotopes I-123, I-131 and I-124

    SciTech Connect

    Jans, H-S; Stypinski, D; Mcquarrie, S; Kumar, P; Mercer, J; McEwan, S; Wiebe, L

    2014-06-15

    Purpose: To compare the radiation dose to normal organs from the radio-iodinated, hypoxia-binding radiosensitizer iodoazomycin arabinoside (IAZA) for three different isotopes of iodine. Methods: Dosimety studies with normal volunteers had been carried out with [{sup 123}I]IAZA, a drug binding selectively to hypoxic sites. Two other isotopes of iodine, {sup 131}I and {sup 124}I, offer the opportunity to use IAZA as an agent for radioisotope therapy and as an imaging tracer for Positron Emission Tomography. Radioisotope dosimetry for {sup 131}I and {sup 124}I was performed by first deriving from the [{sup 123}I]IAZA studies biological uptake and excretion data. The cumulated activities for {sup 131}I or {sup 124}I where obtained by including their half-lives when integrating the biological data and then extrapolating to infinite time points considering a) physical decay only or b) physical and biological excretion. Doses were calculated using the Medical Internal Radiation Dose (MIRD) schema (OLINDA1.1 code, Vanderbilt 2007). Results: Compared to {sup 123}I, organ doses were elevated on average by a factor 6 and 9 for {sup 131}I and {sup 124}I, respectively, if both physical decay and biological excretion were modeled. If only physical decay is considered, doses increase by a factor 18 ({sup 131}I) and 19 ({sup 124}I). Highest organ doses were observed in intestinal walls, urinary bladder and thyroid. Effective doses increased by a factor 11 and 14 for {sup 131}I and {sup 124}I, respectively, if biological and physical decay are present. Purely physical decay yields a 23-fold increase over {sup 123}I for both, {sup 131}I and {sup 124}I. Conclusion: Owing to the significant dose increase, caused by their longer half life and the approximately 10 times larger electronic dose deposited in tissue per nuclear decay, normal tissue doses of IAZA labeled with {sup 131}I and {sup 124}I need to be carefully considered when designing imaging and therapy protocols for clinical trials. Effective blocking of iodine uptake in the thyroid is essential. Alberta Innovates - Health Solutions (AIHS) and Canadian Institutes of Health Research (CIHR)

  5. Improved targeting of 5-[125I/131I]iodo-2‧-deoxyuridine to rat hepatoma by using lipiodol emulsion

    NASA Astrophysics Data System (ADS)

    Yu, Hung-Man; Yeh, Hsin-Pei; Chang, Tien-Kui; Huang, Kuang-Liang; Chuang, Kuo-Tang; Liu, Ren-Shen; Wang, Shyh-Jen; Hwang, Jeng-Jong; Chi, Kwan-Hwa; Chen, Fu-Du; Lin, Wuu-Jyh; Chen, Chin-Hsiung; Wang, Hsin-Ell

    2006-12-01

    This study aims to assess whether emulsion of [ 125/131I]IUdR and lipiodol (IUdR/LP) can improve delivery of IUdR into hepatoma. MethodsIn vitro release profile of IUdR from IUdR/LP to serum was performed. IUdR/LP was injected into N1-S1 hepatoma-bearing SD rat via hepatic artery and IUdR/normal saline (IUdR/NS) was used for comparison. Biodistribution, autoradiography, imaging and tumor DNA incorporation assay were performed. The radioactive metabolites in plasma and urine were analyzed. Radiation doses to tumor and organs were estimated. ResultsIUdR released from lipiodol into serum was fast. There were longer retention, more DNA incorporation and higher radiation dose of IUdR in the tumor by using IUdR/LP. IUdR/LP deposited deep in the hepatomas. Only free iodide was found in the plasma and urine after injection of IUdR/LP. ConclusionsHepatic artery injection of IUdR/LP emulsion could definitely enhance the tumor cell uptake and incorporation to DNA of *IUdR, prolong the tumor retention time and increase radiation dose to tumor. IUdR/LP may be an effective therapeutic agent for the treatment of hepatic tumors.

  6. Sunitinib in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

    ClinicalTrials.gov

    2016-06-17

    Recurrent Thyroid Gland Carcinoma; Stage III Thyroid Gland Follicular Carcinoma; Stage III Thyroid Gland Medullary Carcinoma; Stage IVA Thyroid Gland Follicular Carcinoma; Stage IVA Thyroid Gland Medullary Carcinoma; Stage IVA Thyroid Gland Papillary Carcinoma; Stage IVB Thyroid Gland Follicular Carcinoma; Stage IVB Thyroid Gland Medullary Carcinoma; Stage IVB Thyroid Gland Papillary Carcinoma; Stage IVC Thyroid Gland Follicular Carcinoma; Stage IVC Thyroid Gland Medullary Carcinoma; Stage IVC Thyroid Gland Papillary Carcinoma; Thyroid Gland Oncocytic Follicular Carcinoma

  7. Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or High-Risk Myelodysplastic Syndrome

    ClinicalTrials.gov

    2016-07-18

    Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts; Refractory Anemia With Ring Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts

  8. Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

    ClinicalTrials.gov

    2015-11-16

    Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes

  9. Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma

    ClinicalTrials.gov

    2014-08-04

    Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia

  10. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.

    PubMed

    2003-01-01

    Iodine-131 tositumomab [B1, Bexxar , iodine-131 anti-B1 antibody] is a murine antibody conjugated to iodine 131 that recognises and binds to the B1 (CD20) antigen which is found specifically on B lymphocytes. Iodine-131 tositumomab has a dual mechanism of action. It is capable of initiating a host immune response to those B cells to which it is attached, and it also triggers apoptosis in a significant proportion of the cells to which it binds. The product was first discovered by Coulter Corporation, Miami, in collaboration with the Dana-Farber Cancer Institute and the University of Michigan. The spin-off company Coulter Pharmaceutical, upon its formation, obtained worldwide rights to iodine-131 tositumomab. (Coulter Corporation was acquired subsequently by Beckman Instruments in October 1997. The union of the two companies produced Beckman Coulter.) In December 2000, Coulter Pharmaceutical was acquired by, and merged into, Corixa Corporation.Iodine-131 tositumomab is available for licencing in Japan. Corixa Corporation and GlaxoSmithKline signed an agreement to jointly develop and commercialise iodine-131 tositumomab. The total agreement has a potential value of up to $US132 million, plus shared profits and royalties. The two companies will jointly market the antibody in the US following regulatory approval. Corixa Corporation has announced it expects iodine-131 tositumomab to be approved in the US for non-Hodgkin's lymphoma (NHL). Under the terms of the original agreement, GlaxoSmithKline will receive exclusive marketing rights outside the US, excluding Japan. However, an amended agreement between the two companies will allow Corixa Corporation to also market the product outside the US. In February 2003, the European Commission granted iodine-131 tositumomab orphan-drug designation. Corixa Corporation and GlaxoSmithKline also intend to jointly investigate the use of the product in other indications. GlaxoSmithKline may also receive access to second generation anti-CD20 compounds under its agreement with Corixa Corporation. In May 2003, Corixa Corporation entered into an agreement that will see GlaxoSmithKline market Bexxar in Canada. Under the terms of the agreement, Corixa Corporation will manufacture and supply the product to GlaxoSmithKline, who will register, market and sell it in Canada. In October 2001, Amersham PLC, a supplier of medical equipment, announced that its Amersham Health unit had signed a marketing agreement with Corixa Corporation. The agreement allows Amersham Health to market iodine-131 tositumomab in Europe. Corixa Corporation formed agreements with Boehringer Ingelheim Pharma KG and Lonza Biologics to produce the B1 antibody and radiolabelling of the antibody has been contracted out to MDS Nordion.Iodine-131 tositumomab has received orphan drug and fast track designation for the treatment of NHL. Corixa Corporation submitted a Biologics Licence Application (BLA) to the US FDA in 1999, seeking permission to market Bexxar in the US for the treatment of relapsed or refractory, low grade or transformed low grade B-cell NHL. Following a priority review, the US FDA requested that Corixa Corporation reformat certain sections and perform additional analyses of existing data in its BLA. Corixa Corporation and GlaxoSmithKline resubmitted their BLA to the US FDA in September 2000. The BLA was subsequently accepted by the US FDA in November 2000. However, in March 2001, the US FDA requested additional information in its complete review letter to Corixa Corporation and marketing partner GlaxoSmithKline. The two companies submitted data pertaining to the chemistry, manufacturing and controls section of the BLA, and to the majority of the questions regarding the clinical section of the BLA in August 2001. Corixa Corporation and GlaxoSmithKline submitted the remainder of the response to the US FDA in September 2001, following an independent review of clinical trial data. In March 2002, Corixa Corporation received another complete review letter from the US FDA, which stated that additional clinical trials would have to be conducted in order to provide adequate evidence of the safety and clinical benefit of Bexxa. The US FDA also denied Corixa Corporation's request for accelerated approval, stating that the data provided was inadequate to show that Bexxar filled an unmet medical need. Corixa Corporation has met formally with the US FDA but the two were unable to resolve their differences. Corixa Corporation will now file a formal request for dispute resolution under the Food and Drug Administration Modernisation Act. Corixa Corporation also requested a presentation of Bexxa data to the US FDA's scientific advisors. In June 2002, the US FDA granted the company's appeal for additional regulatory review. In December 2002, the US FDA's Oncologic Drugs Advisory Committee agreed that Bexxar has clinical benefit for patients with NHL. In May 2003, Corixa Corporation and GlaxoSmithKline announced that they had fulfilled many of the steps required for US FDA approval, however the US FDA has extended its review of the application for another 3 months. This extension will allow for further refinement of post marketing commitments and package insert language, and to ensure they are consistent with an updated safety database requested by the US FDA and submitted by Corixa Corporation in early April. GlaxoSmithKline was waiting for the outcome of the situation before deciding on marketing plans for Bexxar. Corixa Corporation and GlaxoSmithKline will conduct a head-to-head study of Bexxar and Idec's Zevalin, planned for mid-2003. The trial will likely be one of three phase IV studies that the US FDA requires for accelerated approval of Bexxar. Corixa Corporation initiated its Expanded Access Program for Bexxar in response to requests from physicians and patients for continued access to Bexxar during the period prior to potential US FDA marketing approval.A phase II multicentre trial of Bexxar in combination with CHOP chemotherapy is underway in the US as first-line therapy in patients with intermediate-grade NHL. Corixa Corporation has initiated a phase II trial of iodine-131 tositumomab in combination with cyclophosphamide, vincristine and prednisone for the treatment of previously untreated low-grade NHL. The trial was initiated while the company was preparing its BLA for Bexxar for use as a single agent for relapsed or refractory NHL. Corixa Corporation intends to pursue additional trials to expand the potential use of iodine-131 tositumomab to other indications, including chronic lymphocytic leukaemia. The agent is also in a clinical trial for preparation in autologous bone marrow transplant patients. The trial is designed to test the combination of iodine-131 tositumomab and chemotherapy. The trial began in 1995 and has so far enrolled 40 patients. In addition, a phase II dose-escalation trial has begun at the University of Nebraska for the combined use of iodine-131 tositumomab and chemotherapy as preparation for autologous bone marrow transplant. Corixa Corporation has received an issued US patent covering methods for administering and dosing radioimmunotherapy for the treatment of B-cell lymphomas. The patent covers iodine-131 tositumomab and other anti-CD20 antibodies used to aid in selective tumour targeting. Corixa Corporation has exclusive rights to the patent.A February 2000 media release from GlaxoSmithKline and Corixa Corporation stated that they had been issued a composition patent relating to radiolabelled monoclonal antibodies (including Bexxar) for the treatment of B-cell lymphomas. On 11 September 2001, IDEC announced that it had filed two separate lawsuits. The first lawsuit is against Corixa Corporation and the University of Michigan on six patents pertaining to products and processes related to radioimmunotherapy. They seek a declaration that Zevalin does not infringe Corixa Corporation's issued US patents. The second lawsuit involves two patents relating to cell culture media, and is against GlaxoSmithKline. IDEC's lawsuit in this case, seeks a declaration that its manufacture of Zevalin does not infringe GlaxoSmithKline's issued US patents. Corixa Corporation and GlaxoSmithKline have also filed a complaint for patent infringement against IDEC. These actions however, should have no effect on the regulatory process that Zevalin is completing, or prevent IDEC from launching the drug before iodine-131 tositumomab.A year earlier, in March 2001, the Financial Times reported that Bexxar could reach peak sales of $US120 million. In 1998, Coulter Pharmaceutical received a licencee fee payment of $US34 million from SmithKline Beecham (now GSK) in the fourth quarter of the year, as part of the joint development and commercialisation agreement for Bexxar. PMID:12899647

  11. Individual thyroid dose estimation for a case-control study of Chernobyl-related thyroid cancer among children of Belarus-part I: 131I, short-lived radioiodines (132I, 133I, 135I), and short-lived radiotelluriums (131MTe and 132Te).

    PubMed

    Gavrilin, Yuri; Khrouch, Valeri; Shinkarev, Sergey; Drozdovitch, Vladimir; Minenko, Victor; Shemiakina, Elena; Ulanovsky, Alexander; Bouville, André; Anspaugh, Lynn; Voillequé, Paul; Luckyanov, Nickolas

    2004-06-01

    Large amounts of radioiodines were released into the atmosphere during the accident at the Chernobyl nuclear power plant on 26 April 1986. In order to investigate whether the thyroid cancers observed among children in Belarus could have been caused by radiation exposures from the Chernobyl accident, a team of Belarusian, Russian, and American scientists conducted a case-control study to compare cases and controls according to estimated thyroid dose. The primary purpose of this paper is to present detailed information on the estimated thyroid doses, due to intakes of 131I, that were used in the case-control study. The range of the 131I thyroid doses among the 107 cases and the 214 controls was found to extend from 0.00002 to 4.3 Gy, with medians of approximately 0.2 Gy for the cases and 0.07 Gy for the controls. In addition, the thyroid doses resulting from the intakes of short-lived radioiodines (132I, 133I, and 135I) and radiotelluriums (131mTe and 132Te) were estimated and compared to the doses from 131I. The ratios of the estimated thyroid doses from the short-lived radionuclides and from I for the cases and the controls range from 0.003 to 0.1, with median values of approximately 0.02 for both cases and controls. PMID:15167120

  12. Iodine-131 labeled anti-CEA antibodies uptake by Huerthle cell carcinoma

    SciTech Connect

    Abdel-Nabi, H.; Hinkle, G.H.; Falko, J.M.; Kelly, D.; Olsen, J.O.; Martin, E.W. Jr.

    1985-10-01

    Localization of Huerthle cell cancer deposits in the lung with I-131 labeled anti-carcinoembryonic antigen (CEA) monoclonal antibody is described. This technique may prove useful if conventional scanning with I-131 sodium iodide for distant metastases is negative.

  13. Follow-up study using iodine-131 metaiodobenzylguanidine imaging in a patient with neuroblastoma

    SciTech Connect

    Ikekubo, K.; Habuchi, Y.; Jeong, S.; Yamaguchi, H.; Saiki, Y.; Ito, H.; Hino, M.; Higa, T.

    1986-11-01

    A new radiopharmaceutical, I-131 metaiodobenzylguanidine (I-131 MIBG) was used to determine the location and to follow-up tumors in a 13-month-old girl with neuroblastoma. I-131 MIBG imaging revealed both a primary abdominal tumor and a distant metastatic orbital tumor. Follow-up study with I-131 MIBG imaging demonstrated significant resolution of tumors after external radiotherapy and chemotherapy. I-131 MIBG imaging is a simple, safe, and specific method of determining the location of tumors and also is clinically useful in the evaluation and management of patients with neuroblastoma.

  14. Salivary gland accumulation of meta-(/sup 131/I)iodobenzylguanidine

    SciTech Connect

    Nakajo, M.; Shapiro, B.; Sisson, J.C.; Swanson, D.P.; Beierwaltes, W.H.

    1984-01-01

    Intense uptake of m-(/sup 131/I)iodobenzylguanidine (I-131 MIBG) has been observed in the salivary glands of patients undergoing scintigraphy for the location of suspected pheochromocytomas. This uptake of radioativity was not due to free I-131 derived from the I-131 MIBG but rather to uptake of I-131 MIBG by sympathetic neuronal elements in the salivary glands. In keeping with this, administration of tricycle antidepressants reversibly blocked salivary uptake of I-131 MIBG. Furthermore, I-131 MIBG uptake was markedly diminished by the ipsilateral salivary glands in a patient with Horner's syndrome, and was bilaterally diminished in a patient with severe idiopathic sympathetic autonomic neuropathy. The salivary gland uptake of I-131 MIBG may provide a means for the study of sympathetic innervation of these organs, and thus for the study of generalized disorders of autonomic innervation.

  15. Radioiodine therapy of hyperthyroidism precludes thallium-201 myocardial scintigraphy

    SciTech Connect

    Orzel, J.A.; Kruyer, W.B.; Borchert, R.D.

    1987-02-01

    The authors attempted to perform Tl-201 myocardial perfusion scintigraphy in a 42-year-old man 23 and 35 days after he received 9.8 mCi of oral I-131 for documented Graves' disease. Interference from primary and scattered photons from residual thyroid I-131 made Tl-201 myocardial scintigraphy technically impossible. A series of phantom and patient studies using I-131 and Tl-201 were performed, yielding guidelines for planning Tl-201 myocardial scintigraphy following radioiodine therapy.

  16. Diagnosis and treatment of neuroblastoma using metaiodobenzylguanidine

    SciTech Connect

    Edeling, C.J.; Frederiksen, P.B.; Kamper, J.; Jeppesen, P.

    1987-08-01

    Neuroblastoma is a lethal and not uncommon tumor in childhood. Early detection and display of the spread of the tumor is highly desirable for proper treatment. Nine children suspected of having neuroblastomas were examined by I-131 metaiodobenzylguanidine (I-131 MIBG) imaging. In two recent studies I-123 metaiodobenzylguanidine (I-123 MIBG) was used. A primary adrenal neuroblastoma was correctly identified in three cases. In two patients additional tumor sites were found. In one patient, who was in complete remission, no pathologic accumulation of I-131 MIBG was found. I-131 MIBG images were also normal in four patients with other types of neoplastic diseases. A boy with multiple metastases was treated with 100 mCi of I-131 MIBG. He developed transient gastrointestinal illness and there was no regression of the tumor deposits. In one girl with a large adrenal neuroblastoma high uptake of I-131 MIBG was observed. She received two therapy doses of I-131 MIBG (35 mCi and 75 mCi) with curative intention giving a total absorbed dose in the tumor of approximately 76 Gy. In spite of high retention of radioactivity in the tumor, regression did not occur, but her general condition was improved. In the present study, images of superior quality were obtained with I-123 MIBG imaging. It is concluded that imaging using I-131 MIBG or I-123 MIBG should be used in both the initial evaluation and the follow-up of children with neuroblastoma.

  17. Short-Term Side Effects after Radioiodine Treatment in Patients with Differentiated Thyroid Cancer

    PubMed Central

    Lu, Liyan; Li, Wenbin

    2016-01-01

    Objectives. I-131 therapy for differentiated thyroid cancer (DTC) could induce adverse effects. The purpose of this study was to report and analyze symptoms after I-131 treatment within the hospitalization and present relevant medical intervention. Methods. I-131 doses ranging from 3.7 to 9.25 GBq (100–250 mCi) were administrated for thyroid remnant ablation or treating DTC metastases. 117 patients with DTC for I-131 therapy were monitored through the video and intercommunicating with standardized questionnaire at different time points after I-131 oral administration. Adverse effects were recorded and relevant clinical factors were analyzed. Results. Among all the 117 patients, 55 cases complained of neck's pain or swelling and 79 cases presented with gastrointestinal symptoms. Pain or swelling of salivary gland occurred in 15 patients, headache and vertigo in 10, insomnia in 9, vocal cord paralysis in 6, fatigue or general malaise in 6, and foreign body sensation in 5. Body numbness and urinary symptoms were observed in only 1 case, respectively. Those side effects were related with sex, pre-I-131 treatment TSH levels, frequency of I-131 therapy, and lymph node metastases. Conclusions. Short-term side effects after I-131 therapy for DTC patients varied individually; severe symptoms were not uncommon but generally did not need emergent medical intervention. PMID:26989683

  18. Diagnosis and therapy of neuroblastoma and other neural crest tumors using Iodine-131-meta-iodobenzylguanidine

    SciTech Connect

    Hoefnagel, C.A.; Delprat, C.C.; De Kraker, J.; Marcuse, H.R.; Voute, P.A.

    1985-05-01

    Like pheochromocytoma, neuroblastoma is capable of synthesis and storage of catecholamines. Therefore the authors evaluated the yield of I-131-MIBG total body scintigraphy in the detection of this tumor and applied I-131-MIBG therapeutically. Total body scintigraphy was performed 24, 48 and 96 hrs after administration of 18.5 or 37 MBq I-131-MIBG. 23 patients with neuroblastoma were examined (47 studies). I-131-MIBG-scintigraphy confirmed complete remission in 7 patients and correctly detected residual/recurrent abdominal tumormasses in 5 patients and metastases in 14 patients. In 1 adult patient the scintigram was false negative. 3 children with metastatic neuroblastoma received multiple therapy doses of I-131-MIBG (1.5-3.9 GBq). Reduction of tumor size and good palliation was achieved in 2 patients with progressive disease. Intense accumulation of I-131-MIBG was observed in 1 patient with inoperable medullary thyroid carcinoma and in another with metastatic pheochromocytoma. Both received I-131-MIBG-therapy (3.7-7.9 GBq), resulting in a reduction of the tumor mass. It is concluded that I-131-MIBG, is a useful agent for diagnosis, follow up and therapy of neuroblastoma. It may occasionally be of use in therapy of other neural crest tumors and should therefore be considered when other treatment modalities are ineffective.

  19. Iodine-131 uptake in a patient with thyroid cancer and rheumatoid arthritis during acupuncture treatment

    SciTech Connect

    Otsuka, N.; Fukunaga, M.; Morita, K.; Ono, S.; Nagai, K.; Katagiri, M.; Harada, T.; Morita, R. )

    1990-01-01

    A patient with thyroid carcinoma had abnormal accumulation of I-131 in the areas of both feet and hands on whole body scan. The sites of abnormal accumulation of I-131 were similar to those on bone scintigraphy. The radiographic examination of the lesions showed characteristic findings of rheumatoid arthritis, and the presence of small gold needles for acupuncture treatment was demonstrated. There were no findings of bone metastases. Although the mechanism of accumulation of I-131 in this patient is unknown, interpreters of I-131 whole body scintigraphs should keep this case in mind when acupuncture treatment has been done. The authors can only speculate on a common blood flow mechanism for enhanced HMDP and I-131 uptake in this arthritic patient who had been treated by acupuncture.

  20. Plant iodine-131 uptake in relation to root concentration as measured in minirhizotron by video camera:

    SciTech Connect

    Moss, K.J.

    1990-09-01

    Glass viewing tubes (minirhizotrons) were placed in the soil beneath native perennial bunchgrass (Agropyron spicatum). The tubes provided access for observing and quantifying plant roots with a miniature video camera and soil moisture estimates by neutron hydroprobe. The radiotracer I-131 was delivered to the root zone at three depths with differing root concentrations. The plant was subsequently sampled and analyzed for I-131. Plant uptake was greater when I-131 was applied at soil depths with higher root concentrations. When I-131 was applied at soil depths with lower root concentrations, plant uptake was less. However, the relationship between root concentration and plant uptake was not a direct one. When I-131 was delivered to deeper soil depths with low root concentrations, the quantity of roots there appeared to be less effective in uptake than the same quantity of roots at shallow soil depths with high root concentration. 29 refs., 6 figs., 11 tabs.

  1. Radioiodine uptake following iodine-131 therapy for Graves' disease: an early indicator of need for retreatment

    SciTech Connect

    Carpentier, W.R.; Gilliland, P.F.; Piziak, V.K.; Petty, F.C.; McConnell, B.G.; Verdonk, C.A.; Ibarra, J.D.; Thompson, J.Q.

    1989-01-01

    Forty-five patients with Graves' disease were studied prospectively to determine if 24-hour I-131 uptake measurements alone or in combination with serum thyroid hormone levels at six weeks would determine the necessity for retreatment of the thyrotoxicosis. All patients with an I-131 uptake greater than 30% at six weeks required retreatment. No patient with an I-131 uptake of less than 15% required retreatment. Patients with uptakes between 15% and 30% were variable. An elevated free thyroxin index at 6 weeks is not helpful to determine which patients will remain thyrotoxic. Patients with a free thyroxin index within the normal range at six weeks can be predicted to be euthyroid by 12 weeks if their 24-hour I-131 uptake is between 15% and 30% and to be hypothyroid if their 24-hour I-131 uptake is below 15%. There was no difference between patient groups treated initially with antithyroid medication and those who were not.

  2. Radioiodine-induced hypothyroidism in Graves' disease: factors associated with the increasing incidence

    SciTech Connect

    Cunnien, A.J.; Hy, I.D.; Gorman, C.A.; Offord, K.P.; Scanlon, P.W.

    1982-11-01

    A retrospective analysis was done of the records of 454 patients who received their first I-131 treatment for Graves' disease during six periods covering 1951 to 1978. In the earliest group, 3% of patients were hypothyroid 3 mo after I-131 use, and 40% were hypothyroid at 1 yr. In the most recent group, 36% of patients were hypothyroid at 3 mo and 91% were myxedematous at 1 yr. Although no obvious trends were noted, whether in the number of patients pretreated with thionamide drugs, in the mean 24-hr I-131 uptake, or in the calculated dose of I-131 (..mu..Ci/estimated gram of thyroid tissue) during the years of the study, the initial mean dose of I-131 administered increased from 8.1 mCi in the earliest group to 13.8 mCi in the latest group. Concurrently, estimates of gland size increased from a mean of 26 g in the first group to 43 g in the last. If, in patients with Graves' disease, the thyroid gland size did not truly increase during the years of the study, the increasing occurrence of early hypothyroidism seen after I-131 use may reflect the conscious or unconscious decision to use larger doses of I-131 calculated on the basis of inflated estimates of thyroid gland weight.

  3. Reduction in relapse rate of radioiodine therapy in patients of toxic multinodular goiter: A quality improvement project

    PubMed Central

    Mitra, Sujata; Muthu, Sonai G

    2012-01-01

    Introduction: Radioiodine (I-131) therapy is the definitive treatment of toxic multinodular goiter (TMNG). Treatment failure may result in relapse after I-131 therapy. The present study was undertaken to reduce treatment failure rate of I-131 therapy in TMNG patients. Materials and Methods: Multiple causes may have lead to treatment failure of I-131 in TMNG patients making it difficult to establish a direct cause–effect relationship and take corrective action. Therefore, the JURAN methodology of quality improvement was applied. The treatment failure rate in 80 TMNG patients treated with I-131 in the period 2003–06 was 29%. The root cause analysis identified delay in decision to radioablate and concomitant antithyroid drugs (ATD) with I-131 therapy as factors leading to relapse. In 2007, a change in management was introduced with decision to radioablate all TMNG patients not remitting at 1 year of ATD and to withdraw ATD for 2 weeks prior to I-131 therapy. A total of 63 patients of TMNG followed the changed protocol between 2007 and 2009. Further analysis showed that one of the factors identified in the initial brainstorming (high iodide pool in the patient) had not been addressed in the protocol currently followed. The protocol was modified to include patient preparation and implemented after standardization. Results: The post-I-131 relapse rate in patients treated after implementation of the new protocol from 2007 to 2009 was 18% which further reduced to 16% in 2011 after modification of the protocol. Conclusion: The failure rate of I-131 therapy in TMNG reduced from 29% to 16% through standardization of the treatment procedure achieved by the use of Juran Methodology that helped to identify process-related defects. PMID:23599590

  4. Laser-induced fluorescence method for on-line molecular isotopologues of iodine-127, iodine-129, iodine-131 detected in gaseous media using a tunable diode laser

    NASA Astrophysics Data System (ADS)

    Kireev, S. V.; Shnyrev, S. L.; Sobolevsky, I. V.

    2016-06-01

    The letter reports on the development of a laser-induced fluorescence method for on-line selective measurement of 127I2, 129I2, 131I2, 129I127I, 127I131I, 129I131I isotopologue concentrations in gaseous media. The method is based on the excitation of molecular iodine isotopologues’ fluorescence by tunable diode laser (632–637 nm) radiation at three or four wavelengths corresponding to the 127I2, 131I2, 129I127I, 129I131I absorption line centers. Boundary relations for concentrations of simultaneously measured iodine isotopologues is about 10‑5–10‑6.

  5. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism

    SciTech Connect

    Holm, L.E.; Lundell, G.; Israelsson, A.; Dahlqvist, I.

    1982-02-01

    We have studied the long-term incidence of hypothyroidism in 4,473 formerly hyperthyroid patients given I-131 therapy between 1951 and 1975. The mean age at the first I-131 treatment was 56 yr. Six percent developed hypothyroidism within one year of therapy, and 72% within 26 yr. Prior antithyroid medication did not affect the incidence of hypothyroidism. Patients cured with one dose of I-131 had a lower cumulative long-term incidence of hypothyroidism than those requiring more than one dose.

  6. Portrayal of pheochromocytoma and normal human adrenal medulla by m-(123I)iodobenzylguanidine: concise communication

    SciTech Connect

    Lynn, M.D.; Shapiro, B.; Sisson, J.C.; Swanson, D.P.; Mangner, T.J.; Wieland, D.M.; Meyers, L.J.; Glowniak, J.V.; Beierwaltes, W.H.

    1984-04-01

    The radiopharmaceutical m-(131I)iodobenzylguanidine (I-131 MIBG), which is readily taken up by adrenergic vesicles, produces scintigraphic images of pheochromocytomas in man but rarely visualizes normal adrenal glands. Iodine-123 has many potential advantages over I-131 as a radiolabel for MIBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency. In this study, diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma. Images of superior quality were obtained with I-123 MIBG, and lesions not visualized using I-131 MIBG were portrayed. In addition, the normal adrenal medullae were visualized on the I-123 MIBG scintigrams in six out of eight patients.

  7. Reverse discordant behavior and progressive filling of a cold nodule on Tc-99m pertechnetate thyroid imaging

    SciTech Connect

    Huot, D.; Ton-That, Q.T.; Le Bel, L.; Carrier, L.; Picard, M. )

    1990-01-01

    The authors report on a patient with reverse discordant behavior between Tc-99m pertechnetate and I-131 associated with progressive filling of a cold nodule on the Tc-99m pertechnetate thyroid scan. Possible mechanisms are discussed.

  8. Axillary iodine-131 accumulation due to perspiration

    SciTech Connect

    Camponovo, E.J.; Goyer, P.F.; Silverman, E.D.; Kistler, A.M.; Yudt, W.M. )

    1989-10-01

    A case of spurious axillary uptake of I-131 proven to be caused by perspiration is presented. False-positive localizations of radioiodine, both pathologic and physiologic, are reviewed to avoid confusion of these entities with functioning thyroid carcinoma metastases.

  9. Effect of technetium-99m on iodine-131 thyroid uptake measurements

    SciTech Connect

    Wasserman, H.J.; Klopper, J.F.; Erlank, P.

    1985-06-01

    Following administration of 2.5-5.0 mCi(/sup 99m/Tc)pertechnetate, several hundred microcuries may be present in the necks of hyperthyroid patients after 6 hr. Coincidence summing of Tc-99m photons may disturb I-131 uptake measurements in such patients if an oral diagnostic dose of I-131 is administered immediately after completion of a (/sup 99m/Tc)pertechnetate scintigram. Using a lower discriminator level of 300 keV, false increases of 10%-50% may occur at 6 hr. The 24-hr uptake is also affected if an I-131 predose measurement is performed after administration of the Tc-99m dose. The authors have shown that these errors may be prevented by using a 1-mm lead filter in front of the scintillation detector. The attenuation of Tc-99m photons by the filter effectively eliminates summation pulses while it reduces the I-131 count rate by approximately 28%.

  10. Treatment of neuroblastoma with /sup 131/I-metaiodobenzylguanidine: experience of the Muenster/Kassel Group

    SciTech Connect

    Fischer, M.; Wehinger, H.; Kraus, C.; Ritter, J.; Schroeter, W.

    1987-01-01

    I-131-metaiodobenzylguanidine was used for treatment of neuroblastoma stage IV in three children after surgery and or chemotherapy had failed to be effective. In two of the children with multilocular lesions, after an impressive improvement of clinical symptoms tumor progression was observed. Because in about 25% of children with relapsing neuroblastoma complete remission may be achieved by combining surgery, chemotherapy, and I-131-MIBG treatment, this therapeutic modality should be included in the therapeutic strategy of stage III and IV neuroblastoma.

  11. Adjuvant Iodine131 Lipiodol after Resection of Hepatocellular Carcinoma

    PubMed Central

    Furtado, Ruelan V.; Ha, Leo; Clarke, Stephen; Sandroussi, Charbel

    2015-01-01

    Background. Survival after liver resection for HCC is compromised by a high rate of intrahepatic recurrence. Adjuvant treatment with a single, postoperative dose of intra-arterial I131 lipiodol has shown promise, as a means of prolonging disease-free survival (DFS). Methodology. DFS and overall survival (OS) after a single dose of postoperative I131 lipiodol were compared to liver resection alone, for treatment of hepatocellular carcinoma (HCC). Data were collected retrospectively for patients who had a curative resection for HCC between December 1993 and September 2011. Seventy-two patients were given I131 lipiodol after surgery and 70 patients had surgery alone. Results. The DFS at 1, 3, and 5 years was 72%, 43%, and 26% in the surgery group and 70%, 39%, and 29% in the adjuvant I131 lipiodol group (p = 0.75). The 1-, 3-, and 5-year OS was 83%, 64%, and 52% in the surgery group and 96%, 72%, and 61% in the adjuvant I131 lipiodol group (p = 0.16). Conclusion. This retrospective study has found no significant benefit to survival, after adjuvant treatment with I131 lipiodol. PMID:26713092

  12. Treatment rationale in thyroid carcinoma. Effect of scan dose

    SciTech Connect

    Ramanna, L.; Waxman, A.D.; Brachman, M.B.; Tanasescu, D.E.; Chapman, N.; Braunstein, G.D.

    1985-10-01

    The authors have previously shown that the definition of ablation of thyroid tissue in patients treated with thyroidectomy and radioiodine (I-131) for thyroid carcinoma depends upon the dose of I-131 used to scan the patient. The therapeutic response to I-131 therapy was evaluated in a group of ten differentiated thyroid cancer patients who had a negative 2-mCi (-2 mCi) diagnostic study, but had a positive 10-mCi (+10 mCi) diagnostic study (group 1) during their follow-up evaluation. These results were compared to another group of ten differentiated thyroid cancer patients who received I-131 ablation therapy based on a positive 2-mCi (+2 mCi) I-131 scan (group 2). Six patients in group 1 and eight in group 2 had improvement or ablation of residual tissue based on the 10-mCi scan following therapy. The difference in response between the two groups was not statistically significant (P = 0.63) by two-tailed Fisher's exact test, indicating that even patients with -2-mCi, but +10-mCi scans may respond to I-131 therapy. Whether the large dose therapy makes any impact on the clinical outcome has not been answered by this study.

  13. Retrospective reconstruction of Ioidne-131 distribution at the Fukushima Daiichi Nuclear Power Plant accident by analysis of Ioidne-129

    NASA Astrophysics Data System (ADS)

    Matsuzaki, Hiroyuki; Muramatsu, Yasuyuki; Toyama, Chiaki; Ohno, Takeshi; Kusuno, Haruka; Miyake, Yasuto; Honda, Maki

    2014-05-01

    Among various radioactive nuclides emitted from the Fukushima Daiichi Nuclear Power Plant (FDNPP) accident, Iodine-131 displayed high radioactivity just after the accident. Moreover if taken into human body, Iodine-131 concentrates in the thyroid and may cause the thyroid cancer. The recognition about the risk of Iodine-131 dose originated from the experience of the Chernobyl accident based on the epidemiological study [1]. It is thus important to investigate the detailed deposition distribution of I-131 to evaluate the radiation dose due to I-131 and watch the influence on the human health. However I-131 decays so rapidly (half life = 8.02 d) that it cannot be detected several months after the accident. At the recognition of the risk of I-131 on the Chernobyl occasion, it had gone several years after the accident. The reconstruction of I-131 distribution from Cs-137 distribution was not successful because the behavior of iodine and cesium was different because they have different chemical properties. Long lived radioactive isotope I-129 (half life = 1.57E+7 yr,), which is also a fission product as well as I-131, is ideal proxy for I-131 because they are chemically identical. Several studies had tried to quantify I-129 in 1990's but the analytical technique, especially AMS (Accelerator Mass Spectrometry), had not been developed well and available AMS facility was limited. Moreover because of the lack of enough data on I-131 just after the accident, the isotopic ratio I-129/I-131 of the Chernobyl derived iodine could not been estimated precisely [2]. Calculated estimation of the isotopic ratio showed scattered results. On the other hand, at the FDNPP accident detailed I-131 distribution is going to be successfully reconstructed by the systematical I-129 measurements by our group. We measured soil samples selected from a series of soil collection taken from every 2 km (or 5km, in the distant area) meshed region around FDNPP conducted by the Japanese Ministry of

  14. Determination of absorbed dose by single photon emission computerized tomography in the radioiodine treatment of distant metastases from thyroid carcinoma

    SciTech Connect

    Kusakabe, K.; Kanaya, S.; Ohta, T.; Kawasaki, Y.; Maki, M.; Hiroe, M.; Obara, T.; Fujimoto, Y.; Yamasaki, T.

    1985-05-01

    The purpose of this paper is to present the results of preliminary experience in the dosimetry of I-131 to metastatic tumors from thyroid cancer, utilizing SPECT for calculation of the absorbed dose. SPECT was performed with a scintillation camera, 1-20 days after the administration of a treatment dose of I-131 78-150 mCi in 15 cases. All patients were performed total thyroidectomy and/or ablation with radioiodine. All had been off thyroid-suppression medication for 2 weeks before I-131 scanning. The study population included 3 men and 12 women, with ages ranging from 20-74 years. Thirteen had had follicular carcinoma and two papillary, including mixed papillary-follicular. A SPECT system with high energy collimater, was calibrated with cylindrical volume sources containing I-131, within a 16-25 cm diameter water filled cylinder. The attenuation coefficient for the 360keV photons of I-131 in water was ..mu..=0.05 cm, resulting in a uniform radioactivity distribution in the reconstructed image. And this value is used for attenuation correction. Half-life data and activities of I-131 have been compiled in which the isotope assumed to be concentrated in tumors. Weight of tumors was estimated by TCT images. Radiation absorbed doses were calculated using the Medical Internal Radiaton Dose (MIRD). The weight of tumors ranged from 2-80 gram and the tumor radiation dose ranged from 500-25,000 rads. These results indicate that dosimetry with SPECT correlate well with clinical course and have the added advantage of I-131 treatment.

  15. A triple energy window scatter subtraction approach for quantitative anger camera imaging of iodine-131

    SciTech Connect

    Grant, E.J.; Macey, D.J.; Bayouth, J.E.

    1994-05-01

    Dose estimates for organs and tumor volumes in radioimmunotherapy with I-131 frequently depend on in-vivo quantitation methods using planar Anger camera images. Compton scatter and collimator septal penetration result in overestimation of activity and dose. The objective of this study was to assess the effectiveness of a triple energy window subtraction method for quantitative imaging of I-131. The energy spectrum of I-131 was modeled as a superposition of the spectra of Cr-51 (320 keV) and Cs-137 (662 keV). Images were acquired with three adjacent 15% energy windows--photopeak(PP), upper scatter(US), and lower scatter(LS)--for small sources of these radionuclides. The PP window was centered at 364 keV for I-131 and Cs-137 and 320 keV for Cr-51. Three scatter multipliers were derived from analysis of count profiles of the Cs-137 and Cr-51 images, and used to sequentially remove septal penetration and scatter events included in the 364 keV photopeak of I-131. This method was tested by acquiring images of an abdominal phantom containing a liver, spleen and spherical {open_quotes}tumor{close_quotes} filled with different concentrations of I-131, both with and without background activity in the surrounding phantom. A body thickness attenuation compensation factor was applied to the geometric mean of the conjugate view counts using a narrow beam linear attenuation coefficient of 0.11 cm{sup -1}. With scatter subtraction, the accuracy and reproducibility of activity quantitation was improved because the background count density was more uniformly scored. Also, the influence of different activity concentrations in source organs relative to background on the accuracy of quantitation was removed, and the perimeters of organs were more clearly defined. This method has been used to provide improved dose estimates for I-131 labeled antibody therapy in breast cancer patients.

  16. DNA Damage of Glioblastoma Multiform Cells Induced by Beta Radiation of Iodine-131 in The Presence or Absence of Topotecan: A Picogreen and Colonogenic Assay

    PubMed Central

    Eyvazzadeh, Nazila; Neshasteh-Riz, Ali; Mahdavi, Seyed Rabee

    2015-01-01

    Objective Glioblastoma multiforme (GBM), one of the most common and aggressive malignant brain tumors, is highly resistant to radiotherapy. Numerous approaches have been pursued to find new radiosensitizers. We used a picogreen and colonogenic assay to appraise the DNA damage and cell death in a spheroid culture of GBM cells caused by iodine-131 (I-131) beta radiation in the presence of topotecan (TPT). Materials and Methods U87MG cells were cultured as spheroids with approximate diameters of 300 μm. Cells were treated with beta radiation of I-131 (at a dose of 2 Gy) and/ or TPT (1 μg/ml for 2 hours). The numbers of cells that survived were compared with untreated cells using a colonogenic assay. In addition, we evaluated possible DNA damages by the picogreen method. The relation between DNA damage and cell death was assessed in the experimental study of groups. Results The findings showed that survival fraction (SF) in the I-131+TPT group (39%) was considerably less than the I-131 group (58.92%; p<0.05). The number of single strand breaks (SSB) and double strand breaks (DSB), in the DNA of U87MG cells treated with beta radiation of I-131 and TPT (I-131+TPT) significantly increased compared to cells treated with only I-131 or TPT (p<0.05). The amount of SSB repair was more than DSB repair (p<0.05). The relationship between cell death and DNA damage was close (r≥0.6) and significant (p<0.05) in the irradiated and treated groups. Also the maximum rate of DNA repair occurred 24 hours after the treatments. A significant difference was not observed on other days of the restoration. Conclusion The findings in the present study indicated that TPT can sensitize U87MG cells to radiation and increase DNA damages. Potentially, TPT can cause an increase in damage from DSB and SSB by its inhibitory effects on topoisomerase enzyme and the cell cycle. The increased complex damages following the use of a genotoxic agent and beta I-131 radiation, causes a significant increase

  17. Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.

    PubMed

    Kayano, Daiki; Kinuya, Seigo

    2015-01-01

    Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE) transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG) via a NE transporter. Since iodine-131 (I-131) MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective response was poor. In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT) obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with other radionuclide formations of MIBG, and in combined use with other therapeutic agents. PMID:25874239

  18. Enhancement of Natural Killer Cell Cytotoxicity by Sodium/Iodide Symporter Gene-Mediated Radioiodine Pretreatment in Breast Cancer Cells

    PubMed Central

    Kim, Hae Won; Kim, Jung Eun; Hwang, Mi-Hye; Jeon, Yong Hyun; Lee, Sang-Woo; Lee, Jaetae; Zeon, Seok Kil; Ahn, Byeong-Cheol

    2013-01-01

    A phase II study of NK cell therapy in treatment of patients with recurrent breast cancer has recently been reported. However, because of the complexities of tumor microenvironments, effective therapeutic effects have not been achieved in NK cell therapy. Radioiodine (I-131) therapy inhibits cancer growth by inducing the apoptosis and necrosis of cancer cells. Furthermore, it can modify cancer cell phenotypes and enhance the effect of immunotherapy against cancer cells. The present study showed that I-131 therapy can modulate microenvironment of breast cancer and improve the therapeutic effect by enhancing NK cell cytotoxicity to the tumor cells. The susceptibility of breast cancer cells to NK cell was increased by precedent I-131 treatment in vitro. Tumor burden in mice treated with I-131 plus NK cell was significantly lower than that in mice treated with NK cell or I-131 alone. The up-regulation of Fas, DR5 and MIC A/B on irradiated tumor cells could be the explanation for the enhancement of NK cell cytotoxicity to tumor cells. It can be applied to breast cancer patients with iodine avid metastatic lesions that are non-responsive to conventional treatments. PMID:23940545

  19. Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective

    PubMed Central

    Kayano, Daiki

    2015-01-01

    Neuroblastoma, which derives from neural crest, is the most common extracranial solid cancer in childhood. The tumors express the norepinephrine (NE) transporters on their cell membrane and take in metaiodobenzylguanidine (MIBG) via a NE transporter. Since iodine-131 (I-131) MIBG therapy was firstly reported, many trails of MIBG therapy in patients with neuroblastoma were performed. Though monotherapy with a low dose of I-131 MIBG could achieve high-probability pain reduction, the objective response was poor. In contrast, more than 12 mCi/kg I-131 MIBG administrations with or without hematopoietic cell transplantation (HCT) obtain relatively good responses in patients with refractory or relapsed neuroblastoma. The combination therapy with I-131 MIBG and other modalities such as nonmyeloablative chemotherapy and myeloablative chemotherapy with HCT improved the therapeutic response in patients with refractory or relapsed neuroblastoma. In addition, I-131 MIBG therapy incorporated in the induction therapy was proved to be feasible in patients with newly diagnosed neuroblastoma. To expand more the use of MIBG therapy for neuroblastoma, further studies will be needed especially in the use at an earlier stage from diagnosis, in the use with other radionuclide formations of MIBG, and in combined use with other therapeutic agents. PMID:25874239

  20. Portrayal of pheochromocytoma and normal human adrenal medulla by m-(/sup 123/I)iodobenzylguanidine: concise communication

    SciTech Connect

    Lynn, M.D.; Shapiro, B.; Sisson, J.C.; Swanson, D.P.; Mangner, T.J.; Wieland, D.M.; Meyers, L.J.; Glowniak, J.V.; Beierwaltes, W.H.

    1984-04-01

    The radiopharmaceutical m-(/sup 131/I)iodobenzylguanidine (I-131 MIBG), which is readily taken up by adrenergic vesicles, produces scintigraphic images of pheochromocytomas in man but rarely visualizes normal adrenal glands. Iodine-123 has many potential advantages over I-131 as a radiolabel for MIBG, including shorter half-life, freedom from beta emissions, and increased gamma-camera efficiency. In this study, diagnostic doses of MIBG labeled with I-131 and I-123, with nearly equivalent radiation dosimetry, were compared as imaging agents in eight patients with known or suspected pheochromocytoma. Images of superior quality were obtained with I-123 MIBG. In addition, the normal adrenal medullae were visualized on the I-123 MIBG scintigrams in six out of eight patients.

  1. Effect of reserpine on salivary gland radioiodine uptake in thyroid cancer

    SciTech Connect

    Levy, H.A.; Park, C.H.

    1987-04-01

    Nine patients with thyroid cancer were treated with reserpine in an attempt to reduce radiation exposure to the salivary glands from 100-150 mCi doses of I-131 therapy to thyroid remnants or metastases. Three control patients were not treated with reserpine but did receive 100-150 mCi of I-131. Parotid/background ratios of activity after radioablative doses of I-131 in patients not treated with reserpine were significantly higher than the patients treated with reserpine, and this was also true seven days after the radioablative dose. Combined therapy with reserpine, chewing gum, lemon candies, and hydration is suggested for the prevention of sialadenitis and xerostomia due to large doses of radioiodine.

  2. Unusual locations of localized myxedema in Graves disease. Report of three cases

    SciTech Connect

    Noppakun, N.; Bancheun, K.; Chandraprasert, S.

    1986-01-01

    Three patients with Graves disease had very unusual locations of localized myxedema. One patient had localized myxedema on the pretibial and shoulder areas after sodium iodide I 131 therapy. The second patient had localized myxedema on his neck, shoulders, and upper part of the back as well as on the pretibial area. The third patient had localized myxedema on the pinnae, also following sodium iodide I 131 therapy. After surgical removal followed by intralesional triamcinolone acetonide injections, the first patient's lesions recurred. The lesions in the second case did not respond to topical steroid cream. The third patient had a partial response to intralesional steroid injections.

  3. Artificial radionuclides in Russia due to the Fukushima NPP accident

    NASA Astrophysics Data System (ADS)

    Polianskaia, Olga; Vakulovsky, Sergey; Kim, Vera; Yahryushin, Valery; Volokitin, Andrey

    2013-04-01

    Radioactive emission into the atmosphere from the damaged reactors of the Fukushima Daiichi nuclear power plant (NPP) started on March 12th, 2011. The network of Federal Hydrometeorology and Environmental Monitoring Service (Rosgydromet) carries out supervision over a radiation situation on the territory of Russia. In Russia, the first radionuclides from Fukushima were detected on March 20th in the Far East by network. From March 20th to April 30th I-131 (particulate form), Cs-137 and Cs-134 were detected in samples of atmospheric aerosols at the 30 stations of networks and the same ones were detected in fallout at the 25 stations of networks. The first detection of I-131 in the European territory of Russia (ETR) occurred on March 23rd; and in the South and the North of Siberia - on March 26th. The volumetric activities of I-131 in the ETR sharply increased from March 28th to 30th. Along with the increasing content of I-131 cesium isotopes appeared in the air. The maximum values of radionuclides volume activity were observed between April 3rd and 4th: for I-131 - 4,0 mBq/m3, for Cs-137 - 1,15 mBq/m3, for Cs-134 - 1,04 mBq/m3. Observed in the Far East, the maximum values for I-131 were 2-4 times lower than in the ETR. The maximum values for I-131 in the Asian territory of Russia (ATR) were 2 - 8 times lower, than in the ETR. The Cs-137/Cs-134 ratio in samples of atmospheric aerosols was about 1. The ratio I-131/Cs-137 in air changed in a wide range. From March 23rd to April 5th the ratio fluctuated within 11 to 34, from April 5th to 20th of the ratio decreased and varied within 1,5 to 7,7, further it became less than 1. The value of cesium isotopes in second quarter of 2011 in fallout was lower than 2 Bq/m2. The addition to the density of soil contamination by Cs-137 by 2 to 3 orders of magnitude less than the decrease of the density of contamination with this isotope of the global origin due to radioactive decay. Based on the obtained experimental data we can

  4. Higher cancer risk continues after Chernobyl

    Cancer.gov

    Nearly 25 years after the accident at the Chernobyl nuclear power plant in Ukraine, exposure to radioactive iodine-131(I-131, a radioactive isotope) from fallout may be responsible for thyroid cancers that are still occurring among people who lived in the Chernobyl area and were children or adolescents at the time of the accident, researchers say. An international team of researchers led by the NCI found a clear dose-response relationship, in which higher absorption of radiation from I-131 led to an increased risk for thyroid cancer that has not seemed to diminish over time.

  5. Micronucleus frequencies in groups receiving external or internal radiation

    PubMed Central

    Özdal, Ayşegül; Erselcan, Taner; Özdemir, Öztürk; Silov, Güler; Erdoğan, Zeynep; Turhal, Özgül

    2016-01-01

    Objective: In the current study, we aimed to explore whether there is alteration between pre- and post-treatment micronucleus (MN) frequencies induced by internal and external ionizing radiation. Materials and Methods: The study enrolled a total of 67 patients including patients admitted to our hospital for treatment of hyperthyroidism (n = 17), scanning with low-dose I-131 (n = 15), and ablative therapy with high-dose I-131 (n = 15) at Department of Nuclear Medicine as well as patients with different diagnoses receiving external radiotherapy with various doses and durations at Department of Radiation Oncology (n = 20). Thirty-two patients who received radioactive iodine and returned for a follow-up visit at 1 month. Results: Considering both pre- and post-treatment MN frequencies of each group, lowest MN frequencies were detected for patients undergoing screening with low-dose I-131, and highest MN frequencies were found in radiotherapy patients. Comparison of pre- and post-treatment MN frequencies among hyperthyroidism, when pre- and post-treatment MN frequencies compared among hyperthyroidism, I-131 whole body scanning, ablation, and radiotherapy patient groups differences between MN frequencies were significant for each group (P < 0.05). Conclusion: Our study showed that MN analysis might be of value in determining chromosome damage that could potentially occur in patients exposed to internal and external radiation. PMID:27385886

  6. 10 CFR Appendix D to Part 835 - Surface Contamination Values

    Code of Federal Regulations, 2013 CFR

    2013-01-01

    ... + Removable) 2,3 U-nat, U-235, U-238, and associated decay products 7 1,000 7 5,000 Transuranics, Ra-226, Ra..., I-126, I-131, I-133 200 1,000 Beta-gamma emitters (nuclides with decay modes other than alpha... to radioactive contamination deposited on, but not incorporated into the interior or matrix of,...

  7. 10 CFR Appendix D to Part 835 - Surface Contamination Values

    Code of Federal Regulations, 2012 CFR

    2012-01-01

    ... + Removable) 2,3 U-nat, U-235, U-238, and associated decay products 7 1,000 7 5,000 Transuranics, Ra-226, Ra..., I-126, I-131, I-133 200 1,000 Beta-gamma emitters (nuclides with decay modes other than alpha... to radioactive contamination deposited on, but not incorporated into the interior or matrix of,...

  8. 10 CFR Appendix D to Part 835 - Surface Contamination Values

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... + Removable) 2,3 U-nat, U-235, U-238, and associated decay products 7 1,000 7 5,000 Transuranics, Ra-226, Ra..., I-126, I-131, I-133 200 1,000 Beta-gamma emitters (nuclides with decay modes other than alpha... to radioactive contamination deposited on, but not incorporated into the interior or matrix of,...

  9. 10 CFR Appendix D to Part 835 - Surface Contamination Values

    Code of Federal Regulations, 2014 CFR

    2014-01-01

    ... + Removable) 2 3 U-nat, U-235, U-238, and associated decay products 7 1,000 7 5,000 Transuranics, Ra-226, Ra..., I-126, I-131, I-133 200 1,000 Beta-gamma emitters (nuclides with decay modes other than alpha... to radioactive contamination deposited on, but not incorporated into the interior or matrix of,...

  10. 8 CFR 245.21 - Adjustment of status of certain nationals of Vietnam, Cambodia, and Laos (section 586 of Public...

    Code of Federal Regulations, 2010 CFR

    2010-01-01

    ... the application. The regulations governing such a request are found at 8 CFR 241.6. (2) The Service in... listed in 8 CFR 103.7(b)(1). If the Service approves the application for employment authorization, the... with the application fee listed in 8 CFR 103.7(b)(1). If the Service approves Form I-131, the...

  11. SU-E-I-78: Establishing a Protocol for Quick Estimation of Thyroid Internal Contamination with 131I in Normal and Emergency Situations

    SciTech Connect

    Naderi, S Mehdizadeh; Karimipourfard, M; Lotfalizadeh, F; Zamani, E; Molaeimanesh, Z; Sadeghi, M; Sina, S; Faghihi, R; Entezarmahdi, M

    2015-06-15

    Purpose: I-131 is one of the most frequent radionuclides used in nuclear medicine departments. The radiation workers, who manipulate the unsealed radio-toxic iodine, should be monitored for internal contamination. In this study a protocol was established for estimating I-131 activity absorbed in the thyroid glands of the nuclear medicine staff in normal working condition and also in accidents. Methods: I-131 with the activity of 10 μCi was injected inside the thyroid gland of a home-made anthropomorphic neck phantom. The phantom is made up of PMMA as soft tissue, and Aluminium as bone. The dose rate at different distances from the surface of the neck phantom was measured using a scintillator detector for duration of two months. Then, calibration factors were obtained, for converting the dose rate at each distance to the iodine activity inside the thyroid. Results: According to the results of this study, the calibration factors for converting the dose rates (nSv/h) at distances of 0cm, 1cm, 6cm, 11cm, and 16cm to the activity (kBq) inside the thyroid were found to be 0.03, 0.04, 0.14, 0.29, and 0.49 . Conclusion: This method can be effectively used for quick estimation of the I-131 concentration inside the thyroid of the staff for daily checks in normal working conditions and also in accidents.

  12. Analysis of Radionuclide Releases from the Fukushima Dai-ichi Nuclear Power Plant Accident Part II

    NASA Astrophysics Data System (ADS)

    Achim, Pascal; Monfort, Marguerite; Le Petit, Gilbert; Gross, Philippe; Douysset, Guilhem; Taffary, Thomas; Blanchard, Xavier; Moulin, Christophe

    2014-03-01

    The present part of the publication (Part II) deals with long range dispersion of radionuclides emitted into the atmosphere during the Fukushima Dai-ichi accident that occurred after the March 11, 2011 tsunami. The first part (Part I) is dedicated to the accident features relying on radionuclide detections performed by monitoring stations of the Comprehensive Nuclear Test Ban Treaty Organization network. In this study, the emissions of the three fission products Cs-137, I-131 and Xe-133 are investigated. Regarding Xe-133, the total release is estimated to be of the order of 6 × 1018 Bq emitted during the explosions of units 1, 2 and 3. The total source term estimated gives a fraction of core inventory of about 8 × 1018 Bq at the time of reactors shutdown. This result suggests that at least 80 % of the core inventory has been released into the atmosphere and indicates a broad meltdown of reactor cores. Total atmospheric releases of Cs-137 and I-131 aerosols are estimated to be 1016 and 1017 Bq, respectively. By neglecting gas/particulate conversion phenomena, the total release of I-131 (gas + aerosol) could be estimated to be 4 × 1017 Bq. Atmospheric transport simulations suggest that the main air emissions have occurred during the events of March 14, 2011 (UTC) and that no major release occurred after March 23. The radioactivity emitted into the atmosphere could represent 10 % of the Chernobyl accident releases for I-131 and Cs-137.

  13. 8 CFR 245.21 - Adjustment of status of certain nationals of Vietnam, Cambodia, and Laos (section 586 of Public...

    Code of Federal Regulations, 2011 CFR

    2011-01-01

    ... the application. The regulations governing such a request are found at 8 CFR 241.6. (2) The Service in... listed in 8 CFR 103.7(b)(1). If the Service approves the application for employment authorization, the... with the application fee listed in 8 CFR 103.7(b)(1). If the Service approves Form I-131, the...

  14. Imaging of primary and metastatic colorectal carcinoma with monoclonal antibody 791T/36 and the therapeutic potential of antibody-drug conjugates

    SciTech Connect

    Pimm, M.V.; Armitage, N.C.; Ballantyne, K.; Baldwin, R.W.; Perkins, A.C.; Durrant, L.G.; Garnett, M.C.; Hardcastle, J.D.

    1987-01-01

    Monoclonal antibody 791T/36, prepared against a tumor-associated 72,000 dalton glycoprotein, reacted with cells from primary and metastatic colorectal carcinomas. I-131 or In-111-labelled antibody localized in xenografts of colorectal carcinomas established from in vitro clonogenic populations. Clinically, with I-131-labelled antibody, 8/11 colonic tumors imaged positively. Imaging was negative in four patients with benign colon disease. 5/11 rectal tumors were positively imaged, but excreted I-131 in the bladder obscured tumors in several studies. In-111-labelled antibody gave superior images and positively imaged primary and metastatic sites in 13/14 patients. Prospectively in the detection of recurrent disease, I-131 or In-111-antibody detected 29/33 separate sites in 24 patients. Seven negative patients remain disease free. There were 3 false positives; overall sensitivity was 88%, with 70% specificity. Specific localization of radiolabel was confirmed immunochemically and by counting radioactivity in resected specimens. Antibody conjugates with methotrexate, vindesine and daunomycin retained drug activity and antibody function, including xenograft localization and conjugates were therapeutically effective against xenografts. 791T/36 antibody has potential for immunodetection of primary and recurrent colorectal carcinoma and for targeting of therapeutic agents.

  15. 78 FR 63226 - GlaxoSmithKline LLC; Withdrawal of Approval of the Indication for Treatment of Patients With...

    Federal Register 2010, 2011, 2012, 2013, 2014

    2013-10-23

    ... From the Federal Register Online via the Government Publishing Office DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration GlaxoSmithKline LLC; Withdrawal of Approval of the... (tositumomab and iodine I 131 tositumomab) Injection held by GlaxoSmithKline LLP, P.O. Box 5089, 1250...

  16. Effect of prolonged hypokinesia on tissue blood flow

    NASA Technical Reports Server (NTRS)

    Levites, Z. P.; Fedotova, V. F.

    1979-01-01

    The influence of hypokinesia on the blood flow in the tissues of rabbits was studied. Motor activity of animals was restricted during 90 days and blood flow recorded through resorption rate of NaI-131. Perfusion of tissues under the influence of hypokinesia was found to be reduced.

  17. Nuclear medicine program progress report for quarter ending March 31, 1996

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, K.R.; Beets, A.L.; Guhlke, S.; Luo, H.; McPherson, D.W.; Mirzadeh, S.; Mokler, F.

    1996-10-01

    Biodistribution studies with the radioiodinated 3(R)- and 3(S)-BMIPP isomers in rats have shown that 3(R)-BMIPP has 20-25% higher heart uptake (15-180 min) than 3(S)-BMIPP, while uptake in other tissues examined is similar. To evaluate the possible differences in metabolic fate of the two isomers, a mixture of [I-125]-3(R)/[I-131]- 3(S)-BMIPP was administered to fasted female Fisher rats. Groups (n=3 rats per group) were sacrificed after 15, 60 and 180 min, and urine and feces collected from another group. Samples of blood, heart, liver, lungs, kidney, and urine were Folch-extracted. The distribution of I-125 and I-131 in the organic, aqueous, and pellet samples were determined. Organic samples were then analyzed by thin-layer chromatography (TLC) and high performance liquid chromatography (HPLC). The relative distribution of I-125/I-131 in the lipid, aqueous, and pellet samples was similar for both isomers. Distribution of I-125/I-131 in the various components of the lipid extracts observed by TLC was similar, with principal incorporation into the free fatty acid (FFA) and triglyceride (TG) pools. HPLC analyses (Cl8) of the FFA fraction showed similar I-125/I-131 profiles, corresponding to BMIPP, and the {alpha}-methyl-C,4 (PIPA) and C12, Cl0 and C6 carbon chain-length catabolites. By TLC, urine I-125/I-131 chromatographed with hippuric acid. HPLC analyses (Cl 8) of acid-hydrolyzed urine gave a single I-125/I-131 component with the same RRT as 2-({beta}-iodophenyl)acetic acid, the final {alpha}/{beta}-oxidative BMIPP catabolite. Unexpectedly, HPLC of lipids from base hydrolyzed TG from the heart tissue, showed I-125/I-125 co-chromatographing with short-chain fatty acids, with only levels in BMIPP. These unexpected results demonstrate that the 3(R)-BMIPP and 3(S)-BMIPP isomers are metabolized similarly in rat tissues, and that the higher myocardial extraction observed for the 3(R)-BMIPP may reflect differences in the relative membrane transport of the two isomers.

  18. In Utero Exposure to Iodine-131 from Chernobyl Fallout and Anthropometric Characteristics in Adolescence

    PubMed Central

    Neta, Gila; Hatch, Maureen; Kitahara, Cari M.; Ostroumova, Evgenia; Bolshova, Elena V.; Tereschenko, Valery P.; Tronko, Mykola D.; Brenner, Alina V.

    2014-01-01

    Prenatal exposure to external radiation has been linked to growth retardation among atomic bomb survivors in adolescence. It is unclear from previous studies whether in utero exposure to internal radiation such as iodine-131 (I-131), which concentrates in the thyroid gland, has an effect on physical growth. We examined the associations between estimated thyroid gland dose from prenatal exposure to I-131 and self-reported height and weight in a cohort of 2,460 individuals exposed to radioactive fallout from the 1986 Chernobyl nuclear accident [mean I-131 dose = 72 (mGy)] and screened for thyroid diseases in adolescence. Using multivariable linear regression models, we estimated the mean differences in height, weight and body mass index (BMI) per unit increase in dose (100 mGy) in models adjusted for gender, age at examination, type of residence (rural/urban) and presence of thyroid disease diagnosed at screening. All of the adjustment factors as well as the trimester of exposure were evaluated as potential modifiers of the dose response. Overall, no significant dose response was found for height (P = 0.29), weight (P = 0.14) or BMI (P = 0.16). We found significant modification of the dose response for weight and BMI by presence/absence of thyroid disease (P = 0.02 and P = 0.03, respectively), but not for other factors. In individuals without thyroid disease (n = 1,856), there was a weak, significant association between I-131 thyroid dose and higher weight (210 g per 100 mGy, P = 0.02) or BMI (70 g/m2 per 100 mGy, P = 0.02) that depended on individuals (n = 52) exposed to ≥500 mGy. In individuals with thyroid disease (n = 579, 67.4% with simple diffuse goiter) no significant association with I-131 for weight (P = 0.14) or BMI (P = 0.14) was found. These results do not support the hypothesis that in utero exposure to I-131 at levels experienced by a majority of study subjects may be associated with meaningful differences in adolescent anthropometry. However

  19. Spatial Distributions of Iodine-131 and the Geochemical "Fingerprint" from the World Trade Center Terrorist Attack in New York Harbor Sediments

    NASA Astrophysics Data System (ADS)

    Oktay, S. D.; Smith, J. P.; Brabander, D. J.; Kada, J.; Olsen, C. R.

    2002-12-01

    The September 11, 2001 terrorist attack on the World Trade Center (WTC) in New York City introduced large amounts of ash and debris over an extensive area including New York Harbor (NYH) and the Lower Hudson Estuary. Previous results have identified a textural and elemental "fingerprint" for this ash/debris that can be seen as a quantifiable event horizon in NYH surface sediments. In addition, the short-lived radioisotope, I-131 (half-life, 8.04 days), was unexpectedly identified in the surface sediments, which corroborated that this sediment was recently deposited and anthropogenically influenced. On July 24-25, 2002, additional sediment cores were collected in the sites occupied in 2001 and in various locations throughout NYH (on both the Manhattan and New Jersey sides of the Hudson river) in order to determine the spatial extent of both the WTC "fingerprint" and the I-131 signal. Gamma spectrometric measurements of I-131 in surface sediments were used to determine its spatial distribution in NYH sediments and its potential use as an indicator of rapid sedimentary processes (days to weeks) initiated by urban input. Potential sources for the I-131 were evaluated, with initial evidence pointing to traces of human waste discharge related to medical treatments as the most likely source. The short-lived radionuclide, Be-7 (half-life, 53.12 days), and textural and elemental characterizations originally identified in the earlier research were examined in order to document the spatial distribution of the geochemical WTC "fingerprint" and investigate how short-to-medium term sediment dynamics (supply, deposition, re-suspension, and net accumulation) in New York Harbor may affect the spatial distribution and preservation of a sedimentological record associated with this event. This research should help delineate the geographical extent of the debris created from the WTC catastrophe and may predict where urban inputs of material such as I-131 can accumulate in NYH.

  20. Management of Differentiated Thyroid Cancer in Children: Focus on the American Thyroid Association Pediatric Guidelines.

    PubMed

    Parisi, Marguerite T; Eslamy, Hedieh; Mankoff, David

    2016-03-01

    First introduced in 1946, radioactive iodine (I-131) produces short-range beta radiation with a half-life of 8 days. The physical properties of I-131 combined with the high degree of uptake in the differentiated thyroid cancers (DTCs) led to the use of I-131 as a therapeutic agent for DTC in adults. There are two indications for the potential use of I-131 therapy in pediatric thyroid disorders: nonsurgical treatment of hyperthyroidism owing to Graves' disease and the treatment of children with intermediate- and high-risk DTC. However, children are not just miniature adults. Not only are children and the pediatric thyroid gland more sensitive to radiation than adults but also the biologic behavior of DTC differs between children and adults as well. As opposed to adults, children with DTC typically present with advanced disease at diagnosis; yet, they respond rapidly to therapy and have an excellent prognosis that is significantly better than that in adult counterparts with advanced disease. Unfortunately, there are also higher rates of local and distant disease recurrence in children with DTC compared with adults, mandating lifelong surveillance. Further, children have a longer life expectancy during which the adverse effects of I-131 therapy may become manifest. Recognizing the differences between adults and children with DTC, the American Thyroid Association commissioned a task force of experts who developed and recently published a guideline to address the unique issues related to the management of thyroid nodules and DTC in children. This article reviews the epidemiology, diagnosis, staging, treatment, therapy-related effects, and suggestions for surveillance in children with DTC, focusing not only on the differences between adults and children with this disease but also on the latest recommendations from the inaugural pediatric management guidelines of the American Thyroid Association. PMID:26897719

  1. A Screening Study of Thyroid Cancer and Other Thyroid Diseases among Individuals Exposed in Utero to Iodine-131 from Chernobyl Fallout

    PubMed Central

    Hatch, M.; Brenner, A.; Bogdanova, T.; Derevyanko, A.; Kuptsova, N.; Likhtarev, I.; Bouville, A.; Tereshchenko, V.; Kovgan, L.; Shpak, V.; Ostroumova, E.; Greenebaum, E.; Zablotska, L.; Ron, E.; Tronko, M.

    2009-01-01

    Background: Like stable iodine, radioiodines concentrate in the thyroid gland, increasing thyroid cancer risk in exposed children. Data on exposure to the embryonic/fetal thyroid are rare, raising questions about use of iodine 131 (I-131) in pregnant women. We present here estimated risks of thyroid disease from exposure in utero to I-131 fallout from the Chernobyl nuclear accident. Methods: We conducted a cross-sectional thyroid screening study (palpation, ultrasound, thyroid hormones, and, if indicated, fine needle aspiration) from 2003 to 2006. Participants were 2582 mother-child pairs from Ukraine in which the mother had been pregnant at the time of the accident on April 26, 1986, or 2 months after the time during which I-131 fallout was still present (1494 from contaminated areas, 1088 in the comparison group). Individual cumulative in utero thyroid dose estimates were derived from estimated I-131 activity in the mother’s thyroid (mean 72 mGy; range 0–3230 mGy). Results: There were seven cases of thyroid carcinoma and one case of Hurthle cell neoplasm identified as a result of the screening. Whereas the estimated excess odds ratio per gray for thyroid carcinoma was elevated (excess odds ratio per gray 11.66), it was not statistically significant (P = 0.12). No radiation risks were identified for other thyroid diseases. Conclusion: Our results suggest that in utero exposure to radioiodines may have increased the risk of thyroid carcinoma approximately 20 yr after the Chernobyl accident, supporting a conservative approach to medical uses of I-131 during pregnancy. PMID:19106267

  2. Biokinetics of a radioiodinated antibreast carcinoma monoclonal antibody and fragment in humans

    SciTech Connect

    Zalutsky, M.R.; Noska, M.; Kaplan, W.D.; Hayes, D.; Colcher, D.; Schlom, J.; Kufe, D.

    1984-01-01

    Monoclonal antibody B6.2 is promising for the detection of breast cancers; it binds to >80% of human breast carcinoma (hbc) lines, its antigen is not seen in serum, and it localizes selectively in hbc xenografts in nude mice. The authors have studied the biokinetics of I-131 activity following injection of I-131-IgG and F(ab')/sub 2/ each in 4 patients (pts). The antibody was labeled using iodogen and tested for specific binding to hbc membrane extracts prior to injection. Pts received 0.6-1.1 mCi of I-131 and 50-100 ..mu..g of protein. Blood clearance of I-131 activity was biphasic with half times of 2 and 15.4 hrs for IgG; 1 and 30 hrs for F(ab')/sub 2/. Dehalogenation was noted: by 72 hrs post-injection, 22% (IgG) and 21% (F(ab')/sub 2/) of the injected dose of I-131 was found in the urine. In 2 pts receiving I-131 IgG, stomach uptake was 7-10% at 24 hrs. Protein associated activity in the blood was >90% for the first 8 hrs and gradually decreased to 79% (IgG) and 58% (F(ab')/sub 2/) at 48 hrs. High liver uptake, reported with other antibody systems, was not observed; <20% of the activity was seen in the liver at all time points for both proteins. In 1/4 pts receiving IgG and 4/4 receiving F(ab')/sub 2/, bone marrow uptake was clearly noted. In these pts, >20% of the activity present in blood was cell associated. This is not inconsistent with the observation that B6.2 binds to granulocytes in vitro. Increased binding to cells in the blood for F(ab')/sub 2/ probably accounts for the anomolously longer blood clearance half times observed for F(ab')/sub 2/ vs IgG and low liver accumulation most likely reflects the absence of hepatic or circulating B6.2 antigen.

  3. Thrombus detection with a radiolabeled antiplatelet monoclonal antibody: Comparison with In-111-oxine technique in coronary and peripheral thrombi in dogs

    SciTech Connect

    Srivastava, S.C.; Esekowitz, M.D.; Meinken, G.E.; Lange, R.C.; Smith, E.; Carbo, P.; Scudder, L.E.; Coller, B.

    1985-05-01

    Platelets (P) labeled with low concentrations of an I-123 or In-111 labeled anti-P monoclonal antibody (7E3) were shown earlier to successfully image in-vivo thrombi. This study was carried out to compare this technique with In-111-oxine-P for localizing coronary and venous thrombi (CT and DVT) in dogs. Thrombi were induced using either transcatheter placement of a dacron pug, mechanical trauma, or electrocoagulation. 7E3 was labeled with I-131 in 70 +- 10% yield (labeling conditions: 100 ..mu..g 7E3; 5 ..mu..g chloramine T; I/sup -//7E3 less than or equal to1; 2 min reaction; 200 ..mu..l pH 7 phosphate buffer; Sp. act. 10-30 ..mu..Ci/..mu..g). Binding of I-131-7E3 to dog P was 75 +- 10% after 1 hr incubation with whole blood. The dogs were injected with 0.5 mCi In-111-oxine-P and 1 mCi I-131-7E3-P in quick succession and data (blood clearance and imaging) were collected for 4 hr. In one experiment, DVT were clearly imaged within 10 min and CT in 30-60 min with I-131-7E3-P. In contrast, In-oxine-P required at least 30 min for imaging DVT and CT were only faintly visualized at 3-4 hr. The DVT to blood and CT to blood ratios at 2.4 hr were 16 and 12.3 for I-131-7E3-P and 9.4 and 6.5 for In-111-oxine-P respectively. In these preliminary studies, I-131-7E3-P thus appears to be superior to In-oxine-P for imaging venous and coronary thrombi. Additionally, 7E3 can be labeled with Tc-99m and I-123 for reduced dose and better imaging properties.

  4. Radioablative therapy with Iodine-131 on a patient with thyroid cancer and chronic renal failure in hemodialysis first experience in Peru

    NASA Astrophysics Data System (ADS)

    Apaza Veliz, D. G.; Herrera Vera, R. D.; Cardenas Abarca, C. A.; Oporto Gonzales, C. A.; Aguilar Ramírez, C.; Vega Ramírez, J. L.; Urquizo Baldomero, R. M.

    2016-07-01

    The Iodine-131 (I-131) is a radioisotope used as a standard treatment for radioablation of thyroid remnants. Among thyroid cancer patients, the ones undergoing hemodialysis represent a specific group. The dose of I-131 is given orally to these patients, part of it is absorbed by the thyroid remnants and the rest of it, largely not incorporated, is excreted primarily by renal excretion. The use of a high dose of radioactivity in the process, and the inability of excretion, represents a high risk of exposure to the patient, medical staff and hemodialysis equipment. This work describes the procedure applied on the radioablation therapy for thyroid cancer while receiving hemodialysis, minimizing the risks for the patient and the staff involved. This clinical procedure will establish the dosimetric measures, a plan on radiation protection and a treatment protocol for this specific type of patients.

  5. Effect of taxol on the therapeutic efficacy of radioimmunotherapy

    SciTech Connect

    Cheng, K.T.; Spicer, K.M.; Means, J.

    1994-05-01

    This investigation was conducted to evaluate the potential of using taxol to maximize the therapeutic effectiveness of radioimmunotherapy. Published studies have shown taxol to be an effective radiosensitizer of tumors to external irradiation by blocking tumor cells in the G{sub 2}/M phases of the cell cycle. In vitro and in vivo studies were carried out to study the effect of low-dose taxol on the therapeutic effectiveness of I-131 anti-CEA monoclonal antibody (OEM-094-20856 MoAb) of human colonic carcinoma (LS-174T cell line). The in vitro clonogenic assay studies indicated taxol effectively enhanced the cell killing effect of I-131 MoAb.

  6. Intrathoracic toxic thyroid nodule causing hyperthyroidism with a multinodular normal functional cervical thyroid gland.

    PubMed

    Serim, Burcu Dirlik; Korkmaz, Ulku; Can, Unal; Altun, Gulay Durmus

    2016-01-01

    Radionuclide scintigraphy with I-131 and Tc-99m pertechnetate ((99)mTc04) has been widely used in detecting toxic nodules. Intrathoracic goiter usually presents as an anterior mediastinal mass. Mostly the connection between intrathoracic mass and the cervical thyroid gland is clearly and easily identified occurring as a result of inferior extension of thyroid tissue in the neck, which is called as secondary intrathoracic goiter. Completely separated, aberrant or in other words primary intrathoracic goiters arise as a result of abnormal embryologic migration of ectopic thyroid closely associated with aortic sac and descend into the mediastinum. Intrathoracic goiters are generally nontoxic nodules existing with mass effect without causing hyperthyroidism. However, mostly reported cases had enlarged thyroid glands in the neck. This report demonstrates the usefulness of I-131 and (99)mTc04 scintigraphy for detecting intrathoracic goiter causing hyperthyroidism with a normal functioned cervical thyroid gland. PMID:27385899

  7. Intrathoracic toxic thyroid nodule causing hyperthyroidism with a multinodular normal functional cervical thyroid gland

    PubMed Central

    Serim, Burcu Dirlik; Korkmaz, Ulku; Can, Unal; Altun, Gulay Durmus

    2016-01-01

    Radionuclide scintigraphy with I-131 and Tc-99m pertechnetate (99mTc04) has been widely used in detecting toxic nodules. Intrathoracic goiter usually presents as an anterior mediastinal mass. Mostly the connection between intrathoracic mass and the cervical thyroid gland is clearly and easily identified occurring as a result of inferior extension of thyroid tissue in the neck, which is called as secondary intrathoracic goiter. Completely separated, aberrant or in other words primary intrathoracic goiters arise as a result of abnormal embryologic migration of ectopic thyroid closely associated with aortic sac and descend into the mediastinum. Intrathoracic goiters are generally nontoxic nodules existing with mass effect without causing hyperthyroidism. However, mostly reported cases had enlarged thyroid glands in the neck. This report demonstrates the usefulness of I-131 and 99mTc04 scintigraphy for detecting intrathoracic goiter causing hyperthyroidism with a normal functioned cervical thyroid gland. PMID:27385899

  8. Correlation between iodine-131 MIBG imaging and biological markers in advanced neuroblastoma

    SciTech Connect

    Yeh, S.D.; Helson, L.; Benua, R.S.

    1988-01-01

    I-131 metaiodobenzylguanidine (MIBG) imaging was performed in 38 patients with advanced neuroblastoma. Abnormal images were found in patients with elevations of urinary vanillylmandelic acid and dopamine and high serum neuron-specific enolase levels. Normal or minimal elevation of markers was seen in patients with negative images. In follow-up studies after chemotherapy, the disappearance of abnormal uptake was noted in those patients with normal marker values. A persistently abnormal uptake occurred in patients with high marker values. Conversion from a normal image to an abnormal image also occurred in patients whose markers became elevated. I-131 MIBG imaging is sensitive in detecting active foci of a neuroblastoma and is useful in monitoring chemotherapy in these patients.

  9. Detection of Fukushima plume within regular Slovenian environmental radioactivity surveillance.

    PubMed

    Glavič-Cindro, D; Benedik, L; Kožar Logar, J; Vodenik, B; Zorko, B

    2013-11-01

    After the Fukushima accident aerosol and rain water samples collected within regular national monitoring programmes were carefully analysed. In rain water samples, aerosol and iodine filters collected in the second half of March and in April 2011 I-131, Cs-134 and Cs-137 were detected. In May 2011 the activities of I-131 and Cs-134 were close or below the detection limit and Cs-137 reached values from the period before the Fukushima accident. Additionally plutonium and americium activity concentrations in aerosol filters were analysed. These measured data were compared with measured data after the Chernobyl contamination in Slovenia in 1986. We can conclude that with adequate regular monitoring programmes influences of radioactivity contamination due to nuclear accidents worldwide can be properly assessed. PMID:23611815

  10. Serial thyroid iodine content in hyperthyroid patients treated with radioiodine

    SciTech Connect

    Lee, G.S.; Sandler, M.P.; Patton, J.A.; Brill, A.B.

    1986-02-01

    X-ray fluorescent scanning was used to measure initial thyroidal iodine content in 64 patients diagnosed as being hyperthyroid and selected for I-131 therapy, and serially in 48 of these patients after therapy in an attempt to determine those patients that were at high risk of becoming hypothyroid. Iodine content fell rapidly after therapy, reaching a nadir at about three months. Based on the population studied, the chance of early hypothyroidism (within 12 months) is about 80% if the iodine content measured at three months is less than 2 mg. If the iodine content is greater than 2 mg, the chance is only about 14%. The serial measurement of thyroidal iodine content (with x-ray fluorescent scanning) may allow early identification of those patients at high risk of developing permanent hypothyroidism following a therapeutic dose of I-131.

  11. Using public relations strategies to prompt populations at risk to seek health information: the Hanford Community Health Project.

    PubMed

    Thomas, Gregory D; Smith, Stephen M; Turcotte, Joseph A

    2009-01-01

    The Hanford Community Health Project (HCHP) addressed health concerns among "downwinders" exposed to releases of radioactive iodine (I-131) from the Hanford Nuclear Reservation in the 1940s and 1950s. After developing educational materials and conducting initial outreach, HCHP had to decide whether to apply its limited resources to an advertising or public relations approach. The decision to apply public relations strategies was effective in driving awareness of the risk communication message at the community level, reinvigorating the affected community, and ultimately increasing the number of people who sought information about their risk of exposure and related health issues. HCHP used a series of communication tools to reach out to local and regional media, medical and health professionals, and community organizations. The campaign was successful in increasing the number of unique visitors to HCHP Web site and educating and activating the medical community around the releases of I-131 and patient care choices. PMID:18353906

  12. Retrospective evaluation of 131I deposition density and thyroid dose in Poland after the Chernobyl accident.

    PubMed

    Pietrzak-Flis, Zofia; Krajewski, Pawel; Radwan, Irena; Muramatsu, Yasuyuki

    2003-06-01

    The 131I deposition in Poland after the Chernobyl accident on 26 April 1986 was evaluated from the determined 129I deposition and the estimated 129I/131I ratio at the time of the arrival of fallout. Concentrations of 129I and 127I were determined by neutron activation analysis in uncultivated soils from 16 locations in Poland. Determination of 137Cs in soils was carried out by gamma spectrometry. The atomic ratio of 129I/131I at the time of fallout arrival was estimated using the 129I/131I ratio at the time of the accident, which, on the basis of the core inventory data, was assumed to be 22.8. It was estimated from the time of fallout arrival and from the weighed mean atomic ratio that the 129I/131I ratio for Poland was 32.8. The calculated 131I deposition ranged from 63.2 to 729 kBq m(-2). High deposition of 131I occurred in the locations with rainfall but occasionally also in locations without rainfall. Committed equivalent doses from 131I were evaluated for 5-y-old children, 10-y-old children, and adults using the computer model CLRP for the situations with and without countermeasures including iodine prophylaxis. The highest thyroid doses from inhalation and ingestion without countermeasures were 178 mSv, 120 mSv, and 45 mSv for 5-y-old children, 10-y-old children, and adults, respectively. The countermeasures reduced these doses by about 30%. PMID:12822579

  13. Participation of the hypophyseal-adrenal cortex system in thrombin clearance during immobilization stress

    NASA Technical Reports Server (NTRS)

    Kudryashov, B. A.; Uljanov, A. M.; Shapiro, F. B.; Bazazyan, G. G.

    1981-01-01

    Thrombin marked with I-131 resulted in a considerable increase of the thrombined clearance rate in healthy male rats during stress caused by an immobilization lasting 30 minutes, and in an increase of thrombin clearance occurred by a combination of immobilization and administration of adrenocorticotropin (ACTH). Contrary to ACTH, the thrombin clearance is not stimulated in healthy animals by hydrocortisone. The results of the examination are presented.

  14. Radionuclide therapy of adrenal tumors.

    PubMed

    Carrasquillo, Jorge A; Pandit-Taskar, Neeta; Chen, Clara C

    2012-10-01

    Adrenal tumors arising from chromaffin cells will often accumulate radiolabeled metaiodobenzylguanidine (MIBG) and thus are amenable to therapy with I-131 MIBG. More recently, therapy studies have targeted the somatostatin receptors using Lu-177 or Y-90 radiolabeled somatostatin analogs. Because pheochromocytoma (PHEO)/paraganglioma (PGL) and neuroblastoma (NB), which often arise from the adrenals, express these receptors, clinical trials have been performed with these reagents. We will review the experience using radionuclide therapy for targeting PHEO/PGL and NBs. PMID:22718415

  15. Avid thyroid uptake of (Tc-99m) sodium pertechnetate in children with goitrous cretinism

    SciTech Connect

    Kim, E.E.; Domstad, P.A.; Choy, Y.C.; DeLand, F.H.

    1981-07-01

    Three children with goitrous hypothyroidism had thyroid scans with (Tc-99m) sodium pertechnetate, which showed symmetrically enlarged thyroid glands with uniformly increased activities compared to little activities in the salivary glands and low body background activities. These scan findings, simulating those of Graves' disease, reflect acid trapping of this tracer, analogous to that seen with I-131. Perchlorate discharge test was positive in two patients, indicating an organification defect.

  16. Iodine-131 tositumomab (Bexxar) in a radiation oncology environment

    SciTech Connect

    Macklis, Roger M. . E-mail: macklir@ccf.org

    2006-10-01

    Iodine-131 (I-131) tositumomab (Bexxar; GlaxoSmithKline, Research Triangle Park, NC) is one of two recently approved radiolabeled antibodies directed against the CD20 surface antigen found on normal B cells and in more than 95% of B cell non-Hodgkin's lymphoma. The compound itself is formulated as an IgG2a immunoglobulin radiolabeled with the mixed beta/gamma emitter I-131. Multicenter clinical trials have repeatedly shown impressive clinical responses (20-40% complete response rates and 60-80% overall response rates) in the patient groups for whom this treatment is indicated. Treatment-related toxicity is generally extremely mild and typically involves only reversible hematopoietic suppression and (in some cases) a risk of treatment-induced hypothyroidism. Owing to Radiation safety concerns necessitated by the clinical use of this targeted radiopharmaceutical, it is important for radiation oncology departments wishing to participate in the care of these patients to establish methodologies and standard operating procedures for safe and efficient departmental use. This summary reviews the pertinent background information related to the current clinical experience with I-131 tositumomab and highlights some of the major opportunities for the participation of radiation oncology in the patient evaluation and treatment process. I-131 tositumomab provides an excellent example of the way in which the increasingly important new field of 'targeted therapy' intersects with the practice of clinical radiotherapy. The author contends that it will be worth the time and effort involved in establishing a firm basis for the development of a comprehensive program for systemic targeted radiopharmaceutical therapies (STaRT) within Radiation medicine domain.

  17. Usefulness of thallium-201 imaging in the diagnosis of metastases from differentiated thyroid carcinoma

    SciTech Connect

    Kusakabe, K.; Kawasaki, S.; Maki, M.; Nara, S.; Kondo, C.; Nishioka, T.; Hiroe, M.; Kurihara, J.; Obara, T.; Yamasaki, T.

    1984-01-01

    To evaluate the usefulness and accuracy of Thallium-201 imaging for detecting metastases from thyroid carcinoma, the authors have compared it with radioiodine scans and serum thyroglobulin levels, which are currently the most sensitive technique for detecting and localizing metastases. Of the sixty-nine patients, fifty-three had lymph node, lung and/or bone metastases. All patients were treated for differentiated thyroid carcinoma with various combinations of total thyroidectomy, radioiodine ablation and thyroid hormone. Scintigraphy with Tl-210 chloride was abnormal in 39 of 53 patients (sensitivity 74%), whereas 34 of 47 patients with I-131 (sensitivity 72%). Positive ratio of I-131 was correlated with histological type (93% of follicular type and 48% of papillary), whereas in the results with Tl-201 no correlation with histopathology was seen. In 13 patients with I-131 scan was negative, but in 11 patients Tl-201 scan revealed the presence of non-functioning metastases. The positive ratio of Tl-201 scans was correlated well with the size of metastases tumors (P<0.005). Of 43 patients with metastases whose thyroglobulin levels (Tg) were measured by radioimmunoassay, Tg were elevated more than 20ng/ml in 37 (86%); the remaining 14% were below 20 ng/ml in spite of having functioning metastases. These patients were subsequently to have elevation of Tg (>80ng/ml) during hypothyroidism. These results indicate Tl-201 scans correlate with serum thyroglobulin levels and have the added advantage of detecting and localizing non-functioning metastases which would not be detected by I-131 scans.

  18. Analysis of thyroid malignant pathological findings identified during three rounds of screening (1997-2008) of a Belarusian cohort of children and adolescents exposed to radioiodines after the Chernobyl accident

    PubMed Central

    Zablotska, Lydia; Nadyrov, Eldar; Rozhko, Alexander; Gong, Zhihong; Polyanskaya, Olga; McConnell, Robert; O'Kane, Patrick; Brenner, Alina; Little, Mark P.; Ostroumova, Evgenia; Bouville, Andre; Drozdovitch, Vladimir; Minenko, Viktor; Demidchik, Yuri; Nerovnya, Alexander; Yauseyenka, Vassilina; Savasteeva, Irina; Nikonovich, Sergey; Mabuchi, Kiyohiko; Hatch, Maureen

    2015-01-01

    Background Recent studies of children and adolescents exposed to radioactive iodine-131 (I-131) after the 1986 Chernobyl nuclear accident in Ukraine showed significant dose-related increase in the risk of thyroid cancer, but the association of radiation doses with tumor histological and morphological features is not clear. Methods A cohort of 11,664 individuals in Belarus ≤18 years at the time of the accident underwent three cycles of thyroid screening in 1997-2008. I-131 thyroid doses were estimated from individual thyroid activity measurements taken within two months after the accident and dosimetric data from questionnaires. Demographic, clinical and pathological characteristics of thyroid cancer cases were analyzed using one-way analysis of variance, chi-square or Fisher's exact tests, and logistic regression. Results As a result of screening, 158 thyroid cancers were identified. The majority of cases had T1a and T1b tumors (93.7%), with many regional N1 (60.6%) but few distant M1 (<1%) metastases. Higher I-131 doses were associated with higher frequency of solid or diffuse sclerosing variants of thyroid cancer (P<0.01) and histological features of cancer aggressiveness, such as lymphatic vessel invasion, intrathyroidal infiltration, and multifocality (all P<0.03). Latency was not correlated with radiation dose. Fifty-two cases of self-reported thyroid cancers diagnosed prior to 1997 were younger at the time of the accident and had a higher percentage of solid variant cancers compared to screening-detected cases (all P<0.0001). Conclusions I-131 thyroid radiation doses were associated with significantly higher frequency of solid or diffuse sclerosing variants of thyroid cancer and various features of tumor aggressiveness. PMID:25351557

  19. Prevalence of Hyperthyroidism Following Exposure During Childhood or Adolescence to Radioiodines from the Chornobyl Nuclear Accident: Dose-Response Results from the Ukrainian-American Cohort Study

    PubMed Central

    Hatch, M.; Furukawa, K.; Brenner, A.; Olinjyk, V.; Ron, E.; Zablotska, L.; Terekhova, G.; McConnell, R.; Markov, V.; Shpak, V.; Ostroumova, E.; Bouville, A.; Tronko, M.

    2013-01-01

    Relatively few data are available on the prevalence of hyperthyroidism (TSH concentrations of < 0.3 mIU/L, with normal or elevated concentrations of free T4) in individuals exposed to radioiodines at low levels. The accident at the Chornobyl (Chernobyl) nuclear plant in Ukraine on April 26, 1986 exposed large numbers of residents to radioactive fallout, principally to iodine-131 (I-131) (mean and median doses = 0.6 Gray (Gy) and 0.2 Gy). We investigated the relationship of I-131 and prevalent hyperthyroidism among 11,853 individuals exposed as children or adolescents in Ukraine who underwent an in-depth, standardized thyroid gland screening examination 12–14 years later. Radioactivity measurements taken shortly after the accident were available for all subjects and were used to estimate individual thyroid doses. We identified 76 cases of hyperthyroidism (11 overt, 65 subclinical). Using logistic regression, we tested a variety of continuous risk models and conducted categorical analyses for all subjects combined and for females (53 cases, n=5,767) and males (23 cases, n=6,086) separately, but found no convincing evidence of a dose response relationship between I-131 and hyperthyroidism. There was some suggestion of elevated risk among females in an analysis based on a dichotomous dose model with a threshold of 0.5 Gy chosen empirically (OR=1.86, P=0.06), but the statistical significance level was reduced (P=0.13) in a formal analysis with an estimated threshold. In summary, after a thorough exploration of the data, we found no statistically significant dose response relationship between individual I-131 thyroid doses and prevalent hyperthyroidism. PMID:21128800

  20. Development, evaluation, and in-vivo validation of two non-invasive methods for quantitation of activity and dosimetry of monoclonal antibodies in humans

    SciTech Connect

    Hammond, N.D.; Moldofsky, P.J.; Exten, R.E.; Gatenby, R.A.; Broder, G.J.

    1985-05-01

    The authors have applied both a conjugate view imaging method and a first pass study for quantitation of absolute I-131 activity in lesions and normal tissue of patients with colon carcinoma in order to study biological clearance of the I-131 F(ab)'/sub 2/ fragments of mouse monoclonal antibody and the resultant dosimetry. Both methods require a transmission scan for determining patient attenuation and measurement of patient lesion or organ size in the region of interest. The conjugate view method is analyzed for both SPECT and planar imaging. The percent error of both methods relates to lesion size and absolute activity when compared to actual well-counter assayed samples of malignant and normal tissue obtained from CT-guided needle biopsies or surgical specimens. Dosimetric evaluation was based on determination of activity, clearance from computer-generated time-activity curves and lesion or organ volumes from volumetric CT scan data. The dose to the thyroid gland was calculated for one population receiving Lugol's solution 3 days prior and for the other who received Lugol's at the time of administration. Data showed no significant difference in absorbed thyroid dose. Lastly, the absolute uptake of I-131, lesion to background ratios, and the dosimetry data were compared for three different monoclonal antibody fragments.

  1. Scintigraphic portrayal of the syndrome of multiple endocrine neoplasia type-2B

    SciTech Connect

    Yobbagy, J.J.; Levatter, R.; Sisson, J.C.; Shulkin, B.L.; Polley, T.

    1988-06-01

    The scintigraphic appearance of the neoplasms in multiple endocrine neoplasia type 2B (MEN-2B) and the interpretations of the image patterns are described. An 18-year-old male patient with the MEN-2B syndrome underwent TI-201 imaging that showed concentrations of TI-201 in the primary medullary thyroid carcinoma (MTC) tumor and in cervical lymph node metastases. After total thyroidectomy and lymph node dissection, the TI-201 image was normal. Catecholamine levels in the blood and urine were only borderline elevated. Yet, greater than normal concentrations of I-131 metaiodobenzylguanidine (I-131 MIBG) were present in both adrenal glands. Computed tomography of the abdomen showed normal adrenal glands. These results were consistent with the diagnosis of adrenal medullary hyperplasia, a precursor of pheochromocytoma. No operation was indicated to remove the adrenal glands. Imaging with TI-201 appears to be useful in identifying sites of MTC in patients with the MEN-2B syndrome. I-131 MIBG imaging, in conjunction with computed tomography of the adrenal glands and appropriate catecholamine measurements, should be performed in patients with the MEN-2B syndrome to determine the status of the adrenal medullae, which then may be classified as normal, hyperplastic, or tumorous with pheochromocytoma.

  2. Environmental radionuclide monitoring of Canadian harbours: a decade of analyses in support of due diligence activities by the Royal Canadian Navy.

    PubMed

    Kelly, David G; Mattson, Kristine M; McDonald, Curtis; Nielsen, Kathy S; Weir, Ron D

    2014-12-01

    The Royal Canadian Navy has conducted a comprehensive programme of safety, security and environmental monitoring since the first visits of nuclear powered and nuclear capable vessels (NPV/NCVs) to Canadian harbours in the late 1960s. The outcomes of baseline monitoring and vessel visit sampling for the period 2003-2012 are described for vessel visits to Halifax (NS), Esquimalt (BC) and Nanoose (BC). Data were obtained by gamma-ray spectroscopy using high purity germanium detectors. No evidence was found for the release of radioactive fission or activation products by NCV/NPVs during the study period, although anthropogenically produced radionuclides were observed as part of the study's baseline monitoring. Background activities of Cs-137 can be observed in sediments from all three locations which are derived from well-documented radioactivity releases. The detection of I-131 in aquatic plants is consistently observed in Halifax at activities as high as 15,000 Bq kg(-1) dry weight. These data are tentatively assigned to the release of medical I-131, followed by bioaccumulation from seawater. I-131 was also observed in aquatic plants samples from Esquimalt (33 Bq kg(-1)) and Nanoose (20 Bq kg(-1)) for a single sampling following the Fukushima Daiichi accident. PMID:24954004

  3. Thyroid doses for evacuees from the Fukushima nuclear accident

    NASA Astrophysics Data System (ADS)

    Tokonami, Shinji; Hosoda, Masahiro; Akiba, Suminori; Sorimachi, Atsuyuki; Kashiwakura, Ikuo; Balonov, Mikhail

    2012-07-01

    A primary health concern among residents and evacuees in affected areas immediately after a nuclear accident is the internal exposure of the thyroid to radioiodine, particularly I-131, and subsequent thyroid cancer risk. In Japan, the natural disasters of the earthquake and tsunami in March 2011 destroyed an important function of the Fukushima Daiichi Nuclear Power Plant (F1-NPP) and a large amount of radioactive material was released to the environment. Here we report for the first time extensive measurements of the exposure to I-131 revealing I-131 activity in the thyroid of 46 out of the 62 residents and evacuees measured. The median thyroid equivalent dose was estimated to be 4.2 mSv and 3.5 mSv for children and adults, respectively, much smaller than the mean thyroid dose in the Chernobyl accident (490 mSv in evacuees). Maximum thyroid doses for children and adults were 23 mSv and 33 mSv, respectively.

  4. Accumulation of iodine-131 and technetium-99m pertechnetate in thyroid carcinoma

    SciTech Connect

    Katagiri, M.; Suzuki, S.; Sadahiro, S.; Kubouchi, K.; Ohmura, T.; Tsumura, O.; Akatsuka, S.

    1988-04-01

    Carcinoma of the thyroid is usually delineated as a cold defect on images with radioiodine and Tc-99m pertechnetate. However, several cases that showed an accumulation of Tc-99m pertechnetate in thyroid carcinoma or in their metastases, but did not show any accumulation of radioiodine, have been reported. This paper presents a rare case of an advanced follicular adenocarcinoma of the thyroid that accumulated both Tc-99m pertechnetate and I-131. In this 41-year-old male patient, there were two primary foci in the thyroid; one occupied the whole left lobe with extension to the mediastinum and the other located in the lower part of the right lobe. In addition, there was a lymph node metastasis in the upper mediastinum adjacent to the left lobe. On images with both I-131 and Tc-99m pertechnetate, the tumor in the left lobe and the metastatic lymph node were delineated, but the tumor in the right lobe was not. Accumulation of Tc-99m pertechnetate in the lower part of the tumor of the left lobe was more distinct than that of I-131. Therefore, it is considered that despite similar histologic findings the trapping ability of the cancerous tissue differed from area to area.

  5. Treatment for Malignant Struma Ovarii in the Eyes of Thyroid Surgeons

    PubMed Central

    Luo, Jiang-rong; Xie, Chun-bao; Li, Zhi-hui

    2014-01-01

    Abstract Malignant struma ovarii (MSO) is a rare malignant ovarian germ cell tumor that has been scarcely reported by thyroid surgeons focusing on treatment. There are no golden standards for its treatment. There has not been any Chinese case included in the English language literatures. This is the first study by collecting all Chinese cases with clinical information. We emphasize on using I131 therapy after operation. Presented is a case of struma ovarii with malignant histologic features who underwent definitive initial surgery of reproductive system tumors and a total thyroidectomy combined with thyroid-stimulating hormone (TSH)-suppressive therapy following treatment with I131. Furthermore, a Chinese full-text database literature search for cases of MSO was performed, and advisable clinical data were collected following our treatment advice. Clinical data from 34 additional cases were compiled. As Chinese genetic background and environment are different from those of Western countries, our clinical data closely mirror theirs in some aspects. In addition, we provide a rare gene mutation type of MSO by the case from our department. Integrating literatures with the experience of thyroid surgeons, we recommend “multidisciplinary joint treatment” for MSO, namely traditional radical initial surgery of ovarian cancer and a total thyroidectomy combined with TSH-suppressive therapy following treatment with I131 for those who do not desire preservation of fertility. PMID:25474425

  6. Thyroid doses for evacuees from the Fukushima nuclear accident

    PubMed Central

    Tokonami, Shinji; Hosoda, Masahiro; Akiba, Suminori; Sorimachi, Atsuyuki; Kashiwakura, Ikuo; Balonov, Mikhail

    2012-01-01

    A primary health concern among residents and evacuees in affected areas immediately after a nuclear accident is the internal exposure of the thyroid to radioiodine, particularly I-131, and subsequent thyroid cancer risk. In Japan, the natural disasters of the earthquake and tsunami in March 2011 destroyed an important function of the Fukushima Daiichi Nuclear Power Plant (F1-NPP) and a large amount of radioactive material was released to the environment. Here we report for the first time extensive measurements of the exposure to I-131 revealing I-131 activity in the thyroid of 46 out of the 62 residents and evacuees measured. The median thyroid equivalent dose was estimated to be 4.2 mSv and 3.5 mSv for children and adults, respectively, much smaller than the mean thyroid dose in the Chernobyl accident (490 mSv in evacuees). Maximum thyroid doses for children and adults were 23 mSv and 33 mSv, respectively. PMID:22792439

  7. Imaging of neuroendocrine tumors in 300 patients following injection of I-123 mIBG or 1-131 mIBG prepared from a {open_quotes}cold kit{close_quotes}

    SciTech Connect

    Karesh, S.M.; Henkin, R.E.

    1994-05-01

    During the past 6 years, we have performed approximately 300 scans for neuroendocrine tumors in an extremely varied patient base, with 65% of patients receiving I-123 mIBG and 35%, I-131 mIBG. Imaging was performed at 24-72 hr, depending upon the isotope used. The most common clinical indication was for pheochromocytoma (>90%), followed by neuroblastoma, paraganglioma, medullary carcinoma of the thyroid, and carcinoid tumors. Radiolabeling was performed by a modification of Mock`s procedure. The radioiodide was added to a very stable {open_quotes}cold kit{close_quotes} developed in-house. The kit contains 1 ml of water for injection, 2 mg of mIBG hemisulfate, and 12 mg of ammonium sulfate. After 2 heating cycles, a yield >85% and a radiochemical purity {>=}96% were routinely obtained. Overall preparation time, including determination of radiochemical purity, is approximately 2.5 hr. The only equipment required is a thermostatically controlled block heater. Biodistribution of our I-131 product was indistinguishable from that distributed by the Nuclear Pharmacy at the University of Michigan, as was the radiochemical purity; the diagnostic efficacy matched that reported in the literature. The image quality obtained using I-123 mIBG was definitely superior, due to both the much higher count rate and the ideal imaging energy of I-123. On one occasion, the I-131 scan was equivocal, whereas the I-123 scan in the same patient was clearly positive. Retrospectively, for studies performed with I-123 mIBG using the {open_quotes}cold kit{close_quotes} method, the specificity and sensitivity both exceed 90%, correlating well with multiple studies reported in the literature. The preparation of I-123 mIBG in-house using this technique is recommended.

  8. Successful radioimmunotherapy for micro and occult metastases in a SCID mouse model

    SciTech Connect

    Yokoyama, K.; Koshida, K.; Kinuya, S. |

    1996-05-01

    It is often addressed that the most appropriate candidate, theoretically, for radioimmunotherapy (RIT) is not bulky tumor burden but for micro or occult metastatic foci, The major obstacles in the verification for veracious efficacy of RIT had been clinically and preclinically the difficulty in obtaining such a model. We have developed the model of testicular tumor (primary site) with visible small metastases to the lymph nodes (LNs) and non-visible (occult) lesions to distant organs in severe combined immunodeficient (SCID) mice. And thus, the suppression of minute tumor depositions after RIT was evaluated. One week after hemilateral intratesticular injection of 2 million of HELA Hep 2 cells that expressed placental alkaline phosphatase (PLAP), the group of the mice were treated with a single dose of I-131 labeled HPMS-1, anti-PLAP MoAb or with saline control. The I-131 labeled HPMS-1 (5.6 MBq / 150 {mu}g) was intravenously administered and at 2 weeks after, the testis, retroperitoneal and intraperitoneal LNs and other gans were removed. For the control group, the testicular tumor and LNs metastases were found in 100% and 86% of the mice. The metastases in the liver and lung were not observed by histological examination but in all mouse samples, the PCR (polymerase chain reaction) assay could identify the human {beta}-globin gene derived from HeLa cells, indicating the presence of definitive metastases. For the treated group, the average testicular tumor weight was significantly reduced by the factor of 2.4 (132 mg vs 311 mg, p<0.01). The LNs metastases were even more distinctively suppressed by the factor of 45.7 (13 mg vs 599 mg, p,0.05). Remarkably, the PCR products from the occult metastases were almost completely controlled; 97% suppression found for the liver and 81% for the lung. Thus, we conclude that using I-131 as a label, RIT is justified to used for targeting and killing minute tumor foci.

  9. Role of single photon emission computed tomography/computed tomography in diagnostic iodine-131 scintigraphy before initial radioiodine ablation in differentiated thyroid cancer

    PubMed Central

    Agrawal, Kanhaiyalal; Bhattacharya, Anish; Mittal, Bhagwant Rai

    2015-01-01

    Objectives: The study was performed to evaluate the incremental value of single photon emission computed tomography/computed tomography (SPECT/CT) over planar radioiodine imaging before radioiodine ablation in the staging, management and stratification of risk of recurrence (ROR) in differentiated thyroid cancer (DTC) patients. Materials and Methods: Totally, 83 patients (21 male, 62 female) aged 17–75 (mean 39.9) years with DTC were included consecutively in this prospective study. They underwent postthyroidectomy planar and SPECT/CT scans after oral administration of 37–114 MBq iodine-131 (I-131). The scans were interpreted as positive, negative or suspicious for tracer uptake in the thyroid bed, cervical lymph nodes and sites outside the neck. In each case, the findings on planar images were recorded first, without knowledge of SPECT/CT findings. Operative and pathological findings were used for postsurgical tumor–node–metastasis staging. The tumor staging was reassessed after each of these two scans. Results: Single photon emission computed tomography/computed tomography localized radioiodine uptake in the thyroid bed in 9/83 (10.8%) patients, neck nodes in 24/83 (28.9%) patients and distant metastases in 8/83 (9.6%) patients in addition to the planar study. Staging was changed in 8/83 (9.6%), ROR in 11/83 (13.2%) and management in 26/83 (31.3%) patients by the pretherapy SPECT/CT in comparison to planar imaging. SPECT/CT had incremental value in 32/83 patients (38.5%) over the planar scan. Conclusion: Single photon emission computed tomography/computed tomography is feasible during a diagnostic I-131 scan with a low amount of radiotracer. It improved the interpretation of pretherapy I-131 scintigraphy and changed the staging and subsequent patient management. PMID:26170564

  10. On developing a pragmatic strategy for clinical trials: A case study of hepatocellular carcinoma.

    PubMed

    Gandhi, Mihir; Tan, Say Beng; Chung Yaw Fui, Alexander; Machin, David

    2015-07-01

    Randomised controlled trials (RCTs) with sufficiently high statistical power are not always feasible for patients when the administration of the treatment is burdensome. Nevertheless, useful information concerning the relative effectiveness of the Test and Standard therapies, may be gleaned from under powered trials, non-randomised comparative studies and/or clinician's beliefs: the latter possibly additionally providing some suggestion of the strength of evidence required in order to adopt the Test therapy into clinical practice. In such circumstances, a Bayesian synthesis may be useful in quantifying the evidence of treatment effectiveness. In this article, we aim to present a Bayesian approach for synthesizing the cumulative evidence of the use of adjuvant hepatic intra-arterial iodine-131-lipiodol (I131L) following curative resection in hepatocellular carcinoma (HCC) patients. We constructed a posterior distribution using the information from two small RCTs, three non-randomised comparative studies, three single arm studies and the views of investigators on the use of I131L. This distribution enables calculation of the probability that the Test therapy is more effective than the Standard by a pre-stipulated amount. If this is very high, then for example, one may conclude the Test may replace the Standard therapy. If it is not, then the Standard would be retained for clinical use. Despite a strong early indication of the effectiveness of I131L, the evolving evidence over a 10-year period became more sceptical of its value. Although highly recommended, difficulties of implementing a Bayesian approach in this context are highlighted. PMID:26111924

  11. Iodine-131 Dose Dependent Gene Expression in Thyroid Cancers and Corresponding Normal Tissues Following the Chernobyl Accident

    PubMed Central

    Abend, Michael; Pfeiffer, Ruth M.; Ruf, Christian; Hatch, Maureen; Bogdanova, Tetiana I.; Tronko, Mykola D.; Riecke, Armin; Hartmann, Julia; Meineke, Viktor; Boukheris, Houda; Sigurdson, Alice J.; Mabuchi, Kiyohiko; Brenner, Alina V.

    2012-01-01

    The strong and consistent relationship between irradiation at a young age and subsequent thyroid cancer provides an excellent model for studying radiation carcinogenesis in humans. We thus evaluated differential gene expression in thyroid tissue in relation to iodine-131 (I-131) doses received from the Chernobyl accident. Sixty three of 104 papillary thyroid cancers diagnosed between 1998 and 2008 in the Ukrainian-American cohort with individual I-131 thyroid dose estimates had paired RNA specimens from fresh frozen tumor (T) and normal (N) tissue provided by the Chernobyl Tissue Bank and satisfied quality control criteria. We first hybridized 32 randomly allocated RNA specimen pairs (T/N) on 64 whole genome microarrays (Agilent, 4×44 K). Associations of differential gene expression (log2(T/N)) with dose were assessed using Kruskall-Wallis and trend tests in linear mixed regression models. While none of the genes withstood correction for the false discovery rate, we selected 75 genes with a priori evidence or P kruskall/P trend <0.0005 for validation by qRT-PCR on the remaining 31 RNA specimen pairs (T/N). The qRT-PCR data were analyzed using linear mixed regression models that included radiation dose as a categorical or ordinal variable. Eleven of 75 qRT-PCR assayed genes (ACVR2A, AJAP1, CA12, CDK12, FAM38A, GALNT7, LMO3, MTA1, SLC19A1, SLC43A3, ZNF493) were confirmed to have a statistically significant differential dose-expression relationship. Our study is among the first to provide direct human data on long term differential gene expression in relation to individual I-131 doses and to identify a set of genes potentially important in radiation carcinogenesis. PMID:22848350

  12. Development of a Novel Thyroid Function Fluctuated Animal Model for Thyroid-Associated Ophthalmopathy

    PubMed Central

    Tu, Yunhai; Wang, Yilong; Ding, Luna; Zhang, Jiao; Wu, Wencan

    2016-01-01

    Background The establishment of a suitable and stable animal model is critical for research on thyroid-associated ophthalmopathy (TAO). In clinical practice, we found that patients treated with I-131 often exhibit TAO; therefore, we aimed to establish a novel thyroid function fluctuated animal model of TAO by simulating the clinical treatment process. Methods We treated SD rats with I-131 to damage the thyroid and then used sodium levothyroxine (L-T4) to supplement the thyroid hormone (TH) levels every seven days, leading to a fluctuating level of thyroid hormones that simulated the status of clinical TAO patients. Rats administered normal saline were considered as a control. The weight, intraocular pressure, and serum T3, T4, TSH and TRAb levels of the rats were measured, and the pathological changes were analyzed by H&E staining and transmission electron microscopy (TEM). Results The experimental rats (TAO group) exhibited significantly reduced weight and elevated intraocular pressure compared with the control rats. Meanwhile, the serum levels of T3 and T4 were up-regulated in the TAO group, but the TSH level decreased during the 10-week study. Moreover, increased numbers of blood vessels and inflammatory cell infiltrations were observed in the orbital tissues of the TAO rats, while no abnormal changes occurred in the control rats. The orbital myofibrils in the TAO rats appeared fractured and dissolved, with twisted structures. Mitochondrial swelling and vacuoles within the endoplasmic reticulum, swelling nerve fibers, shedding nerve myelin, and macrophages were found in the TAO group. Conclusion Rats treated with I-131 and sodium levothyroxine exhibited characteristics similar to those of TAO patients in the clinic, providing an effective and simple method for the establishment of a stable animal model for research on the pathogenesis and treatment of TAO. PMID:26872324

  13. Monte Carlo verification of polymer gel dosimetry applied to radionuclide therapy: a phantom study

    NASA Astrophysics Data System (ADS)

    Gear, J. I.; Charles-Edwards, E.; Partridge, M.; Flux, G. D.

    2011-11-01

    This study evaluates the dosimetric performance of the polymer gel dosimeter 'Methacrylic and Ascorbic acid in Gelatin, initiated by Copper' and its suitability for quality assurance and analysis of I-131-targeted radionuclide therapy dosimetry. Four batches of gel were manufactured in-house and sets of calibration vials and phantoms were created containing different concentrations of I-131-doped gel. Multiple dose measurements were made up to 700 h post preparation and compared to equivalent Monte Carlo simulations. In addition to uniformly filled phantoms the cross-dose distribution from a hot insert to a surrounding phantom was measured. In this example comparisons were made with both Monte Carlo and a clinical scintigraphic dosimetry method. Dose-response curves generated from the calibration data followed a sigmoid function. The gels appeared to be stable over many weeks of internal irradiation with a delay in gel response observed at 29 h post preparation. This was attributed to chemical inhibitors and slow reaction rates of long-chain radical species. For this reason, phantom measurements were only made after 190 h of irradiation. For uniformly filled phantoms of I-131 the accuracy of dose measurements agreed to within 10% when compared to Monte Carlo simulations. A radial cross-dose distribution measured using the gel dosimeter compared well to that calculated with Monte Carlo. Small inhomogeneities were observed in the dosimeter attributed to non-uniform mixing of monomer during preparation. However, they were not detrimental to this study where the quantitative accuracy and spatial resolution of polymer gel dosimetry were far superior to that calculated using scintigraphy. The difference between Monte Carlo and gel measurements was of the order of a few cGy, whilst with the scintigraphic method differences of up to 8 Gy were observed. A manipulation technique is also presented which allows 3D scintigraphic dosimetry measurements to be compared to polymer

  14. Human radiation studies: Remembering the early years. Oral history of Dr. Nadine Foreman, M.D., August 19, 1994

    SciTech Connect

    1995-07-01

    Dr. Nadine Foreman was interviewed by representatives of the US DOE Office of Human Radiation Experiments (OHRE). Dr. Foreman was selected for interview because of the position she held at the University of California, San Francisco. Following a brief biographical sketch, Dr. Foreman describes her work with Dr. Mayo Soley using I-131 in treatment of hyperthyroidism, selection criteria for patients in the radioiodine project, work with Dr. Earl Miller, work at Highland Hospital, radioiodine treatment of diffuse toxic goiter (myxedema), the radiophosphorus and radioiodine programs with Dr. Bert Low-Beer, and treatment of polycythemia vera.

  15. Electron-tracking Compton gamma-ray camera for small animal and phantom imaging

    NASA Astrophysics Data System (ADS)

    Kabuki, Shigeto; Kimura, Hiroyuki; Amano, Hiroo; Nakamoto, Yuji; Kubo, Hidetoshi; Miuchi, Kentaro; Kurosawa, Shunsuke; Takahashi, Michiaki; Kawashima, Hidekazu; Ueda, Masashi; Okada, Tomohisa; Kubo, Atsushi; Kunieda, Etuso; Nakahara, Tadaki; Kohara, Ryota; Miyazaki, Osamu; Nakazawa, Tetsuo; Shirahata, Takashi; Yamamoto, Etsuji; Ogawa, Koichi; Togashi, Kaori; Saji, Hideo; Tanimori, Toru

    2010-11-01

    We have developed an electron-tracking Compton camera (ETCC) for medical use. Our ETCC has a wide energy dynamic range (200-1300 keV) and wide field of view (3 sr), and thus has potential for advanced medical use. To evaluate the ETCC, we imaged the head (brain) and bladder of mice that had been administered with F-18-FDG. We also imaged the head and thyroid gland of mice using double tracers of F-18-FDG and I-131 ions.

  16. Management and autopsy of a radioactive cadaver.

    PubMed

    Wallace, A B; Bush, V

    1991-06-01

    A 69 year old male was treated with an ablative dose of 3.7 GBq (100 mCi) of I131 for carcinoma of the thyroid and died 10 days after administration. The requirement for an autopsy and the level of radiation still present in the body necessitated the intervention of Radiation Safety Personnel to minimise support staff radiation exposure and area contamination. Preventative measures were taken in accordance with the ALARA principle and a detailed procedure is presented as a suggested model for any future occurrence. PMID:1747080

  17. Radiochemical analysis of the first plateout probe from the Fort St. Vrain high-temperature gas-cooled reactor

    SciTech Connect

    Burnette, R.D.

    1982-06-01

    This report presents the analysis of radioactive elements on the first plateout probe from the Fort St. Vrain high-temperature gas-cooled reactor. The plateout probe is a device which samples the primary coolant for condensible fission products. Circuit inventories of individual radionuclides are estimated from the probe analysis. The analysis shows that the radioactive contamination in the primary circuit is remarkable low, with activation product concentrations much greater than that of fission products. The analysis demonstrates that the concentrations of the key fission products I-131 and Sr-90 are far below the limits allowed by the technical specification.

  18. Patient-specific dosimetry based on quantitative SPECT imaging and 3D-DFT convolution

    SciTech Connect

    Akabani, G.; Hawkins, W.G.; Eckblade, M.B.; Leichner, P.K.

    1999-01-01

    The objective of this study was to validate the use of a 3-D discrete Fourier Transform (3D-DFT) convolution method to carry out the dosimetry for I-131 for soft tissues in radioimmunotherapy procedures. To validate this convolution method, mathematical and physical phantoms were used as a basis of comparison with Monte Carlo transport (MCT) calculations which were carried out using the EGS4 system code. The mathematical phantom consisted of a sphere containing uniform and nonuniform activity distributions. The physical phantom consisted of a cylinder containing uniform and nonuniform activity distributions. Quantitative SPECT reconstruction was carried out using the Circular Harmonic Transform (CHT) algorithm.

  19. Nondestructive measurement of environmental radioactive strontium

    NASA Astrophysics Data System (ADS)

    Saiba, Shuntaro; Okamiya, Tomohiro; Tanaka, Saki; Tanuma, Ryosuke; Totsuka, Yumi; Murata, Jiro

    2014-03-01

    The Fukushima Daiichi nuclear power plant accident was triggered by the 2011 Great East Japan Earthquake. The main radioactivity concerns after the accident are I-131 (half-life: 8.0 days), Cs-134 (2.1 years), Cs-137 (30 years), Sr-89 (51 days), and Sr-90 (29 years). We are aiming to establish a new nondestructive measurement and detection technique that will enable us to realize a quantitative evaluation of strontium radioactivity without chemical separation processing. This technique is needed to detect radiation contained in foods, environmental water, and soil, to prevent us from undesired internal exposure to radiation.

  20. Development of Nondestructive Measuring Technique of Environmental Radioactive Strontium

    NASA Astrophysics Data System (ADS)

    Saiba, Shuntaro; Okamiya, Tomohiro; Tanaka, Saki; Tanuma, Ryosuke; Yoshida, Tatsuru; Murata, Jiro

    The Fukushima first nuclear power plant accident was triggered by the Japanese big earthquake in 2011. The main radioactivity concerned after the accident are I-131 (half-life 8.0 days), Cs-134 (2.1 years) and 137 (30 years), Sr-89 (51 days) and 90 (29 years). We are aiming to establish a new detection technique which enables us to realize quantitative evaluation of the strontium radioactivity by means of nondestructive measurement without chemical separation processing, which is concerned to be included inside foods, environmental water and soil around us, in order to prevent us from undesired internal exposure to the radiation.

  1. Improved radioimmunotherapy of hematologic malignancies. Final technical report

    SciTech Connect

    Press, O.W.

    1996-08-15

    Experiments were performed to study the rates of endocytosis, intracellular routing, and metabolic degradation of radiolabeled monoclonal antibodies targeting tumor-associated antigens on human leukemia and lymphoma cells. An attempt was made to examine in vivo the effects of lysosomotropic amines and thioamides on the retention of radiolabeled monoclonal antibodies by tumor cells. Experiments also examined the impact of newer radioiodination techniques on the metabolic degradation of radioiodinated antibodies, and on the radioimmunoscintigraphy and radioimmunotherapy of neoplasms. The endocytosis, intracellular routing, and degradation of radioimmunoconjugates prepared with I-131, In-111, and Y-90 were compared. The utility of radioimmunoconjugates targeting oncogene products for the radioimmunotherapy and radioimmunoscintigraphy of cancer was investigated.

  2. Los Alamos Air Monitoring Data Related to the Fukushima Daiichi Reactor

    SciTech Connect

    McNaughton, Michael

    2011-01-01

    In response to the disasters in Japan on March 11, 2011, Los Alamos National Laboratory (LANL) is collecting air data and analyzing the data for fission products. At present, we report preliminary data from three high-volume air samplers and one stack sampler. Iodine-131 (I-131) is not optimally measured by our standard polypropylene filters. In addition to the filter data, we have one measurement obtained from a charcoal cartridge. These data, together with measurements of other radionuclides are adequate for a preliminary assessment and assure us that radionuclides from Fukushima Daiichi do not present a threat to human health at or near Los Alamos.

  3. Sublingual pyramidal lobe. Complications of subtotal thyroidectomy for Graves' disease

    SciTech Connect

    Sternberg, J.L.

    1986-11-01

    A potential complication of subtotal thyroidectomy where a large pyramidal lobe is present is described. The pyramidal lobe normally is immobilized inferiorly by its attachment to the thyroidal isthmus. When the isthmus is removed and the pyramidal lobe is left in situ during subtotal thyroidectomy its superior attachments will allow the pyramidal lobe to become situated sublingually. This may produce gagging and nausea. To avoid the complication, it is recommended that the pyramidal lobe be removed during subtotal thyroidectomy. If the patient also is thyrotoxic, I-131 can be used to treat this complication successfully.

  4. Determination of Columbia River flow times from Pasco, Washington using radioactive tracers introduced by the Hanford reactors

    USGS Publications Warehouse

    Nelson, Jack L.; Perkins, R.W.; Haushild, W.L.

    1966-01-01

    Radioactive tracers introduced into the Columbia River in cooling water from the Hanford reactors were used to measure flow times downstream from Pasco, Washington, as far as Astoria, Oregon. The use of two tracer methods was investigated. One method used the decay of a steady release of Na24 (15-hour half-life) to determine flow times to various downstream locations, and flow times were also determined from the time required for peak concentration of instantaneous releases of I131 (8-day half-life) to reach these locations. Flow times determined from the simultaneous use of the two methods agreed closely. The measured flow times for the 224 miles from Pasco to Vancouver, Washington, ranged from 14.6 to 3.6 days, respectively, for discharges of 108,000 and 630,000 ft3/sec at Vancouver, Washington. A graphic relation for estimating flow times at discharges other than those measured and for several locations between Pasco and Vancouver was prepared from the data of tests made at four river discharges. Some limited data are also presented on the characteristics of dispersion of I131 in the Columbia River. (Keywords: Radioactivity; time of flow; Columbia River.)

  5. Management and follow-up results of an incidental thyroid carcinoma in a young woman with ovarian teratoma.

    PubMed

    Uzum, Ayse Kubat; Iyibozkurt, Cem; Canbaz, Bulent; Ciftci, Sema Dogansen; Aksakal, Nihat; Kapran, Yersu; Aral, Ferihan; Ozbey, Nese Colak

    2013-07-01

    Thyroid cancer in ovarian teratoma is reported to be rare and experiences are limited. A 26-year-old woman had undergone bilateral cystectomy and omentectomy for bilateral cystic adnexial masses. Pathological examination showed 1.5 cm follicular variant papillary thyroid carcinoma on the basis of unilateral mature cystic teratoma. Increased CA-125 and CA19-9 levels decreased to normal reference ranges after surgery, but postoperative magnetic resonance imaging indicated multiple abdominal cystic loci. After total thyroidectomy, high dose I-131 was administered to ablate thyroid tissue. Thereafter, levothyroxine was started to achieve subclinical hyperthyroidism. No iodine uptake was detected in post-therapeutic whole body scan (WBS) other than thyroid bed. This finding supported that tumor did not show dissemination to abdomen. No uptake on the first-year evaluation with low-dose I-131 WBS suggested the complete ablation of the thyroid gland. It is recommended that thyroid carcinoma arising from ectopic thyroid tissue in a teratoma should be managed as thyroid carcinoma in thyroid. However, direct dissemination to contiguous regions in abdomen and hematogenous dissemination to distant organs should be in mind. Radical surgery including total abdominal hysterectomy, bilateral salphingo-oopherectomy, pelvic and paraaortic lymph node excision and thyroidectomy is recommended. Fertility preserving surgery may be the surgical procedure as in the present case. PMID:23772787

  6. A review of treatment options for Graves' disease: why total thyroidectomy is a viable option in selected patients.

    PubMed

    Mohan, Vinuta; Lind, Robert

    2016-01-01

    Graves' disease is the most common cause of hyperthyroidism. If left untreated, patients may have multiple systemic complications such as cardiac, reproductive, and skeletal disease. Thionamides, such as methimazole and propylthiouracil, and I(131) iodine ablation are the most commonly prescribed treatment for Graves' disease. Total thyroidectomy is often overlooked for treatment and is usually only offered if the other options have failed. In our case, we discuss a patient who was admitted to our medical center with symptomatic hyperthyroidism secondary to long-standing Graves' disease. She had a history of non-compliance with medications and medical clinic follow-up. The risks and benefits of total thyroidectomy were explained and she consented to surgery. A few months after the procedure, she was biochemically and clinically euthyroid on levothyroxine. She had no further emergency room visits or admissions for uncontrolled thyroid disease. Here we review the advantages and disadvantages of the more typically prescribed treatments, thionamides and I(131)iodine ablation. We also review the importance of shared decision making and the benefits of total thyroidectomy for the management of Graves' disease. Given the improvement in surgical techniques over the past decade and a significant reduction of complications, we suggest total thyroidectomy be recommended more often for patients with Graves' disease. PMID:27609732

  7. [Effect of radio therapy on the magnitude of iodine radioisotope half-life in the thyroid tissue remnants in patients with differentiated thyroid cancer].

    PubMed

    Kozak, O V; Trembach, O M; Romanenko, L V; Butrym, O I

    2008-01-01

    The use of external irradiation in the treatment of patients with differentiated thyroid cancer is still under consideration. The aim of the study was to compare Tef in the thyroid remnants in patients with and without external irradiation prior to radioiodine treatment. 70 patients with thyroid remnants after resection of thyroid and dissection of pathological lymph nodes were treated by I-131. Patients were divided into two groups: Group 1--with external irradiation (25-60 Gy)-21 patient, and Group 2--patients who did not received external irradiation prior to radioiodine treatment (49 patients). Activities administered ranged from 1000 to 4500 MBq. I-131 kinetics was followed daily during first 4 days after activity administration on the basis of mathematical analysis of scintigraphy. T(ef) was calculated under the assumption of exponential excretion of 131-I from remnants. It was shown that in Group 1 T(eff) = 3.87 +/- 2.5 days, in Group 2 T(eff) amounted to 2.9 +/- 2.2 days. Thus, external irradiation resulted in slowing down of 131-I excretion in thyroid remnants. The probability of the full remnants ablation after the first course of 131-I treatment (p) has been calculated. It was shown that p is higher in the Group 2 in every activity interval. Teff in sequential courses of 131-I treatment has been measured at the same patients. Thus, external irradiation influences in different way at the previously irradiated and not irradiated cells. PMID:19253734

  8. Radiological Impact Assessment (RIA) following a postulated accident in PHWRS

    SciTech Connect

    Soni, N.; Kansal, M.; Rammohan, H. P.; Malhotra, P. K.

    2012-07-01

    Radiological Impact Assessment (RIA) following postulated accident i.e Loss of Coolant Accident (LOCA) with failed Emergency Core Cooling System (ECCS), performed as part of the reactor safety analysis of a typical 700 MWe Indian Pressurized Heavy Water Reactor(PHWR). The rationale behind the assessment is that the public needs to be protected in the event that the postulated accident results in radionuclide release outside containment. Radionuclides deliver dose to the human body through various pathways namely, plume submersion, exposure due to ground deposition, inhalation and ingestion. The total exposure dose measured in terms of total effective dose equivalent (TEDE) is the sum of doses to a hypothetical adult human at exclusion zone boundary by all the exposure pathways. The analysis provides the important inputs to decide upon the type of emergency counter measures to be adopted during the postulated accident. The importance of the various pathways in terms of contribution to the total effective dose equivalent(TEDE) is also assessed with respect to time of exposure. Inhalation and plume gamma dose are the major contributors towards TEDE during initial period of accident whereas ingestion and ground shine dose start dominating in TEDE in the extended period of exposure. Moreover, TEDE is initially dominated by I-131, Kr-88, Te-132, I-133 and Sr-89, whereas, as time progresses, Xe-133,I-131 and Te-132 become the main contributors. (authors)

  9. Body water compartments during bed rest: Evaluation of analytical methods

    NASA Technical Reports Server (NTRS)

    Young, H. L.; Juhos, L.; Castle, B. L.; Yusken, J.; Greenleaf, J. E.

    1973-01-01

    Nine healthy young men were studied to determine the reproducibility and interchangeability of the use of radio-iodinated human serum albumin and Evans Blue dye for estimating plasma volume, sodium bromide for extracellular fluid volume, and deuterium oxide for total body water volume. All subjects were tested in a semibasal condition and allowed to rest for at least 30 min. after arriving at the laboratory. The results indicate that there was uniform distribution of I131 and Evans Blue dye 10 min. after injection and of NaBr and D2O 3 hours after oral ingestion; the buildup of residual tracer did not interfere appreciably with the measurement of either or Evans Blue spaces when they are administered at equal intervals, and the buildup of background tracer after ingestion of NaBr and D2O once per week for three consecutive weeks did not affect the accuracy of the measurement. It was found that I131 and Evans Blue may be used interchangeably for estimating plasma volume; for estimating bromide and D2O spaces, one 3-hour equilibrium blood sample gives results similar to the extrapolation of multiple samples.

  10. Long-term follow-up after iodine-131 treatment for Plummer's disease (autonomous goiter)

    SciTech Connect

    Wiener, J.D.

    1985-04-01

    A follow-up study is presented in 88 patients treated with I-131 for Plummer's disease (localized autonomous thyroid function, either multifocal or as a solitary nodule) one to 17 years before the present study. Studies included clinical examination, scintigraphy, and function tests. One patient was hypothyroid, seven were marginally hyperthyroid, and five still received low dose antithyroid drugs. Of 75 euthyroid patients, the thyrotropin (TSH) response to thyrotropin-releasing hormone (TRH) was absent in 16 (generally with scintigraphic evidence of autonomous function), subnormal in 20, and normal in 39. A single autonomous nodule prior to treatment was found relatively frequently in males and in patients with a normal TRH test at follow-up. Most goiters had become smaller and one third of all solitary nodules could not be detected anymore. Autonomous function at follow-up was probably due to residual rather than recurrent disease in most, if not all, cases. It is concluded that I-131 therapy is at least as satisfactory as partial thyroidectomy in the treatment of Plummer's disease; lifelong follow-up was not found to be necessary.

  11. Sodium Iodide Symporter for Nuclear Molecular Imaging and Gene Therapy: From Bedside to Bench and Back

    PubMed Central

    Ahn, Byeong-Cheol

    2012-01-01

    Molecular imaging, defined as the visual representation, characterization and quantification of biological processes at the cellular and subcellular levels within intact living organisms, can be obtained by various imaging technologies, including nuclear imaging methods. Imaging of normal thyroid tissue and differentiated thyroid cancer, and treatment of thyroid cancer with radioiodine rely on the expression of the sodium iodide symporter (NIS) in these cells. NIS is an intrinsic membrane protein with 13 transmembrane domains and it takes up iodide into the cytosol from the extracellular fluid. By transferring NIS function to various cells via gene transfer, the cells can be visualized with gamma or positron emitting radioisotopes such as Tc-99m, I-123, I-131, I-124 and F-18 tetrafluoroborate, which are accumulated by NIS. They can also be treated with beta- or alpha-emitting radionuclides, such as I-131, Re-186, Re-188 and At-211, which are also accumulated by NIS. This article demonstrates the diagnostic and therapeutic applications of NIS as a radionuclide-based reporter gene for trafficking cells and a therapeutic gene for treating cancers. PMID:22539935

  12. Radioimmunoimaging of pneumocystis carinii infection in rats

    SciTech Connect

    Vallabhajosula, S.; Shane, L.B.; Goldsmith, S.J.; Lipszyc, H.; Walzer, P.

    1984-01-01

    Pneumocystis carinil pneumonia (PCP) is seen in patients with impaired immunity due to chemotherapeutic suppression or to a primary disorder, congenital or AIDS. Although radiogallium imaging has been helpful in the workup of PCP, it is non-specific. Since there is no early specific non-invasive method to diagnose PCP, the authors are developing an imaging technique using radiolabeled antibodies. Fulminant PCP was induced in rats by injecting cortisone, 20mg 2-3 times/wk for 8 wks. PC cells isolated from rat lung were injected into rabbits. The antiserum thus derived was separated and purified using Protein-A bound sepharose column with identification of IgG by polyacrylamide gel electrophoresis. Both rabbit antipneumocystis antibodies and purified IgG(Sigma) were iodinated with I-131 to a high specific activity (3-5..mu..Ci/ug) using a lactoperoxidase method. /sup 131/I-labeled specific and non-specific IgG were injected into rats with PC infection and imaged with an Anger camera. After sacrifice, I-131 activity/gram tissue (lung, liver, heart) was determined and expressed as organ ratios. An increased uptake of specific antibody in lungs of rats with PCP was demonstrated by organ counting and imaging. This increase was not seen in normal controls or rats injected with non-specific IgG. These data provide a basis for radioimmunoimaging of infectious diseases.

  13. Hepatic cancer: Correlative imaging with radioimmunodetection, NMR, and TCT

    SciTech Connect

    De Lund, F.H.; Lieber, A.; Ram, M.D.; Goldenberg, D.M.

    1984-01-01

    The purpose of this study was to compare the sensitivity of radioimmunodetection (RAID) imaging and nuclear magnetic resonance imaging in the detection of hepatic tumors. Twelve consecutive patients with metastatic (11) or primary (1) carcinoma of the liver were imaged concurrently with labeled antibodies-to-tumor antigens and by nuclear magnetic resonance. Evidence of hepatic tumors was corrected with other diagnostic procedures including TCT. Eleven patients were imaged with I-131 labeled antibodies to CEA, CSAP and one with I-131 labeled antibodies to AFP. Polyclonal, monoclonal, and Fab'/sub 2/ antibodies were used. The preparation and labeling of the antibodies have been described previously. Each patient received 2-3 mCi of labeled antibodies and was imaged at 24 to 48 hrs. Nontarget radioactivity was diminished by other radionuclides simulating nontumor distribution using a computer subtraction technique. NMR images were obtained with a 0.15T resistive instrument. In all twelve patients hepatic tumor was diagnosed by RAID. Nine of the hepatic tumors were confirmed by other methods. NMR demonstrated four positive findings in these nine. Computerized tomography detected tumors in three of the nine patients at the time of the first RAID examination, and subsequently in one more patient when RAID and NMR examinations were performed concurrently. In this series of patients the detection of hepatic cancer by RAID showed twice the sensitivity of NMR or TCT.

  14. Savannah River Site radioiodine atmospheric releases and offsite maximum doses

    SciTech Connect

    Marter, W.L.

    1990-11-01

    Radioisotopes of iodine have been released to the atmosphere from the Savannah River Site since 1955. The releases, mostly from the 200-F and 200-H Chemical Separations areas, consist of the isotopes, I-129 and 1-131. Small amounts of 1-131 and 1-133 have also been released from reactor facilities and the Savannah River Laboratory. This reference memorandum was issued to summarize our current knowledge of releases of radioiodines and resultant maximum offsite doses. This memorandum supplements the reference memorandum by providing more detailed supporting technical information. Doses reported in this memorandum from consumption of the milk containing the highest I-131 concentration following the 1961 1-131 release incident are about 1% higher than reported in the reference memorandum. This is the result of using unrounded 1-131 concentrations of I-131 in milk in this memo. It is emphasized here that this technical report does not constitute a dose reconstruction in the same sense as the dose reconstruction effort currently underway at Hanford. This report uses existing published data for radioiodine releases and existing transport and dosimetry models.

  15. An overview of radioactive waste disposal procedures of a nuclear medicine department.

    PubMed

    Ravichandran, R; Binukumar, J P; Sreeram, Rajan; Arunkumar, L S

    2011-04-01

    Radioactive wastes from hospitals form one of the various types of urban wastes, which are managed in developed countries in a safe and organized way. In countries where growth of nuclear medicine services are envisaged, implementations of existing regulatory policies and guidelines in hospitals in terms of handling of radioactive materials used in the treatment of patients need a good model. To address this issue, a brief description of the methods is presented. A designed prototype waste storage trolley is found to be of great help in decaying the I-131 solid wastes from wards before releasing to waste treatment plant of the city. Two delay tanks with collection time of about 2 months and delay time of 2 months alternately result in 6 releases of urine toilet effluents to the sewage treatment plant (STP) of the hospital annually. Samples of effluents collected at releasing time documented radioactive releases of I-131 much below recommended levels of bi-monthly release. External counting of samples showed good statistical correlation with calculated values. An overview of safe procedures for radioactive waste disposal is presented. PMID:21731225

  16. Activity concentrations of environmental samples collected in Fukushima Prefecture immediately after the Fukushima nuclear accident

    PubMed Central

    Hosoda, Masahiro; Tokonami, Shinji; Tazoe, Hirofumi; Sorimachi, Atsuyuki; Monzen, Satoru; Osanai, Minoru; Akata, Naofumi; Kakiuchi, Hideki; Omori, Yasutaka; Ishikawa, Tetsuo; Sahoo, Sarata K.; Kovács, Tibor; Yamada, Masatoshi; Nakata, Akifumi; Yoshida, Mitsuaki; Yoshino, Hironori; Mariya, Yasushi; Kashiwakura, Ikuo

    2013-01-01

    Radionuclide concentrations in environmental samples such as surface soils, plants and water were evaluated by high purity germanium detector measurements. The contribution rate of short half-life radionuclides such as 132I to the exposure dose to residents was discussed from the measured values. The highest values of the 131I/137Cs activity ratio ranged from 49 to 70 in the environmental samples collected at Iwaki City which is located to the south of the F1-NPS. On the other hand, the 132I/131I activity ratio in the same environmental samples had the lowest values, ranging from 0.01 to 0.02. By assuming that the 132I/131I activity ratio in the atmosphere was equal to the ratio in the environmental samples, the percent contribution to the thyroid equivalent dose by 132I was estimated to be less than 2%. Moreover, the contribution to the thyroid exposure by 132I might be negligible if 132I contamination was restricted to Iwaki City. PMID:23887080

  17. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer- APPENDICES Appendices-Volume 1A

    SciTech Connect

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-07-01

    This report consists of all the appendices for the report described below: In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values as appendices. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest

  18. Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956)- An Assessment of Quantities released, Off-Site Radiation Doses, and Potential Excess Risks of Thyroid Cancer, Volume 1

    SciTech Connect

    Apostoaei, A.I.; Burns, R.E.; Hoffman, F.O.; Ijaz, T.; Lewis, C.J.; Nair, S.K.; Widner, T.E.

    1999-07-01

    In the early 1990s, concern about the Oak Ridge Reservation's past releases of contaminants to the environment prompted Tennessee's public health officials to pursue an in-depth study of potential off-site health effects at Oak Ridge. This study, the Oak Ridge dose reconstruction, was supported by an agreement between the U.S. Department of Energy (DOE) and the State of Tennessee, and was overseen by a 12-member panel appointed by Tennessee's Commissioner of Health. One of the major contaminants studied in the dose reconstruction was radioactive iodine, which was released to the air by X-10 (now called Oak Ridge National Laboratory) as it processed spent nuclear reactor fuel from 1944 through 1956. The process recovered radioactive lanthanum for use in weapons development. Iodine concentrates in the thyroid gland so health concerns include various diseases of the thyroid, such as thyroid cancer. The large report, ''Iodine-131 Releases from Radioactive Lanthanum Processing at the X-10 Site in Oak Ridge, Tennessee (1944-1956) - An Assessment of Quantities Released, Off-site Radiation Doses, and Potential Excess Risks of Thyroid Cancer,'' is in two volumes. Volume 1 is the main body of the report, and Volume 1A, which has the same title, consists of 22 supporting appendices. Together, these reports serve the following purposes: (1) describe the methodologies used to estimate the amount of iodine-131 (I-131) released; (2) evaluate I-131's pathway from air to vegetation to food to humans; (3) estimate doses received by human thyroids; (4) estimate excess risk of acquiring a thyroid cancer during ones lifetime; and (5) provide equations, examples of historical documents used, and tables of calculated values. Results indicate that females born in 1952 who consumed milk from a goat pastured a few miles east of X-10 received the highest doses from I-131 and would have had the highest risks of contracting thyroid cancer. Doses from cow's milk are considerably less . Detailed

  19. Detailed source term estimation of atmospheric release during the Fukushima Dai-ichi nuclear power plant accident by coupling atmospheric and oceanic dispersion models

    NASA Astrophysics Data System (ADS)

    Katata, Genki; Chino, Masamichi; Terada, Hiroaki; Kobayashi, Takuya; Ota, Masakazu; Nagai, Haruyasu; Kajino, Mizuo

    2014-05-01

    Temporal variations of release amounts of radionuclides during the Fukushima Dai-ichi Nuclear Power Plant (FNPP1) accident and their dispersion process are essential to evaluate the environmental impacts and resultant radiological doses to the public. Here, we estimated a detailed time trend of atmospheric releases during the accident by combining environmental monitoring data and coupling atmospheric and oceanic dispersion simulations by WSPEEDI-II (Worldwide version of System for Prediction of Environmental Emergency Dose Information) and SEA-GEARN developed by the authors. New schemes for wet, dry, and fog depositions of radioactive iodine gas (I2 and CH3I) and other particles (I-131, Te-132, Cs-137, and Cs-134) were incorporated into WSPEEDI-II. The deposition calculated by WSPEEDI-II was used as input data of ocean dispersion calculations by SEA-GEARN. The reverse estimation method based on the simulation by both models assuming unit release rate (1 Bq h-1) was adopted to estimate the source term at the FNPP1 using air dose rate, and air sea surface concentrations. The results suggested that the major release of radionuclides from the FNPP1 occurred in the following periods during March 2011: afternoon on the 12th when the venting and hydrogen explosion occurred at Unit 1, morning on the 13th after the venting event at Unit 3, midnight on the 14th when several openings of SRV (steam relief valve) were conducted at Unit 2, morning and night on the 15th, and morning on the 16th. The modified WSPEEDI-II using the newly estimated source term well reproduced local and regional patterns of air dose rate and surface deposition of I-131 and Cs-137 obtained by airborne observations. Our dispersion simulations also revealed that the highest radioactive contamination areas around FNPP1 were created from 15th to 16th March by complicated interactions among rainfall (wet deposition), plume movements, and phase properties (gas or particle) of I-131 and release rates

  20. Correction for collimator-detector response in SPECT using point spread function template.

    PubMed

    Chun, Se Young; Fessler, Jeffrey A; Dewaraja, Yuni K

    2013-02-01

    Compensating for the collimator-detector response (CDR) in SPECT is important for accurate quantification. The CDR consists of both a geometric response and a septal penetration and collimator scatter response. The geometric response can be modeled analytically and is often used for modeling the whole CDR if the geometric response dominates. However, for radionuclides that emit medium or high-energy photons such as I-131, the septal penetration and collimator scatter response is significant and its modeling in the CDR correction is important for accurate quantification. There are two main methods for modeling the depth-dependent CDR so as to include both the geometric response and the septal penetration and collimator scatter response. One is to fit a Gaussian plus exponential function that is rotationally invariant to the measured point source response at several source-detector distances. However, a rotationally-invariant exponential function cannot represent the star-shaped septal penetration tails in detail. Another is to perform Monte-Carlo (MC) simulations to generate the depth-dependent point spread functions (PSFs) for all necessary distances. However, MC simulations, which require careful modeling of the SPECT detector components, can be challenging and accurate results may not be available for all of the different SPECT scanners in clinics. In this paper, we propose an alternative approach to CDR modeling. We use a Gaussian function plus a 2-D B-spline PSF template and fit the model to measurements of an I-131 point source at several distances. The proposed PSF-template-based approach is nearly non-parametric, captures the characteristics of the septal penetration tails, and minimizes the difference between the fitted and measured CDR at the distances of interest. The new model is applied to I-131 SPECT reconstructions of experimental phantom measurements, a patient study, and a MC patient simulation study employing the XCAT phantom. The proposed model

  1. Littoral cell angioma presenting as metastatic thyroid carcinoma to the spleen.

    PubMed

    Mohan, Vineeth; Jones, Ralph C; Drake, Almond J; Daly, Patrick L; Shakir, K M Mohamed

    2005-02-01

    Papillary thyroid carcinoma (PTC) commonly metastasizes to cervical lymph nodes. Distant metastases are unusual with the lungs most frequently involved. Well-differentiated thyroid carcinoma very rarely presents with metastases to the spleen. This is the case of a 25-year-old man with a history of PTC (1.4 cm primary; no capsular invasion and negative lymph node metastases). One year after initial surgery, recurrent disease was found in multiple neck nodes by central neck dissection. Whole body scan (WBS) following a therapeutic ablation dose of 150 mCi I(131) revealed mediastinal metastases. Computerized axial tomography (CT) of the chest one year later showed no gross mediastinal or pulmonary disease. However, multiple large splenic lesions were incidentally noted. Evaluation by ultrasound (US) showed lesions to be solid echogenic masses without remarkable Doppler characteristics to suggest vascular tumors. US-guided percutaneous fine-needle aspiration biopsy (FNAB) of one lesion was nondiagnostic. After withdrawal from Levothyroxine, serum TSH was >100 mU/L with a thyroglobulin of 9.4 ng/mL and negative anti-thyroglobulin antibodies. Diagnostic WBS revealed faint splenic uptake but was otherwise unremarkable. Following treatment with 192 mCi I(131), WBS demonstrated increased activity in the mediastinum as well as in the spleen suggesting mediastinal and splenic metastases. Contrast CT of the abdomen showed multiple low-attenuated heterogeneously enhancing splenic masses, normal liver and no intra-abdominal lymphadenopathy. The largest mass (4.5 x 3.5 cm) was exophytic and in close proximity to the splenic capsule. Despite the serum thyroglobulin of only 9.4 ng/mL, the finding of I(131) accumulation within solid splenic masses led to a preoperative diagnosis of thyroid carcinoma metastases. To establish the diagnosis and to remove the risk for splenic rupture, a laparoscopic splenectomy was performed. Histopathologic analysis showed large littoral cell angiomas

  2. Possible consequences of severe accidents at the Lubiatowo site, Poland

    NASA Astrophysics Data System (ADS)

    Seibert, Petra; Philipp, Anne; Hofman, Radek; Gufler, Klaus; Sholly, Steven

    2014-05-01

    The construction of a nuclear power plant is under consideration in Poland. One of the sites under discussion is near Lubiatowo, located on the cost of the Baltic Sea northwest of Gdansk. An assessment of possible environmental consequences is carried out for 88 real meteorological cases with the Lagrangian particle dispersion model FLEXPART. Based on literature research, three reactor designs (ABWR, EPR, AP 1000) were identified as being under discussion in Poland. For each of the designs, a set of accident scenarios was evaluated and two source terms per reactor design were selected for analysis. One of the selected source terms was a relatively large release while the second one was a severe accident with an intact containment. Considered endpoints of the calculations are ground contamination with Cs-137 and time-integrated concentrations of I-131 in air as well as committed doses. They are evaluated on a grid of ca. 3 km mesh size covering eastern Central Europe.

  3. The fifth BIOMOVS meeting

    SciTech Connect

    Not Available

    1988-01-01

    The fifth workshop and Coordinating Group meeting were held in Grand Canyon, US, November 30 to December 4, 1987 with the US Department of Energy and National Council of Radiation Protection and Measurement acting as host. The workshop focused on discussions of results of Approach A and B scenarios as well as on proposals for new scenarios. The following scenarios under Approach A were discussed: release of mercury into a river; I-131 in milk after the Chernobyl accident; Cs-137 in milk, beef and barley after the Chernobyl accident and dynamics within a lake ecosystem. The following scenarios under Approach B were discussed: atmospheric deposition; irrigation with contaminated ground water; release into a lake from a river; aging of a lake; transport of contaminated groundwater to soil; and transport of contaminated ground water to a river. Reports on data quality and uncertainty analysis were also given.

  4. Cyclotron production of I-123: An evaluation of the nuclear reactions which produce this isotope

    NASA Technical Reports Server (NTRS)

    Sodd, V. J.; Scholz, K. L.; Blue, J. W.; Wellman, H. N.

    1970-01-01

    The use of the various nuclear reactions is described by which I-123,a low radiation dose radiopharmaceutical, can be cyclotron-produced. Methods of directly producing I-123 and those which indirectly produce the radionuclide through the beta (+) decay of its nautral precursor, Xe-123. It is impossible to separate from the radioiodine contaminants, notably I-124, which occur in the direct method. Thus, it is preferable to produce pure I-123 from Xe-123 which is easily separated from the radioiodines. Among the characteristics of I-123 is the capability of reducing the patient dose in a thyroid uptake measurement to a very small percentage of that delivered by the more commonly used I-131.

  5. Comparison of magnetic resonance imaging and radionuclide imaging in the evaluation of renal transplant failure

    SciTech Connect

    Goldsmith, M.S.; Tanasescu, D.E.; Waxman, A.D.; Crues, J.V. III

    1988-04-01

    Magnetic resonance imaging (MRI) was compared with radionuclide scintigraphy (RNS) in 16 patients with renal transplants undergoing renal failure to determine which modality could best discriminate between rejection, acute tubular necrosis (ATN), and cyclosporin nephrotoxicity (CN). Although all rejecting transplants had reduced corticomedullary differentiation (CMD) on T1-weighted MR images, four of five cases of ATN had appearances that could not be distinguished from rejection. A normal CMD suggests nonrejection, but diminished CMD is nonspecific. Tc-99m DTPA/I-131 hippuran RNS was superior to MRI in differentiating rejection from ATN. Although ATN and CN have similar RNS patterns, this distinction can usually be made based on the clinical time course. Other potential uses of MRI in the evaluation of the renal transplants are discussed.

  6. Diagnosis of hepatobiliary disease in infants and children with Tc-99m-diethyl-IDA imaging

    SciTech Connect

    Ohi, R.; Klingensmith, W.C.; Lilly, J.R.

    1981-07-01

    Thirteen infants and children from 42 days to 14 years old with hepatobiliary disease underwent Tc-99m-diethyl-IDA hepatobiliary imaging. Five patients had biliary atresia, four had biliary hypoplasia, two had neonatal hepatitis, and there were single examples of alpha-1-antitrypsin deficiency and congenital hepatic fibrosis. Tc-99m-diethyl-IDA imaging accurately differentiated biliary atresia (complete bile duct obstruction) from other forms of childhood hepatobiliary disease by demonstrating no intestinal radioactivity in the former and the presence of intestinal radioactivity in the latter. In addition, two of four patients with biliary hypoplasia had nonhomogeneous parenchymal transit, and the one patient with congenital hepatic fibrosis showed possible intrahepatic cysts. In conclusion, these preliminary data indicate that Tc-99m-diethyl-IDA provides information not previously available with I-131-rose bengal; this information is likely to be useful in the noninvasive evaluation of childhood hepatobiliary disease.

  7. Thyroid and parathyroid imaging

    SciTech Connect

    Sandler, M.P.; Patton, J.A.; Partain, C.L.

    1986-01-01

    This book describes the numerous modalities currently used in the diagnosis and treatment of both thyroid and parathyroid disorders. Each modality is fully explained and then evaluated in terms of benefits and limitations in the clinical context. Contents: Production and Quality Control of Radiopharmaceutics Used for Diagnosis and Therapy in Thyroid and Parathyroid Disorders. Basic Physics. Nuclear Instrumentation. Radioimmunoassay: Thyroid Function Tests. Quality Control. Embryology, Anatomy, Physiology, and Thyroid Function Studies. Scintigraphic Thyroid Imaging. Neonatal and Pediatric Thyroid Imaging. Radioiodine Thyroid Uptake Measurement. Radioiodine Treatment of Thyroid Disorders. Radiation Dosimetry of Diagnostic Procedures. Radiation Safety Procedures for High-Level I-131 Therapies. X-Ray Fluorescent Scanning. Thyroid Sonography. Computed Tomography in Thyroid Disease. Magnetic Resonance Imaging in Thyroid Disease. Parathyroid Imaging.

  8. Clinical application of SPECT in adrenal imaging with iodine-131 6 beta-iodomethyl-19-norcholesterol

    SciTech Connect

    Ishimura, J.; Kawanaka, M.; Fukuchi, M.

    1989-04-01

    Forty-one patients with or without adrenocortical disorders were studied to evaluate the clinical usefulness of SPECT in adrenal imaging with I-131 Adosterol. In the SPECT images from this study, all glands with either normally functioning or hyperfunctioning adrenal cortices could be detected, while those glands with hypofunctioning adrenal cortices could not be detected. Particularly in transaxial and sagittal slices, the adrenal gland was identified posteriorly and was clearly distinguished from the gallbladder. In preliminary results using SPECT by a standard method, uptake in 68 detectable glands ranged from 1.7% to 4.9% in four glands with Cushing's syndrome, from 1.1% to 1.3% in seven glands with primary aldosteronism, and were distributed below 1.0% in the remaining glands with normally functioning adrenal cortices. These data show that it is possible to evaluate the adrenocortical functioning status simply by analyzing the SPECT images of the adrenal.

  9. Fission products in National Atmospheric Deposition Program—Wet deposition samples prior to and following the Fukushima Dai-Ichi Nuclear Power Plant incident, March 8?April 5, 2011

    USGS Publications Warehouse

    Wetherbee, Gregory A.; Debey, Timothy M.; Nilles, Mark A.; Lehmann, Christopher M.B.; Gay, David A.

    2012-01-01

    Radioactive isotopes I-131, Cs-134, or Cs-137, products of uranium fission, were measured at approximately 20 percent of 167 sampled National Atmospheric Deposition Program monitoring sites in North America (primarily in the contiguous United States and Alaska) after the Fukushima Dai-Ichi Nuclear Power Plant incident on March 12, 2011. Samples from the National Atmospheric Deposition Program were analyzed for the period of March 8-April 5, 2011. Calculated 1- or 2-week radionuclide deposition fluxes at 35 sites from Alaska to Vermont ranged from 0.47 to 5,100 Becquerels per square meter during the sampling period of March 15-April 5, 2011. No fission-product isotopes were measured in National Atmospheric Deposition Program samples obtained during March 8-15, 2011, prior to the arrival of contaminated air in North America.

  10. Environmental radionuclide concentrations in the vicinity of the peach bottom atomic power station: 1985-1986. Data report

    SciTech Connect

    Domotor, S.L.; McLean, R.I.

    1989-07-01

    High-resolution gamma spectroscopy was used to determine radionuclide concentrations in over 450 biota and sediment samples collected from the Susquehanna River-Chesapeake Bay system in the vicinity of the Peach Bottom Atomic Power Station (PBAPS) during 1985-1986. Low concentrations of PBAPS-related radionuclides (Zn65, Cs-134, and Cs-137) were detected in finfish, mussels, and crayfish. These PBAPS-related radionuclides and Co-60 were also detected in sediments. I-131 attributable to the Chernobyl reactor accident (April 26, 1986) was detected in environmental samples collected in May 1986. PBAPS-related radionuclide concentrations in biota and sediments represent small increments to the Susquehanna River-Chesapeake Bay system relative to natural and weapons test levels; radionuclide releases by PBAPS, and radiation doses to man, are well within regulatory limits.

  11. Thyroid cancer radioiodine therapy: health service performance and radiation safety.

    PubMed

    Vogiatzi, S; Liossis, A; Lamprinakou, M

    2015-07-01

    Greek Atomic Energy Commission collected data related to radioiodine I-131 therapy (RAIT) delivery to differentiated thyroid carcinoma patients, for the period 2003-13, corresponding to 100 % of hospitals at national level. Radiation safety and health service performance outcome indicators were assessed. The numbers of hospitals and nuclear medicine (NM) therapy wards, as well as RAIT annual frequencies, have increased. Geographical inhomogeneous distribution of existing infrastructure is recorded. In some cases, the observed inefficient use of NM therapy wards seems to be due to lack of human resources (e.g. nurses). Regular assessment of appropriate key indicators could serve as a useful tool for radiation safety monitoring and health service performance improvement. PMID:25809109

  12. Observation of radioactive iodine ((131)I, (129)I) in cropland soil after the Fukushima nuclear accident.

    PubMed

    Fujiwara, Hideshi

    2016-10-01

    During the early stages of the Fukushima nuclear accident, the temporal variations of (131)I deposited on the ground and of (131)I accumulated in cropland soil were monitored at a fixed location in Japan. Moreover, concentrations of long-lived radioactive iodine ((129)I) in atmospheric deposits and soil were measured to examine the feasibility of retrospectively reconstructing (131)I levels from the levels of accident-derived (129)I. The exceptionally high levels of (131)I in deposits and soil were attributed to rainfall-related deposition of radionuclides. In the crop field studied, the losses of deposited (131)I and (129)I due to volatilization were small. The atomic ratio (129)I/(131)I in the topsoil corresponded to the same ratio in deposits. The (131)I concentrations measured in the topsoil were very consistent with the (131)I concentrations reconstructed from the (129)I concentrations in the soil. PMID:27320744

  13. Imaging secondary neuroendocrine tumours of the liver: comparison of I123 metaiodobenzylguanidine (MIBG) and In111-labelled octreotide (Octreoscan).

    PubMed

    Ramage, J K; Williams, R; Buxton-Thomas, M

    1996-07-01

    Functional imaging of neuroendocrine tumours with Octreoscan and I123-metaiodobenzylguanidine (MIBG) is important for assessment prior to various therapies and assessing response. The two imaging methods have not been directly compared in hepatic neuroendocrine tumours. Patients (n = 18) were studied with both imaging techniques. The sensitivity of Octreoscan was 94%, and that of MIBG 39%. No previously occult primary sites were detected. Concurrent octreotide therapy did not reduce the sensitivity of Octreoscan. Widespread bone metastases were seen in two post-liver-transplant patients using Octreoscan. Octreoscan is a sensitive means of detecting hepatic neuroendocrine tumours, and the more specific technique. MIBG has poor sensitivity, reducing its clinical utility. Therapy with I131-MIBG is likely to be applicable to relatively few patients. PMID:8759495

  14. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-11-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (Z)-4-Hydroxytamoxifen, [18F]-FPS; Adalimumab, alefacept, alemtuzumab, alfimeprase, aprepitant, aripiprazole, atomoxetine hydrochloride; Belatacept, bortezomib; C340, caspofungin acetate, clazosentan sodium, Cypher; Darbepoetin alfa, DB-289, decitabine, dronedarone hydrochloride, duloxetine hydrochloride; Eletriptan, entecavir, ertapenem sodium, escitalopram oxalate, eszopiclone, etoricoxib; Gaboxadol, gadofosveset sodium, galiximab, gemifloxacin mesilate, glutamine; Human insulin; I-131 ch-TNT-1/B, indiplon, inhaled insulin, isatoribine; L-Arginine hydrochloride, liposomal doxorubicin, lopinavir/ritonavir, lumiracoxib; Magnesium sulfate; Natalizumab; Olmesartan medoxomil, omapatrilat, OncoVEX (GM-CSF); rDNA insulin, rupatadine fumarate; Sorafenib; Tadalafil, teduglutide, temsirolimus, tenofovir disoproxil fumarate, tiotropium bromide; Valdecoxib, vardenafil hydrochloride hydrate. PMID:16357953

  15. Yttrium-90/indium-111 DOTA peptide chimeric L6; pharmacokinetics, dosimetry and initial therapeutic studies in patients with breast cancer

    SciTech Connect

    DeNardo, S.J.; Shen, S.; Richman, C.M.

    1995-05-01

    Chimeric L6 MoAb(ChL6) as I-131 ChL6 has shown therapeutic promise in breast cancer patients. To enhance this potential, we developed yttrium-90 (Y-90) and indium-111 (In-111) ChL6 radiopharmaceuticals by conjugating Y-90 and In-111 DOTA peptide ChL6. Immunoreactivity of In-111 and Y-90 ChL6 was 80-100% of ChL6. Dosimetry was calculated from pharmacokinetics obtained in four studies of patients with metastatic breast cancer using 200 mg ChL6 and 4mCi In-111/3mCi Y-90 DOTA peptide ChL6 in 3 studies and 10 mCi In-111 in one (specific activity 1.1-3.5mCi/mg). Quantitative imaging of In-111 and in vitro analysis of Y-90/In-111 blood and urine clearances and biopsies for bone and marrow uptake were performed. In-111 and Y-90 DOTA peptide ChL6 blood clearances were compared in each patient with {beta} intercepts for each initial study of 13.9/12.7, 4.9/5.8, 25.2/16.2 (%ID), and {beta} T{1/2} 32/30, 33/35, and 41/57 (h) for In- 111/Y-90, respectively. Normal organ and tumor dosimetry for Y-90 DOTA peptide ChL6 was extrapolated from the In-111 kinetics: WB 2.1-2.3, Liver 3.8-5.9, Lung 6.2-7.9, Kidney 8.1-11.3, Spleen 4.4-14.0 (cGy/mCi). Dosimetry of 13 tumored areas (1-10 g) ranged from 42-260 (mean = 103) cGy/mCi. Marrow doses calculated from Y-90 in blood ranged from 0.6-1.5. Marrow biopsies at 5 d pi showed In-111 and Y-90 (%ID/g), 1-2 x 10{sup -3} and 6-7x10{sup -4} and bone 1-3x10{sup -3} and 0.1-3x10{sup -4}, respectively. Compared to our previous I-131 ChL6 dosimetry, this study indicates that the Y-90 DOTA peptide ChL6 radiation dose to tumor is 4-8 times that of I-131 ChL6 whereas normal organs receive less than twice that of I-131 from Y-90. Based on this calculated enhancement of the therapeutic ratio, a multicycle Y-90 DOTA peptide ChL6 therapy protocol has been initiated in breast cancer patients.

  16. Rats with spontaneous high level of NaCl intake have hypothyroidism.

    PubMed

    Belló, A A; Covian, M R

    1991-11-01

    The thyroid function was studied by means of a comparison between rats that drank daily less than 2 mEq of a NaCl solution (control) and rats that spontaneously drank daily above 4 mEq of this solution (0.25 M), which is considered aversive to rats. It was found that, in these rats, the protein-bound iodine (PBI-127) and the radioactive iodine uptake (I-131) were less than in the control rats, in spite of similar thyroid weight. It seems, therefore, that the rats that drank high levels of the aversive salt solution have hypothyroidism. This finding shows another link between the thyroid gland and NaCl intake. These data have implications in the design and interpretation of experiments in which NaCl intake is studied. PMID:1805272

  17. 124I-MIBG: a new promising positron-emitting radiopharmaceutical for the evaluation of neuroblastoma.

    PubMed

    Cistaro, Angelina; Quartuccio, Natale; Caobelli, Federico; Piccardo, Arnoldo; Paratore, Rosario; Coppolino, Pietro; Sperandeo, Alessandro; Arnone, Gaspare; Ficola, Umberto

    2015-01-01

    Neuroblastoma is the most common extra-cranial solid tumor in pediatric patients. Despite the established role of 123I-MIBG and 131I-MIBG scintigraphy in this tumor, only limited data are available regarding the use of 124I-metaiodobenzylguanidine (MIBG) positron emission tomography (PET)/computed tomography (CT). We present our preliminary experience with 124I-MIBG PET/CT: two pediatric patients affected by neuroblastoma, who underwent 124I-MIBG PET/CT for pre-therapy distribution evaluation and restaging purposes. We aimed to evaluate whether 124I-MIBG PET/CT can detect as many or more neuroblastoma lesions than 123I/131I-MIBG imaging. Our cases show promising results, although further validation and standardization of 124I-MIBG PET/CT are required. PMID:26315872

  18. Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome.

    PubMed

    Armstrong, Amy E; Weese-Mayer, Debra E; Mian, Amir; Maris, John M; Batra, Vandana; Gosiengfiao, Yasmin; Reichek, Jennifer; Madonna, Mary Beth; Bush, Jonathan W; Shore, Richard M; Walterhouse, David O

    2015-11-01

    Neuroblastoma in patients with congenital central hypoventilation syndrome (CCHS) as part of a neurocristopathy syndrome is a rare finding and has only been associated with paired-like homeobox 2b (PHOX2B) non-polyalanine-repeat-expansion mutations. To the best of our knowledge, we report the first case of a child with CCHS and Hirschsprung disease who had a PHOX2B polyalanine-repeat-expansion mutation (PARM) (genotype 20/33) and developed high-risk neuroblastoma. We further describe his treatment including chemotherapy and therapeutic I(131) -metaiodobenzylguanidine. This case highlights the need to consider neuroblastoma in patients with CCHS and the longest PHOX2B PARMs and to individualize treatment based on co-morbidities. PMID:26011159

  19. Therapeutic use of /sup 131/I-metaiodobenzylguanidine (MIBG) in neuroblastoma: a phase II study in nine patients

    SciTech Connect

    Hartmann, O.; Lumbroso, J.; Lemerle, J.; Schlumberger, M.; Ricard, M.; Aubert, B.; Coonaert, S.; Merline, L.; Olive, D.; De Lumley, L.

    1987-01-01

    Effects of high activities of I 131 meta-iodobenzylguanidine (mIBG) were evaluated in nine children with advanced neuroblastoma. All patients had been previously heavily treated and had either primarily refractory disease or resistant relapse. Twenty-two doses of mIBG labeled with 1.3 to 4 GBq (35-108 mCi) of iodine 131 were administered. Three subjective effects, especially relief of pain, and two objective effects were observed. Transient blood pressure increase was observed once and did not recur after prolongation of the infusion time to 6 hours. A major side effect was bone marrow toxicity, essentially marked by thrombopenia, particularly severe in previously bone-marrow-transplanted patients.

  20. Adult Neuroblastoma Complicated by Increased Intracranial Pressure: A Case Report and Review of the Literature

    PubMed Central

    Stevens, Patrick L.; Johnson, Douglas B.; Thompson, Mary Ann; Keedy, Vicki L.; Frangoul, Haydar A.; Snyder, Kristen M.

    2014-01-01

    Neuroblastoma is the third most commonly occurring malignancy of the pediatric population, although it is extremely rare in the adult population. In adults, neuroblastoma is often metastatic and portends an extremely poor overall survival. Our case report documents metastatic neuroblastoma occurring in a healthy 29-year-old woman whose course was complicated by an unusual presentation of elevated intracranial pressures. The patient was treated with systemic chemotherapy, I131 metaiodobenzylguanidine (MIBG) radiotherapy, and autologous stem cell transplant (SCT). Unfortunately the patient's response to therapy was limited and she subsequently died. We aim to review neuroblastoma in the context of increased intracranial pressure and the limited data of neuroblastoma occurring in the adult population, along with proposed treatment options. PMID:25328733

  1. Adult neuroblastoma complicated by increased intracranial pressure: a case report and review of the literature.

    PubMed

    Stevens, Patrick L; Johnson, Douglas B; Thompson, Mary Ann; Keedy, Vicki L; Frangoul, Haydar A; Snyder, Kristen M

    2014-01-01

    Neuroblastoma is the third most commonly occurring malignancy of the pediatric population, although it is extremely rare in the adult population. In adults, neuroblastoma is often metastatic and portends an extremely poor overall survival. Our case report documents metastatic neuroblastoma occurring in a healthy 29-year-old woman whose course was complicated by an unusual presentation of elevated intracranial pressures. The patient was treated with systemic chemotherapy, I(131) metaiodobenzylguanidine (MIBG) radiotherapy, and autologous stem cell transplant (SCT). Unfortunately the patient's response to therapy was limited and she subsequently died. We aim to review neuroblastoma in the context of increased intracranial pressure and the limited data of neuroblastoma occurring in the adult population, along with proposed treatment options. PMID:25328733

  2. I-123 MIBG imaging of metastatic carcinoid tumor from the rectum.

    PubMed

    Watanabe, N; Seto, H; Ishiki, M; Shimizu, M; Kageyama, M; Wu, Y W; Nagayoshi, T; Kamisaki, Y; Kakishita, M

    1995-04-01

    I-131 MIBG, a specific radiopharmaceutical agent for scintigraphic imaging and treatment of pheochromocytoma and neuroblastoma may be useful for detection of apudomas. Scintigraphy with I-123 radiolabeled MIBG was performed in a patient with metastatic carcinoid tumor from the rectum. I-123 MIBG scintigraphic findings showed multiple areas of abnormal tumor uptake of hepatic and bone metastases from the rectal carcinoid. Bone scintigraphy demonstrated multiple metastatic lesions. Computed tomography revealed multiple solid tumors of the liver. This report describes accumulation of I-123 MIBG in the liver and bone metastases from the rectal carcinoid. Radioiodine MIBG scintigraphy may be useful for detecting metastatic lesions, for evaluating postoperative recurrence, and also for the treatment of the carcinoid tumor. PMID:7788995

  3. Biological investigation of 131I-labeled new water soluble Ru(II) polypyridyl complex.

    PubMed

    Ocakoglu, Kasim; Yildirim, Yeliz; Yurt Lambrecht, Fatma; Ocal, Jale; Icli, Siddik

    2008-02-01

    New [Ru(L1)(dcbpy)(NCS)2] complex was synthesized in a one-pot reaction starting from [RuCl2(p-cymene)]2, where the ligands (dcbpy=4,4'-dicarboxy-2,2'-bipyridine, L1=dipyrido[3,2-a:2',3'-c]phenazine-11-ylcarbonyl)-sodium) are introduced sequentially. The resulting complex was characterized by IR, NMR, and elemental analysis. The complex was labeled with I-131. Biodistribution study of the complex was carried out using 131I-labeled [Ru(L1)(dcbpy)(NCS)2] complex. The biodistribution study performed with albino Wistar male rats has shown that the complex has high uptake in the lung, small intestine, fat, and spleen. PMID:17913501

  4. Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

    SciTech Connect

    Holm, L.E.

    1982-02-01

    The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 though 1975 (p less than 0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays.

  5. Changing annual incidence of hypothyroidism after iodine-131 therapy for hyperthyroidism, 1951-1975

    SciTech Connect

    Holm, L.E.

    1982-02-01

    The incidence of hypothyroidism was analyzed in 4,553 hyperthyroid patients treated with I-131 between 1951 and 1975. The average annual rate of hypothyroidism during the first 7 yr after therapy increased continuously for each 5-yr period of treatment, from 3.6% for patients treated between 1951 and 1955 to 7.7% for patients treated during the period from 1971 through 1975 (p<0.001). The increase in the incidence of hypothyroidism was seen before the introduction of TSH assays and when allowance was made for thyroid gland size, the age of the patient, and the experience of the radiotherapist. The use of TSH assays has probably resulted in an earlier recognition of hypothyroidism, which may explain why the most marked rise in the incidence of hypothyroidism was observed after the introduction of TSH assays.

  6. Cancer radioimmunotherapy: Development of an effective approach. Progress report, 1985

    SciTech Connect

    DeNardo, S.J.

    1985-12-31

    The objective of this program is the development of effective approaches for delivering radiation therapy to patients with cancer using radiopharmaceuticals produced from monoclonal antibodies. One major achievement of this program has been the development of a new, Cu-67 chelator (Teta). This chelator firmly holds copper even in the presence of competitive serum proteins. Copper has proven to be labile with other chelators. Also, a single photon emission tomographic camera was purchased with University and philanthropic funds specifically for this program. This allows full-time developmental work on quantitative imaging approaches and in vivo kinetics of our various radiopharmaceutical antibody products. The pharmakinetics of I-123 antibody and antibody fragments have been obtained in patients utilizing quantitative imaging and have demonstrated significant differences as well as the need for long- term studies with I-131 and Cu-67.

  7. Cancer radioimmunotherapy: Development of an effective approach

    SciTech Connect

    DeNardo, S.J.

    1985-01-01

    The objective of this program is the development of effective approaches for delivering radiation therapy to patients with cancer using radiopharmaceuticals produced from monoclonal antibodies. One major achievement of this program has been the development of a new, Cu-67 chelator (Teta). This chelator firmly holds copper even in the presence of competitive serum proteins. Copper has proven to be labile with other chelators. Also, a single photon emission tomographic camera was purchased with University and philanthropic funds specifically for this program. This allows full-time developmental work on quantitative imaging approaches and in vivo kinetics of our various radiopharmaceutical antibody products. The pharmakinetics of I-123 antibody and antibody fragments have been obtained in patients utilizing quantitative imaging and have demonstrated significant differences as well as the need for long- term studies with I-131 and Cu-67.

  8. The necessity of nuclear reactors for targeted radionuclide therapies.

    PubMed

    Krijger, Gerard C; Ponsard, Bernard; Harfensteller, Mark; Wolterbeek, Hubert T; Nijsen, Johannes W F

    2013-07-01

    Nuclear medicine has been contributing towards personalized therapies. Nuclear reactors are required for the working horses of both diagnosis and treatment, i.e., Tc-99m and I-131. In fact, reactors will remain necessary to fulfill the demand for a variety of radionuclides and are essential in the expanding field of targeted radionuclide therapies for cancer. However, the main reactors involved in the global supply are ageing and expected to shut down before 2025. Therefore, the fields of (nuclear) medicine, nuclear industry and politics share a global responsibility, faced with the task to secure future access to suitable nuclear reactors. At the same time, alternative production routes should be industrialized. For this, a coordinating entity should be put into place. PMID:23731577

  9. Dose and risk in diagnostic radiology: How big How little Lecture Number 16

    SciTech Connect

    Webster, E.W.

    1992-01-01

    This lecture is divided into two parts: dose and risk. The dose segment is technical and noncontroversial since it deals with straightforward measurements or calculations which do not depend on unproven hypotheses. Some conflicting contributions of low dose epidemiological studies to the appraisal of risk are briefly presented. Attention is focused on the following: dose reduction in radiography; dose reduction in fluoroscopy; limitations of dose reduction; estimated radiation risks for diagnostic radiology examinations; excess breast cancer following X-ray examinations for scoliosis; dose-response relation for human mammary cancer; lung cancer from protracted X-irradiation; leukemia and diagnostic X-ray exposure; and thyroid cancer after diagnostic dose of I-131.

  10. Radionuclide imaging and treatment of thyroid cancer.

    PubMed

    Wang, Xiu Juan; Li, XianFeng; Ren, Yuan

    2016-01-01

    Over the past decades, the diagnostic methods and therapeutic tools for thyroid cancer (TC) have been greatly improved. In addition to the classical method of ingestion of radioactive iodine-131 (I131) and subsequent I123 and I124 positron emission tomography (PET) in therapy and examination, I124 PET-based 3-dimensional imaging, Ga68-labeled [1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid]-1-NaI(3)-octreotide (DOTANOC) PET/computed tomography (CT), Tc99m tetrofosmin, pre-targeted radioimmunotherapy, and peptide receptor radionuclide therapy have all been used clinically. These novel methods are useful in diagnosis and therapy of TC, but also have unavoidable adverse effects. In this review, we will discuss the development of nuclear medicine in TC examination and treatment. PMID:27100499

  11. Accuracy of quantitative reconstructions in SPECT/CT imaging

    NASA Astrophysics Data System (ADS)

    Shcherbinin, S.; Celler, A.; Belhocine, T.; van der Werf, R.; Driedger, A.

    2008-09-01

    The goal of this study was to determine the quantitative accuracy of our OSEM-APDI reconstruction method based on SPECT/CT imaging for Tc-99m, In-111, I-123, and I-131 isotopes. Phantom studies were performed on a SPECT/low-dose multislice CT system (Infinia-Hawkeye-4 slice, GE Healthcare) using clinical acquisition protocols. Two radioactive sources were centrally and peripherally placed inside an anthropometric Thorax phantom filled with non-radioactive water. Corrections for attenuation, scatter, collimator blurring and collimator septal penetration were applied and their contribution to the overall accuracy of the reconstruction was evaluated. Reconstruction with the most comprehensive set of corrections resulted in activity estimation with error levels of 3-5% for all the isotopes.

  12. Synchronous double primary cancer - intrahepatic cholangiocarcinoma with bone metastases and thyroid carcinoma: A case report

    PubMed Central

    WANG, QING-LIANG; LI, XIAO-JIE; ZHAO, KUN; LIU, BO; YE, XIAO-MING

    2015-01-01

    There is a low incidence of multiple primary cancer, particularly when the cancer is synchronous. The present report presents a case of synchronous double primary malignancies. A 58-year-old woman was admitted to Ling Nan Hospital (Guangzhou, China) complaining of pain in the left hip. X-ray revealed an osteolytic lesion and further examination indicated the presence of double primary cancer, consisting of hepatic cholangiocarcinoma and thyroid carcinoma. Biopsy of the osteolytic lesion showed a metastatic adenocarcinoma of unknown origin. Subsequently, final diagnosis was confirmed by I-131 scan and liver lesion biopsy. The patient received positive multidisciplinary treatments and survived for 9 months following diagnosis. The results of the present case suggest that multiplicity of primary malignancy is not necessarily an indicator of poor prognosis, as long as effective diagnosis and adequate disease management are achieved. PMID:26788211

  13. The radiation dosimetry of intrathecally administered radionuclides

    SciTech Connect

    Stabin, M.G.; Evans, J.F.

    1999-01-01

    The radiation dose to the spine, spinal cord, marrow, and other organs of the body from intrathecal administration of several radiopharmaceuticals was studied. Anatomic models were developed for the spine, spinal cerebrospinal fluid (CSF), spinal cord, spinal skeleton, cranial skeleton, and cranial CSF. A kinetic model for the transport of CSF was used to determine residence times in the CSF; material leaving the CSF was thereafter assumed to enter the bloodstream and follow the kinetics of the radiopharmaceutical as if intravenously administered. The radiation transport codes MCNP and ALGAMP were used to model the electron and photon transport and energy deposition. The dosimetry of Tc-99m DTPA and HSA, In-111 DTPA, I-131 HSA, and Yb-169 DTPA was studied. Radiation dose profiles for the spinal cord and marrow in the spine were developed and average doses to all other organs were estimated, including dose distributions within the bone and marrow.

  14. Post-PET ultrasound improves specificity of 18F-FDG-PET for recurrent differentiated thyroid cancer while maintaining sensitivity

    PubMed Central

    Kråkenes, Jostein; Brauckhoff, Katrin; Haugland, Hans Kristian; Heinecke, Achim; Akslen, Lars A; Varhaug, Jan Erik; Brauckhoff, Michael

    2015-01-01

    Background Positron emission tomography (PET) using fluor-18-deoxyglucose (18F-FDG) with or without computed tomography (CT) is generally accepted as the most sensitive imaging modality for diagnosing recurrent differentiated thyroid cancer (DTC) in patients with negative whole body scintigraphy with iodine-131 (I-131). Purpose To assess the potential incremental value of ultrasound (US) over 18F-FDG-PET-CT. Material and Methods Fifty-one consecutive patients with suspected recurrent DTC were prospectively evaluated using the following multimodal imaging protocol: (i) US before PET (pre-US) with or without fine needle biopsy (FNB) of suspicious lesions; (ii) single photon emission computed tomography (≥3 GBq I-131) with co-registered CT (SPECT-CT); (iii) 18F-FDG-PET with co-registered contrast-enhanced CT of the neck; (iv) US in correlation with the other imaging modalities (post-US). Postoperative histology, FNB, and long-term follow-up (median, 2.8 years) were taken as composite gold standard. Results Fifty-eight malignant lesions were identified in 34 patients. Forty lesions were located in the neck or upper mediastinum. On receiver operating characteristics (ROC) analysis, 18F-FDG-PET had a limited lesion-based specificity of 59% at a set sensitivity of 90%. Pre-US had poor sensitivity and specificity of 52% and 53%, respectively, increasing to 85% and 94% on post-US, with knowledge of the PET/CT findings (P < 0.05 vs. PET and pre-US). Multimodal imaging changed therapy in 15 out of 51 patients (30%). Conclusion In patients with suspected recurrent DTC, supplemental targeted US in addition to 18F-FDG-PET-CT increases specificity while maintainin sensitivity, as non-malignant FDG uptake in cervical lesions can be confirmed. PMID:25770086

  15. Uncertainty and sensitivity analysis of food pathway results with the MACCS Reactor Accident Consequence Model

    SciTech Connect

    Helton, J.C.; Johnson, J.D.; Rollstin, J.A.; Shiver, A.W.; Sprung, J.L.

    1995-01-01

    Uncertainty and sensitivity analysis techniques based on Latin hypercube sampling, partial correlation analysis and stepwise regression analysis are used in an investigation with the MACCS model of the food pathways associated with a severe accident at a nuclear power station. The primary purpose of this study is to provide guidance on the variables to be considered in future review work to reduce the uncertainty in the important variables used in the calculation of reactor accident consequences. The effects of 87 imprecisely-known input variables on the following reactor accident consequences are studied: crop growing season dose, crop long-term dose, milk growing season dose, total food pathways dose, total ingestion pathways dose, total long-term pathways dose, area dependent cost, crop disposal cost, milk disposal cost, condemnation area, crop disposal area and milk disposal area. When the predicted variables are considered collectively, the following input variables were found to be the dominant contributors to uncertainty: fraction of cesium deposition on grain fields that is retained on plant surfaces and transferred directly to grain, maximum allowable ground concentrations of Cs-137 and Sr-90 for production of crops, ground concentrations of Cs-134, Cs-137 and I-131 at which the disposal of milk will be initiated due to accidents that occur during the growing season, ground concentrations of Cs-134, I-131 and Sr-90 at which the disposal of crops will be initiated due to accidents that occur during the growing season, rate of depletion of Cs-137 and Sr-90 from the root zone, transfer of Sr-90 from soil to legumes, transfer of Cs-137 from soil to pasture, transfer of cesium from animal feed to meat, and the transfer of cesium, iodine and strontium from animal feed to milk.

  16. Localization of radiolabeled anti-DNA monoclonal antibodies in murine systemic lupus erythematosus (SLE)

    SciTech Connect

    Wahl, R.; Hahn, B.; Ebling, F.

    1984-01-01

    The diagnosis of SLE can be extremely difficult. This multi-system disease is characterized by the deposition of DNA-anti-DNA antibody (Ab) complexes in many tissues, producing glomerulonephritis and systemic vasculitis. This study evaluates an IGG monoclonal (Mo) Ab directe3d against DNA (MrSSl) for potential radioimmunodiagnosis of SLE. Six 15 wk. old F-1 female hybrids of NZB+NZW mice (an animal SLE model that develops vasculitis and nephritis) were injected with 50 ..mu..Cl of I-131 MrSSl and 15 ..mu..Cl of I-125 isotype-matched control mouse myeloma (LPC-1) (non-reactive with DNA). Imaging and tissue distribution were studied. Two animals were also imaged using I-131 LPC Ab. Images at 2 and 9 days showed no clear differences in scan patterns using MrSSl or LPC-1 Ab. Tissue distribution studies at six days, however, showed a significantly higher accumulation of MrSSl in the kidneys vs. control Ab (2.7% vs. 1.8% of injected dose) (p < .04). Similarly, higher levels of MrSS were also seen in the spleen, liver and lungs (p < .03). Blood levels tended to be higher with the specific antibody as well. These differences were not apparent at 3 days post injection. The increased concentration of MrSSl present at 9 days in several organs may be secondary to MrSSl binding to DNA containing immune complexes present in diseased tissues. Blocked clearance by immune complexes or DNA, or differences in electrical charges of the antibodies could be contributing to the higher MrSSl levels seen. Images did not suggest deiodination as responsible. Further studies are necessary to determine if the amount of MrSSl retained by diseased animals is indicative of SLE disease activity.

  17. Therapeutic applications of radioactive 131iodine: Procedures and incidents with capsules

    PubMed Central

    Al Aamri, Marwa; Ravichandran, Ramamoorthy; Binukumar, John Pichy; Al Balushi, Naima

    2016-01-01

    Background: Treatments for thyrotoxicosis and carcinoma thyroid are carried out by oral administration of radioactive iodine (131I) in the form of liquid or capsules. The liquid form of 131I has higher risk factors such as vapourization, spillage and need for management of higher activity wastes. Use of 131I in capsule form simplify procedures of handling compared to liquid form of 131I. The guidelines of safe handling and quality assurance aspects for therapeutic use 131I are well outlined by International Atomic Energy Agency (IAEA) reports. Aim: A few unusual incidents with I-131 capsules encountered in the past need to be highlighted from health physics point of view. Materials and Methods: In Royal Hospital, Oman, I-131 is imported in capsules, and the total activity handled/year steadily increased over 10 years. Discrete activities range from 185 MBq (5 mCi) up to 7.4 GBq (200 mCi). In four incidents deviations in standard operational procedures were recorded. Results: Nature of incidents is described as follows: (1) After assay of activity, the capsule was directly put in the lead container with missing of inner cap. (2) Patient poured water in the Perspex tube, when the capsule was handed over to her, making an emergency situation. (3) In 3 high activity capsules (2 nos 2.96 GBq, 1 no. 4.26 GBq), observed sticky behavior in capsule holder on the 2nd day post receipt, which were in order on the 1st day. (4) A capsule could not be swallowed by a patient, which was taken back from the mouth. Monitoring of patient later did not show residual ingested activity. Conclusions: The report documents some of the unusual incidents for information to other centers engaged in such radioactive administrations. PMID:27385885

  18. Speciation of radiocesium and radioiodine in aerosols from Tsukuba after the Fukushima nuclear accident.

    PubMed

    Xu, Sheng; Zhang, Luyuan; Freeman, Stewart P H T; Hou, Xiaolin; Shibata, Yasuyuki; Sanderson, David; Cresswell, Alan; Doi, Taeko; Tanaka, Atsushi

    2015-01-20

    Aerosol samples were collected from Tsukuba, Japan, soon after the 2011 Fukushima nuclear accident and analyzed for speciation of radiocesium and radioiodine to explore their chemical behavior and isotopic ratios after the release. Most (134)Cs and (137)Cs were bound in organic matter (53–91%) and some in water-soluble fractions (5–15%), whereas a negligible proportion of radiocesium remained in minerals. This pattern suggests that sulfate salts and organic matter may be the main carrier of Cs-bearing particles. The (129)I in aerosol samples is contained in various proportions as soluble inorganic iodine (I(–) and IO3(–)), soluble organic iodine, and unextractable iodine. The measured mean (129)I/(131)I atomic ratio of 16.0 ± 2.2 is in good agreement with that measured from rainwater and consistent with ratios measured in surface soil samples. Together with other aerosols and seawater samples, an initial (129)I/(137)Cs activity ratio of ∼4 × 10(–7) was obtained. In contrast to the effectively constant (134)Cs/(137)Cs activity ratios (1.04 ± 0.04) and (129)I/(131)I atomic ratios (16.0 ± 2.2), the (129)I/(137)Cs activity ratios scattered from 3.5 × 10(–7) to 5 × 10(–6) and showed temporally and spatially different dispersion and deposition patterns between radiocesium and radioiodine. These findings confirm that (129)I, instead of (137)Cs, should be considered as a proxy for (131)I reconstruction. PMID:25522224

  19. A review of source term and dose estimation for the TMI-2 reactor accident

    SciTech Connect

    Gudiksen, P.H.; Dickerson, M.H.

    1990-09-01

    The TMI-2 nuclear reactor accident, which occurred on March 28, 1979 in Harrisburg, Pennsylvania, produced environmental releases of noble gases and small quantities of radioiodine. The releases occurred over a roughly two week period with almost 90% of the noble gases being released during the first three days after the initiation of the accident. Meteorological conditions during the prolonged release period varied from strong synoptic driven flows that rapidly transported the radioactive gases out of the Harrisburg area to calm situations that allowed the radioactivity to accumulate within the low lying river area and to subsequently slowly disperse within the immediate vicinity of the reactor. The results reported by various analysts, revealed that approximately 2.4--10 million curies of noble gases (mainly Xe-133), and about 14 curies of I-131 were released. During the first two days, when most of the noble gas release occurred, the plume was transported in a northerly direction causing the most exposed area to lie within a northwesterly to northeasterly direction from TMI. Changing surface winds caused the plume to be subsequently transported in a southerly direction, followed by an easterly direction. The calculated maximum whole body dose due to plume passage exceeded 100 mrem over an area extending several kilometers north of the plant, although the highest measured dose was 75 mrem. The collective dose equivalent (within a radius of 80 km) due to the noble gas exposure ranged over several orders of magnitude with a central estimate of 3300 person-rem. The small I-131 release produced barely detectable levels of activity in air and milk samples. This may have produced thyroid doses of a few milirem to a small segment of the population. 7 refs., 4 figs., 2 tabs.

  20. Evaluation of the Transfer Coefficient Matrix (TCM) approach to model the atmospheric radionuclide air concentrations from Fukushima

    NASA Astrophysics Data System (ADS)

    Draxler, Roland R.; Rolph, Glenn D.

    2012-03-01

    A procedure is developed and tested to provide operational plume forecasts in real-time by continuously updating the previous day's simulations as new meteorological data become available. Simulations are divided into smaller time segments and each segment is continued as an independent calculation using a unit source emission. Multiple computational species are tracked at the same time to represent different classes of radionuclides, each with different dry and wet deposition characteristics. When quantitative air concentration results are required, the unit source calculations are multiplied by the appropriate temporally varying emission rates and decay factors for the radionuclide species involved. Air concentrations for multiple emission scenarios can easily be created in a few minutes and used to optimize model results as more measurement data become available. The procedure was evaluated for the Fukushima accident using publically available emission estimates and some I-131 and Cs-137 monitoring data. The model performance was evaluated at four sampling locations (Dutch Harbor, Alaska; Seattle, Washington; Dublin, Ireland; and Huelva, Spain) at various distances from Japan. The model results showed a very high correlation for the I-131 particulate predictions (0.94) and a moderate correlation for the Cs-137 predictions (0.40). The cesium predictions at Seattle showed five distinct time periods of concentration over-predictions associated with two peak emission periods. Adjusting these emission rates downward to correspond more closely with the time-adjacent rates eliminated the over-prediction but resulted in total emissions of Cs-137 (3 PBq) that were much less than estimated by other researchers (36 PBq).

  1. Tumor affinity of radiolabeled peanut agglutinin compared with that of Ga-67 citrate in animal models

    SciTech Connect

    Yokoyama, K.; Aburano, T.; Watanabe, N.; Kawabata, S.; Ishida, H.; Mukai, K.; Tonami, N.; Hisada, K.

    1985-05-01

    Peanut agglutinin (PNA) binds avidly to the immunodominant group of the tumor associated T antigen. The purpose of this study was to evaluate oncodiagnostic potential of radiolabeled PNA in animal models. PNA was labeled with I-125 or I-131 by Iodogen and also with In-111 by cyclic DTPA anhydride. The biological activity of PNA was examined by a hemaglutination titer with a photometer before and after labeling. Animal tumor models used were Lewis Lung Cancer(LLC), B-16 Melanotic Melanoma(MM), Yoshida Sarcoma(YS), Ehrlich Ascites Tumor(EAT and Hepatoma AH109A(HAH). Inflammatory tissue induced by turpentine oil was used as an abscess model. Serial scintigraphic images were obtained following IV injections of 100 ..mu..Ci of I-131 or In-111-DTPA-PNA. The tumor affinity of Ga-67 citrate was studied to compare that of radiolabeled PNA. Tissue biodistribution was studied in EAT bearing mice. All of these tumor models except HAH were clearly visible by radiolabeled PNA without subtraction techniques. In the models of LLC and EAT, PNA showed the better accumulation into the tumor tissue than Ga-67 citrate. In YS and MM, PNA represented almost the same accumulation as Ga-67 citrate. The localization of PNA into abscess tissue wasn't found although Ga-67 citrate markedly accumulated into abscess tissue as well as tumor tissue. The clearance of PNA from tumor was slower than those from any other organs. Tumor to muscle ratio was 5.1 at 48hrs. and tumor to blood ratio increased with time to 2.3 at 96hrs. These results suggested that radiolabeled PNA may have a potential in the detection of tumor.

  2. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2008-10-01

    Gateways to clinical trials is a guide to the most recent trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (+)-Dapoxetine hydrochloride, (S)-Tenatoprazole sodium salt monohydrate 19-28z, Acotiamide hydrochloride hydrate, ADV-TK, AE-37, Aflibercept, Albinterferon alfa-2b, Aliskiren fumarate, Asenapine maleate, Axitinib; Bavituximab, Becatecarin, beta-1,3/1,6-Glucan, Bevacizumab, Bremelanotide; Calcipotriol/betamethasone dipropionate, Casopitant mesylate, Catumaxomab, CDX-110, Cediranib, CMD-193, Cositecan; Darinaparsin, Denosumab, DP-b99, Duloxetine hydrochloride; E75, Ecogramostim, Elacytarabine, EMD-273063, EndoTAG-1, Enzastaurin hydrochloride, Eplerenone, Eribulin mesilate, Esomeprazole magnesium, Etravirine, Everolimus, Ezetimibe; Faropenem daloxate, Febuxostat, Fenretinide; Ghrelin (human); I-131 ch-TNT-1/B, I-131-3F8, Iclaprim, Iguratimod, Iloperidone, Imatinib mesylate, Inalimarev/Falimarev, Indacaterol, Ipilimumab, Iratumumab, Ispinesib mesylate, Ixabepilone; Lapatinib ditosylate, Laquinimod sodium, Larotaxel dehydrate, Linezolid, LOR-2040; Mapatumumab, MKC-1, Motesanib diphosphate, Mycophenolic acid sodium salt; NK-012; Olanzapine pamoate, Oncolytic HSV, Ortataxel; Paclitaxel nanoparticles, Paclitaxel poliglumex, Paliperidone palmitate, Panitumumab, Patupilone, PCV-9, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pertuzumab, Picoplatin, Pimavanserin tartrate, Pimecrolimus, Plerixafor hydrochloride, PM-02734, Poly I:CLC, PR1, Prasugrel, Pregabalin, Progesterone caproate, Prucalopride, Pumosetrag hydrochloride; RAV-12, RB-006, RB-007, Recombinant human erythropoietin alfa, Rimonabant, Romidepsin; SAR-109659, Satraplatin, Sodium butyrate; Tadalafil, Talampanel, Tanespimycin, Tarenflurbil, Tariquidar

  3. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2009-03-01

    ABT-869, Acadesine, Acetylsalicylic acid/omeprazole, Adefovir, Adefovir dipivoxil, AEG-35156, Agatolimod sodium, Albiglutide, Alemtuzumab, Alipogene tiparvovec, Alogliptin benzoate, AMG-386, Amrubicin hydrochloride, Apremilast, Aripiprazole, Asoprisnil, Atorvastatin/fenofibrate, AVN-944, Axitinib; Belinostat, Bevacizumab, BHT-3021, BI-2536, Biapenem, Bilastine, Biphasic insulin aspart, Blinatumomab, Bortezomib, Bosentan; Catumaxomab, CD-NP, Cediranib, Certolizumab pegol, Cetuximab, Choline fenofibrate, Ciclesonide, CK-1827452,Clevudine, Clofarabine, CSL-360, CYT-997; Dapagliflozin, Darinaparsin, Denosumab, Densiron 68, Desloratadine, Dulanermin; Edoxaban tosilate, Emtricitabine, Entecavir, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe, Ezetimibe/simvastatin; Fidaxomicintiacumiv, Fulvestrant; G-207, GCR-8015, Gefitinib, Ghrelin (human), Glufosfamide; HPV16L1E7CVLP; Ibutamoren mesilate, Imatinib mesylate, Insulin detemir, Insulin glargine, Iodine (I131) tositumomab, Istaroxime, ITMN-191, Ixabepilone; JZP-4, Lenalidomide; Levetiracetam, Linaclotide acetate, Liposomal cytarabine/daunorubicin, Liposomal doxorubicin, Liraglutide, LY-518674; Milatuzumab, MMR-V, Motesanib diphosphate, Mycophenolic acid sodium salt; Niacin/simvastatin; Obatoclax mesylate, Odanacatib; Paclitaxel nanoparticles, Paclitaxel-eluting stent, Pazufloxacin, PBT-2, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Peginterferon alfa-2b/ribavirin, Pemetrexed disodium, Perampanel, PfCP2.9, Pitavastatin calcium, Poly I:CLC, Pomalidomide, Pralatrexate, Pramlintide acetate, Prucalopride; rhGAD65, Roflumilast; RTS,S/AS02D; SCH-530348, Semagacestat, Sirolimus-eluting coronary stent, Sirolimus-Eluting Stent, SIR-Spheres, Sivelestat sodium hydrate, Sorafenib, Sunitinib malate; Tadalafil, Tafluprost, Tanespimycin, Teduglutide, Telaprevir, Telbivudine, Tenofovir disoproxil fumarate, Tiotropium bromide, TMC-435350, Tositumomab/iodine (I131) tositumomab, Travoprost/timolol, Triciribine

  4. Evolution of Flavone Synthase I from Parsley Flavanone 3β-Hydroxylase by Site-Directed Mutagenesis1[W][OA

    PubMed Central

    Gebhardt, Yvonne Helen; Witte, Simone; Steuber, Holger; Matern, Ulrich; Martens, Stefan

    2007-01-01

    Flavanone 3β-hydroxylase (FHT) and flavone synthase I (FNS I) are 2-oxoglutarate-dependent dioxygenases with 80% sequence identity, which catalyze distinct reactions in flavonoid biosynthesis. However, FNS I has been reported exclusively from a few Apiaceae species, whereas FHTs are more abundant. Domain-swapping experiments joining the N terminus of parsley (Petroselinum crispum) FHT with the C terminus of parsley FNS I and vice versa revealed that the C-terminal portion is not essential for FNS I activity. Sequence alignments identified 26 amino acid substitutions conserved in FHT versus FNS I genes. Homology modeling, based on the related anthocyanidin synthase structure, assigned seven of these amino acids (FHT/FNS I, M106T, I115T, V116I, I131F, D195E, V200I, L215V, and K216R) to the active site. Accordingly, FHT was modified by site-directed mutagenesis, creating mutants encoding from one to seven substitutions, which were expressed in yeast (Saccharomyces cerevisiae) for FNS I and FHT assays. The exchange I131F in combination with either M106T and D195E or L215V and K216R replacements was sufficient to confer some FNS I side activity. Introduction of all seven FNS I substitutions into the FHT sequence, however, caused a nearly complete change in enzyme activity from FHT to FNS I. Both FHT and FNS I were proposed to initially withdraw the β-face-configured hydrogen from carbon-3 of the naringenin substrate. Our results suggest that the 7-fold substitution affects the orientation of the substrate in the active-site pocket such that this is followed by syn-elimination of hydrogen from carbon-2 (FNS I reaction) rather than the rebound hydroxylation of carbon-3 (FHT reaction). PMID:17535823

  5. Use of PET for estimation of radiation dose variations within the thyroid from radioiodine therapy in thyrotoxic patients

    SciTech Connect

    Ott, R.J.; Batty, V.; Clack, R.; Flower, M.A.; Leach, M.O.; Marsden, P.; McCready, V.R.; Webb, S.

    1985-05-01

    A series of 22 patients have been studied using a prototype Multiwire Proportional Chamber Positron Camera to determine the accuracy of measurement of thyroid uptake of radioiodine. The patients being treated for thyrotoxicosis were given a solution containing 1.5 mCi of I-131 and 0.7 mCi of I-124. In a few case 0.3 mCi of I-124 was given prior to I-131 therapy. Data acquisition consisted of 8 contiguous views of the thyroid covering the full 360 degrees around the patient. Each study contained approximately 400,000 events. Data analysis consisted of a simple backprojection and 3D deconvolution of the point source response function to produce a 64x64x64 volume matrix using 0.27ml voxels. The volume of the thyroid was obtained using a simple thresholding technique to determine the number of voxels within the thyroid. Phantom measurements show that the functional volume and hence the radiation dose to the thyroid can be estimated to approx. =10%. From conventional imaging with a gamma camera plus pinhole collimator, 18 out of 22 patients were diagnosed as having uniform Graves disease. The high resolution tomographic information provided by PET imaging has shown that the uptake in 5 of these 18 patients was multinodular. In one case the volume of the nodules within the thyroid was estimated to be 45% of the organ volume. This non-uniform uptake of iodine within the thyroid has consequences for the overall management of hyperthyroidism in patients thought to have Graves disease. It may in part explain the cases of unexpected post therapy hypothyroidism.

  6. Radioimmunotherapy of micrometastases: Theoretical evaluation of adjuvant treatment

    SciTech Connect

    Sgouros, G.; Yorke, E.D.; Willins, J.D.

    1994-05-01

    Failure of current cancer treatment modalities is generally associated with the inability to control distant metastatic disease. This work examines the adjuvant use of radiolabeled antibodies for targeting micrometastases. A Monte Carlo program is used to estimate the number and size distribution of metastases that are present in a given (node-negative) prostate cancer patient population at the time of diagnosis. These results are used in a second program that solves the equations associated with antibody (Ab) diffusion, binding, and dissociation to yield the kinetics of Ab penetration within pre-vascularized micrometastases. These simulated kinetic data are then micrometastasis. Using a two-compartment macroscopic model of Ab distribution, the red marrow dose is also calculated. Calculations are performed for I-123 and for I-131-labeled antibody. With these results, the fraction of the patient population that would benefit from radioimmunotherapy is estimated. The analysis suggests that a single administration of radioimmunotherapy following surgery or external beam radiotherapy will yield a potentially lethal dose ({ge} 20 Gy for I-123 and {ge} 38 Gy for I-131) to 23% of micrometastases present at the time of initial diagnosis without inducing prohibitive red marrow morbidity (absorbed dose {le}2.5 Gy). Multiple courses of radioimmunotherapy, designed to target micrometastases that are initially too small but that eventually reach a targetable size (i.e., 20 {mu}m {le} micromet. radius {le}200{mu}m), will yield a potentially lethal results suggest that approximately 25% of high risk prostate cancer patients (i.e., patients with occult metastases at the time of diagnosis) could benefit from single course of radioimmunotherapy; multiple courses of radioimmunotherapy could benefit 75% of high risk prostate cancer patients.

  7. The effect of gamma ray penetration on angle-dependent sensitivity for pinhole collimation in nuclear medicine

    SciTech Connect

    Smith, M.F.; Jaszczak, R.J. |

    1997-11-01

    The sensitivity of a pinhole collimator for gamma ray imaging in nuclear medicine is dependent on the angle of incidence of the gamma rays. The effect of penetration near the pinhole aperture on angle-dependent sensitivity was investigated using experimental measurements and numerical modeling. Projection data measurements were acquired with Tc-99m and I-131 point sources using tungsten pinhole inserts with 1.0 to 4.0 mm diameter apertures. Curves of the form sin{sup x}{theta}, where {theta} is the angle of the incident ray with the surface of the detector crystal, were fit to sensitivity measurements from the projection data. Experimentally measured x values were between 3.3 and 4.1 for Tc-99m and between 5.1 and 7.2 for I-131. Penetration near the pinhole aperture was modeled using (1) an expression for effective pinhole diameter that is a generalization of Anger{close_quote}s formula for normally incident photons and (2) a photon transport simulation code. Experimentally measured sensitivity exponents x from new and previously reported experimental observations were modeled within 15{percent} by the numerical simulations. For modeling using the generalized expression for effective diameter the average error was 1.4{percent} and the standard deviation was 7.7{percent}. For the photon transport simulation code the average error was 1.5{percent} and the standard deviation also was 7.7{percent}. The effect of pinhole aperture design parameters on angle-dependent sensitivity for high resolution pinhole apertures was modeled using a photon transport simulation code. The sensitivity exponents x were greater for 364 keV photons than for 140 keV photons and were greater for small aperture diameters, small acceptance angles, and large aperture channel heights. (Abstract Truncated)

  8. A MODEL FOR PREDICTING FISSION PRODUCT ACTIVITIES IN REACTOR COOLANT: APPLICATION OF MODEL FOR ESTIMATING I-129 LEVELS IN RADIOACTIVE WASTE

    SciTech Connect

    Lewis, B.J.; Husain, A.

    2003-02-27

    A general model was developed to estimate the activities of fission products in reactor coolant and hence to predict a value for the I-129/Cs-137 scaling factor; the latter can be applied along with measured Cs-137 activities to estimate I-129 levels in reactor waste. The model accounts for fission product release from both defective fuel rods and uranium contamination present on in-core reactor surfaces. For simplicity, only the key release mechanisms were modeled. A mass balance, considering the two fuel source terms and a loss term due to coolant cleanup was solved to estimate fission product activity in the primary heat transport system coolant. Steady state assumptions were made to solve for the activity of shortlived fission products. Solutions for long-lived fission products are time-dependent. Data for short-lived radioiodines I-131, I-132, I-133, I-134 and I-135 were analyzed to estimate model parameters for I-129. The estimated parameter values were then used to determine I-1 29 coolant activities. Because of the chemical affinity between iodine and cesium, estimates of Cs-137 coolant concentrations were also based on parameter values similar to those for the radioiodines; this assumption was tested by comparing measured and predicted Cs-137 coolant concentrations. Application of the derived model to Douglas Point and Darlington Nuclear Generating Station plant data yielded estimates for I-129/I-131 and I-129/Cs-137 which are consistent with values reported for pressurized water reactors (PWRs) and boiling water reactors (BWRs). The estimated magnitude for the I-129/Cs-137 ratio was 10-8 - 10-7.

  9. High-Dose [131I]Tositumomab (anti-CD20) Radioimmunotherapy and Autologous Hematopoietic Stem Cell Transplantation for Adults ≥ 60 Years Old with Relapsed or Refractory B-Cell Lymphoma

    SciTech Connect

    Gopal, Ajay K.; Rajendran, Joseph G.; Gooley, Ted; Pagel, John M.; Fisher, Darrell R.; Petersdorf, Stephen; Maloney, David G.; Eary, Janet F.; Appelbaum, Frederick R.; Press, Oliver W.

    2007-04-10

    Purpose: The majority of patients with relapsed or refractory B-cell, non-Hodgkin’s lymphoma (NHL) are over 60 years of age, yet they are often denied potentially curative high-dose therapy and autologous stem cell transplants (ASCT) due to the risk of excessive treatment-related morbidity and mortality. Myeloablative anti-CD20 radioimmunotherapy (RIT) can deliver curative radiation doses to tumor sites while limiting exposure to normal organs and may be particularly suited for older adults requiring high-dose therapy. Methods: Patients over age 60 with relapsed B-NHL received infusions of tositumomab anti-CD20 antibody labeled with 5-10mCi I-131 tracer for dosimetry purposes followed 10 days later by individualized therapeutic infusions of I-131-tositumomab (median 525 mCi, range 328-1154 mCi) to deliver 25-27Gy to the critical normal organ receiving the highest radiation dose. ASCT was performed approximately 2 weeks after therapy. Results: Twenty-four patients with a median age of 64 (range 60-76) who had received a median of four prior regimens (range 2-14) were treated. Thirteen (54%) had chemotherapy-resistant disease. The estimated 3-year overall and progression-free survivals were 59% and 51%, respectively with a median follow-up of 2.9 years (range 1-6 years). All patients experienced expected myeloablation with engraftment of platelets (≥20K/µL) and neutrophils (≥500/µL) occurring a median of 9 and 15 days, respectively following ASCT. There were no treatment-related deaths, and only two patients experienced grade 4 non-hematologic toxicity. Conclusions: Myeloablative RIT and ASCT is a safe and effective therapeutic option for older adults with relapsed B-NHL.

  10. Tracing Fukushima Radionuclides in the Northern Hemisphere -An Overview

    NASA Astrophysics Data System (ADS)

    Thakur, Punam; Ballard, Sally; Nelson, Roger

    2013-04-01

    A massive 9.0 earthquake and ensuing tsunami struck the northern coast of the Honshu-island, Japan on March 11, 2011 and severely damaged the electric system of the Fukushima- Daiichi Nuclear Power Plant (NPP). The structural damage to the plant disabled the reactor's cooling systems. Subsequent fires, a hydrogen explosion and possible partial core meltdowns released radioactive fission products into the atmosphere. The atmospheric release from the crippled Fukushima NPP started on March 12, 2011 with a maximum release phase from March 14 to 17. The radioactivity released was dominated by volatile fission products including isotopes of the noble gases xenon (Xe-133) and krypton (Kr-85); iodine (I-131,I-132); cesium (Cs-134,Cs-136,Cs-137); and tellurium (Te-132). The non-volatile radionuclides such as isotopes of strontium and plutonium are believed to have remained largely inside the reactor, although there is evidence of plutonium release into the environment. Global air monitoring across the northern hemisphere was increased following the first reports of atmospheric releases. According to the source term, declared by the Nuclear and Industrial Safety Agency (NISA) of Japan), approximately 160 PBq (1 PBq (Peta Becquerel = 10^15 Bq)) of I-131 and 15 PBq of Cs-137 (or 770 PBq "iodine-131 equivalent"), were released into the atmosphere. The 770 PBq figure is about 15% of the Chernobyl release of 5200 PBq of "iodine-131 equivalent". For the assessment of contamination after the accident and to track the transport time of the contaminated air mass released from the Fukushima NPP across the globe, several model calculations were performed by various research groups. All model calculations suggested long-range transport of radionuclides from the damaged Fukushima NPP towards the North American Continent to Europe and to Central Asia. As a result, an elevated level of Fukushima radionuclides were detected in air, rain, milk, and vegetation samples across the northern

  11. Evaluation of Z-(R,R)-IQNP for the potential imaging of m2 mAChR rich regions of the brain and heart.

    PubMed

    McPherson, D W; Greenbaum, M; Luo, H; Beets, A L; Knapp, F F

    2000-01-01

    Alterations in the function or density of the m2 muscarinic (mAChR) subtype have been postulated to play an important role in various dementias such as Alzheimer's disease. The ability to image and quantify the m2 mAChR subtype is of importance for a better understanding of the m2 subtype function in various dementias. Z-(R)-1-Azabicyclo[2.2.2]oct-3-y (R)-alpha-hydroxy-alpha-(1-iodo-1-propen-3-yl)-alpha-phenylacetate (Z-(R,R)-IQNP) has demonstrated significant uptake in cerebral regions that contain a high concentration of m2 mAChR subtype in addition to heart tissue. The present study was undertaken to determine if the uptake of Z-(R,R)-IQNP in these regions is a receptor mediated process and to identify the radiospecies responsible for binding at the receptor site. A blocking study demonstrated cerebral and cardiac levels of activity were significantly reduced by pretreatment (2-3 mg/kg) of (R)-3-quinuclidinyl benzilate, dexetimide and scopolamine, established muscarinic antagonists. A direct comparison of the cerebral and cardiac uptake of [I-125]-Z-(R,R)-IQNP and [I-131]-E-(R,R)-IQNP (high uptake in ml, m4 rich mAChR cerebral regions) demonstrated Z-(R,R)-IQNP localized to a higher degree in cerebral and cardiac regions containing a high concentration of the m2 mAChR subtype as directly compared to E-(R,R)-IQNP. In addition, a study utilizing [I-123]-Z-(R,R)-IQNP, [I-131]-iododexetimide and [I-125]-R-3-quinuclidinyl S-4-iodobenzilate, Z-(R,R)-IQNP demonstrated significantly higher uptake and longer residence time in those regions which contain a high concentration of the m2 receptor subtype. Folch extraction of global brain and heart tissue at various times post injection of [I-125]-Z-(R,R)-IQNP demonstrated that approximately 80% of the activity was extracted in the lipid soluble fraction and identified as the parent ligand by TLC and HPLC analysis. These results demonstrate Z-(R,R)-IQNP has significant uptake, long residence time and high stability in

  12. Occurrence of osteoporosis & factors determining bone mineral loss in young adults with Graves’ disease

    PubMed Central

    Biswas, Dibakar; Dutta, Deep; Maisnam, Indira; Mukhopadhyay, Satinath; Chowdhury, Subhankar

    2015-01-01

    Background & objectives: There is a paucity of data with conflicting reports regarding the extent and pattern of bone mineral (BM) loss in Graves’ disease (GD), especially in young adults. Also, interpretation of BM data in Indians is limited by use of T-score cut-offs derived from Caucasians. This study was aimed to evaluate the occurrence of osteoporosis in active treatment naive patients with GD and determine the factors predicting BM loss, using standard T-scores from Caucasians and compare with the cut-offs proposed by the Indian Council of Medical Research (ICMR) for diagnosing osteoporosis in Indians. Methods: Patients with GD, >20 yr age without any history of use of anti-thyroid drugs, and normal controls without fracture history, drugs use or co-morbidities underwent BM density (BMD) assessment at lumbar spine, hip and forearm, thyroid function and calcium profile assessment. Women with menopause or premature ovarian insufficiency and men with androgen deficiency were excluded. Results: Patients with GD (n=31) had significantly lower BMD at spine (1.01±0.10 vs. 1.13±0.16 g/cm2), hip (0.88±0.10 vs. 1.04±0.19 g/cm2) and forearm (0.46±0.04 vs. 0.59±0.09 g/cm2) compared with controls (n=30) (P<0.001). Nine (29%) and six (19.3%) patients with GD had osteoporosis as per T-score and ICMR criteria, respectively. None of GD patients had osteoporosis at hip or spine as per ICMR criteria. Serum T3 had strongest inverse correlation with BMD at spine, hip and femur. Step-wise linear regression analysis after adjusting for age, BMI and vitamin D showed T3 to be the best predictor of reduced BMD at spine, hip and forearm, followed by phosphate at forearm and 48 h I131 uptake for spine BMD in GD. Interpretation & conclusions: Osteoporosis at hip or spine is not a major problem in GD and more commonly involves forearm. Diagnostic criterion developed from Caucasians tends to overdiagnose osteoporosis in Indians. T3 elevation and phosphate are important predictors

  13. Pharmacokinetics and biodistribution of intravenous Lu-177 CC49 murine monoclonal antibody (MAb) in patients with metastatic adenocarcinoma

    SciTech Connect

    Carrasquillo, J.; Mulligan, T.; Chung, Y.

    1994-05-01

    The pharmacokinetics of Lu-177 labeled CG49, a murine monoclonal antibody that is undergoing testing for radioimmunotherapy, was evaluated. CC49 is a second generation murine MAb that recognizes TAG-72, a pan-carcinoma tumor associated antigen. Labeling of CC49 MAb with Lu-177, a beta emitter was performed by first labeling a derivative of 1,4,5,10-tetraazacyclododecane-tetraacetic acid (PA-DOTA) with Lu-177 and then attaching the Lu-177 labeled PA-DOTA to CC49. CC49 was labeled with Lu-177 at a maximum specific activity of 185 MBq/mg. HPLC showed 96-100% protein bound Lu-177 and <4% aggregate formation. A Phase I dose escalation study was performed. Nine patients with TAG-72 positive, advanced metastatic adenocarcinoma (5- breast, 3- colorectal and 1- lung) were treated with escalating iv doses of Lu-177-(PA-DOTA) CC49: 370 MBq/m2, 555 MBq/m2 and 925 MBq/m2 (range 560-1575 MBq). Pharmacokinetics showed that the plasma cleared with a T1/2 of {approximately}67 hrs which is in the range seen with I-131 CC49. The whole body retention of Lu-177 was prolonged with a biological T1/2 of 223 hr. Urinary excretion ranged from 7 to 26% in the first 96 hrs. Serial images showed early blood pool distribution with prominent uptake in the liver, spleen and marrow. Some intestinal excretion was noted. Tumor imaging was seen in all patients although riot all tumors were visualized. Bone marrow biopsies were obtained in all patients and suggested that the accumulation seen on scan was predominantly in the marrow rather than the bone. MIRDOSE estimates from the first 6 patients suggested doses to the marrow in the range of {approximately}4 cG/37 MBq. This study indicated that while the serum pharmacokinetics of Lu-177-(PA-DOTA)-CC49 are similar to those seen with I-131 CC49, the whole body retention and bone marrow accumulation are different and therefore require further investigation to minimize the bone marrow accumulation.

  14. Analysis of time series of Cs-137 concentration in sewage sludge at Fukushima City

    NASA Astrophysics Data System (ADS)

    Fischer, Helmut W.; Mack, Majvor; Shikano, Yudai; Yokoo, Yoshiyuki

    2015-04-01

    Daily routine radioisotope measurements of sewage sludge at the sewage plant of Fukushima City starting in 2011 have provided a detailed data set for the isotopes Cs-137, Cs-134 and I-131. The long-term trend for the Cs isotopes is comparable to data sets from Central Europe caused by the Chernobyl emissions in 1986 - the average Cs-137 concentration decreases faster in the first year (T1/2 < 1 yr) and slower in later years (T1/2 > 1 yr). Absolute values at Fukushima City are comparably low (mostly below 1 kBq/kg dry mass), due to the existence of separate wastewater and rainwater sewer systems, with only a small portion of rainwater and erosion products reaching the purification plant. Cs-134 data decay faster due to the shorter radioactive half-life. I-131 appears even years after the NPP releases and is assumed to originate from the common medical usage of the isotope for thyroid treatment. Short-term Cs data show a clear dependence on rainfall: each significant rainfall event causes a concentration increase in sludge of up to a factor of ten. Therefore the time series exhibits high short-term variability. Here we attempt to numerically analyse the detailed Cs-137 data set, using two separate approaches: The first method tries to connect parameters like the local surface deposition density, surface types (sealed/unsealed), rainfall statistics, rainfall-induced erosion rate, leakage rate from rainwater to wastewater sewer, transport time in the sewer and residence time in the purification plant for a basically physical approach. As not all parameters are known, values have to be assumed or can be extracted in the course of the fitting process. The second approach is purely heuristic, based on a water surface runoff and transport model. Whilst there is no ad-hoc physical meaning in the extracted parameters, they can possibly be interpreted as such when compared with physical modeling results. The combination of both methods is expected to give a deeper insight

  15. Freshwater sediments and sludges: two important terrestrial sinks for emissions from damaged NPPs

    NASA Astrophysics Data System (ADS)

    Fischer, Helmut W.; Evangelia Souti, Maria; Ulbrich, Susanne; Hormann, Volker

    2013-04-01

    Surface deposition of radionuclides released from the damaged Fukushima NPPs is well documented and emissions to the Pacific Ocean and their distribution with time and space are also subject to monitoring and research. In both cases, solid matter (soil and sea sediment, respectively) acts as a sink for radioisotopes after their transport through air and water. The possible hazards from direct irradiation of workers and public and from entry of radionuclides into food chains are well recognized. Apart from direct deposition onto soil, plants, building roofs etc., aerosols and contaminated rainwater will reach surface waters, leading to long-term deposition in freshwater sediments (and possibly to interim contamination of drinking water). In populated and industrial areas, drained rainwater will enter the wastewater collection and treatment chain if a combined rain and wastewater sewer is used. Depending on the processes in the wastewater treatment plant and chemical element and speciation, the isotopes will either concentrate in treatment sludge or be released with the effluent to rivers and lakes and their sediments. The mentioned media may act as long-term storage for radioisotopes when disposed of properly, but can also contribute to direct irradiation of workers or public, lead to continuous releases to the environment and possibly enter the food chain in the same way as soil and sea sediments. It appears therefore essential to monitor these environmental compartments as well. However, very few data on Fukushima-related radioisotope concentration in sludges and freshwater sediments have been published to date. We will therefore compare data for regional surface deposition and related concentrations in surface water, river sediments and sewage sludge obtained in Europe during 1986 to published data from Japan in 2011 for the most important common short-lived (I-131, half-life = 8.02 d) and long-lived (Cs-137, half-life = 30.17 yr) isotopes. As in central Europe

  16. Graves’ Disease in Albanian Children

    PubMed Central

    GJIKOPULLI, A.; TOMORI, SONILA; KOLLÇAKU, L.; HOXHA, P.; GRIMCI, LINDITA; YLLI, ZAMIRA

    2014-01-01

    Background: Graves’ disease (GD) accounts for 10–15% of thyroid disorders in patients less than 18 years of age. It is the most common cause of thyrotoxicosis in children and accounts for at least 95% of cases in children. Pediatric Treatment of Graves’ disease consists of anti-thyroid drugs, radioactive iodide and thyroidectomy but the optimal treatment of GD in children is still controversial. Objective: To review treatment outcome of pediatric Graves’ disease in Albania. Material and Method: Descriptive review of 15 children with Graves’ disease, diagnosed from Jan.2007 to Dec. 2013, at the Division of Pediatric Endocrinology, Department of Pediatrics, University Hospital Centre “Mother Teresa”, Albania was performed. Results: All patients, mean age 10.56 ± 3.37 years, (range 2.02-16.09 years) were presented with goiter and increased serum FT4, mean 39.80 ± 16.02 ng/mL, (range 21.0-74.70 ng/mL), serum FT3, mean 12.98 ± 3.45 pg/mL, (range 6.90 -17.90 pg/mL) and suppressed TSH levels, mean 0.02 ± 0.01 mUI/L, (range 0.01-0.05 mUI/L). Anti TSH Receptor were positive in 100% of patients mean value 6.51 ± 3.61 UI/mL (range 1.63 – 14.10 UI/mL). Anti-thyroglobulin and Anti-TPO antibodies were positive in 60% and 46.6% respectively. Clinical course of 15 patients after treatment with anti-thyroid drugs mainly MMI for 3.19 ± 1.48 (range 0.60 - 6.20) years is as follows: seven (46.66%) underwent remission, five out of seven (71.41%) who underwent remission, relapsed. Three of them (20%) were treated with I131, and two (13.3%) underwent to total thyroidectomy. Conclusion: MMI was the most common first line therapy in the presented patients with Graves’ disease. Remission rate was 46.66% after an average 1.48 ± 0.71 years (range 0.60 – 2.70 years) of treatment with anti-thyroid drugs. Remission period was 2.70 ± 0.36 years (2.1 – 3.1 years) Relapse occurred in 71.41% of patient. I131 and thyroidectomy were used as second line therapy in the

  17. A software to digital image processing to be used in the voxel phantom development.

    PubMed

    Vieira, J W; Lima, F R A

    2009-01-01

    Anthropomorphic models used in computational dosimetry, also denominated phantoms, are based on digital images recorded from scanning of real people by Computed Tomography (CT) or Magnetic Resonance Imaging (MRI). The voxel phantom construction requests computational processing for transformations of image formats, to compact two-dimensional (2-D) images forming of three-dimensional (3-D) matrices, image sampling and quantization, image enhancement, restoration and segmentation, among others. Hardly the researcher of computational dosimetry will find all these available abilities in single software, and almost always this difficulty presents as a result the decrease of the rhythm of his researches or the use, sometimes inadequate, of alternative tools. The need to integrate the several tasks mentioned above to obtain an image that can be used in an exposure computational model motivated the development of the Digital Image Processing (DIP) software, mainly to solve particular problems in Dissertations and Thesis developed by members of the Grupo de Pesquisa em Dosimetria Numérica (GDN/CNPq). Because of this particular objective, the software uses the Portuguese idiom in their implementations and interfaces. This paper presents the second version of the DIP, whose main changes are the more formal organization on menus and menu items, and menu for digital image segmentation. Currently, the DIP contains the menus Fundamentos, Visualizações, Domínio Espacial, Domínio de Frequências, Segmentações and Estudos. Each menu contains items and sub-items with functionalities that, usually, request an image as input and produce an image or an attribute in the output. The DIP reads edits and writes binary files containing the 3-D matrix corresponding to a stack of axial images from a given geometry that can be a human body or other volume of interest. It also can read any type of computational image and to make conversions. When the task involves only an output image

  18. Effective atomic numbers and electron densities of some human tissues and dosimetric materials for mean energies of various radiation sources relevant to radiotherapy and medical applications

    NASA Astrophysics Data System (ADS)

    Kurudirek, Murat

    2014-09-01

    Effective atomic numbers, Zeff, and electron densities, neff, are convenient parameters used to characterise the radiation response of a multi-element material in many technical and medical applications. Accurate values of these physical parameters provide essential data in medical physics. In the present study, the effective atomic numbers and electron densities have been calculated for some human tissues and dosimetric materials such as Adipose Tissue (ICRU-44), Bone Cortical (ICRU-44), Brain Grey/White Matter (ICRU-44), Breast Tissue (ICRU-44), Lung Tissue (ICRU-44), Soft Tissue (ICRU-44), LiF TLD-100H, TLD-100, Water, Borosilicate Glass, PAG (Gel Dosimeter), Fricke (Gel Dosimeter) and OSL (Aluminium Oxide) using mean photon energies, Em, of various radiation sources. The used radiation sources are Pd-103, Tc-99, Ra-226, I-131, Ir-192, Co-60, 30 kVp, 40 kVp, 50 kVp (Intrabeam, Carl Zeiss Meditec) and 6 MV (Mohan-6 MV) sources. The Em values were then used to calculate Zeff and neff of the tissues and dosimetric materials for various radiation sources. Different calculation methods for Zeff such as the direct method, the interpolation method and Auto-Zeff computer program were used and agreements and disagreements between the used methods have been presented and discussed. It has been observed that at higher Em values agreement is quite satisfactory (Dif.<5%) between the adopted methods.

  19. (University of California, Davis) annual report for radioimmunotherapy program, Year 4, (1986)

    SciTech Connect

    Not Available

    1986-01-28

    The goal of this program is to answer the fundamental scientific questions for the development of an effective approach to delivering radiation therapy to cancer on antibody-based radiopharmaceuticals. These basic questions refer to the choice of antibody fragments related to their biokinetics, the variation of the biokinetics with variations in the radiochemistry of labeling and the radionuclide used to label, the radionuclide radiation dosimetry, and the feasibility calculated from quantitative imaging in patients and implementation of a proven kinetic model. To approach these problems this program has five discrete, but interrelated aims. Radionuclide choices for effective therapy for solid tumors and bone marrow infiltrating tumor cells; The development of radiochemistry to optimize tumor uptake and increase non-target tissue clearance of the radiopharmaceuticals; Further development and documentation of the peri-fusion system for screening antibodies for human tumor uptake, normal tissue cross-reactivity, and tissue stability of new antibody radiometal linkages; Quantitation in vivo of pharmacokinetics and radiation dosimetry for radioiodinated and radiometal chelate-labeled antibodies and fragments; and Verification of dosimetry predictions and therapy feasibility in patients using selected I-131 and Cu-67 radioimmunopharmaceuticals.

  20. [University of California, Davis] annual report for radioimmunotherapy program, Year 4, [1986

    SciTech Connect

    Not Available

    1986-01-28

    The goal of this program is to answer the fundamental scientific questions for the development of an effective approach to delivering radiation therapy to cancer on antibody-based radiopharmaceuticals. These basic questions refer to the choice of antibody fragments related to their biokinetics, the variation of the biokinetics with variations in the radiochemistry of labeling and the radionuclide used to label, the radionuclide radiation dosimetry, and the feasibility calculated from quantitative imaging in patients and implementation of a proven kinetic model. To approach these problems this program has five discrete, but interrelated aims. Radionuclide choices for effective therapy for solid tumors and bone marrow infiltrating tumor cells; The development of radiochemistry to optimize tumor uptake and increase non-target tissue clearance of the radiopharmaceuticals; Further development and documentation of the peri-fusion system for screening antibodies for human tumor uptake, normal tissue cross-reactivity, and tissue stability of new antibody radiometal linkages; Quantitation in vivo of pharmacokinetics and radiation dosimetry for radioiodinated and radiometal chelate-labeled antibodies and fragments; and Verification of dosimetry predictions and therapy feasibility in patients using selected I-131 and Cu-67 radioimmunopharmaceuticals.

  1. Renal blood flow transit time in the study of renal transplants

    SciTech Connect

    Sfakianakis, G.; Ihmeidan, I.; Kyriakides, G.; Martinez, B.; Hourani, M.; Miller, J.; Serafini, A.

    1985-05-01

    Radio-hippurate scintigraphy has been used to study renal transplant function because of its unique advantages over other noninvasive methods. Despite a great sensitivity in diagnosing the existence of a functional problem the test lacks in specificity. In an effort to differentiate between acute tubular necrosis (ATN) and graft rejection (RJ) the authors preceded hippurate scintigraphy by measurements of renal flow transit time (TT). After an intravenous injection of 8 mCi of Tc-99m-sulfur-colloid flow curves from the kidney and the abdominal aorta in 1 sec intervals for 1 min were obtained. Renal transit time was mathematically calculated and corrected for bolus and circulatory differences by dividing it with the corresponding Aortic TT (corrected Renal TT(cRTT). Radiohippuran (O-I-131-Hippurate), 150 ..mu..Ci was injected subsequently and of the different computer generated parameters the 30 min net cortical residual (% of the peak) activity (Hippuran Residual Activity, HRA) was found more sensitive and reproducible for comparisons. Results of documented cases showed a statistically significant difference. Uncomplicated cases (usually on antirejection therapy) showed a tendency to increasing the cRTTs with time (not significantly) but their HRAs were significantly lower than in ATN and RJ (p< 0.001).

  2. Single visit captopril renography for the diagnosis of curable renovascular hypertension (RVH)

    SciTech Connect

    Sfakianakis, G.; Kyriakides, G.; Jaffe, D.; Bourgoigne, J.; Freundlich, M.; Spoliansky, G.; Bisset, R.

    1985-05-01

    Renal scintigraphy has a sensitivity of 85% and it is not entirely specific for RVH. Angiotensino converting enzyme inhibitors (captopril or enalapril) increase the sensitivity and specificity of differential renal vein renin determinations for diagnosing potentially curable RVH, but this is an invasive test. Captopril decreases renal function in RVH through alterations in renal hemodynamics of the affected kidney. The authors studied the yield of one visit captopril renography for the diagnosis of potentially curable renovascular hypertension. Twelve studies in patients with clinical RVH were performed without technical problems as following: After hydration (10ml/kg) the patient was injected iv with 300 ..mu..Ci of I-131-Hippuran and routine imaging in 2 min intervals with computer assisted generation of renograms in 30 sec intervals was performed for at least twenty min. Three hours later the patient received an oral dose of 50mg (weight adjusted for children) of captopril and one hour later the above test was repeated. Four patients showed normal baseline scintigraphy but unilateral decrease in split function and increase in Hippuran transit time (cortical retention at 20 min); two of them, who had angiography and transluminal angioplasty, were cured and repeat studies showed no effect of captopril. Six patients had normal studies (without response to captopril) two with proven lack of RVH (one angiography and one transient post transplantation hypertension); the remaining are followed clinically. The noninvasive approach appears promising for the diagnosis of potentially curable RVH.

  3. Nuclear medicine progress report for quarter ending March 31, 1987

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, K.R.; Srivastava, P.C.

    1987-08-01

    Studies using Langendorff-perfused rat hearts have shown for the first time the formation of a polar metabolite from the methyl-branched fatty acid, BMIPP. Evaluation of the radioactive components in the outflow tract of hearts after administration of the straight-chain analogue (I-131)IPPA and (I-125)BMIPP were pursued. Analysis of lipid extracts by thin-layer chromatography illustrated the presence of a product considerably more polar than BMIPP. These results suggest for the first time that the slow myocardial clearance observed with BMIPP in clinical studies may be associated with the wash-out of an unidentified metabolite. As a continuation of an evaluation of the effects of tellurium (Te) heteroatom position and the position of alkenyliodide substitution on myocardial uptake and retention properties, several new Te fatty acids have been synthesized and studied in rats. The new agents were prepared by coupling of internal alkenyl iodides prepared from the corresponding boronic acid analogues with sodium alkoxycarbonyl tellurols. Evaluation of the four new analogues demonstrated an unexpected relationship between chain length, and the position of the Te heteroatom and alkenyliodide moiety. 5 figs., 1 tab.

  4. Nuclear Medicine Program progress report for quarter ending December 31, 1990

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, K.R.; Callahan, A.P.; McPherson, D.W.; Mirzadeh, S.; Srivastava, P.C.; Allred, J.F.; Hasan, A.; Lambert, C.R.; Lambert, S.J.; Rice, D.E.

    1991-06-01

    In this report the development of a solvent extraction technique for the efficient separation of iridium radioisotopes from osmium radioisotopes is described. The Os-191 (Os-VIII) was efficiently separated from iridium-192 by extraction of a 1 M HCl solution with <10{sup {minus}2}M tetrahexylamine (THA) in methyl isobutyl ketone. Over 99% of the osmium is extracted in one step, leaving the radioactive iridium in the aqueous acidic solution. This simple extraction technique may be useful for the development of a new Os-194/Ir-194 generator prototype which is currently being explored. Also in this report, biodistribution studies of the two iodine-125 (I-125)-labeled spiroperidol analogues, E-3-N-(iodo-1-propen-3-yl)- and E-3-N-(iodo-1-penten-5-yl)spiroperidol in male Balb C mice are described. Several samples were supplied for collaborative research projects during this period and included I-125 and I-131 methyl-branched fatty acids, samples of tin-117m (Sn-117m), gold-199 (Au-199) and scandium-47 (Sc-47). 11 refs., 2 figs., 3 tabs.

  5. Modelling the dispersion of radionuclides following short duration releases to rivers: Part 1. Water and sediment.

    PubMed

    Smith, J T; Bowes, M J; Denison, F H

    2006-09-15

    This paper evaluates and generalises state-of-the-art approaches for modelling short duration liquid discharges of radionuclides ((3)H, (14)C, (60)Co, (134)Cs, (137)Cs, (65)Zn, (89)Sr, (90)Sr, (125)I, (131)I, (241)Am, isotopes of Pu and U) to rivers. An advection-dispersion model was parameterised and used to predict the concentrations of radionuclides in the river environment, i.e. in river water, river bed sediment and fish (Part II of this paper covers uptake to fish). The coupled transport and bio-uptake model was used to predict the concentrations of radionuclides in the River Thames, UK, and one of its tributaries as a result of hypothetical short duration discharges. A simplified version of this model was developed and presented as "look-up" graphs. The influence of various environmental parameters on model output was evaluated by sensitivity analysis. Time-integrated water and sediment concentrations and maximum sediment concentrations may be predicted for all rivers on the basis of the river volumetric flow rate only. Maximum concentration in water is, however, also dependent on other river characteristics. For this latter case, generalised modelling approaches are tested for use in situations where detailed hydrological and dispersion data are not available. PMID:16678242

  6. First human Cerenkography

    NASA Astrophysics Data System (ADS)

    Spinelli, Antonello Enrico; Ferdeghini, Marco; Cavedon, Carlo; Zivelonghi, Emanuele; Calandrino, Riccardo; Fenzi, Alberto; Sbarbati, Andrea; Boschi, Federico

    2013-02-01

    Cerenkov luminescence imaging is an emerging optical preclinical modality based on the detection of Cerenkov radiation induced by beta particles when traveling though biological tissues with a velocity greater than the speed of light. We present the first human Cerenkography obtained by detecting Cerenkov radiation escaping the thyroid gland of a patient treated for hyperthyroidism. The Cerenkov light was detected using an electron multiplied charge coupled device and a conventional C-mount lens. The system set-up has been tested by using a slab of ex vivo tissue equal to a 1 cm slice of chicken breast in order to simulate optical photons attenuation. We then imaged for 2 min the head and neck region of a patient treated orally 24 h before with 550 MBq of I-131. Co-registration between photographic and Cerenkov images showed a good localization of the Cerenkov light within the thyroid region. In conclusion, we showed that it is possible to obtain a planar image of Cerenkov photons escaping from a human tissue. Cerenkography is a potential novel medical tool to image superficial organs of patients treated with beta minus radiopharmaceuticals and can be extended to the imaging of beta plus emitters.

  7. Immune thrombocytopenia and autoimmune thyroid disease: a controversial overlap

    PubMed Central

    de Campos, Fernando Peixoto Ferraz

    2015-01-01

    Immune thrombocytopenia (ITP) is an entity characterized by a platelet count of less than 100 × 109/L in the absence of other causes of thrombocytopenia, such as viral infections, rheumatic diseases, or drugs. Grave’s disease is also an autoimmune condition in which thrombocytopenia is often observed. Moreover, in the literature, many reports show a marked interference of the thyroid dysfunction (mainly hyperthyroidism) in the control of thrombocytopenia. Although this issue still remains debatable, the authors report the case of a young woman with a previous diagnosis of ITP with a brilliant initial response to corticotherapy. Some years after this diagnosis, the patient presented thyrotoxicosis due to Grave’s disease and the thrombocytopenia relapsed, but this time there was no response to the glucocorticoids. Only after the radioiodine I-131 thyroid ablation the control of thrombocytopenia was achieved. The authors call attention to this overlap and for testing thyroid function in every patient with an unexpected negative response to corticotherapy. PMID:26484334

  8. Radioimmunotherapy and autologous stem cell transplantation for the treatment of B-cell lymphomas.

    PubMed

    Cilley, Jeffrey; Winter, Jane N

    2006-01-01

    Relapse continues to be the primary cause of treatment failure in patients with non-Hodgkin's lymphomas (NHL) undergoing high-dose therapy and autologous stem cell transplantation. The anti-CD20 radioimmunoconjugates, Y-90 ibritumomab tiuxetan (Zevalin; Biogen Idec, Inc., Cambridge, MA, USA) and I-131 tositumomab (Bexxar; Corixa, Seattle, WA; and Glaxo Smith Kline; Philadelphia, PA, USA) have been associated with high response rates, durable remissions and limited toxicity apart from myelosuppression, making them ideal candidates for use in autotransplantation. Tested first as single agents in relapsed patients with indolent and transformed NHL, and then at much higher doses with stem cell support, these agents have now been combined with high-dose chemotherapy prior to autologous stem cell transplant. Radioimmunoconjugates have been used to replace total body irradiation (TBI) in some studies and to augment standard chemotherapy regimens in others. Thus far the results are promising, with combinations of radioimmunoconjugates and chemotherapy producing long-lasting responses in high-risk patients with no more toxicity than that caused by standard conditioning regimens. These results are notable in light of the fact that the dose of radiation delivered to the tumor is 10-fold higher than the dose achievable with TBI. Whether this increase in radiation dose to the targeted lymphoma translates into more durable remissions and an improvement in overall survival requires further investigation. PMID:16434379

  9. Kinetics of intralymphatically delivered monoclonal antibodies

    SciTech Connect

    Wahl, R.L.; Geatti, O.; Liebert, M.; Beers, B.; Jackson, G.; Laino, L.; Kronberg, S.; Wilson, B.S.; Beierwaltes, W.H.

    1985-05-01

    Radiolabeled monoclonal antibody (MoAb) administration subcutaneously (sq), so that preferential uptake is to the lymphatics, holds significant promise for the detection of lymph node metastases. Only limited information is available about clearance rates of intralymphatically administered MoAbs. I-131 labeled intact IgG (225.28S), F(ab's)2 (225.28S) or IgM (FT162) were administered sq to anesthetized Balb/C mice. Eight mice were studied with each MoAb, 4 with a foot-pad injection, 4 with an anterior abdominal injection. Gamma camera images were collected into a computer, over the first 6 hrs after injection with the animals anesthetized and immobile. Animals were then allowed to move about freely. Additional images were then acquired out to 48 hrs. Regions of interest wre selected over the injection site and the kinetics of antibody egress determined. Clearance rates from local sq injection sites are influenced by motion and somewhat by location. The class and fragment status of the MoAb appear relatively less important in determining clearance rates from sq injections than they are in determining whole-body clearance after iv injections. Additional studies using Fab fragments and additional monoclonals will be useful in extending these observations.

  10. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy

    SciTech Connect

    Macey, D.J.; DeNardo, S.J.; DeNardo, G.L.; DeNardo, D.A.; Sui Shen

    1995-02-01

    Myelotoxicity is the dose-limiting factor in radioimmunotherapy. Traditional methods most commonly used to estimate the radiation adsorbed dose to the bone marrow of patients consider contribution from radionuclide in the blood and/or total body. Targeted therapies, such as radioimmunotherapy, add a third potential source for radiation to the bone marrow because the radiolabeled targeting molecules can accumulate specifically on malignant target cells infiltrating the bone marrow. A non-invasive method for estimating the radiation absorbed dose to the red marrow of patients who have received radiolabeled monoclonal antibodies (MoAb) has been developed and explored. The method depends on determining the cumulated activity in three contributing sources: (1) marrow; (2) blood; and (3) total body. The novel aspect of this method for estimating marrow radiation dose is derivation of the radiation dose for the entire red marrow from radiation dose estimates obtained by detection of cumulated activity in three lumbar vertebrae using a gamma camera. Contributions to the marrow radiation dose form marrow, blood, and total body cumulated activity were determined for patients who received an I-131 labeled MoAb, Lym-1, that reacts with malignant B-lymphocytes of chronic lymphocytic leukemia and nonHodgkin`s lymphoma. Six patients were selected for illustrative purposes because their vertebrae were readily visualized on lumbar images. 32 refs., 6 figs., 1 tab.

  11. Synthesis and in vivo evaluation of ortho-[(124)I]iodohippurate for PET renography in healthy rats.

    PubMed

    Pathuri, Gopal; Hedrick, Andria F; Awasthi, Vibhudutta; Cowley, Benjamin D; Gali, Hariprasad

    2016-09-01

    Ortho-[(131)I]iodohippurate [(131)I]OIH (marketed as Hippuran I 131), a gold standard for radionuclide renography, and [(123)I]OIH were in clinical use for decades. Here we radiolabeled OIH with (124)I (a positron emitter) to combine the desirable biological properties of OIH and to enable the use of positron emission tomography (PET) for renography. [(124)I]OIH was synthesized with a slight modification to a previously reported method for the kit preparation of [(123)I]OIH based on the Cu(II) catalyzed isotope-exchange reaction. Our method utilized heating at 120°C under sealed condition in a heating block instead of autoclaving. [(124)I]OIH was obtained with a radiochemical purity of >99.3%, radiochemical yield of 94.5%, and specific activity of ~17 MBq/mg. Biodistribution studies in healthy Sprague Dawley rats revealed results comparable to that of [(131)I]OIH as reported in the literature. The PET-derived [(124)I]OIH renograms revealed an average time-to-peak of 2.8±0.4min and the average time-to-half-maximal activity of 11.4±1.5min, which are also comparable to that of [(131)I]OIH as reported in the literature. Results from this study indicate that the synthesis of [(124)I]OIH without using an autoclave and [(124)I]OIH PET renography are feasible. PMID:27434486

  12. The current status of ARAC (Atmospheric Release Advisory Capability) and its application to the Chernobyl event

    SciTech Connect

    Gudiksen, P.H.; Sullivan, T.J.; Harvey, T.F.

    1986-10-01

    The Atmospheric Release Advisory Capability (ARAC) project, developed by the Lawrence Livermore National Laboratory (LLNL), provides real-time dose assessments and estimates of the extent of surface contamination that may result from an atmospheric release of radioactivity. It utilizes advanced computer-based data communication and processing systems to acquire the meteorological and source term information needed by the three-dimensional atmospheric dispersion models to derive the consequence assessments. The ARAC responded to the recent Chernobyl reactor accident in the Soviet Union by estimating the source term and the radiation dose distribution due to exposure to the radioactive cloud over Europe and the Northern Hemisphere. This analysis revealed that approximately 50% of the estimated core inventories of I-131 and Cs-137 were released. The estimated committed effective dose equivalent due to inhalation of radioactivty during cloud passage is of the order of 10 mrem within parts of Scandinavia and eastern Europe, while most of the populations within central Europe were exposed to levels ranging from 1 to 10 mrem. The amount of Cs-137 released by the Chernobyl accident far exceeds that released by previous reactor accidents, but is only about 6% of the Cs-137 produced by the atmospheric weapon testing programs. 9 refs., 4 figs., 2 tabs.

  13. The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of 131I in Hyperthyroidism

    PubMed Central

    Kartamihardja, A. Hussein Sundawa; Massora, Stepanus

    2016-01-01

    The influence of antithyroid drugs (ATDs) on the therapeutic efficacy of radioactive iodine in hyperthyroidism is still controversial. The aim of this study was to evaluate the effect of ATD discontinuation to the therapeutic efficacy of I-131 in hyperthyroidism patients with long-term ATD treatment. Retrospective study was done to 39 subjects with hyperthyroidism who had been treated with doses of 300 MBq radioactive iodine. The subjects were divided into three groups: Group I (n = 14) had been using ATDs for more than one year and discontinued more than three days; group II (n = 14) had been using ATDs for more than one year but discontinued only for three days or less, and group III (n = 11) has never been used any ATD before radioactive iodine treatment. There was a significant difference in the therapeutic efficacy after three months of radioactive iodine treatment between group I and group II (P = 0.018), group II and group III (P = 0.017), but not between group I and group III (P = 1.0). There was no observed difference on the therapeutic efficacy between the three groups at 6 months after radioactive iodine therapy (P = 0.143). Administration of ATDs more than 1 year without discontinuation decreased response of radioactive iodine treatment in 3 months follow-up. Discontinuation of ATDs for more than 3 days before radioactive iodine treatment is recommended. PMID:27134556

  14. A peculiar case of the abscopal effect: radioactive iodine therapy incidentally palliating marginal zone lymphoma.

    PubMed

    Kornas, Robert C; Shields, Sarah-Kim; Goldman, Lyle S

    2015-01-01

    The abscopal effect is an extremely rare phenomenon occurring when irradiation or treatment of a primary tumor burden not only results in debulking of the targeted site but also reduces tumor size at distant sites from the intended treatment area. We present the abscopal effect occurring in a patient with low-grade marginal zone lymphoma who subsequently received radioactive iodine therapy for papillary thyroid carcinoma. She was 67 years old when a routine complete blood count at her primary care physician's office yielded a persistent leukocytosis of 14,500/μL with lymphocytosis of 9,870/μL. Immunophenotyping and fluorescence in situ hybridization (FISH) analysis confirmed low-grade marginal zone lymphoma. Over eight years, her peak leukocyte and lymphocyte counts were 24,100/μL and 18,100/μL, respectively. Subsequently, she was diagnosed with papillary thyroid carcinoma after presenting with a new complaint of dysphagia. A total thyroidectomy was performed, followed by 172.1 millicuries of oral I-131 sodium iodine radioactive ablation therapy. Following treatment, her leukocyte and lymphocyte counts were 3,100/μL and 1,100/μL, respectively. Over the next four years, her leukocyte and lymphocyte counts remained within normal limits and she remained symptom free. To our knowledge, there has never been a published report describing the use of radioactive iodine causing abscopal effect benefits for patients with underlying lymphoproliferative diseases. PMID:25709847

  15. METASTATIC RADIOIODINE AVID STRUMA OVARII ASSOCIATED WITH PSEUDO-MEIGS' SYNDROME.

    PubMed

    Riaz, Saima; Bashir, Humayun; Hassan, Aamna; Syed, Aamir Ali; Hussain, Mudassar; Imtiaz, Saba

    2015-01-01

    We report a case of 21 years old lady who presented with ascites, left adnexal mass and elevated CA-125. With suspicion of ovarian malignancy, she underwent left salpingo-oophorectomy with omental biopsy. Histopathology revealed: 'follicular variant of papillary thyroid carcinoma arising in struma ovarii' with metastatic papillary thyroid carcinoma in omental and peritoneal nodules. Patient underwent total thyroidectomy followed by radioactive iodine therapy for metastatic omental and peritoneal disease. Post-therapy whole body scan, revealed extensive I-131 avid disease metastatic disease involving the chest, abdomen, pelvis and the musculoskeletal system. Patient was treated with multiple doses of high dose radioactive iodine. She became symptom free on supra-physiologic doses of oral thyroxin however her high thyroglobulin levels and residual radioiodine avid metastatic disease required further treatment. In literature a few cases of struma ovarii have been reported with elevated CA-125 and associated pseudo-Meigs' syndrome. The treatment for this rare disease is still not standardized and poses a therapeutic challenge. Our case emphasizes the need for a multidisciplinary approach for managing struma ovarii. PMID:26721055

  16. The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism.

    PubMed

    Kartamihardja, A Hussein Sundawa; Massora, Stepanus

    2016-01-01

    The influence of antithyroid drugs (ATDs) on the therapeutic efficacy of radioactive iodine in hyperthyroidism is still controversial. The aim of this study was to evaluate the effect of ATD discontinuation to the therapeutic efficacy of I-131 in hyperthyroidism patients with long-term ATD treatment. Retrospective study was done to 39 subjects with hyperthyroidism who had been treated with doses of 300 MBq radioactive iodine. The subjects were divided into three groups: Group I (n = 14) had been using ATDs for more than one year and discontinued more than three days; group II (n = 14) had been using ATDs for more than one year but discontinued only for three days or less, and group III (n = 11) has never been used any ATD before radioactive iodine treatment. There was a significant difference in the therapeutic efficacy after three months of radioactive iodine treatment between group I and group II (P = 0.018), group II and group III (P = 0.017), but not between group I and group III (P = 1.0). There was no observed difference on the therapeutic efficacy between the three groups at 6 months after radioactive iodine therapy (P = 0.143). Administration of ATDs more than 1 year without discontinuation decreased response of radioactive iodine treatment in 3 months follow-up. Discontinuation of ATDs for more than 3 days before radioactive iodine treatment is recommended. PMID:27134556

  17. Landfarming of municipal sewage sludge at Oak Ridge, Tennessee

    SciTech Connect

    Tischler, M.L.; Pergler, C.; Wilson, M.; Mabry, D.; Stephenson, M.

    1995-12-01

    The City of Oak Ridge, Tennessee, has been applying municipal sanitary sludge to 9 sites comprising 90 ha on the US Department of Energy (DOE) Oak Ridge Reservation (ORR) since 1983. Approximately 13,000,000 L are applied annually by spraying sludge (2 to 3% solids) under pressure from a tanker. Under an ongoing monitoring program, both the sludge and the soil in the application areas are analyzed for organic, inorganic, and radioactive parameters on a regular basis. Organic pollutants are analyzed in sludge on a semiannual basis and in the soil application areas on an annual basis. Inorganic parameters are analyzed daily (e.g., pH, total solids) or monthly (e.g., nitrogen, manganese) in sludge and annually in soil in application areas. Radionuclides (Co-60, Cs-137, I-131, Be-7, K-40, Ra-228, U-235, U-238) are scanned daily during application by the sewage treatment plant and analyzed weekly in composite sludge samples and annually in soil. Additionally, data on radioactive body burden for maximally exposed workers who apply the sludge show no detectable exposures. This monitoring program is comprehensive and is one of the few in the United States that analyzes radionuclides. Results from the monitoring program show heavy metals and radionuclides are not accumulating to levels in the soil application areas.

  18. From Alamogordo to the Nuclear Test-Ban Treaty

    NASA Astrophysics Data System (ADS)

    Friedlander, Michael

    2008-04-01

    After W.W.II., the U.S. continued its program for the development of nuclear weapons. Winds carried radioactive debris far beyond the Nevada test site, and these fission products were deposited by rain, to enter the human food chain. The isotopes of greatest concern were Sr90 and I131, that, after ingestion, become concentrated in bone and thyroid respectively. There was a growing public anxiety about possible heath hazards posed by radiation from this fallout. In March 1958, the Greater St. Louis Citizens' Committee for Nuclear Information (C.N.I.) was formed. Among the leaders of C.N.I. were E. U. Condon and Barry Commoner. The aim of C.N.I. was ``to collect and distribute in the widest possible manner information which the public requires to understand the present and future problems which arise from potential large-scale use of nuclear weapons in war; testing of nuclear weapons; and nonmilitary uses of nuclear energy.'' In accordance with its objectives, members of C.N.I. gave many nontechnical talks, where we described the various forms of radiation and what was then known about the biological effects of radiation. Some of our members testified at Congressional committee hearings. We published a newsletter, initially titled Nuclear Information, and later Scientist and Citizen. In this presentation, I will describe some of the activities of this idealistic organization.

  19. Distribution and source of (129)I, (239)(,240)Pu, (137)Cs in the environment of Lithuania.

    PubMed

    Ežerinskis, Ž; Hou, X L; Druteikienė, R; Puzas, A; Šapolaitė, J; Gvozdaitė, R; Gudelis, A; Buivydas, Š; Remeikis, V

    2016-01-01

    Fifty five soil samples collected in the Lithuania teritory in 2011 and 2012 were analyzed for (129)I, (137)Cs and Pu isotopes in order to investigate the level and distribution of artificial radioactivity in Lithuania. The activity and atomic ratio of (238)Pu/((239,24)0)Pu, (129)I/(127)I and (131)I/(137)Cs were used to identify the origin of these radionuclides. The (238)Pu/(239+240)Pu and (240)Pu/(239)Pu ratios in the soil samples analyzed varied in the range of 0.02-0.18 and 0.18-0.24, respectively, suggesting the global fallout as the major source of Pu in Lithuania. The values of 10(-9) to 10(-6) for (129)I/(127)I atomic ratio revealed that the source of (129)I in Lithuania is global fallout in most cases though several sampling sites shows a possible impact of reprocessing releases. Estimated (129)I/(131)I ratio in soil samples from the southern part of Lithuania shows negligible input of the Chernobyl fallout. No correlation of the (137)Cs and Pu isotopes with (129)I was observed, indicating their different sources terms. Results demonstrate uneven distribution of these radionuclides in the Lithuanian territory and several sources of contamination i.e. Chernobyl accident, reprocessing releases and global fallout. PMID:26476410

  20. Glucose metabolism in different regions of the rat brain under hypokinetic stress influence

    NASA Technical Reports Server (NTRS)

    Konitzer, K.; Voigt, S.

    1980-01-01

    Glucose metabolism in rats kept under long term hypokinetic stress was studied in 7 brain regions. Determination was made of the regional levels of glucose, lactate, glutamate, glutamine, aspartate, gamma-aminobutyrate and the incorporation of C-14 from plasma glucose into these metabolites, in glycogen and protein. From the content and activity data the regional glucose flux was approximated quantitatively. Under normal conditions the activity gradient cortex and frontal pole cerebellum, thalamus and mesencephalon, hypothalamus and pons and medulla is identical with that of the regional blood supply (measured with I131 serum albumin as the blood marker). Within the first days of immobilization a functional hypoxia occurred in all brain regions and the utilization of cycle amino acids for protein synthesis was strongly diminished. After the first week of stress the capillary volumes of all regions increased, aerobic glucose metabolism was enhanced (factors 1.3 - 2.0) and the incorporation of glucose C-14 via cycle amino acids into protein was considerably potentiated. The metabolic parameters normalized between the 7th and 11th week of stress. Blood supply and metabolic rate increased most in the hypothalamus.

  1. Monte Carlo calculated doses to treatment volumes and organs at risk for permanent implant lung brachytherapy

    NASA Astrophysics Data System (ADS)

    Sutherland, J. G. H.; Furutani, K. M.; Thomson, R. M.

    2013-10-01

    Iodine-125 (125I) and Caesium-131 (131Cs) brachytherapy have been used with sublobar resection to treat stage I non-small cell lung cancer and other radionuclides, 169Yb and 103Pd, are considered for these treatments. This work investigates the dosimetry of permanent implant lung brachytherapy for a range of source energies and various implant sites in the lung. Monte Carlo calculated doses are calculated in a patient CT-derived computational phantom using the EGsnrc user-code BrachyDose. Calculations are performed for 103Pd, 125I, 131Cs seeds and 50 and 100 keV point sources for 17 implant positions. Doses to treatment volumes, ipsilateral lung, aorta, and heart are determined and compared to those determined using the TG-43 approach. Considerable variation with source energy and differences between model-based and TG-43 doses are found for both treatment volumes and organs. Doses to the heart and aorta generally increase with increasing source energy. TG-43 underestimates the dose to the heart and aorta for all implants except those nearest to these organs where the dose is overestimated. Results suggest that model-based dose calculations are crucial for selecting prescription doses, comparing clinical endpoints, and studying radiobiological effects for permanent implant lung brachytherapy.

  2. Micrometer-level naked-eye detection of caesium particulates in the solid state

    NASA Astrophysics Data System (ADS)

    Mori, Taizo; Akamatsu, Masaaki; Okamoto, Ken; Sumita, Masato; Tateyama, Yoshitaka; Sakai, Hideki; Hill, Jonathan P.; Abe, Masahiko; Ariga, Katsuhiko

    2013-02-01

    Large amounts of radioactive material were released from the Fukushima Daiichi nuclear plant in Japan, contaminating the local environment. During the early stages of such nuclear accidents, iodine I-131 (half-life 8.02 d) is usually detectable in the surrounding atmosphere and bodies of water. On the other hand, in the long-term, soil and water contamination by Cs-137, which has a half-life of 30.17 years, is a serious problem. In Japan, the government is planning and carrying out radioactive decontamination operations not only with public agencies but also non-governmental organizations, making radiation measurements within Japan. If caesium (also radiocaesium) could be detected by the naked eye then its environmental remediation would be facilitated. Supramolecular material approaches, such as host-guest chemistry, are useful in the design of high-resolution molecular sensors and can be used to convert molecular-recognition processes into optical signals. In this work, we have developed molecular materials (here, phenols) as an optical probe for caesium cation-containing particles with implementation based on simple spray-on reagents and a commonly available fluorescent lamp for naked-eye detection in the solid state. This chemical optical probe provides a higher spatial resolution than existing radioscopes and gamma-ray cameras.

  3. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-09-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in the current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: AAV-NGFbeta, aprepitant, aripiprazole, atomoxetine hydrochloride; beta-Methyl-6-chloromelatonin, BMS-214662, bortezomib, bosentan; Calcipotriol/betamethasone dipropionate, CEA-TRICOM, cetuximab, ciclesonide, clofarabine, Cypher; Dalbavancin, darbepoetin alfa, darifenacin hydrobromide, desloratadine, Dexamet, drospirenone, drospirenone/ethinylestradiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, ertapenem sodium, escitalopram oxalate, eszopiclone; Fenretinide; Gefitinib, gestodene, ghrelin (human); hMaxi-K, human papillomavirus vaccine; Imatinib mesylate, indiplon, iodine (i131) tositumomab, irofulven, ISS-1018; Lasofoxifene tartrate, levodopa/carbidopa/entacapone, liposomal doxorubicin; Nemifitide ditriflutate, nesiritide; Omalizumab; Pegfilgrastim, peginterferon alfa-2a, peginterferon alfa-2b, phVEGF-A165, pimecrolimus, pramlintide acetate; Rasburicase, rimonabant hydrochloride; Satraplatin, St. John's Wort extract, sunitinib malate; Tadalafil, tanaproget, Taxus, tiotropium bromide, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate; Ximelagatran; Zileuton. PMID:16258596

  4. Radionuclide (131)I labeled reduced graphene oxide for nuclear imaging guided combined radio- and photothermal therapy of cancer.

    PubMed

    Chen, Lei; Zhong, Xiaoyan; Yi, Xuan; Huang, Min; Ning, Ping; Liu, Teng; Ge, Cuicui; Chai, Zhifang; Liu, Zhuang; Yang, Kai

    2015-10-01

    Nano-graphene and its derivatives have attracted great attention in biomedicine, including their applications in cancer theranostics. In this work, we develop 131I labeled, polyethylene glycol (PEG) coated reduced nano-graphene oxide (RGO), obtaining 131I-RGO-PEG for nuclear imaging guided combined radiotherapy and photothermal therapy of cancer. Compared with free 131I, 131IRGO- PEG exhibits enhanced cellular uptake and thus improved radio-therapeutic efficacy against cancer cells. As revealed by gamma imaging, efficient tumor accumulation of 131I-RGO-PEG is observed after its intravenous injection. While RGO exhibits strong near-infrared (NIR) absorbance and could induce effective photothermal heating of tumor under NIR light irradiation, 131I is able to emit high-energy X-ray to induce cancer killing as the result of radio ionization effect. By utilizing the combined photothermal therapy and radiotherapy, both of which are delivered by a single agent 131IRGO- PEG, effective elimination of tumors is achieved in our animal tumor model experiments. Toxicology studies further indicate that 131I-RGO-PEG induces no appreciable toxicity to mice at the treatment dose. Our work demonstrates the great promise of combing nuclear medicine and photothermal therapy as a novel therapeutic strategy to realize synergistic efficacy in cancer treatment. PMID:26188609

  5. Temporal Movement of the Geochemical "Fingerprint" of the World Trade Center Terrorist Attack in New York Harbor Sediments

    NASA Astrophysics Data System (ADS)

    Smith, J. P.; Oktay, S. D.; Brabander, D. J.; Olsen, C. R.; Kada, J.

    2002-12-01

    The September 11, 2001 terrorist attack on the World Trade Center (WTC) in New York City introduced large amounts of ash and debris over a wide area including New York Harbor (NYH) and the Lower Hudson River Estuary. Previous results, based on data from ash/debris collected after the event and from sediment cores taken on October 12, 2001 in inactive harbor slips along the lower west side of Manhattan, have identified a textural and elemental "fingerprint" for the ash/debris, and have documented a stratigraphic horizon for the event in New York Harbor sediments. On July 24 and July 25, 2002, almost eleven months after the attack, the same sample sites were revisited and new sediment cores collected. Sediment samples were analyzed using radionuclide tracers (Be-7, Cs-137, I-131) and textural and elemental (major- and trace-element) characterizations were made in order to: 1) document the temporal progression of the fingerprint as a distinct horizon preserved in the sediments of New York Harbor; and 2) investigate how short-to-medium term sediment dynamics (supply, deposition, re-suspension, and net accumulation) may affect the preservation of a sedimentological record associated with the event. These results will be used to evaluate whether the WTC geochemical fingerprint may serve as a tool to help assess the impact of the attack and as a tracer for short to medium term sediment dynamics in the Lower Hudson River Estuary.

  6. Radioimmunotherapy for non-Hodgkin's lymphoma: A review for radiation oncologists

    SciTech Connect

    Macklis, Roger M. . E-mail: macklir@ccf.org; Pohlman, Brad

    2006-11-01

    Purpose: The aim of this study was to review advances in radioimmunotherapy (RIT) for non-Hodgkin's lymphoma (NHL) and to discuss the role of Radiation oncologist in administering this important new form of biologically targeted radiotherapy. Methods and Materials: A review of articles and abstracts on the clinical efficacy, safety, and radiation safety of yttrium Y 90 ({sup 9}Y) ibritumomab tiuxetan (Zevalin) and iodine I 131 tositumomab (Bexxar) was performed. Results: The clinical efficacy of RIT in NHL has been shown in numerous clinical trials of {sup 9}Y ibritumomab tiuxetan and {sup 131}I tositumomab. Both agents have produced significant responses in patients with low-grade, follicular, or transformed NHL, including patients with disease that had not responded or had responded poorly to previous chemotherapy or immunotherapy. Reversible toxicities such as neutropenia, thrombocytopenia, and anemia are the most common adverse events with both agents. Conclusions: Radioimmunotherapy is safe and effective in many patients with B-cell NHL. {sup 9}Y ibritumomab tiuxetan and {sup 131}I tositumomab can produce clinically meaningful and durable responses even in patients in whom chemotherapy has failed. Treatment with RIT requires a multispecialty approach and close communication between Radiation oncologist and other members of the treatment team. Radiation oncologist plays an important role in treating patients with RIT and monitoring them for responses and adverse events after treatment.

  7. Assessment of the potential impact of Nuclear Power Plant accidents on aviation

    NASA Astrophysics Data System (ADS)

    Wotawa, Gerhard; Arnold, Delia; Maurer, Christian

    2014-05-01

    The nuclear accidents in Chernobyl in 1986 and in Fukushima in 2011 demonstrated the urgent need to provide adequate guidance for land-based, marine and airborne transport. Quick assessments of potential impacts are essential to avoid unnecessary traffic disruptions while guaranteeing appropriate safety levels for staff in the transport industry as well as travellers. Such estimates are to be provided under difficult circumstances, mostly due to the lack of reliable initial information on the severity of the accident and the exact source term of radionuclides. Regarding aviation, there are three equally relevant aspects to look at, namely aircraft in cruising altitude (about 40000 ft), aircraft approaching an airport, and finally the airports as such as critical infrastructure, including airport operations and ground transport. Based on the accident scenarios encountered in the Chernobyl and Fukushima cases, exemplary case studies shall be provided to assess the potential impacts of such events on aviation. The study is based on the Atmospheric Transport and Dispersion Model (ATDM) FLEXPART and a simplified scheme to calculate effective dose rates based on a few key radionuclides (Cs-137, I-131 and Xe-133). Besides the impact assessment, possible new products provided by WMO Regional Specialized Meteorological Centres in the event of an accident shall be discussed as well.

  8. Meta-iodobenzylguanidine (mIBG) scintigraphy: A one year experience

    SciTech Connect

    Baulieu, J.L.; Guilloteau, D.; Chambon, C.; Viel, C.; Baulieu, F.; Itti, R.; Pourcelot, L.; Besnard, J.C.

    1984-01-01

    During one year, mIBG scintigraphy was performed in 31 patients: group I (n=27): I-131 mIBG: 18 patients without pheochromocytoma, and 9 patients with proved pheochromocytoma; grout II (n=4): I-123 mIBG: two children without neuroblastoma and two children with proved neuroblastoma. Uptake in various organs or sites of activity was evaluated by an entire score varying from 0 to 3 according respectively to no visualization, visualization only from digitalized images, visualization on analogic images and predominant activity. Most of the organs appeared more visible in patients without pheochromocytoma. In patients with pheochromocytoma, the heart was not apparent on 48 hours views. In group I, pathologic examination resulted in eight true positives one false positive and one false negative. In group II, the neuroblastoma exhibited mIBG accumulation, while no abnormal uptake was observed in children without neuroblastoma. According to the final diagnosis, sensitivity was found to be .91 and specificity .95. The results confirm that mIBG is valuable for pheochromocytoma localization and suggest that I-123 mIBG could be useful in investigating neuroblastoma in children.

  9. Update on basic research and clinical experience with metaiodobenzylguanidine

    SciTech Connect

    Beierwaltes, W.H.

    1987-01-01

    I-131-metaiodobenzylguanidine (MIBG) is an aralkylguanidine with certain structural similarities to norepinephrine (NE). It is concentrated, stored, and released from chromaffin granules in a manner almost identical with that of NE. It will image the enlarged adrenal medullae of adrenal medullary hyperplasia when the CAT and NMR scans are normal. It is more sensitive in detecting extra-adrenal pheochromocytomas than CAT and NMR imaging. Because 46% of our 176 patients with histopathologically proved ''benign'' pheochromocytomas (pheos) have developed demonstrable metastases, with or without elevated plasma and urinary catecholamines, we now image all patients with benign pheos yearly. As of January 22, 1986 we had treated 28 patients with malignant pheos 71 times with MIBG. As of July 24, 1986, we had given 34 neuroblastoma patients 55 tracer doses. In some cases MIBG demonstrates more neuroblastoma than all other imaging modalities and this is helpful in staging. We have had 30-50% objective regressions in neuroblastoma tumor mass in 3 out of the first 12 patients treated. These three patients had slower-growing tumors and a lower body burden than the nonresponders. We also record the sensitivity of MIBG imaging of neuroendocrine tumors other than pheos and neuroblastomas. 31 references.

  10. New cholescintigraphic agent: ruthenium-97-DISIDA

    SciTech Connect

    Zanzi, I.; Srivastava, S.C.; Meinken, G,E.; Robeson, W.; Mausner, L.F.; Fairchild, R.G.; Margouleff, D.

    1986-06-01

    These studies demonstrate the first application of Ru-97-DISIDA in human subjects. High quality images were obtained. Scintigraphic findings in patients with hepatobiliary disorders were consistent with the biodistribution data obtained in experinmental animals and with other imaging procedures and clinical findings. Administration of Ru-97-DISIDA I.V. and of a solid test meal labeled with Tc-99m-Sulfur Colloid allowed simulateneous detection and quantification of deodenogastric reflux and determination of the gastric emptying rate. This represents an advantage as compared to the currently used techniques which necessitate two separate studies if a solid meal is used, or would mandate a liquid meal for a simultaneous study. The excellent nuclear decay characteristics of Ru-97 (tl/2 69.6 h, gamma 216 keV, 86%, no betas) permit delayed study of the hepatobiliary system with considerably less radiation exposure than I-131 Rose Bengal and with a marked improvement in image quality. 5 refs., 3 figs., 3 tabs.

  11. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2009-05-01

    (-)-Gossypol; Abacavir sulfate/lamivudine, ACAM-1000, ACE-011, Agomelatine, AGS-004, Alemtuzumab, Alvocidib hydrochloride, AMG-317, Amlodipine, Aripiprazole, Atazanavir sulfate, Azacitidine; Becatecarin, Belinostat, Bevacizumab, BMS-387032, BMS-690514, Bortezomib; Casopitant mesylate, Cetuximab, Choline fenofibrate, CK-1827452, Clofarabine, Conivaptan hydrochloride; Dabigatran etexilate, DADMe-Immucillin-H, Darbepoetin alfa, Darunavir, Dasatinib, DC-WT1, Decitabine, Deferasirox, Degarelix acetate, Denenicokin, Denosumab, Dienogest, Duloxetine hydrochloride; Ecogramostim, Eculizumab, Edoxaban tosilate, Elacytarabine, Elesclomol, Eltrombopag olamine, Enfuvirtide, Enzastaurin hydrochloride, Eribulin mesilate, Erlotinib hydrochloride, Escitalopram oxalate, Eszopiclone, Etravirine; Flibanserin, Fludarabine, Fondaparinux sodium, Fosamprenavir calcium; Gefitinib, Genistein; I-131-L19-SIP, Idrabiotaparinux sodium, Imatinib mesylate, IMGN-901, Ipilimumab; Laromustine, Lenalidomide, Liposomal cisplatin, Liraglutide, Lisdexamfetamine mesilate, Lopinavir, Lopinavir/ritonavir; Maraviroc, MDV-3100, Mecasermin rinfabate, MP-470, Mycophenolic acid sodium salt; Naproxcinod, NB-002, Nesiritide, Nilotinib hydrochloride monohydrate, NK-012; Palonosetron hydrochloride, Panobinostat, Pegfilgrastim, Peginterferon alfa-2a, Pitavastatin calcium, PL-3994, Plerixafor hydrochloride, Plitidepsin, PM-10450; Raltegravir potassium, Recombinant human soluble thrombomodulin, ReoT3D, RHAMM R3 peptide, Rivaroxaban, Romiplostim, Rosuvastatin calcium, Rozrolimupab; Sabarubicin hydrochloride, Salinosporamide A, Sirolimus-eluting stent, Smallpox (Vaccinia) Vaccine, Live, Sorafenib; Tenofovir disoproxil fumarate, Tenofovir disoproxil fumarate/emtricitabine, Teriparatide, Tipifarnib, Tipranavir, Trabectedin, Trifluridine/TPI; Vardenafil hydrochloride hydrate, Vinflunine, Volociximab, Vorinostat; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Ziprasidone hydrochloride, Zoledronic acid monohydrate

  12. Feasibility studies of an EMCCD-based beta imaging probe for radioguided thyroid surgery

    NASA Astrophysics Data System (ADS)

    Shestakova, Irina; Nagarkar, Vivek V.; Gaysinskiy, Valeriy; Entine, Gerald; Stack, Brendan C.; Miller, Brian

    2006-08-01

    We are developing a probe for image-guided surgery of cancer to be used in conjunction with traditional beta emitting radiopharmaceuticals such as I 131 and F 18-FDG. This device is based on a combination of two novel technologies, a microcolumnar film scintillator, CsI(Tl) and low-noise high sensitivity Electron-Multiplying CCD (EMCCD). The former allows high spatial resolution nuclear imaging and the latter facilitates detection of signal with significantly higher SNR than conventional CCDs by the virtue of internal signal gain built into its readout register. CsI(Tl) is bonded to the EMCCD via a flexible coherent fiberopic cable for easy handling. Due to its high sensitivity the probe is capable of functioning in real time providing high spatial resolution nuclear images for precise detection, delineation and excision of tumors. The evaluation of the probe using standard clinical phantoms as well as the operational data obtained on swine models and in clinical surgery will be presented.

  13. Survival outcome of radioiodine therapy in post thyroidectomy thyroid carcinoma patients: Outcome of long term follow up

    NASA Astrophysics Data System (ADS)

    Haque, F.; Nahar, N.; Sultana, S.; Nasreen, F.; Jabin, Z.; Alam, A. S. M. M.

    2016-03-01

    The overall prognosis of patients with thyroid carcinoma is excellent whenever managed following best practice guidelines. Objective: To calculate sex and age group affected by thyroid cancer; to compare between single or multiple dose of radio ablation needed after thyroidectomy and to determine the percentage of patients become disease free during their follow up. Methods: This was a retrospective study done in NINMAS, Bangladesh on 687 patients from 1984 to 2004. In all cases total or near total thyroidectomy was done before commencing radioiodine therapy. Patients TG level, neck ultrasonography, thyroid scan, whole body I131 scans, neck examination were done every six monthly/yearly. Results: Among 687 patients, female were more sufferers (68.1%) and female to male ratio was 2:1. Age group 19-40 years was mostly affected (57.8%). Most common type seen was papillary carcinoma (81.8%). After ablation 100 patients did not follow-up. Total 237 patients discontinued within 4 years. Remaining 450 patients undergone regular follow-up for 5 years and more, 394 were disease free (87.6%). Total recurrence of metastasis was 23 and 12 patients expired at different times. Conclusions: Long-term regular follow-up is necessary after radioiodine ablation to become free of disease.

  14. Molecular Imaging of Neuroendocrine Tumors

    PubMed Central

    Carrasquillo, Jorge A.; Chen, Clara C.

    2014-01-01

    Neuroendocrine tumors (NET) are a heterogeneous group of tumors that arise from neuroendocrine cells. These tumors may arise from various organs, including lung, thymus, thyroid, stomach, duodenum, small bowel, large bowel, appendix, pancreas, adrenal, and skin. Most are well differentiated and have the ability to produce biogenic amines and various hormones. NET usually occur sporadically but they also be associated with various familial syndromes. For the vast majority of NET, surgical resection is the treatment of choice whenever feasible. Localization of NET prior to surgery and for staging and follow-up relies on both anatomic and functional imaging modalities. In fact, the unique secretory characteristics of these tumors lend themselves to imaging by molecular imaging modalities, which can target specific metabolic pathways or receptors. Neuroendocrine cells have a variety of such target receptors and pathways for which radiopharmaceuticals have been developed, including [123I/131I]-metaiodobenzylguanidine (MIBG), [ 111In]pentetreotide, [68Ga] somatostatin analogs, [18F] fluorodeoxyglucose (FDG), [11C/18F] dihydroxyphenylalanine (DOPA), [11C] 5-hydroxytryptophan (5-HTP) 99mTc pentavalent dimercaptosuccinic acid ([99mTc] (V) DMSA, and [18F] fluorodopamine (FDA). Here, we review the molecular imaging approaches for NET using various radiopharmaceuticals. PMID:21167384

  15. Air Monitoring of Emissions from the Fukushima Daiichi Reactor

    SciTech Connect

    McNaughton, Michael; Allen, Shannon P.; Archuleta, Debra C.; Brock, Burgandy; Coronado, Melissa A.; Dewart, Jean M.; Eisele, William F. Jr.; Fuehne, David P.; Gadd, Milan S.; Green, Andrew A.; Lujan, Joan J.; MacDonell, Carolyn; Whicker, Jeffrey J.

    2012-06-12

    In response to the disasters in Japan on March 11, 2011, and the subsequent emissions from Fukushima-Daiichi, we monitored the air near Los Alamos using four air-monitoring systems: the standard AIRNET samplers, the standard rad-NESHAP samplers, the NEWNET system, and high-volume air samplers. Each of these systems has advantages and disadvantages. In combination, they provide a comprehensive set of measurements of airborne radionuclides near Los Alamos during the weeks following March 11. We report air-monitoring measurements of the fission products released from the Fukushima-Daiichi nuclear-power-plant accident in 2011. Clear gamma-spectrometry peaks were observed from Cs-134, Cs-136, Cs-137, I-131, I132, Te-132, and Te-129m. These data, together with measurements of other radionuclides, are adequate for an assessment and assure us that radionuclides from Fukushima Daiichi did not present a threat to human health at or near Los Alamos. The data demonstrate the capabilities of the Los Alamos air-monitoring systems.

  16. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2009-06-01

    (+)-Dapoxetine hydrochloride; Abatacept, Adalimumab, Agalsidase beta, Alemtuzumab, Alglucosidase alfa, Aliskiren fumarate, Ambrisentan, Amlodipine, Aripiprazole, Atrasentan, Azacitidine, Azelnidipine; Belotecan hydrochloride, Bevacizumab, Bilastine, Biphasic insulin aspart, Bortezomib, Bosentan; Caspofungin acetate, CG-100649, Cinacalcet hydrochloride, Clindamycin phosphate/ benzoyl peroxide; Dasatinib, Denosumab, Duloxetine hydrochloride, Dutasteride, Dutasteride/tamsulosin; Ecogramostim, Eculizumab, Eltrombopag olamine, EndoTAG-1, Erlotinib hydrochloride, Everolimus, Exenatide, Ezetimibe; FAHF-2, Fondaparinux sodium; Gefitinib, Golimumab; HEV-239, HSV-TK; Imatinib mesylate, Indium 111 ((111)In) ibritumomab tiuxetan, Influenza vaccine(surface antigen, inactivated, prepared in cell culture), Insulin glargine; Kisspeptin-54; Lidocaine/prilocaine, Lomitapide; Maraviroc, Mirodenafil hydrochloride, MK-8141, MVA-Ag85A; Nilotinib hydrochloride monohydrate; Olmesartan medoxomil; Paclitaxel-eluting stent, Pegfilgrastim, Peginterferon alfa-2a, Peginterferon alfa-2b, Pemetrexed disodium, Pitavastatin calcium, Prasugrel; Recombinant human relaxin H2, RHAMM R3 peptide, Rivaroxaban, Rosuvastatin calcium, RRz2; Sagopilone, Salinosporamide A, SB-509, Serlopitant, Sirolimus-eluting stent, Sorafenib, Sunitinib malate; Tadalafil, Temsirolimus, Teriparatide, TG-4010, Tositumomab/iodine (I131) tositumomab; Velusetrag Hydrochloride; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan. PMID:19649342

  17. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-12-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: 131I-chTNT; Abatacept, adalimumab, alemtuzumab, APC-8015, aprepitant, atazanavir sulfate, atomoxetine hydrochloride, azimilide hydrochloride; Bevacizumab, bortezomib, bosentan, buserelin; Caspofungin acetate, CC-4047, ChAGCD3, ciclesonide, clopidogrel, curcumin, Cypher; Dabigatran etexilate, dapoxetine hydrochloride, darbepoetin alfa, darusentan, denosumab, DMXB-Anabaseine, drospirenone, drospirenone/estradiol, duloxetine hydrochloride, dutasteride; Edodekin alfa, efaproxiral sodium, elaidic acid-cytarabine, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, eszopiclone, etonogestrel/testosterone decanoate, exenatide; Fulvestrant; Gefitinib, glycine, GVS-111; Homoharringtonine; ICC-1132, imatinib mesylate, iodine (I131) tositumomab, i.v. gamma-globulin; Levetiracetam, levocetirizine, lintuzumab, liposomal nystatin, lumiracoxib, lurtotecan; Manitimus, mapatumumab, melatonin, micafungin sodium, mycophenolic acid sodium salt; Oblimersen sodium, OGX-011, olmesartan medoxomil, omalizumab, omapatrilat, oral insulin; Parathyroid hormone (human recombinant), pasireotide, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, phVEGF-A165, pimecrolimus, pitavastatin calcium, plerixafor hydrochloride, posaconazole, pramlintide acetate, prasterone, pregabalin, PT-141; Quercetin; Ranolazine, rosuvastatin calcium, rubitecan, rupatadine fumarate; Sardomozide, sunitinib malate; Tadalafil, talactoferrin alfa, tegaserod maleate, telithromycin, testosterone transdermal patch, TH-9507, tigecycline, tiotropium bromide, tipifarnib, tocilizumab, treprostinil sodium; Valdecoxib, vandetanib

  18. Evaluation of an immunoextraction procedure for the estimation of free thyroxine concentration

    SciTech Connect

    Witherspoon, L.R.; Shuler, S.E.; Gilbert, S.S.

    1984-02-01

    The authors have examined the performance of a commercial free-thyroxine assay in which a radiolabeled T/sub 4/ derivative permits the competitive quantitation of extracted T/sub 4/ in the presence of serum proteins. After the total T/sub 4/ pool had been radiolabeled with either I-125 T/sub 4/ or I-131 T/sub 4/, the solid-phase antibody was found to be associated with 4-8% of the total T/sub 4/ present in the assay tube. Of this, 15-60% was displaceable (antibody-bound). The assay estimated free T/sub 4/ to be 0.6-1.8 ng/dl in euthyroid patients, and distinguished them from hyperthyroid (sensitivity 91%) and hypothyroid patients (sensitivity 91%) without apparent TBG dependence. In patients with severe nonthyroidal illnesses, the assay correctly quantitated a reduced extracted mass in some. In other patients, however, the assay results were inappropriately lower than the actual extracted mass, in agreement with the FTI but not with the measurements of free T/sub 4/ by dialysis. This assay appears to produce clinically appropriate results in most patients. In some nonthyroidally ill patients however, the indicated free T/sub 4/ is spuriously low.

  19. Improving cancer treatment with cyclotron produced radionuclides

    SciTech Connect

    Larson, S.M.; Finn, R.D.

    1992-08-04

    Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.

  20. Improving cancer treatment with cyclotron produced radionuclides. Progress report

    SciTech Connect

    Larson, S.M.; Finn, R.D.

    1992-08-04

    Our goal is to improve the scientific basis for tumor diagnosis, treatment and treatment follow-up based on the use of cyclotron produced radiotracers in oncology. The grant includes 3 interactive components: Radiochemistry/Cyclotron; Pharmacology; and Immunology. The radiochemistry group seeks to develop innovative cyclotron targetry, radiopharmaceuticals, and radiolabeled antibodies, which are then used to assess important unanswered questions in tumor pharmacology and immunology. Examples include selected positron emitting radionuclides, such as Iodine-124, and Ga-66; I-124, I-123, I-131 labeled iododeoxyuridine, C-11 colchicine, and antimetabolites, like C-11 methotrexate; and radiolabeled antibodies, 3F8, M195, A33, and MRK16 for application in the pharmacology and immunology projects. The pharmacology program studies tumor resistance to chemotherapy, particularly the phenomenon of multidrug resistance and the relationship between tumor uptake and retention and the tumor response for anti-metabolite drugs. The immunology program studies the physiology of antibody localization at the tissue level as the basis for novel approaches to improving tumor localization such as through the use of an artificial lymphatic system which mechanically reduces intratumoral pressures in tumors in vivo. Quantitative imaging approaches based on PET and SPECT in radioimmunotherapy are studied to give greater insight into the physiology of tumor localization and dosimetry.

  1. Development of a software tool for an internal dosimetry using MIRD method

    NASA Astrophysics Data System (ADS)

    Chaichana, A.; Tocharoenchai, C.

    2016-03-01

    Currently, many software packages for the internal radiation dosimetry have been developed. Many of them do not provide sufficient tools to perform all of the necessary steps from nuclear medicine image analysis for dose calculation. For this reason, we developed a CALRADDOSE software that can be performed internal dosimetry using MIRD method within a single environment. MATLAB software version 2015a was used as development tool. The calculation process of this software proceeds from collecting time-activity data from image data followed by residence time calculation and absorbed dose calculation using MIRD method. To evaluate the accuracy of this software, we calculate residence times and absorbed doses of 5 Ga- 67 studies and 5 I-131 MIBG studies and then compared the results with those obtained from OLINDA/EXM software. The results showed that the residence times and absorbed doses obtained from both software packages were not statistically significant differences. The CALRADDOSE software is a user-friendly, graphic user interface-based software for internal dosimetry. It provides fast and accurate results, which may be useful for a routine work.

  2. Modelling the activity of 129I in the primary coolant of a CANDU reactor

    NASA Astrophysics Data System (ADS)

    Lewis, Brent J.; Husain, Aamir

    2003-01-01

    A mathematical treatment has been developed to describe the activity levels of 129I as a function of time in the primary heat transport system during constant power operation and for a reactor shutdown situation. The model accounts for a release of fission-product iodine from defective fuel rods and tramp uranium contamination on in-core surfaces. The physical transport constants of the model are derived from a coolant activity analysis of the short-lived radioiodine species. An estimate of 3×10 -9 has been determined for the coolant activity ratio of 129I/ 131I in a CANDU Nuclear Generating Station (NGS), which is in reasonable agreement with that observed in the primary coolant and for plant test resin columns from pressurized and boiling water reactor plants. The model has been further applied to a CANDU NGS, by fitting it to the observed short-lived iodine and long-lived cesium data, to yield a coolant activity ratio of ˜2×10 -8 for 129I/ 137Cs. This ratio can be used to estimate the levels of 129I in reactor waste based on a measurement of the activity of 137Cs.

  3. Myocardial imaging with a radioiodinated norepinephrine storage analog

    SciTech Connect

    Wieland, D.M.; Brown, L.E.; Rogers, W.L.; Worthington, K.C.; Wu, J.L.; Clinthorne, N.H.; Otto, C.A.; Swanson, D.P.; Beierwaltes, W.H.

    1981-01-01

    Meta-iodobenzylguanidine (M-IBG), an iodinated aromatic analog of the hypotensive drug guanethidine, localizes in the heart of the rat, dog, and rhesus monkey. A comparative study of tissue distribution in the dog has been performed with five myocardiophilic agents: thallium-201, I-125 16-iodohexadecanoic acid, H-3 norepinephrine, C-14 guanethidine and I-125 M-IBG. The last two compounds give heart concentrations and heart-to-blood concentration ratios similar to those of thallium-201. Planar and tomographic images of the hearts of the dog and rhesus monkey were obtained using I-131 or I-123 labeled M-IBG. Blocking studies with reserpine suggest that a major component of myocardial retention of M-IBG is sequestration within the norepinephrine storage vesicles of the adrenergic nerves. The localization of M-IBG in other organs with rich sympathetic innervation and the relative insensitivity of myocardial uptake to a wide range of loading doses lend additional support for a neuronal mode of retention.

  4. Large Multinodular Toxic Goiter: Is Surgery Always Necessary?

    PubMed Central

    Negro, Roberto; Greco, Gabriele

    2016-01-01

    Patients suffering from multinodular toxic goiter (MNTG) are candidates to thyroidectomy or radioiodine 131I (131I) therapy. Thyroidectomy may be preferable especially when the volume of hyperfunctioning tissue is so large that a single administration of 131I is unlikely to cure the patient in terms of nodule's volume reduction and thyroid function. We describe the case of a 71-year-old man suffering from thyrotoxic state for the presence of two large hyperfunctioning thyroid nodules. As the patient refused surgery, at first we administered 600 MBq dose of 131I, which was unable to solve hyperthyroidism and local compressive symptoms. Then, before administering another 131I dose, the patient underwent a laser ablation treatment (LAT) in both nodules. After a significant shrinkage due to LAT, the patient received 400 MBq 131I. This procedure was able to definitely cure hyperthyroidism, to induce a significant reduction of nodules' volume, and to render the patient asymptomatic for compressive symptoms. This case demonstrates that 131I preceded by LAT represents a valid alternative strategy to surgery, even in the presence of two large coexistent hot nodules. PMID:27099796

  5. Self-irradiation of the blood from selected nuclides in nuclear medicine

    NASA Astrophysics Data System (ADS)

    Hänscheid, H.; Fernández, M.; Eberlein, U.; Lassmann, M.

    2014-03-01

    Nuclear medicine dosimetry and research in biodosimetry often require the knowledge of the absorbed dose to the blood. This study provides coefficients for the absorbed dose rates to the blood related to the activity concentration in the blood as a function of the vessel radius for radionuclides commonly used in targeted radiotherapy and in PET-diagnostics: C-11, F-18, Ga-68, Y-90, Tc-99 m, I-124, I-131, and Lu-177. The energy deposition patterns after nuclear disintegrations in blood vessel lumina (cylinders homogeneously filled with blood) with radii from 0.01 to 25.0 mm were simulated with the Monte-Carlo radiation transport code MCNPX. An additional contribution from photon radiation from activity in blood in the remainder of the body was taken into account based on a reasonable blood distribution model. The fraction of energy absorbed from non-penetrating radiation in the blood is low in thin blood vessels but approaches the total energy emitted by particles with increasing lumen radius. For photon radiation, irradiation to blood in small vessels is almost completely due to radioactive decays in distant blood distributed throughout the body, whereas the contribution from activity in the vessel becomes dominant for lumen radii exceeding 13 mm. The dependences of the absorbed dose rates on the lumen radius can be described with good accuracy by empirical functions which can be used to determine the absorbed doses to the blood and to the surrounding tissue.

  6. Biodistribution and dosimetry of free 211At, 125I- and 131I- in rats.

    PubMed

    Spetz, Johan; Rudqvist, Nils; Forssell-Aronsson, Eva

    2013-11-01

    131I is widely used for therapy in the clinic and 125I and 131I, and increasingly 211At, are often used in experimental studies. It is important to know the biodistribution and dosimetry for these radionuclides to determine potential risk organs when using radiopharmaceuticals containing these radionuclides. The purpose of this study was to investigate the biodistribution of 125I-, 131I-, and free 211At in rats and to determine absorbed doses to various organs and tissues. Male Sprague Dawley rats were injected simultaneously with 0.1-0.3 MBq 125I- and 0.1-0.3 MBq 131I-, or 0.05-0.2 MBq 211At and sacrificed 1 hour to 7 days after injection. The activities and activity concentrations in organs and tissues were determined and mean absorbed doses were calculated. The biodistribution of 125I- was similar to that of 131I- but the biodistribution of free 211At was different compared to 125I- and 131I-. The activity concentration of radioiodine was higher compared with 211At in the thyroid and lower in all extrathyroidal tissues. The mean absorbed dose per unit injected activity was highest to the thyroid. 131I gave the highest absorbed dose to the thyroid, and 211At gave the highest absorbed dose to all other tissues studied. PMID:23789969

  7. Radionuclides in the ground-level atmosphere in Vilnius, Lithuania, in March 2011, detected by gamma-ray spectrometry.

    PubMed

    Gudelis, A; Druteikienė, R; Lujanienė, G; Maceika, E; Plukis, A; Remeikis, V

    2012-07-01

    This study presents the ground-level air monitoring results obtained in Vilnius, the capital of Lithuania, on 14 March-14 April 2011 after the recent earthquake and subsequent Tsunami having a crucial impact on Japanese nuclear reactors at the Fukushima Daiichi Nuclear Power Plant (NPP) on 11 March 2011. To collect representative diurnal aerosol samples a powerful sampling system ensuring the air filtration rate of 5500 m(3) h(-1) was used. The following artificial gamma-ray emitting radionuclides have been determined: (129m)Te, (132)Te (in equilibrium with its daughter (132)I), (131)I, (134)Cs, (136)Cs and (137)Cs. Activity concentration of the globally distributed fission product (137)Cs has increased from a background value of 1.6 μBq m(-3) to the value of 0.9 mBq m(-3) at the beginning of April. The activity ratio (134)Cs/(137)Cs was found to be close to 1, with a slightly higher activity of (134)Cs. The maximum aerosol-associated (131)I activity concentration of 3.45 mBq m(-3) was by four orders of magnitude lower than that measured at the same location in April-May 1986 as a consequence of the Chernobyl NPP accident. The estimated gaseous fraction of iodine-131 constituted about 70% of the total (131)I activity. PMID:22541992

  8. Management of differentiated thyroid carcinoma with bone metastasis: a case report and review of the Chinese literature*

    PubMed Central

    Zhang, Wei-dong; Liu, Da-ren; Feng, Cheng-cheng; Zhou, Chuan-biao; Zhan, Chen-ni; Que, Ri-sheng; Chen, Li

    2014-01-01

    Differentiated thyroid carcinoma (DTC) is a common malignancy. The general treatments are thyroidectomy of the affected lobe along with lymphadenectomy. However, bone metastasis is rare in DTC compared with other malignancies and the management of metastasis foci is still controversial. Here we present a case of follicular thyroid carcinoma with the 6th cervical vertebra body metastasis successfully treated by total thyroidectomy, cervical corpectomy, and internal fixation, followed by hormone replacement therapy and radioiodine therapy. Eleven additional patients diagnosed as thyroid carcinoma with bone metastasis collected from Chinese literature between January 1996 and December 2013 were also reviewed. The mean age of the 12 patients at presentation was (53.9±9.2) years (rang, 42–72 years) and the male to female ratio was 1:2. Nine cases received total/near-total thyroidectomy or lobectomy while the other three patients refused for personal reasons. The interventions for bone metastasis were one-stage operation (9/12), I131 adjuvant therapy (3/12), chemotherapy (1/12), and no intervention (1/12). During the follow-up, two patients died of metastatic carcinoma recurrence, one died of multiple organ metastasis, and one with an unknown reason. We conclude that the management of thyroid carcinoma with bone metastasis needs multidisciplinary cooperation. Surgical resection is still the first choice for cure, while the combined one-stage operation on the primary and metastatic sites followed by hormone replacement therapy and radioiodine therapy is an applicable treatment. PMID:25471838

  9. NEMA NU1-2001 performance tests of four Philips Brightview cameras

    NASA Astrophysics Data System (ADS)

    Seret, Alain

    2011-08-01

    The Brightview is the latest generation dual-head SPECT and SPECT-CT camera from Philips. It is equipped with two large field of view γ-ray digital Anger detectors and with an X-ray flat panel detector. All primary and some secondary NEMA NU1-2001 performance tests were conducted on four (two SPECT and two SPECT-CT) recently installed Brightview systems mainly with 99mTc and low energy high resolution (LEHR) collimators. Intrinsic uniformity for four other isotopes (67Ga, 123I, 131I, 111In) and system uniformity with medium (ME) and high (HE) energy collimators were also measured. The measured parameters were almost identical for all the tested systems and the vast majority of measurements were within the manufacturer’s specifications. The only exception was some of the uniformity indexes of two of the heads but a new calibration solved that particular problem. System alignment could not be processed using the NEMA performance tests due to a file writing problem when performing 360° rotation for each head. However, the Philips COR test was conducted and found to be satisfactory.

  10. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2003-04-01

    Gateways to clinical trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies knowledge area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 5A8; Agomelatine, alefacept, almotriptan, anakinra, APC-8015, atazanavir, atomoxetine hydrochloride, azimilide hydrochloride; Bicifadine; Cannabidiol, caspofungin acetate, CAT-213, CGP-51901, ciclesonide, cipamfylline; Darbepoetin alfa, desloratadine, dibotermin alfa, DX-9065a; Ecogramostim, efalizumab, eletriptan, eniluracil, EPI-KAL2, erlosamide, ertapenem sodium, etilevodopa, etoricoxib, ezetimibe; Fosamprenavir calcium, fosamprenavir sodium, fumagillin; Gadofosveset sodium, gefitinib, gemtuzumab ozogamicin; HSPPC-96, human papillomavirus vaccine; Icatibant Id-KLH, imatinib mesylate, INS-37217, iodine (I131) tositumomab; LAS-34475, levobupivacaine hydrochloride, levocetirizine, linezolid, 131I-lipiodol, lonafarnib, lopinavir, LY-450108; Magnetites, MBI-594AN, melagatran, melatonin, mepolizumab, mycophenolic acid sodium salt; NC-100100; 1-Octanol, omalizumab, omapatrilat, onercept; PEG-filgrastim, (PE)HRG21, peginterferon alfa-2a, peginterferon alfa-2b, pleconaril, pneumococcal 7-valent conjugate vaccine, prasterone; Ranelic acid distrontium salt, rasagiline mesilate, reslizumab, rFGF-2, rhOP-1, rosuvastatin calcium, roxifiban acetate; Sitaxsentan sodium, sodium lauryl sulfate; Tadalafil, telithromycin, tenofovir disoproxil fumarate, tipranavir, TMC-114, tucaresol; Valdecoxib, voriconazole; Ximelagatran; Zofenopril calcium, zosuquidar trihydrochloride. PMID:12743628

  11. Radiation epidemiology: Past and present

    SciTech Connect

    Boice, J.D. Jr.

    1997-03-01

    Major advancements in radiation epidemiology have occurred during the last several years in studies of atomic bomb survivors, patients given medical radiation, and radiation workers, including underground miners. Risks associated with the Chernobyl accident, indoor radon and childhood exposure to I-131 have yet to be elucidated. Situations in the former Soviet Union around Chelyabinsk, a nuclear installation in the southern Urals, and in the Altai, which received radioactive fallout from weapons testing at Semipalatinsk, Kazakhstan, have the potential to provide information on the effects of chronic radiation exposure. Since Roentgen`s discovery of x-rays just 100 years ago, a tremendous amount of knowledge has been accumulated about human health effects following irradiation. The 1994 UNSCEAR report contains the latest compilation and synthesis of radiation epidemiology. This overview will cover epidemiology from a radiation perspective. The different types of study methodologies will be described, followed by a kaleidoscope coverage of past and present studies; ending with some remaining questions in radiation epidemiology. This should set the stage for future chapters, and stimulate thinking about implications of the new data on radiation cancer risks.

  12. Diagnosis and treatment of Graves' disease with particular emphasis on appropriate techniques in nuclear medicine. General state of knowledge.

    PubMed

    Prasek, Karolina; Płazińska, Maria Teresa; Królicki, Leszek

    2015-01-01

    Graves' disease is an autoimmune disease. It accounts for 50-80% of cases of hyperthyroidism. Antibodies against the TSH receptor (TRAb) are responsible for hyperthyroidism (TRAB). The key role in monitoring and diagnosis of Graves' disease plays the level of hormones of free thyroxine and triiodothyronine. Helpful is an ultrasound of the thyroid scintigraphy which due to its functional character is both a valuable addition to morphological studies as well as plays an important role in the diagnosis and therapy in patients with Graves' disease. There is no perfect treatment for Graves' disease. The reason for this is the lack of therapy directed against primary pathogenic mechanisms. Currently available treatments need to be thoroughly discussed during the first visit as the patient's understanding of the choice of a treatment constitutes a vital role in the success of therapy. Graves' disease treatment is based on three types of therapies that have been carried out for decades including: pharmacological treatment anti-thyroid drugs, I131 therapy and radical treatment - thyroidectomy. The purpose of the treatment is to control symptoms and patient to return to euthyreosis. Treatment of Graves' disease is of great importance because if left untreated, it can lead to long-term harmful effects on the heart, bone and mental well-being of patients. PMID:26315874

  13. Intracellular uptake and fluorescence imaging potential in tumor cell of zinc phthalocyanine.

    PubMed

    Avşar, Göktürk; Sari, Fatma Aslıhan; Yuzer, A Celil; Soylu, Hale Melis; Er, Ozge; Ince, Mine; Lambrecht, Fatma Yurt

    2016-05-30

    A near IR absorbing phthalocyanine bearing four binaphtyl group has been synthesized in order to investigate its cytotoxicity and intracellular uptake of sensitizer on MCF-7 (human breast cancer), MDAH (ovarian cancer), HeLa (human epitheloid cervix carcinoma), EMT-6 (mouse breast cancer) and WI-38 (human fibroblast lung) cell lines. ZnPc showed four time higher intracellular uptake in carcinoma cells (MCF-7) than normal (WI-38) cell lines. With the aim of studying in detail the biodistribution feature and tumor nuclear imaging capacity, ZnPc was also labeled with I-131. The efficiency of radiolabeled compound was 95±4.6%. In addition, ZnPc reveals to be very efficient singlet oxygen generators (ΦΔ=0.612 in DMSO) and promising PS for PDT application. In vitro fluorescence imaging study with MCF-7 cells showed that ZnPc localized in cytoplasm of the cells. This results showed that synthesized ZnPc is promising candidate for dual fluorescence/nuclear imaging breast cancer and shows potential PS for PDT application. PMID:27085647

  14. Calidad de Imagen del Telescopio UNAM212

    NASA Astrophysics Data System (ADS)

    Cobos, F. J.; Teiada de Vargas, C.

    1987-05-01

    El telescopio UNAM2l2, del Observatorio Astronómico Nacional, situado en la Sierra de San Pedro Mártir (Baja California, México), cumplira en un futuro muy cercano siete años de uso para fines de investigación astronómica. Aunque en este tiempo no se ha efectuado un estudio sistemático acerca de su comportamiento óptico y de los factores que influyen en la calidad de las imágenes, se han realizado pruebas diversas, estudios parciales y reuniones especificas, cuyos resultados no siempre se han difundido ampliamente y generalmente no se han presentado por escrito. Es por ello que hemos creido necesario intentar una recopilación de la información existente para poder con ella establecer un diagnóstjco que, aunque no sea definitivo, sirva de base para futuros trabajos tendientes a optimizar el comportamiento óptico del telescopio. Es evidente que un buen número de las conclusiones que se presentan son resultado del trabajo de muchas personas ó de esfuerzos colectivos. Asimismo, hemos tratado de localizar información bibliográfica que pueda ser de utilidad. Nuestro objetivo primordial ha consistido en centrarnos en la óptica del telescopio y su calidad, pero también se han considerado otros aspectos que puedan afectar las imágenes obtenidas tales como: celda del primario, `seeing' local y externo, flexiones posibles en la estructura mecánica del telescopio, etc.

  15. Post-Reconstruction Non-Local Means Filtering Methods using CT Side Information for Quantitative SPECT

    PubMed Central

    Chun, Se Young; Fessler, Jeffrey A.; Dewaraja, Yuni K.

    2013-01-01

    Quantitative SPECT techniques are important for many applications including internal emitter therapy dosimetry where accurate estimation of total target activity and activity distribution within targets are both potentially important for dose-response evaluations. We investigated non-local means (NLM) post-reconstruction filtering for accurate I-131 SPECT estimation of both total target activity and the 3D activity distribution. We first investigated activity estimation versus number of ordered-subsets expectation-maximization (OSEM) iterations. We performed simulations using the XCAT phantom with tumors containing a uniform and a non-uniform activity distribution, and measured the recovery coefficient (RC) and the root mean squared error (RMSE) to quantify total target activity and activity distribution, respectively. We observed that using more OSEM iterations is essential for accurate estimation of RC, but may or may not improve RMSE. We then investigated various post-reconstruction filtering methods to suppress noise at high iteration while preserving image details so that both RC and RMSE can be improved. Recently, NLM filtering methods have shown promising results for noise reduction. Moreover, NLM methods using high-quality side information can improve image quality further. We investigated several NLM methods with and without CT side information for I-131 SPECT imaging and compared them to conventional Gaussian filtering and to unfiltered methods. We studied four different ways of incorporating CT information in the NLM methods: two known (NLM CT-B and NLM CT-M) and two newly considered (NLM CT-S and NLM CT-H). We also evaluated the robustness of NLM filtering using CT information to erroneous CT. NLM CT-S and NLM CT-H yielded comparable RC values to unfiltered images while substantially reducing RMSE. NLM CT-S achieved −2.7 to 2.6% increase of RC compared to no filtering and NLM CT-H yielded up to 6% decrease in RC while other methods yielded lower RCs

  16. Nuclear Medicine in Pediatric and Adolescent Tumors.

    PubMed

    Kiratli, Pınar Özgen; Tuncel, Murat; Bar-Sever, Zvi

    2016-07-01

    Nuclear medicine has an important role in the management of many cancers in pediatric age group with multiple imaging modalities and radiopharmaceuticals targeting various biological uptake mechanisms. 18-Flourodeoxyglucose is the radiotracer of choice especially in patients with sarcoma and lymphoma. (18)FDG-PET, for sarcoma and lymphomas, is proved to be superior to conventional imaging in staging and therapy response. Although studies are limited in pediatric population, (18)FDG-PET/CT has found its way through international guidelines. Limitations and strengths of PET imaging must be noticed before adapting PET imaging in clinical protocols. Established new response criteria using multiple parameters derived from (18)FDG-PET would increase the accuracy and repeatability of response evaluation. Current data suggest that I-123 metaiodobenzylguanidine (MIBG) remains the tracer of choice in the evaluation of neuroblastoma (NB) because of its high sensitivity, specificity, diagnostic accuracy, and prognostic value. It is valuable in determining the response to therapy, surveillance for disease recurrence, and in selecting patients for I-131 therapy. SPECT/CT improves the diagnostic accuracy and the interpretation confidence of MIBG scans. (18)FDG-PET/CT is an important complementary to MIBG imaging despite its lack of specificity to NB. It is valuable in cases of negative or inconclusive MIBG scans and when MIBG findings underestimate the disease status as determined from clinical and radiological findings. F-18 DOPA is promising tracer that reflects catecholamine metabolism and is both sensitive and specific. F-18 DOPA scintigraphy provides the advantages of PET/CT imaging with early and short imaging times, high spatial resolution, inherent morphologic correlation with CT, and quantitation. Regulatory and production issues currently limit the tracer's availability. PET/CT with Ga-68 DOTA appears to be useful in NB imaging and may have a unique role in selecting

  17. Application of Frequency of Detection Methods in Design and Optimization of the INL Site Ambient Air Monitoring Network

    SciTech Connect

    Rood, Arthur S.; Sondrup, A. Jeffrey

    2015-11-01

    This report presents an evaluation of a hypothetical INL Site monitoring network and the existing INL air monitoring network using frequency of detection methods. The hypothetical network was designed to address the requirement in 40 CFR Part 61, Subpart H (2006) that “emissions of radionuclides to ambient air from U.S. DOE facilities shall not exceed those amounts that would cause any member of the public to receive in any year an effective dose equivalent exceeding 10 mrem/year.” To meet the requirement for monitoring only, “radionuclide releases that would result in an effective dose of 10% of the standard shall be readily detectable and distinguishable from background.” Thus, the hypothetical network consists of air samplers placed at residence locations that surround INL and at other locations where onsite livestock grazing takes place. Two exposure scenarios were used in this evaluation: a resident scenario and a shepherd/rancher scenario. The resident was assumed to be continuously present at their residence while the shepherd/rancher was assumed to be present 24-hours at a fixed location on the grazing allotment. Important radionuclides were identified from annual INL radionuclide National Emission Standards for Hazardous Pollutants reports. Important radionuclides were defined as those that potentially contribute 1% or greater to the annual total dose at the radionuclide National Emission Standards for Hazardous Pollutants maximally exposed individual location and include H-3, Am-241, Pu-238, Pu 239, Cs-137, Sr-90, and I-131. For this evaluation, the network performance objective was set at achieving a frequency of detection greater than or equal to 95%. Results indicated that the hypothetical network for the resident scenario met all performance objectives for H-3 and I-131 and most performance objectives for Cs-137 and Sr-90. However, all actinides failed to meet the performance objectives for most sources. The shepherd/rancher scenario showed

  18. Production and Clinical Applications of Radiopharmaceuticals and Medical Radioisotopes in Iran.

    PubMed

    Jalilian, Amir Reza; Beiki, Davood; Hassanzadeh-Rad, Arman; Eftekhari, Arash; Geramifar, Parham; Eftekhari, Mohammad

    2016-07-01

    During past 3 decades, nuclear medicine has flourished as vibrant and independent medical specialty in Iran. Since that time, more than 200 nuclear physicians have been trained and now practicing in nearly 158 centers throughout the country. In the same period, Tc-99m generators and variety of cold kits for conventional nuclear medicine were locally produced for the first time. Local production has continued to mature in robust manner while fulfilling international standards. To meet the ever-growing demand at the national level and with international achievements in mind, work for production of other Tc-99m-based peptides such as ubiquicidin, bombesin, octreotide, and more recently a kit formulation for Tc-99m TRODAT-1 for clinical use was introduced. Other than the Tehran Research Reactor, the oldest facility active in production of medical radioisotopes, there is one commercial and three hospital-based cyclotrons currently operational in the country. I-131 has been one of the oldest radioisotope produced in Iran and traditionally used for treatment of thyrotoxicosis and differentiated thyroid carcinoma. Since 2009, (131)I-meta-iodobenzylguanidine has been locally available for diagnostic applications. Gallium-67 citrate, thallium-201 thallous chloride, and Indium-111 in the form of DTPA and Oxine are among the early cyclotron-produced tracers available in Iran for about 2 decades. Rb-81/Kr-81m generator has been available for pulmonary ventilation studies since 1996. Experimental production of PET radiopharmaceuticals began in 1998. This work has culminated with development and optimization of the high-scale production line of (18)F-FDG shortly after installation of PET/CT scanner in 2012. In the field of therapy, other than the use of old timers such as I-131 and different forms of P-32, there has been quite a significant advancement in production and application of therapeutic radiopharmaceuticals in recent years. Application of (131)I

  19. Post-reconstruction non-local means filtering methods using CT side information for quantitative SPECT

    NASA Astrophysics Data System (ADS)

    Chun, Se Young; Fessler, Jeffrey A.; Dewaraja, Yuni K.

    2013-09-01

    Quantitative SPECT techniques are important for many applications including internal emitter therapy dosimetry where accurate estimation of total target activity and activity distribution within targets are both potentially important for dose-response evaluations. We investigated non-local means (NLM) post-reconstruction filtering for accurate I-131 SPECT estimation of both total target activity and the 3D activity distribution. We first investigated activity estimation versus number of ordered-subsets expectation-maximization (OSEM) iterations. We performed simulations using the XCAT phantom with tumors containing a uniform and a non-uniform activity distribution, and measured the recovery coefficient (RC) and the root mean squared error (RMSE) to quantify total target activity and activity distribution, respectively. We observed that using more OSEM iterations is essential for accurate estimation of RC, but may or may not improve RMSE. We then investigated various post-reconstruction filtering methods to suppress noise at high iteration while preserving image details so that both RC and RMSE can be improved. Recently, NLM filtering methods have shown promising results for noise reduction. Moreover, NLM methods using high-quality side information can improve image quality further. We investigated several NLM methods with and without CT side information for I-131 SPECT imaging and compared them to conventional Gaussian filtering and to unfiltered methods. We studied four different ways of incorporating CT information in the NLM methods: two known (NLM CT-B and NLM CT-M) and two newly considered (NLM CT-S and NLM CT-H). We also evaluated the robustness of NLM filtering using CT information to erroneous CT. NLM CT-S and NLM CT-H yielded comparable RC values to unfiltered images while substantially reducing RMSE. NLM CT-S achieved -2.7 to 2.6% increase of RC compared to no filtering and NLM CT-H yielded up to 6% decrease in RC while other methods yielded lower RCs

  20. FSV experience in support of the GT-MHR reactor physics, fuel performance, and graphite

    SciTech Connect

    Baxter, A.M.; McEachern, D.; Hanson, D.L.; Vollman, R.E.

    1994-11-01

    The Fort St. Vrain (FSV) power plant was the most recent operating graphite-moderated, helium-cooled nuclear power plant in the United States. Many similarities exist between the FSV design and the current design of the GT-MHR. Both designs use graphite as the basic building blocks of the core, as structural material, in the reflectors, and as a neutron moderator. Both designs use hexagonal fuel elements containing cylindrical fuel rods with coated fuel particles. Helium is the coolant and the power densities vary by less than 5%. Since material and geometric properties of the GT-MHR core am very similar to the FSV core, it is logical to draw upon the FSV experience in support of the GT-MHR design. In the Physics area, testing at FSV during the first three cycles of operation has confirmed that the calculational models used for the core design were very successful in predicting the core nuclear performance from initial cold criticality through power operation and refueling. There was excellent agreement between predicted and measured initial core criticality and control rod positions during startup. Measured axial flux distributions were within 5% of the predicted value at the peak. The isothermal temperature coefficient at zero power was in agreement within 3%, and even the calculated temperature defect over the whole operating range for cycle 3 was within 8% of the measured defect. In the Fuel Performance area, fuel particle coating performance, and fission gas release predictions and an overall plateout analysis were performed for decommissioning purposes. A comparison between predicted and measured fission gas release histories of Kr-85m and Xe-138 and a similar comparison with specific circulator plateout data indicated good agreement between prediction and measured data. Only I-131 plateout data was overpredicted, while Cs-137 data was underpredicted.

  1. The retention of iodine in stainless steel sample lines

    SciTech Connect

    Evans, G.J.; Deir, C.; Ball, J.M.

    1995-02-01

    Following an accident in a multi-unit CANDU nuclear generating station, decontamination of air vented from containment would play a critical role in minimizing the release of iodine to the environment. The concentration of gas phase iodine in containment air would be measured using the post accident radiation monitoring system, requiring that air samples be passed through a considerable length of tubing to a remote location where the desired measurements could safely be made. A significant loss of iodine, due to adsorption on the sample line surfaces, could greatly distort the measurement. In this study, the retention of I{sub 2}(g) on stainless steel was evaluated in bench scale experiments in order to evaluate, and if possible minimise, the extent of any such line losses. Experiments at the University of Toronto were performed using 6 inch lengths of 1/4 inch stainless steel tubing. Air, containing I-131 labelled I{sub 2}(g), ranging in concentration from 10{sup {minus}10} to 10{sup {minus}6} mol/dm{sup 3} and relative humidity (:RH) from 20 to 90 %, was passed through tubing samples maintained at temperatures ranging from 25 to 90{degrees}C. Adsorption at low gas phase iodine concentrations differed substantially from that at higher concentrations. The rate of deposition was proportional to the gas phase concentration, giving support to the concept of a first order deposition velocity. The surface loading increased with increasing relative humidity, particularly at low RH values, while the deposition rate decreased with increasing temperature. Surface water on the steel may play an important role in the deposition process. The chemisorbed iodine was located primarily in areas of corrosion. Furthermore, water used to wash the steel contained Fe, Mn and iodine in the form of iodide, suggesting that I{sub 2} reacted to form metal iodides. The deposition of I{sub 2} was also found to depend on the initial surface condition.

  2. Quantifying Atmospheric Fallout of Fukushima-derived Radioactive Isotopes in the Hawaiian Islands

    NASA Astrophysics Data System (ADS)

    McKenzie, Trista; Dulai, Henrietta

    2016-04-01

    On March 11, 2011, several reactors at the Fukushima Dai-ichi Nuclear Power Plant suffered damage and released the radioisotopes iodine-131, cesium-134, and cesium-137 into the atmosphere. A week later, these isotopes were detected in aerosols over the state of Hawaii and in milk samples analyzed from the Big Island. Because the detected levels were significantly below levels of health concern, the state did not attempt to quantify the deposition of these nuclides on the islands. This study estimated the magnitude of atmospheric fallout of cesium and iodine, and examined the patterns of cesium wet deposition with precipitation observed in March 2011. Mushroom and soil samples were collected along precipitation gradients on Oahu and the island of Hawaii and analyzed for cesium isotopes using gamma spectrometry. Fukushima-derived fallout was differentiated from historic nuclear weapons testing fallout by the presence of Cs-134, which has a shorter half-life of 2.06 years and the fact that Cs-134 and 137 were released from the severed power plant nearly in parity. We found that Fukushima-derived cesium was present in both mushrooms and soil and the soil inventories ranged 2.2-60.9 Bq/m2 for Cs-137 and 16.1-445.8 Bq/m2 for I-131. Additionally, we found that Fukushima-derived cesium inventories in soils were correlated with precipitation gradients. This research confirmed and quantified the presence of Fukushima-derived fallout in Hawaii, however the activities detected were orders of magnitude lower than fallout associated with the nuclear weapons testing in the Pacific.

  3. Imaging the Norepinephrine Transporter in Neuroblastoma: A Comparison of [18F]-MFBG and 123I-MIBG

    PubMed Central

    Zhang, Hanwen; Huang, Ruimin; Cheung, Nai-Kong V.; Guo, Hongfen; Zanzonico, Pat B.; Thaler, Howard T.; Lewis, Jason S.; Blasberg, Ronald G.

    2014-01-01

    Purpose The norepinephrine transporter (NET) is a critical regulator of catecholamine uptake in normal physiology and is expressed in neuroendocrine tumors like neuroblastoma. Although the norepinephrine analog, meta-iodobenzylguanidine (MIBG), is an established substrate for NET, 123I/131I-MIBG has several clinical limitations for diagnostic imaging. In the current studies, we evaluated meta-[18F]-fluorobenzylguanidine ([18F]-MFBG) and compared it to 123I-MIBG for imaging NET-expressing neuroblastomas. Experimental Design NET expression levels in neuroblastoma cell lines were determined by Western blot and 123I-MIBG uptake assays. Five neuroblastoma cell lines and two xenografts (SK-N-BE(2)C and LAN1) expressing different levels of NET were used for comparative in vitro and in vivo uptake studies. Results The uptake of [18F]-MFBG in cells was specific and proportional to the expression level of NET. Although [18F]-MFBG had a 3-fold lower affinity for NET and approximately 2-fold lower cell uptake in vitro compared to that of 123I-MIBG, the in vivo imaging and tissue radioactivity concentration measurements demonstrated higher [18F]-MFBG xenograft uptake and tumor-to-normal organ ratios at 1 and 4 h post-injection. A comparison of 4 h [18F]-MFBG PET imaging with 24 h 123I-MIBG SPECT imaging showed a ~3-fold higher tumor uptake of [18F]-MFBG, but slightly lower tumor-to-background ratios in mice. Conclusions [18F]-MFBG is a promising radiopharmaceutical for specifically imaging NET-expressing neuroblastomas, with fast pharmacokinetics and whole-body clearance. [18F]-MFBG PET imaging shows higher sensitivity, better detection of small lesions with low NET expression, allows same day scintigraphy with a shorter image acquisition time, and has the potential for lower patient radiation exposure compared to 131I/123I-MIBG. PMID:24573553

  4. Nuclear Medicine Program progress report for quarter ending September 30, 1988

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, K.R.; Callahan, A.P.; McPherson, D.W.; Srivastava, P.C.; Allred, J.F.; Blystone, S.L.; Kropp, A.; Lisic, E.C.; Rice, D.E.

    1989-03-01

    During this period the properties of the unknown metabolite released from Langendorff-perfused rat hearts administered radioiodinated 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) have been further evaluated. Identification of this metabolite is important to provide a better understanding of the myocardial metabolism of methyl-branched fatty acids and to illuminate the factors affecting myocardial retention of such agents. The metabolite is the principal component in the outflow of the isolated rat hearts. Following isolation and purification of the metabolite, treatment with NaBH/sub 4/ had no effect on the chromatographic properties. In contrast, a much less polar product was formed by treatment with acetic anhydride, suggesting the presence of a primary or secondary hydroxyl group. In addition, the metabolite is soluble in dilute base and extracted from an acid solution with ether, demonstrating the presence of a carboxyl group. These combined results suggest BMIPP is metabolized to a hydroxy acid of unknown structure. Studies are now in progress to identify this material. Studies of the effects of chain length on the complexation of a series of p-carboxyalkylphenylglyoxal bis-(N-alkylthiosemicarbazones) (TSC) have continued. After complexation with either Cu-64 or Cu-67 followed by activation to the tetrafluorophenyl esters, the bifunctional ligands were attached to BSA and purified by G-25 Sephadex. Yields varied from 2--3% to 40%, with higher yields for the shorter chain analogues. Because of simpler formation and higher yield, future studies will focus on the radiolabeling of antibodies with the short-chain analogues of the 1,2-diketone TSC derivatives. Also during this period (I-131)IPPA was supplied to collaborators at the Institute of Clinical and Experimental Nuclear Medicine in Bonn, West Germany, for studies with an isolated working rat heart model.

  5. Nuclear medicine program: Progress report for quarter ending June 30, 1988

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, A.P.; Callahan, A.P.; Allred, J.F.; Blystone, S.L.; Lisic, E.C.; McPherson, D.W.; Srivastava, P.C.; Rice, D.E.; Rogers, C.J.; Umbricht, G.

    1989-02-01

    This report describes our initial studies on developing techniques of attaching radioisotopes of copper (Cu-64 and Cu-67) and rhenium (Re-186 and Re-188) to proteins. Our work has focussed on the synthesis of para-carboxyalkylphenylglyoxal-bis-(N/sub 4/-methylthiosemi-carbazone) ligands (TSC). Because of the strong binding of Cu(II) to the bis-TSC ligand, the development of bifunctional chelates for attachment of radioisotopes of copper to antibodies is of interest. We have developed an improved synthesis of the requisite ..cap alpha..-ketoaldehyde and 1,2-diketone substrates used for derivatization to the bis-TSC ligand chelates. This approach uses the ''Kornbloom'' method which provides a simple alternative to the usual method for fabrication of the 1,2-bis-thiosemicarbazone compounds and avoids the use of selenium dioxide for oxidation of substituted acetophenones. Acylation of the -phenyl carboxylic acid with bromoacetyl chloride or 2-bromopropionyl chloride followed by treatment with silver nitrate readily provides the nitrate esters. Oxidative elimination with sodium acetate in DMSO then provides the ..cap alpha..-ketoaldehyde or 1,2-diketo products. The overall yields are in the 40-60% range. Also in this report are the results of studies with the Langendorff-perfused rat heart system. Comparison of the incorporation of (I-131)IPPA and (I-125)BMIPP in dual-labeled studies under normoxia and hypoxia (pO/sub 2/ > 120 mm) clearly showed the expected preferential incorporation into triglyceride (TG) storage products. Basic hydrolysis of the TG fraction purified by chromatography showed release of the radioactivity into products chromatographing in the free fatty acid fraction.

  6. Preparation and use of 131I magic gel as a dosimeter for targeted radionuclide therapy.

    PubMed

    Courbon, Frédéric; Love, Peter; Chittenden, Sarah; Flux, Glen; Ravel, Patrice; Cook, Gary

    2006-10-01

    Clinical interest in targeted radiotherapy is increasing, but accurate dosimetry studies are difficult to achieve. The aim of this study was to investigate the preparation and use of a "normoxic" polymer gel (with a tissue-equivalent density), known as MAGIC gel, and magnetic resonance imaging (MRI) for nonsealed source dosimetry. MAGIC gel samples were mixed with deionized water (MAGIC95) or a solution of 131I (131I-MAGIC95). By measuring the radioinduced variations of R2 values (relaxivity) of irradiated gels, we analyzed the response of MAGIC95 and MAGIC samples to external photon beam or 131I irradiation (131I-MAGIC95). MRI showed that a homogeneous dose distribution from 131I can be achieved if the MAGIC gel, at a temperature of approximately 35 degrees C, is mixed in 131I solution and the resulting mixture shaken gently for 30 minutes. It is important that the vials are completely filled, as residual air reduces polymerization and causes spontaneous polymerization stripes. Responses of MAGIC95 or MAGIC gels to external photon beam irradiation are similar. The variations of R2 values for 131I-MAGIC95 gel depend on the absorbed dose and not on the duration of the irradiation being reproducible from one batch of gel to another. MAGIC gel responses to 131I or external beam irradiation (EBI) are different. Our preliminary results suggest that radiolabeled "normoxic" polymer can be easily and safely produced. Radiolabeled MAGIC gel may, therefore, be suitable for the creation of phantoms dedicated to nonsealed source dosimetry. PMID:17105417

  7. Impact of high 131I-activities on quantitative 124I-PET

    NASA Astrophysics Data System (ADS)

    Braad, P. E. N.; Hansen, S. B.; Høilund-Carlsen, P. F.

    2015-07-01

    Peri-therapeutic 124 I-PET/CT is of interest as guidance for radioiodine therapy. Unfortunately, image quality is complicated by dead time effects and increased random coincidence rates from high 131 I-activities. A series of phantom experiments with clinically relevant 124 I/131 I-activities were performed on a clinical PET/CT-system. Noise equivalent count rate (NECR) curves and quantitation accuracy were determined from repeated scans performed over several weeks on a decaying NEMA NU-2 1994 cylinder phantom initially filled with 25 MBq 124 I and 1250 MBq 131 I. Six spherical inserts with diameters 10-37 mm were filled with 124 I (0.45 MBq ml-1 ) and 131 I (22 MBq ml-1 ) and placed inside the background of the NEMA/IEC torso phantom. Contrast recovery, background variability and the accuracy of scatter and attenuation corrections were assessed at sphere-to-background activity ratios of 20, 10 and 5. Results were compared to pure 124 I-acquisitions. The quality of 124 I-PET images in the presence of high 131 I-activities was good and image quantification unaffected except at very high count rates. Quantitation accuracy and contrast recovery were uninfluenced at 131 I-activities below 1000 MBq, whereas image noise was slightly increased. The NECR peaked at 550 MBq of 131 I, where it was 2.8 times lower than without 131 I in the phantom. Quantitative peri-therapeutic 124 I-PET is feasible.

  8. p-carboxyethyl-phenylglyoxal bis(n-methylthiosemicarbazone) (CE-DTS), a bifunctional chelating agent for Tc-99m labeled monoclonal antibody

    SciTech Connect

    Arano, Y.; Yokoyama, A.; Furukawa, T.; Saji, H.; Endo, K.; Torizaka, K.

    1985-05-01

    In the search for bifunctional chelating agents (BCA) with better affinity, selectivity and stability as for Tc-99m, synthesis of a novel BCA containing di-thio-semicarbazone as for Tc-99m chelating site has offered interesting characteristics for the labeling of macromolecules. In the present paper, monoclonal IgG (MoAb) against human thyroglobulin was selected as a model and conditions for coupling, labeling reactions were tested along with immunological reactivity. CE-DTS was coupled to MoAb by the azido method and effect of conjugation on the MoAb immunoreactivity was followed by RIA. When CE-DTS was coupled to MoAb at the molar ratio of 1:1, no loss of its original immunoreactivity was observed. Tc-99m labeling, using the stannous ion reducing method, indicated the reaction pH as being a determinant parameter. The reducing agent prepared in tartrate buffer (pH 3) offered high yield and stable Tc-99m-CE-DTS-MoAb, as evidence by HPLC. In vivo studies in mice indicated percent of injected dose and blood clearance alike the I-131-MoAb. This good labeled state of Tc-99m-CE-DTS-MoAb was also demonstrated by using second antibody reaction in serum of mice. The newly synthesized CE-DTS offered good basis for the Tc-99m labeling of monclonal antibodies with preserved immunological properties, as desirable for the radioimmunodetection. Work with tumor related monoclonal antibodies is under progress.

  9. Comparison of the accident process, radioactivity release and ground contamination between Chernobyl and Fukushima-1.

    PubMed

    Imanaka, Tetsuji; Hayashi, Gohei; Endo, Satoru

    2015-12-01

    In this report, we have reviewed the basic features of the accident processes and radioactivity releases that occurred in the Chernobyl accident (1986) and in the Fukushima-1 accident (2011). The Chernobyl accident was a power-surge accident that was caused by a failure of control of a fission chain reaction, which instantaneously destroyed the reactor and building, whereas the Fukushima-1 accident was a loss-of-coolant accident in which the reactor cores of three units were melted by decay heat after losing the electricity supply. Although the quantity of radioactive noble gases released from Fukushima-1 exceeded the amount released from Chernobyl, the size of land area severely contaminated by (137)Cesium ((137)Cs) was 10 times smaller around Fukushima-1 compared with around Chernobyl. The differences in the accident process are reflected in the composition of the discharged radioactivity as well as in the composition of the ground contamination. Volatile radionuclides (such as (132)Te-(132)I, (131)I, (134)Cs and (137)Cs) contributed to the gamma-ray exposure from the ground contamination around Fukishima-1, whereas a greater variety of radionuclides contributed significantly around Chernobyl. When radioactivity deposition occurred, the radiation exposure rate near Chernobyl is estimated to have been 770 μGy h(-1) per initial (137)Cs deposition of 1000 kBq m(-2), whereas it was 100 μGy h(-1) around Fukushima-1. Estimates of the cumulative exposure for 30 years are 970 and 570 mGy per initial deposition of 1000 kBq m(-2) for Chernobyl and Fukusima-1, respectively. Of these exposures, 49 and 98% were contributed by radiocesiums ((134)Cs + (137)Cs) around Chernobyl and Fukushima-1, respectively. PMID:26568603

  10. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP)

    NASA Astrophysics Data System (ADS)

    Bitar, A.; Lisbona, A.; Thedrez, P.; Sai Maurel, C.; LeForestier, D.; Barbet, J.; Bardies, M.

    2007-02-01

    Murine models are useful for targeted radiotherapy pre-clinical experiments. These models can help to assess the potential interest of new radiopharmaceuticals. In this study, we developed a voxel-based mouse for dosimetric estimates. A female nude mouse (30 g) was frozen and cut into slices. High-resolution digital photographs were taken directly on the frozen block after each section. Images were segmented manually. Monoenergetic photon or electron sources were simulated using the MCNP4c2 Monte Carlo code for each source organ, in order to give tables of S-factors (in Gy Bq-1 s-1) for all target organs. Results obtained from monoenergetic particles were then used to generate S-factors for several radionuclides of potential interest in targeted radiotherapy. Thirteen source and 25 target regions were considered in this study. For each source region, 16 photon and 16 electron energies were simulated. Absorbed fractions, specific absorbed fractions and S-factors were calculated for 16 radionuclides of interest for targeted radiotherapy. The results obtained generally agree well with data published previously. For electron energies ranging from 0.1 to 2.5 MeV, the self-absorbed fraction varies from 0.98 to 0.376 for the liver, and from 0.89 to 0.04 for the thyroid. Electrons cannot be considered as 'non-penetrating' radiation for energies above 0.5 MeV for mouse organs. This observation can be generalized to radionuclides: for example, the beta self-absorbed fraction for the thyroid was 0.616 for I-131; absorbed fractions for Y-90 for left kidney-to-left kidney and for left kidney-to-spleen were 0.486 and 0.058, respectively. Our voxel-based mouse allowed us to generate a dosimetric database for use in preclinical targeted radiotherapy experiments.

  11. Regulatory analysis on emergency preparedness for fuel cycle and other radioactive material licensees. Draft report for comment

    SciTech Connect

    McGuire, S.A.

    1985-06-01

    Potential accidents for 15 types of fuel cycle and other radioactive material licensees were analyzed. The most potentially hazardous accident, by a large margin, was determined to be the sudden rupture of a heated multi-ton cylinder of UF/sub 6/. Acute fatalities offsite are probably not credible. Acute permanent injuries may be possible for many hundreds of meters, and clinically observable transient effects of unknown long term consequences may be possible for distances up to a few miles. These effects would be caused by the chemical toxicity of the UF/sub 6/. Radiation doses would not be significant. The most potentially hazardous accident due to radiation exposure was determined to be a large fire at certain facilities handling large quantities of alpha-emitting radionuclides (i.e., Po-210, Pu-238, Pu-239, Am-241, Cm-242, Cm-244) or radioiodines (I-125 and I-131). However, acute fatalities or injuries to people offsite due to accidental releases of these materials do not seem plausible. The only other significant accident was identified as a long-term pulsating criticality at fuel cycle facilities handling high-enriched uranium or plutonium. An important feature of the most serious accidents is that releases are likely to start without prior warning. The releases would usually end within about half an hour. Thus protective actions would have to be taken quickly to be effective. There is not likely to be enough time for dose projections, complicated decisionmaking during the accident, or the participation of personnel not in the immediate vicinity of the site. The appropriate response by the facility is to immediately notify local fire, police, and other emergency personnel and give them a brief predetermined message recommending protective actions. Emergency personnel are generally well qualified to respond effectively to small accidents of these types.

  12. Gateways to clinical trials.

    PubMed

    Tomillero, A; Moral, M A

    2010-11-01

    fumarate, Tocilizumab, Tositumomab/iodine (I131) tositumomab, Trabectedin, TransVax™ hepatitis C vaccine; Ustekinumab; V-260, Valspodar, Varenicline tartrate, VCL-IPT1, Vildagliptin, VRC-HIVADV014-00-VP, VRC-HIVDNA009-00-VP, VRC-HIVDNA016-00-VP; Yttrium 90 (90Y) ibritumomab tiuxetan, Yttrium Y90 Epratuzumab; Zibotentan, Zotarolimus-eluting stent. PMID:21225019

  13. Sub-Classification of Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma by Pathologic Criteria

    PubMed Central

    Jeon, Min Ji; Kim, Won Gu; Jang, Eun Kyung; Choi, Yun Mi; Song, Dong Eun; Sung, Tae-Yon; Yoon, Jong Ho; Chung, Ki-Wook; Hong, Suck Joon; Ryu, Jin-Sook; Han, Ji Min; Kim, Tae Yong; Shong, Young Kee; Kim, Won Bae

    2015-01-01

    Background Lateral cervical lymph node (LCLN) metastasis, or pathologic N1b disease, is an important risk factor in papillary thyroid carcinoma (PTC). However, many patients have favorable prognosis even with pathologic N1b patients in clinical practice. The study aims to identify high- and intermediate-risk groups based on initial pathologic characteristics in these patients. Patients This study included 518 classical PTC patients confirmed as pathologic N1b at initial surgery between 2001 and 2010. All patients underwent a single fixed activity (5.6 GBq) of radioactive I-131 remnant ablation. Results Patients with a primary tumor larger than 4 cm, gross extrathyroidal extension, metastatic LN larger than 3 cm, or greater than 10 metastatic LCLN were classified as high-risk group. These comprehensive pathologic criteria were retrieved from cox proportional hazard models. Twenty two percent of patients (n = 113) were classified as high-risk and 78% (n = 405) as intermediate-risk group. Successful ablation was identified in only 32% of the patients in the high-risk group and 61% in the intermediate-risk group (p < 0.001). The difference between the two risk groups was independent to gender. There was a significant difference in disease-free survival between the high- and intermediate- risk N1b groups during 5.1 years of median follow-up (84% vs. 59%, p < 0.001). Distant metastasis was more prevalent in the high-risk group (20%) than in the intermediate-risk group (4%, p < 0.001). Conclusions The prognosis of PTC patients with LCLN metastasis varies depending on initial pathologic characteristics. We proposed the comprehensive pathologic criteria for sub-classification of N1b into high- and intermediate-risk groups and this sub-classification may permit personalized management of N1b PTC patients. PMID:26186205

  14. Prevention of DNA Double-Strand Breaks Induced by Radioiodide-131I in FRTL-5 Thyroid Cells

    PubMed Central

    Okunyan, Armen; Rivina, Yelena; Cannon, Sophie; Hogen, Victor

    2011-01-01

    Radioiodine-131 released from nuclear reactor accidents has dramatically increased the incidence of papillary thyroid cancer in exposed individuals. The deposition of ionizing radiation in cells results in double-strand DNA breaks (DSB) at fragile sites, and this early event can generate oncogenic rearrangements that eventually cause cancer. The aims of this study were to develop a method to show DNA DSBs induced by 131I in thyroid cells; to test monovalent anions that are transported by the sodium/iodide symporter to determine whether they prevent 131I-induced DSB; and to test other radioprotective agents for their effect on irradiated thyroid cells. Rat FRTL-5 thyroid cells were incubated with 131I. DSBs were measured by nuclear immunofluorescence using antibodies to p53-binding protein 1 or γH2AX. Incubation with 1–10 μCi 131I per milliliter for 90 min resulted in a dose-related increase of DSBs; the number of DSBs increased from a baseline of 4–15% before radiation to 65–90% after radiation. GH3 or CHO cells that do not transport iodide did not develop DSBs when incubated with 131I. Incubation with 20–100 μm iodide or thiocyanate markedly attenuated DSBs. Perchlorate was about 6 times more potent than iodide or thiocyanate. The effects of the anions were much greater when each was added 30–120 min before the 131I. Two natural organic compounds recently shown to provide radiation protection partially prevented DSBs caused by 131I and had an additive effect with perchlorate. In conclusion, we developed a thyroid cell model to quantify the mitogenic effect of 131I. 131I causes DNA DSBs in FRTL-5 cells and had no effect on cells that do not transport iodide. Perchlorate, iodide, and thiocyanate protect against DSBs induced by 131I. PMID:21190956

  15. SU-E-T-345: Validation of a Patient-Specific Monte Carlo Targeted Radionuclide Therapy Dosimetry Platform

    SciTech Connect

    Besemer, A; Bednarz, B

    2014-06-01

    Purpose: There is a compelling need for personalized dosimetry in targeted radionuclide therapy given that conventional dose calculation methods fail to accurately predict dose response relationships. To address this need, we have developed a Geant4-based Monte Carlo patient-specific 3D dosimetry platform for TRT. This platform calculates patient-specific dose distributions based on serial CT/PET or CT/SPECT images acquired after injection of the TRT agent. In this work, S-values and specific absorbed fractions (SAFs) were calculated using this platform and benchmarked against reference values. Methods: S-values for 1, 10, 100, and 1000g spherical tumors with uniform activity distributions of I-124, I-125, I-131, F-18, and Ra-223 were calculated and compared to OLINDA/EXM reference values. SAFs for monoenergetic photons of 0.01, 0.1, and 1 MeV and S factors for monoenergetic electrons of 0.935 MeV were calculated for the liver, kidneys, lungs, pancreas, spleen, and adrenals in the Zubal Phantom and compared with previously published values. Sufficient particles were simulated to keep the voxel statistical uncertainty below 5%. Results: The calculated spherical S-values agreed within a few percent of reference data from OLINDA/EXM for each radionuclide and sphere size. The comparison of photon SAFs and electron S-values with previously published values showed good agreement with the previously published values. The S-values and SAFs of the source organs agreed within 1%. Conclusion: Our platform has been benchmarked against reference values for a variety of radionuclides and over a wide range of energies and tumor sizes. Therefore, this platform could be used to provide accurate patientspecific dosimetry for use in radiopharmaceutical clinical trials.

  16. Radioiodide imaging of pertechnetate ''hot'' solitary thyroid nodules

    SciTech Connect

    Chapman, C.N.; Sziklas, J.J.; Spencer, R.P.; Bower, B.F.; Rosenberg, R.J.

    1984-01-01

    In 5,100 consecutive patients having pertechnetate thyroid images, 96 were noted to have solitary ''hot'' nodules (1.9%). Each was reimaged (by 2 months) with I-123 sodium iodide (I-131 in 1 case). In 84 of the 96 cases (88%), the nodules were also ''hot'' on the radioiodide images. Seven of these cases were biopsied; all were follicular adenomas. In 9 cases, the solitary radiotechnetium ''hot'' nodules were not delineated on the radioiodide images; hence, 8% of the cases had areas that would not have been noted if radioiodide was the sole imaging agent. Of the 9 ''nondelineated'' nodules, 3 were biopsied. One was reported as being normal (adequate tissue removal), one was a follicular adenoma, and one was a folicular adenoma with a focus of metastatic tumor from an undetermined site (there were other metastases in the lungs and mediastinum). Hence, the 3 biopsied areas showed benign thyroid tissue (with one metastatic site). In 3 cases (4%) the pertechnetate ''hot'' nodule was ''cold'' on the radioiodide study. Two of these were biopsied. One was a follicular carcinoma, while the second was a follicular adenoma with pleomorphic Hurthle cells. The authors conclude that, in this series, 88% of the ''hot'' pertechnetate thyroid solitary nodules were also ''hot'' to radioiodide; all those biopsied were nonmalignant. In 8% of the cases, the pertechnetate ''hot'' areas were not delineated on the radioiodide images. Biopsies in this group showed nonmalignant lesions (although one had a metastatic area). In 3 cases with pertechnetate ''hot'', but radioiodide cold areas, 2 were biopsied and showed malignant or premalignant elements.

  17. Measurement of long-lived radionuclides in surface soil around F1NPP accident site by Accelerator Mass Spectrometry

    NASA Astrophysics Data System (ADS)

    Miyake, Yasuto; Matsuzaki, Hiroyuki; Sasa, Kimikazu; Takahashi, Tsutomu

    2015-10-01

    In March 2011, vast amounts of radionuclides were released into the environment due to the Fukushima Daiichi Nuclear Power Plant (F1NPP) accident. However, very little work has been done concerning accident-derived long-lived nuclides such as 129I (T1/2 = 1.57 × 107 year) and 36Cl (T1/2 = 3.01 × 105 year). 129I and 131I are both produced by 235U fission in nuclear reactors. Being isotopes of iodine, these nuclides are expected to behave similarly in the environment. This makes 129I useful for retrospective reconstruction of 131I distribution during the initial stages of the accident. On the other hand, 36Cl is generated during reactor operation via neutron capture reaction of 35Cl, an impurity in the coolant or reactor component. Resulting 36Cl/Cl ratio within the reactor is thus much higher compared to that in environment. Similar to 129I, 36Cl is expected to have leaked out during the accident and it is important to evaluate its effects. In this study, 129I concentrations were determined in several surface soil samples collected around F1NPP. Average 129I/131I ratio was estimated to be 26.1 ± 5.8 as of March 11, 2011, consistent with calculations using ORIGEN2 code and other published data. 36Cl/Cl ratios in some of the soil samples were likewise measured and ranged from 1.1 × 10-12 to 2.6 × 10-11. These are higher compared to ratios measured around F1NPP before the accident. A positive correlation between 36Cl and 129I concentration was observed.

  18. Impact of lithium on radioactive iodine therapy for hyperthyroidism

    PubMed Central

    Lingudu, Brahmanandam; Bongi, Vivekanand; Ayyagari, Mythili; Venkata, Subrahmanyam Kandregula Appala

    2014-01-01

    Context: Radioactive Iodine (RAI) is a common therapy for hyperthyroidism. However hyperthyroidism recurs or persists in 15-18% of patients after RAI. Studies report variable percentage of failure after RAI therapy depending on several variables including I131. Lithium enhances efficacy of treatment by increasing RAI retention in the thyroid. Aims: To evaluate the efficacy of Lithium to RAI therapy in terms of cure, reduction of mean thyroid volume, and its safety. Settings and Design: A prospective comparative study. Subjects and Methods: Forty hyperthyroid patients were assigned to two groups, RAI alone and RAI plus lithium and followed for 1 year. Lithium was given in a dose of 900 mg/day in three divided doses for 6 days starting on the day of RAI therapy. Total T3, total T4, and thyroid-stimulating hormone (TSH) were done at baseline, 2,4,6,9, and 12 months. Ultrasound of thyroid was done at baseline and at the end of 1 year. Monitoring was done for side effects of lithium and RAI therapy. Statistical Analysis: Cure rate and time to cure were assessed by Chi-square test. Mean change in thyroid volume was compared by student's t-test. P < 0.05 was considered significant. Results: RAI combined with lithium had a trend towards better cure rate (90%) compared to RAI alone (70%) (P 0.11). Mean time taken to cure was 4.69 months in RAI plus lithium and 7.12 months in RAI alone (P 0.001). Mean change in thyroid volume was similar in both the groups (P = 0.75). There were no side effects of Lithium or RAI. Conclusions: RAI therapy combined with lithium showed a trend towards higher cure rate, safe and time to cure was less than RAI alone. Hence RAI combined with lithium is a better option in the management of hyperthyroidism than RAI alone. PMID:25285284

  19. Investigation of Depth Distribution of Radionuclides in Soil Contaminated by the Fukushima Dai-ichi Nuclear Power Plant Accident

    NASA Astrophysics Data System (ADS)

    Sato, Haruo; Niizato, Tadafumi; Tanaka, Shingo; Abe, Hironobu; Aoki, Kazuhiro

    2014-05-01

    This work was conducted as one of the researches relating to distribution maps of radiation dose rate etc. which the government has promoted as one of the counter-measures to the Fukushima Dai-ichi Nuclear Power Plant accident in March 2011, and the 2nd investigation on the depth distribution of radionuclides (RNs) in soil was conducted after about 1 year from the accident, succeedingly to the 1st investigation which was conducted after about 3 months from the accident. Soil core samples to about 50cm deep were taken at 11 locations in Nihonmatsu-city, Kawamata-town and Namie-town. Sorption-desorption experiments of Cs-137 and I-131, CEC and AEC measurements and mineralogical analyses by XRD were conducted for 3 types of soils (sandy, clayey, organic) and those elutriated components (clay, silt, sand). Radiocaesium (Cs-134 and Cs-137) and Ag-110m were detected at all locations investigated and only at locations where radiation dose rate is high, respectively. Radiocaesium more than 95% and 99% of the inventory distributed within 5cm and 10cm deep in soil in the surface layer (mainly sandy soil), respectively, and distributed within 16cm and 20cm deep in organic soil and soil at locations where are supposed to have been used as farmland, respectively. Radiocaesium tended to extend to deeper parts in soil that organic and clayey soils are the support layer, particularly in organic soil, compared with the 1st investigation. Distribution coefficients of Cs-137 onto organic soil and its elutriated components were also lower than that onto other soils. This is consistent with trend of penetration profile.

  20. Iodine isotopes in precipitation: temporal responses to (129)i emissions from the fukushima nuclear accident.

    PubMed

    Xu, Sheng; Freeman, Stewart P H T; Hou, Xiaolin; Watanabe, Akira; Yamaguchi, Katsuhiko; Zhang, Luyuan

    2013-10-01

    The Fukushima Dai-ichi Nuclear Power Plant accident in 2011 has released a large amount of radionuclides to the atmosphere, and the radioactive plume has been dispersed to a large area in Europe and returned to Asia. To explore long-term trend of the Fukushima-derived radioactive plume and the behavior of harmful radioiodine in the atmosphere, long-term precipitation samples have been collected over 2010-2012 at Fukushima, Japan for determination of long-lived (129)I. It was observed that (129)I concentrations of 1.2 × 10(8) atom/L in 2010 before the accident dramatically increased by ∼4 orders of magnitude to 7.6 × 10(11) atom/L in March 2011 immediately after the accident, with a (129)I/(127)I ratio up to 6.9 × 10(-5). Afterward, the (129)I concentrations in precipitation decreased exponentially to ∼3 × 10(9) atom/L by October 2011 with a half-life of about 29 days. This declining trend of (129)I concentrations in precipitation was interrupted around October 2011 by a new input of (129)I to the atmosphere following a second exponential decrease. Such a cycle has occurred three times until the present. This temporal variation can be attributed to alternating (129)I dispersion and resuspension from the contaminated local environment. A (129)I/(131)I atomic ratio of 16 ± 1 obtained from rainwater samples is comparable with a value estimated for surface soil samples. (129)I results from Denmark suggest an insignificant effect of (129)I released from Fukushima to the (129)I levels in Europe. PMID:24000802

  1. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2004-06-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 101M; Adalimumab, adefovir dipivoxil, adenosine triphosphate, albumin interferon alfa, alefacept, alemtuzumab, aminolevulinic acid hexyl ester, autologous renal tumor vaccine, azimilide hydrochloride; Bortezomib, bosentan, BR-1; C340, cantuzumab mertansine, caspofungin acetate, CGP-36742, CHAMPION everolimus-eluting coronary stent, cypher; Dalbavancin, darbepoetin alfa, desloratadine, duloxetine hydrochloride, dutasteride; Efalizumab, emtricitabine, enfuvirtide, erlosamide, ertapenem sodium, everolimus, ezetimibe; Flesinoxan hydrochloride, fosamprenavir calcium, FR-901228, frovatriptan; Gadofosveset sodium, gadomer-17, galiximab, gamma-hydroxybutyrate sodium, gefitinib; HuOKT3gamma1(Ala234-Ala235); IDN-6556, imatinib mesylate, iodine (I131) tositumomab, iseganan hydrochloride, ixabepilone; Keratinocyte growth factor; LB-80380, levocetirizine, liposomal doxorubicin, LMB-9, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Mecasermin, midostaurin, morphine hydrochloride; Natalizumab, nelfinavir, nesiritide, niacin/lovastatin; Olcegepant, omalizumab, oregovomab; Parecoxib sodium, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ ribavirin, perospirone hydrochloride, pexelizumab, pimecrolimus, prinomastat; Resiquimod, rhIGFBP-3, rhIGF-I/rhIGFBP-3, ritanserin, ro-31-7453, rosuvastatin calcium; SCIO-469, SDZ-SID-791, SU-11248, suberanilohydroxamic acid; Tadalafil, taxus, telithromycin, tenofovir disoproxil fumarate, TER-286, tezosentan disodium, TH-9507, tipifarnib, tipranavir, tolvaptan, tramadol hydrochloride/acetaminophen, travoprost, treprostinil sodium, tucaresol

  2. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2004-03-01

    Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity(R), the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: Activated protein C concentrate, Ad-CD154, Adeno-Interferon gamma, alemtuzumab, APC-8024, 9-aminocamptothecin, aprepitant, l-arginine hydrochloride, aripiprazole, arsenic trioxide, asimadoline; O6-Benzylguanine, bevacizumab, Bi-20, binodenoson, biphasic insulin aspart, bivatuzumab, 186Re-bivatuzumab, BMS-181176, bosentan, botulinum toxin type B, BQ-123, bryostatin 1; Carboxy- amidotriazole, caspofungin acetate, CB-1954, CC-4047, CDP-860, cerivastatin sodium, clevidipine, CTL-102; 3,4-DAP, darbepoetin alfa, decitabine, desloratadine, DHA-paclitaxel, duloxetine hydrochloride; Efalizumab, EGF vaccine, eletriptan, eniluracil, ENMD-0997, eplerenone, eplivanserin, erlosamide, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, eszopiclone, everolimus, exatecan mesilate, exenatide, ezetimibe; Fondaparinux sodium, FR-901228, FTY-720; Gefitinib, gemtuzumab ozogamicin, gepirone hydrochloride; Hexyl insulin M2, human insulin; Imatinib mesylate, insulin detemir, insulin glargine, iodine (I131) tositumomab, ISV-205, ivabradine hydrochloride, ixabepilone; Levetiracetam, levocetirizine, linezolid, liposomal NDDP, lonafarnib, lopinavir, LY-156735; Mafosfamide cyclohexylamine salt, magnesium sulfate, maxacalcitol, meclinertant, melagatran, melatonin, MENT, mepolizumab, micafungin sodium, midostaurin, motexafin gadolinium; Nesiritide, NS-1209, NSC-601316, NSC-683864; Osanetant; Palonosetron hydrochloride, parecoxib sodium, pegaptanib sodium, peginterferon alfa-2a, peginterferon alfa-2b, pegylated OB protein, pemetrexed disodium, perillyl alcohol, picoplatin, pimecrolimus, pixantrone maleate, plevitrexed

  3. Reinforcement of Dental Methacrylate with Glass Fiber after Heated Silane Application

    PubMed Central

    Fonseca, Rodrigo Borges; de Paula, Marcella Silva; Favarão, Isabella Negro; Kasuya, Amanda Vessoni Barbosa; de Almeida, Letícia Nunes; Mendes, Gustavo Adolfo Martins; Carlo, Hugo Lemes

    2014-01-01

    This study evaluated the influence of silane heat treatment and glass fiber fabrication type, industrially treated (I) or pure (P), on flexural and compressive strength of methacrylate resin bars (BISGMA/TEGDMA, 50/50%). Six groups (n = 10) were created: I-sil: I/silanated; P-sil: P-silanated; I-sil/heat: I/silanated heated to 100°; P-sil/heat: P/silanated heated to 100°; (I: I/not silanated; and P: P/not silanated. Specimens were prepared for flexural strength (10 × 2 × 1 mm) and for compressive strength 9.5 × 5.5 × 3 mm) and tested at 0.5 mm/min. Statistical analysis demonstrated the following for flexural strength (P < 0.05): I-sil: 155.89 ± 45.27BC; P-sil: 155.89 ± 45.27BC; I-sil/heat: 130.20 ± 22.11C; P-sil/heat: 169.86 ± 50.29AB; I: 131.87 ± 15.86C. For compressive strength, the following are demonstrated: I-sil: 1367.25 ± 188.77ab; P-sil: 867.61 ± 102.76d; I-sil/heat: 1162.98 ± 222.07c; P-sil/heat: 1499.35 ± 339.06a; and I: 1245.78 ± 211.16bc. Due to the impossibility of incorporating the stipulated amount of fiber, P group was excluded. Glass fiber treatment with heated silane enhanced flexural and compressive strength of a reinforced dental methacrylate. PMID:24967361

  4. Pathway of radioisotopes from land surface to sewage sludge

    NASA Astrophysics Data System (ADS)

    Fischer, Helmut W.; Yokoo, Yoshiyuki

    2014-05-01

    Radioactive surface contaminations will only partially remain at the original location - a fraction of the inventory will take part in (mainly terrestrial and aquatic) environmental transport processes. The probably best known and most important process comprises the food chain. Besides, the translocation of dissolved and particle-bound radioisotopes with surface waters plays an important role. These processes can have the effect of displacing large radioisotope amounts over considerable distances and of creating new sinks and hot spots, as it is already known for sewage sludge. We are reporting on a combined modeling and experimental project concerning the transport of I-131 and Cs-134/Cs-137 FDNPP 2011 depositions in the Fukushima Prefecture. Well-documented experimental data sets are available for surface deposition and sewage sludge concentrations. The goal is to model the pathway in between, involving surface runoff, transport in the sewer system and processes in the sewage treatment plant. Watershed runoff and sewer transport will be treated with models developed recently by us in other projects. For sewage treatment processes a new model is currently being constructed. For comparison and further validation, historical data from Chernobyl depositions and tracer data from natural and artificial, e.g. medical, isotopes will be used. First results for 2011 data from Fukushima Prefecture will be presented. The benefits of the study are expected to be two-fold: on one hand, the abundant recent and historical data will help to develop and improve environmental transport models; on the other hand, both data and models will help in identifying the most critical points in the envisaged transport pathways in terms of radiation protection and waste management.

  5. Promising therapeutic targets in neuroblastoma.

    PubMed

    Matthay, Katherine K; George, Rani E; Yu, Alice L

    2012-05-15

    Neuroblastoma, the most common extracranial solid tumor in children, is derived from neural crest cells. Nearly half of patients present with metastatic disease and have a 5-year event-free survival of <50%. New approaches with targeted therapy may improve efficacy without increased toxicity. In this review we evaluate 3 promising targeted therapies: (i) (131)I-metaiodobenzylguanidine (MIBG), a radiopharmaceutical that is taken up by human norepinephrine transporter (hNET), which is expressed in 90% of neuroblastomas; (ii) immunotherapy with monoclonal antibodies targeting the GD2 ganglioside, which is expressed on 98% of neuroblastoma cells; and (iii) inhibitors of anaplastic lymphoma kinase (ALK), a tyrosine kinase that is mutated or amplified in ~10% of neuroblastomas and expressed on the surface of most neuroblastoma cells. Early-phase trials have confirmed the activity of (131)I-MIBG in relapsed neuroblastoma, with response rates of ~30%, but the technical aspects of administering large amounts of radioactivity in young children and limited access to this agent have hindered its incorporation into treatment of newly diagnosed patients. Anti-GD2 antibodies have also shown activity in relapsed disease, and a recent phase III randomized trial showed a significant improvement in event-free survival for patients receiving chimeric anti-GD2 (ch14.18) combined with cytokines and isotretinoin after myeloablative consolidation therapy. A recently approved small-molecule inhibitor of ALK has shown promising preclinical activity for neuroblastoma and is currently in phase I and II trials. This is the first agent directed to a specific mutation in neuroblastoma, and marks a new step toward personalized therapy for neuroblastoma. Further clinical development of targeted treatments offers new hope for children with neuroblastoma. PMID:22589483

  6. Improving cancer treatment with cyclotron produced radionuclides. [Multiple Drug Resistance (MDR)

    SciTech Connect

    Larson, S.M.; Finn, R.D.

    1990-10-15

    The overall objective of this work was to promote nuclear medicine applications in oncology. This is being done by improving the scientific basis of diagnosis, treatment and treatment follow-up with cyclotron-produced tracers. For diagnostic use, positron-emitting isotopes such as Ga-66 and I-124 are being used. Initial studies on the characterization of He-4 particle energies required for Ga-66 production have been completed. Parameters for I-124 radiolabelling of monoclonal antibodies have been determined; the labelled antibodies have been used in animal studies using positron emission tomography (PET) to quantify antibody concentration within tumors in vivo. Imaging physics studies have demonstrated that I-124 can be quantitatively imaged by PET, even in the presence of 100-told greater concentrations of I-131. Measurement of concentrations of label in vivo has been accomplished in nuclei mice bearing neuroblastoma tumors and nude rats bearing human ovarian cancer cells. These studies have major implications for both the quantification of dosimetry and quantification kinetic assessment of anti-tumor antibody localization in vivo. For treatment of tumors, F-18 has been incorporated in 2-fluoro-2-deoxy glucose and 5-fluoro uridine, and O-15 labelled water has been produced. Reagents incorporating C-11 and N-13 are under development. In a related area, C-14 labelled colchicine is being studied as a means of assaying cells for multiple drug resistance (MDR). Cells expressing MDR are shown to retain significantly less C-14 colchiene. This suggest that colchiene retention may be of useful probe in modelling and studying MDR development in human tumors. The precursor required for producing C-11 colchicine has also been synthesized. 11 refs. (MHB)

  7. Autoimmune alternating hyper- and hypo-thyroidism: a rare condition in pediatrics

    PubMed Central

    Coutinho, Ana Rita; Jerónimo, Mónica; Caetano, Joana Serra; Cardoso, Rita; Dinis, Isabel; Mirante, Alice

    2016-01-01

    Summary Alternating between hyper- and hypo-thyroidism may be explained by the simultaneous presence of both types of TSH receptor autoantibodies (TRAbs) – thyroid stimulating autoantibodies (TSAbs) and TSH blocking autoantibodies (TBAbs). It is a very rare condition, particulary in the pediatric age. The clinical state of these patients is determined by the balance between TSAbs and TBAbs and can change over time. Many mechanisms may be involved in fluctuating thyroid function: hormonal supplementation, antithyroid drugs and levels of TSAbs and TBAbs. Frequent dose adjustments are needed in order to achieve euthyroidism. A definitive therapy may be necessary to avoid switches in thyroid function and frequent need of therapeutic changes. We describe an immune-mediated case of oscillating thyroid function in a 13-year-old adolescent. After a short period of levothyroxine treatment, the patient switched to a hyperthyroid state that was only controlled by adding an antithyroid drug. Learning points Autoimmune alternating hypo- and hyper-thyroidism is a highly uncommon condition in the pediatric age.It may be due to the simultaneous presence of both TSAbs and TBAbs, whose activity may be estimated in vitro through bioassays.The clinical state of these patients is determined by the balance between TSAbs and TBAbs and can change over time.The management of this condition is challenging, and three therapeutic options could be considered: I-131 ablation, thyroidectomy or pharmacological treatment (single or double therapy).Therapeutic decisions should be taken according to clinical manifestations and thyroid function tests, independent of the bioassays results.A definitive treatment might be considered due to the frequent switches in thyroid function and the need for close monitoring of pharmacological treatment. A definitive treatment might be considered due to the frequent switches in thyroid function and the need for close monitoring of pharmacological treatment. PMID

  8. Iodine-131 avid distant metastasis in differentiated thyroid cancer: An initial institutional experience from the northern part of India

    PubMed Central

    Khan, Shoukat Hussain; Hassan, Masood ul; Bhau, Rajesh Singh

    2015-01-01

    Objective: The aim of the study was to study the clinical profile in patients of differentiated thyroid cancer (DTC) with Iodine-131 avid distant metastasis at presentation. The study also attempted to evaluate factors influencing survival among these patients. Material and Methods: The cohort includes 35 patients (26 Female, 9 Male) studied retrospectively and prospectively over a period of 5 years at the Sher-I-Kashmir Institute of Medical Sciences, Srinagar, India. Results: The five years cause specific survival among patients of DTC with distant metastasis in the study group was 74.3%. The mean age at presentation was 41.4 years with female patients outnumbering the male patients in a ratio of 5:1. Papillary histopathology was the commonest in 65.7% followed by Follicular in 31.4% and poorly differentiated cancer in 2.9% of patients.31.4% 0f patients presented with relatively advanced AJC/UICC tumor stage of T3-T4. Bone was the commonest site of metastasis in 42.85% of patients followed by lung in 40% 0f patients. 82.9% of patients had only single organ metastasis. Therapeutic Radioiodine was administered in 31 (88.6%) patients. On univariate analysis of various factors that may be influencing the cause specific survival at 5 years, age ≥ 45 years, T3-T4 tumor stage, regional lymph node metastasis, follicular histopathology and non administration of radioiodine revealed significant (P<0.05) association with a poor 5 year survival. However multivariate analysis identified advanced tumor stage (T3-T4) and non administration of radioiodine to be the only independent factors associated with poor survival. Conclusion: Patients of differentiated thyroid cancer with distant metastasis having advanced tumor stage (T3-T4) and those in whom therapeutic radioiodine (I-131) is not administered seem to have an unfavorable prognosis in terms of a 5 years cause specific survival. PMID:26170565

  9. Radiation measurements at the campus of Fukushima Medical University through the 2011 off the Pacific Coast of Tohoku earthquake and subsequent nuclear power plant crisis.

    PubMed

    Kobayashi, Tsuneo

    2011-01-01

    An earthquake, Tohoku region Pacific Coast earthquake, occurred on the 11th of March, 2011, and subsequent Fukushima nuclear power plant accidents have been stirring natural radiation around the author's office in Fukushima Medical University (FMU). FMU is located in Fukushima city, and is 57 km (35 miles) away from northwest of the Fukushima Daiichi nuclear power plant. This paper presents three types of radiation survey undertaken through the unprecedented accidents at the campus and the hospital of FMU. First, a group of interested people immediately began radiation surveillance; the group members were assembled from the faculty members of " Life Sciences and Social Medicine" and " Human and Natural Sciences." Second, the present author, regardless of the earthquake, had serially observed natural radiations such as gamma radiation in air with NaI scintillation counter, atmospheric radon with Lucas cell, and second cosmic rays with NaI scintillation. Gamma radiation indicated most drastic change, i.e., peak value (9.3 times usual level) appeared on March 16, and decreased to 1.7 times usual level after two months. A nonlinear least squares regression to this decreasing data gave short half-life of 3.6 days and long half-life of 181 days. These two apparent half-lives are attributed to two groups of radioisotopes, i.e., short half-life one of I-131 and long half-life ones of Cs-134, Cs-137 and Sr-90. Also, atmospheric radon concentration became high since a stop of ventilation, while second cosmic rays did not show any response. Third, late April, 2011, a team of radiation dosimetry under the direct control of Dean, School of Medicine, was established for the continuation of radiation survey in the campus and the hospital of Fukushima Medical University. PMID:22353655

  10. Radiometals as payloads for radioimmunotherapy for lymphoma.

    PubMed

    DeNardo, Gerald L; Kennel, Stephen J; Siegel, Jeffry A; Denardo, Sally J

    2004-10-01

    Because of their remarkable effectiveness in radioimmunotherapy (RIT), 2 anti-CD20 monoclonal antibody (MAb) drugs, one labeled with indium 111 for imaging or yttrium 90 for therapy, and another labeled with iodine I 131 for imaging and therapy, have been approved for use in patients with non-Hodgkin's lymphoma (NHL). Successful RIT for lymphomas is due in large part to the rapid and efficient binding of the targeted MAb to lymphoma cells. Carcinomas are more difficult to access, necessitating novel strategies matched with radionuclides with specific physical properties. Because there are many radionuclides from which to choose, a systematic approach is required to select those preferred for a specific application. Thus far, radionuclides with g emissions for imaging and particulate emissions for therapy have been investigated. Radionuclides of iodine were the first to be used for RIT. Many conventionally radioiodinated MAbs are degraded after endocytosis by target cells, releasing radioiodinated peptides and amino acids. In contrast, radiometals have been shown to have residualizing properties, advantageous when the MAb is localized in malignant tissue. b-emitting lanthanides like those of 90Y, lutetium 177, etc. have attractive combinations of biologic, physical, radiochemical, production, economic, and radiation safety characteristics. Other radiometals, such as copper-67 and copper-64, are also of interest. a-emitters, including actinium-225 and bismuth-213, have been used for therapy in selected applications. Evidence for the impact of the radionuclide is provided by data from the randomized pivotal phase III trial of 90Y ibritumomab tiuxetan (Zevalin) in patients with NHL; responses were about 2 times greater in the 90Y ibritumomab tiuxetan arm than in the rituximab arm. It is clear that RIT has emerged as a safe and efficient method for treatment of NHL, especially in specific settings. PMID:15498149

  11. Radioimmunotherapy treatment planning based on radiation absorbed dose or patient size

    SciTech Connect

    Eary, J.F.; Krohn, K.A.; Press, O.W. |

    1996-05-01

    Several approaches have been used to plan treatment doses for patients undergoing radioimmunotherapy. Investigators often use fixed doses, or doses based on patient size (mCi/kg or mCi/m{sup 2}). Our treatment protocols for lymphoma and leukemia involved calculation of tissue radiation absorbed dose based on images from a trace labeled infusion of antibody prior to treatment. In a recent analysis of patients treated in the Phase I and II dose escalation trial for treatment of non-Hodgkin`s lymphoma with I-131 anti-CD20 antibody (B1), we investigated the relationship between our dosimetry based treatment and dose based on patient size. Tissue radiation dose for several normal organs and for tumors were plotted versus the mCi administered per kg or m{sup 2} of the patient to evaluate the relationship between the two treatment approaches. These graphs showed correlation coefficients ranging from 0.021 to 0.684, demonstrating the variability in antibody catabolism between patients. This means that fixed doses or administrations based on patient size do not deliver consistent radiation doses to normal organs or tumors. This finding was extrapolated to show that toxicity from doses based on patient size di not correlate with treatment dose; those based on calculated rad/organ did. Phase I clinical trials using treatment doses based on patient size where there are likely to be variations in patient antibody catabolism will result in confounding toxicities at apparently similar mCi dose levels. Use of pre-treatment scans for treatment dose planning are worth the additional effort by normalizing the normal tissue toxicity.

  12. Comparison of the accident process, radioactivity release and ground contamination between Chernobyl and Fukushima-1

    PubMed Central

    Imanaka, Tetsuji; Hayashi, Gohei; Endo, Satoru

    2015-01-01

    In this report, we have reviewed the basic features of the accident processes and radioactivity releases that occurred in the Chernobyl accident (1986) and in the Fukushima-1 accident (2011). The Chernobyl accident was a power-surge accident that was caused by a failure of control of a fission chain reaction, which instantaneously destroyed the reactor and building, whereas the Fukushima-1 accident was a loss-of-coolant accident in which the reactor cores of three units were melted by decay heat after losing the electricity supply. Although the quantity of radioactive noble gases released from Fukushima-1 exceeded the amount released from Chernobyl, the size of land area severely contaminated by 137Cesium (137Cs) was 10 times smaller around Fukushima-1 compared with around Chernobyl. The differences in the accident process are reflected in the composition of the discharged radioactivity as well as in the composition of the ground contamination. Volatile radionuclides (such as 132Te-132I, 131I, 134Cs and 137Cs) contributed to the gamma-ray exposure from the ground contamination around Fukishima-1, whereas a greater variety of radionuclides contributed significantly around Chernobyl. When radioactivity deposition occurred, the radiation exposure rate near Chernobyl is estimated to have been 770 μGy h−1 per initial 137Cs deposition of 1000 kBq m−2, whereas it was 100 μGy h−1 around Fukushima-1. Estimates of the cumulative exposure for 30 years are 970 and 570 mGy per initial deposition of 1000 kBq m−2 for Chernobyl and Fukusima-1, respectively. Of these exposures, 49 and 98% were contributed by radiocesiums (134Cs + 137Cs) around Chernobyl and Fukushima-1, respectively. PMID:26568603

  13. The Cu-64 uptake test for evaluation of zinc therapy in Wilson's disease

    SciTech Connect

    Juni, J.E.; Brewer, G.J.; Dick, R.D.; Hill, G.M.; Wehr, L.

    1984-01-01

    The reduced hepatic excretion of dietary copper (Cu) by pts with Wilson's disease (WD) leads to accumulation in tissue which may result in disability or death. Penicillamine (PNC), the current treatment of choice, promotes urinary excretion causing a -Cu balance, but frequently has toxic effects. A recent therapeutic approach attempts to reduce absorption of Cu from the diet. Zinc is known to induce production of metallothionine (MT), a metal-binding protein, in gut mucosa. MT binds Cu with a high affinity, thus preventing its absorption. To assess the effects of oral zinc therapy for WD, the authors measured the absolute plasma uptake of oral Cu-64 in 8 pts. Four received elemental zinc 100-250 mg p.o. qD for at least 3 months. Four were untreated or taking PNC. Pts were hospitalized for measurements of dietary intake and total urinary and fecal excretion of Cu. Plasma volume was determined by I-131 serum albumin. Pts. then swallowed 0.5 mCi Cu-64 in 40 cc of cow's milk. Blood samples were drawn q 15 min x 90 mins with 5 additional samples over 24 hrs. Sample counts were corrected for decay and hematocrit. Total plasma uptake of Cu-64 over time was plotted as a fraction of the administered dose. Plasma uptake reached an initial peak within 90 min. in all cases and was 3.4-11.9% (mean=7.5) in pts not taking zinc but only 0.3-1.98% (mean=1.2) in those on zinc therapy (p=0.013). Preliminary data indicated a -Cu balance in zinc treated pts and a +Cu balance in those off zinc. The oral Cu-64 absorption test is far more easily performed than longterm measurements of Cu balance. It provides a rapid and simple means of assessing the efficacy of anti-absorptive therapy.

  14. Studies on the Ozyorsk population: dosimetry

    SciTech Connect

    Khokhryakov, Victor V.; Drozhko, Evgeniy G.; Glagolenko, Y V.; Rovny, Sergey I.; Vasilenko, E K.; Suslov, A; Anspaugh, L R.; Napier, Bruce A. ); Bouville, A; Khokhryakov, V F.; Suslova, K G.; Romanov, S A.

    2001-12-01

    The Mayak Production Association (MPA) is located in the northern part of Chelyabinsk Oblast. Operating areas are about 10 km from the town of Ozyorsk, the largest populated area nearby, but other nearby populated areas include Novogorny Village, New Metlino Village, and Kyshtym Town. The long-term objective of this (unfunded) project is reconstruction of the time-dependent individual radiation doses to residents of Ozyorsk and the surrounding area from atmospheric releases of radionuclides from the facilities of the Mayak Production Association (MPA). The time period is from 1948 to the present. This information could be used in several epidemiologic studies of the regional population. Two pilotscale studies of thyroid disease among residents of Ozyorsk have found an increase in thyroid nodules among exposed persons compared to unexposed persons and an increase in thyroid carcinoma in Ozyorsk. The success of follow-on studies would depend upon the availability of thyroid doses proposed to be provided. The availability of credible thyroid doses would allow the quantification of risk of thyroid disease and the evaluation of factors such as host susceptibility, age and time effects, and gender differences. Perhaps more importantly, studies of the Ozyorsk residents would not be encumbered with the complications associated with previous early detection screening, as in the Chernobyl studies, or previous medical conditions, as in the I-131 medical studies. The releases to the atmosphere from MPA stacks are a source of exposure to other populations that are the subject of epidemiologic investigation; these populations include the Extended Techa River Cohort (JCCRER Direction 1), the MPA workers (JCCRER Direction 2), and proposed studies of the East Urals Radioactive Trace (EURT) cohort. The doses received by these cohorts from atmospheric releases at the MPA represent a confounding variable that cannot be considered without the information proposed to be provided.

  15. Nuclear medicine program progress report for quarter ending June 30, 1994

    SciTech Connect

    Knapp, F.F. Jr.; Ambrose, K.R.; Beets, A.L.; Lambert, C.R.; McPherson, D.W.; Mirzadeh, S.; Luo, H.

    1994-08-01

    In this report we describe tile first successful synthesis and in vivo evaluation of a fluorinated analogue of the IQNP muscarinic-cholinergic receptor ligand. Unanticipated synthetic hurdles lead to several unsuccessful approaches before the synthesis of a model compound was achieved. The successful route involved introduction of the fluoroethyl moiety at an early stage of the synthesis by alkylation of ethyl 1,3-dithiane-2-carboxylate with 1-fluoro-2-bromoethane. Subsequent unmasking of the carbonyl, followed by introduction of the phenyl group with phenylmagnesium bromide and subsequent transesterification with racemic quinuclidinol afforded the target compound, 1-azabicyclo[2.2.2]oct-3-yl {alpha}-(1-fluoroethan-2-yl)-{alpha}-hydroxy-{alpha}-phenylacetate (QNF). Pretreatment of Fisher rats with QNF one hour prior to the intravenous administration of the [I-131]-Z-(R,R) IQNP isomer demonstrated that the new fluoro analogue blocked uptake of iodine-131 in those regions of the brain rich in muscarinic-cholinergic receptors measured three hours after injection. As an example, the control values for group of nontreated animals were (5 animals; mean {+-} SD): cortex, 1.20{+-}0.27; striatum, 0.73{+-}0.19; pons, 0.70{+-}0.20; cerebellum, 0.43{+-}0.114. Brains from animals pretreated with the fluoro analogue had the following values (mean{+-}SD; % decrease): cortex, 0.67{+-}0.15 (65%); striatum, 0.35{+-}0.114 (52%); pons, 0.40{+-}0.08 (43%); cerebellum, 0.16{+-}0.09(63%). Also during this period several tungsten-188/rhenium-188 generators and tin-117m samples were provided for collaborative studies.

  16. Advances in the management of patients with thyroid disease.

    PubMed

    Dworkin, H J; Meier, D A; Kaplan, M

    1995-07-01

    Discoveries related to thyroid immunology, especially concerning the thyroid-stimulating hormone (TSH) receptor, may facilitate new immunologic approaches to the therapy of Graves' disease and the thyroiditis syndromes. Advances in genetics are being applied to the thyroid hormone resistance syndromes and papillary and medullary carcinomas. The development of ever more sensitive TSH assays has led to the detection of subclinical thyroid disease, which has special implications for the sick and elderly patients. Sensitive TSH assays also allow more precise titration of levothyroxine (T4) dosages, especially for patients with a past history of thyroid cancer. Evidence continues to accumulate suggesting that postmenopausal women on T4 doses that suppress the TSH level below 0.1 ulU/mL have lower bone mineral density than matched patients with healthy TSH levels. Also, pregnant hypothyroid women need higher T4 doses to normalize the TSH levels. In the evaluation of thyroid nodules, fine-needle aspiration biopsy is the single most definitive modality in selecting the patients for surgery. Scintigraphy provides a complimentary role, especially in defining autonomously functioning thyroid adenomas (AFTA), because these should not be treated with T4 suppression. Ultrasound-guided needle biopsy is occasionally helpful with nodules that are difficult to palpate. Concern for possible tracheal compression after treatment of toxic multinodular goiter with large doses of radioactive iodine (I-131) in the range of 50 to 150 mCi (1.85 to 5.5 GBq) does not seem warranted. Work, primarily out of Italy, suggests AFTA can be ablated with repeat ethanol injections. Residual tissues after thyroidectomy for differentiated carcinoma can be "stunned" by tracer doses of 131I greater than 3.0 mCi (111 MBq), which diminishes the uptake and effectiveness of a subsequent therapy dose. Positron emission tomograph, imaging with thallium-201, and Technetium 99m Sestamibi can identify a small number

  17. Assessing sediment connectivity to understand dynamics of contaminated sediment within coastal catchments of Fukushima Prefecture (Japan)

    NASA Astrophysics Data System (ADS)

    Chartin, Caroline; Evrard, Olivier; Onda, Yuichi; Ottlé, Catherine; Brossoni, Camille; Lefèvre, Irène; Lepage, Hugo; Bonté, Philippe; Patin, Jeremy; Ayrault, Sophie

    2013-04-01

    The Fukushima Dai-ichi Nuclear Power Plant accident has led to the release of large radionuclide quantities (e.g., about 20 PBq of Cs-137 and 200 PBq of I-131) into the atmosphere. About 80% of the release was blown out and over the Pacific Ocean. The remaining 20% of emissions were deposited as wet and dry deposits on soils of Fukushima Prefecture, mainly between 15-16 March. As most radionuclides are strongly sorbed by fine particles, they are likely to be redistributed within the landscape in association with soil and sediment particles transported by runoff and erosion processes. A spatial analysis of Ag-110m:Cs-137 ratio in soils and river sediments provided a way to trace those transfers. This fingerprinting study showed that particles eroded from inland mountain ranges exposed to the highest initial radionuclide fallout were already dispersed along coastal rivers, most likely during summer typhoons and spring snowmelt. Those results suggest that hillslopes and rivers have become a perennial source of radioactive contaminants to the Pacific Ocean off Fukushima Prefecture. This study aims to specify the location and nature of the preferential sources supplying contaminated material to the main rivers draining the Fukushima contamination plume. To this end, important parameters controlling soil erosion and sediment transfers within catchments, i.e. landscape morphology and land use characteristics, were preliminary derived from DEM data and satellite images for the River Mano, Nitta and Ota catchments (ca. 525 km²) draining the most radioactive part of the contamination plume that formed across Fukushima Prefecture. Then, those data were used to compute indices assessing the potential sediment connectivity (i) between hillslopes and rivers and (ii) between hillslopes and catchment outlets. Finally, spatially-distributed values of connectivity indices were confronted to gamma-emitting radionuclide activities (Cs-134, Cs-137 and Ag-110m) measured in riverbed

  18. Examining Changes in Radioxenon Isotope Activity Ratios during Subsurface Transport

    NASA Astrophysics Data System (ADS)

    Annewandter, Robert

    2014-05-01

    volume method. The parabolic and hyperbolic problem can be solved separately by operator-splitting. The resulting system of linear equations is solved by the algebraic multigrid library SAMG, developed at the Fraunhofer Institute for Algorithms and Scientific Computing, Germany. CSMP++ is developed at Montan University of Leoben, ETH Zuerich, Imperial College London and Heriot-Watt University in Edinburgh. This study examines barometric pumping-driven subsurface transport of Xe-135, Xe-133m, Xe-133, Xe-131m including I-131, I-133 and I-135 on arrival times and isotopic activity ratios. This work was funded by the CTBTO Research Award for Young Scientist and Engineers (2013).

  19. The Fukushima releases: an inverse modelling approach to assess the source term by using gamma dose rate observations

    NASA Astrophysics Data System (ADS)

    Saunier, Olivier; Mathieu, Anne; Didier, Damien; Tombette, Marilyne; Quélo, Denis; Winiarek, Victor; Bocquet, Marc

    2013-04-01

    The Chernobyl nuclear accident and more recently the Fukushima accident highlighted that the largest source of error on consequences assessment is the source term estimation including the time evolution of the release rate and its distribution between radioisotopes. Inverse modelling methods have proved to be efficient to assess the source term due to accidental situation (Gudiksen, 1989, Krysta and Bocquet, 2007, Stohl et al 2011, Winiarek et al 2012). These methods combine environmental measurements and atmospheric dispersion models. They have been recently applied to the Fukushima accident. Most existing approaches are designed to use air sampling measurements (Winiarek et al, 2012) and some of them use also deposition measurements (Stohl et al, 2012, Winiarek et al, 2013). During the Fukushima accident, such measurements are far less numerous and not as well distributed within Japan than the dose rate measurements. To efficiently document the evolution of the contamination, gamma dose rate measurements were numerous, well distributed within Japan and they offered a high temporal frequency. However, dose rate data are not as easy to use as air sampling measurements and until now they were not used in inverse modelling approach. Indeed, dose rate data results from all the gamma emitters present in the ground and in the atmosphere in the vicinity of the receptor. They do not allow one to determine the isotopic composition or to distinguish the plume contribution from wet deposition. The presented approach proposes a way to use dose rate measurement in inverse modeling approach without the need of a-priori information on emissions. The method proved to be efficient and reliable when applied on the Fukushima accident. The emissions for the 8 main isotopes Xe-133, Cs-134, Cs-136, Cs-137, Ba-137m, I-131, I-132 and Te-132 have been assessed. The Daiichi power plant events (such as ventings, explosions…) known to have caused atmospheric releases are well identified in

  20. Iodine-129 in soils from Northern Ukraine and the retrospective dosimetry of the iodine-131 exposure after the Chernobyl accident.

    PubMed

    Michel, R; Handl, J; Ernst, T; Botsch, W; Szidat, S; Schmidt, A; Jakob, D; Beltz, D; Romantschuk, L D; Synal, H-A; Schnabel, C; López-Gutiérrez, J M

    2005-03-20

    Forty-eight soil profiles down to a depth of 40 cm were taken in Russia and Ukraine in 1995 and 1997, respectively, in order to investigate the feasibility of retrospective dosimetry of the 131I exposure after the Chernobyl accident via the long-lived 129I. The sampling sites covered areas almost not affected by fallout from the Chernobyl accident such as Moscow/Russia and the Zhitomir district in Ukraine as well as the highly contaminated Korosten and Narodici districts in Ukraine. 129I was analyzed by radiochemical neutron activation analysis (RNAA) and accelerator mass spectrometry (AMS). 127I was measured for some profiles by RNAA or ion chromatography (IC). The results for 127I demonstrated large differences in the capabilities of the soils to store iodine over long time spans. The depth profiles of 129I and of 137Cs showed large differences in the migration behavior between the two nuclides but also for each nuclide among the different sampling sites. Though it cannot be quantified how much 129I and 137Cs was lost out of the soil columns into deeper depths, the inventories in the columns were taken as proxies for the total inventories. For 129I, these inventories were at least three orders of magnitude higher than a pre-nuclear value of 0.084+/-0.017 mBq m(-2) derived from a soil profile taken in 1939 in Lutovinovo/Russia. From the samples from Moscow and Zhitomir, a pre-Chernobyl 129I inventory of (44+/-24) mBq m(-2) was determined, limiting the feasibility of 129I retrospective dosimetry to areas where the 129I inventories exceed 100 mBq m(-2). Higher average 129I inventories in the Korosten and Narodici districts of 130 and 848 mBq m(-2), respectively, allowed determination of the 129I fallout due to the Chernobyl accident. Based on the total 129I inventories and on literature data for the atomic ratio of 129I/131I=13.6+/-2.8 for the Chernobyl emissions and on aggregated dose coefficients for 131I, the thyroid exposure due to 131I after the Chernobyl

  1. Radiation epidemiology and recent paediatric computed tomography studies.

    PubMed

    Boice, J D

    2015-06-01

    Recent record-linkage studies of cancer risk following computed tomography (CT) procedures among children and adolescents under 21 years of age must be interpreted with caution. The reasons why the examinations were performed were not known, and the dosimetric approaches did not include individual dose reconstructions or account for the possibility for missed examinations. The recent report (2013) on children by the United Nations Scientific Committee on the Effects of Atomic Radiation concluded that the associations may have resulted from confounding by indication (also called 'reverse causation'), and not radiation exposure. The reported cancer associations may very well have been related to the patients' underlying health conditions that prompted the examinations. Reverse causation has been observed in other epidemiological investigations, such as a Swedish study of thyroid cancer risk following I-131 scintillation imaging scans, and in studies of brain cancer risk following Thorotrast for cerebral angiography. Epidemiological patterns reported in the CT studies were also inconsistent with the world's literature. For example, in a UK study, teenagers had a higher risk of brain tumour than young children; in an Australian study, cancers not previously linked to radiation were significantly elevated; and in a Taiwanese study, the risk of benign tumours decreased with age at the time of CT examination. In all studies, solid tumours appeared much earlier than previously reported. Remarkably, in the Australian study, brain cancer excesses were seen regardless of whether or not the CT was to the head, i.e. a significant excess was reported for CT examinations of the abdomen and extremities, which involved no radiation exposure to the brain. In the UK study, the significance of the 'leukaemia' finding was only because myelodysplastic syndrome was added to the category, and there was no significance for leukaemia alone. Without knowledge of why CT examinations were

  2. Detailed analysis of isotopic ratio of radioactive iodine in surface soil around Fukushima Daiichi Nuclear Power Plant

    NASA Astrophysics Data System (ADS)

    Miyake, Yasuto; Matsuzaki, Hiroyuki; Fujiwara, Takeshi; Saito, Takumi; Yamagata, Takeyasu; Honda, Maki

    2013-04-01

    In March 2011, there was an accident at the Fukushima Daiichi Nuclear Power Plant (FDNPP) and a lot of radionuclides were discharged into the environment, resulting from a powerful earthquake and tsunami. Considering the impact on human health, the radiation dosimetry is the most important for Iodine-131 among radionuclides in the initial stage immediately following the release of radionuclides. However, Iodine-131 cannot be detected after several months owing to its short half-life (8 days). Cesium-137 was also leaked out from the FDNPP and this can be detected now. But this did not identically act with Iodine-131 and be suitable for the reconstruction of Iodine-131 distribution at the initial stage. Since Iodine-129 (half-life: 1.57E7 yrs) can be detected in the future and it act chemically identically with Iodine-131, the reconstruction by Iodine-129 analysis is important. For this reconstruction, it is necessary to know the isotopic ratio of radioactive iodine (129I/131I) released from the FDNPP. In this study, the Iodine-129 concentration was measured by accelerator mass spectrometry (AMS) in several surface soil samples collected around the FDNPP for which the Iodine-131level had already been determined. Soil samples were put into a U8 standard vessel after being roughly homogenized and dried. Then, samples were homogenized again more completely and several grams were taken for Iodine-129 measurement. Each sample was combusted in a quartz tube and outgas was trapped in alkali solution. An aliquot was taken from the trap solution for the determination of the Iodine-127 concentration by inductively coupled plasma mass spectrometry (ICP-MS). The iodine carrier was added to the trap solution, from which the iodine fraction was purified by solvent extraction and back extraction. Finally, silver iodide precipitation was obtained by adding silver nitrate solution. After dried, the precipitation was mixed with niobium powder and pressed into a cathode for the target

  3. Fukushima Daiichi Nuclear Accident; based on the Final Report of Atomic Energy Society of Japan

    NASA Astrophysics Data System (ADS)

    Sekimura, Naoto

    2014-09-01

    The Atomic Energy Society of Japan (AESJ) published the Final Report of the AESJ Investigation Committee on Fukushima Daiichi NPS Accident in March 2014. The AESJ is responsible to identify the underlying root causes of the accident through technical surveys and analyses, and to offer solutions for nuclear safety. At the Fukushima Daiichi, Units 1 to 3, which were under operation, were automatically shut down at 14:46 on March 11, 2011 by the Tohoku District-off the Pacific Ocean Earthquake. About 50 minutes later, the tsunami flooded and destroyed the emergency diesel generators, the seawater cooling pumps, the electric wiring system and the DC power for Units 1, 2 and 4, resulting in loss of all power except for an air-cooled emergency diesel generator at Unit 6. Unit 3 lost all AC power, and later lost DC before dawn of March 13. Cooling the reactors and monitoring the results were heavily dependent on electricity for high-pressure water injection, depressurizing the reactor, low pressure water injection, and following continuous cooling. In Unit 3, for example, recent re-evaluation in August 2014 by TEPCO shows that no cooling water was injected into the reactor core region after 8 PM on March 12, leading to the fuel melting from 5:30 AM on March 13. Even though seawater was injected from fire engines afterwards, the rupture of pressure vessel was caused and the majority of melted fuel dropped into the containment vessel of Unit 3. The estimation of amount of radioactive materials such as Xe-133, I-131, Cs-137 and Cs-134, emitted to the environment from Units 1 to 3 is discussed in the presentation. Direct causes of the accident identified in the AESJ Report were, 1) inadequate tsunami measures, 2) inadequate severe accident management measures and 3) inadequate emergency response, post-accident management/mitigation, and recovery measures. These were caused by the following underlying factors, i.e., a) lack of awareness on the roles and responsibilities by

  4. Transuranium radionuclide pollution in the waters of the La Maddalena National Marine Park.

    PubMed

    Aumento, F; Le Donne, K; Eroe, K

    2005-01-01

    Following the grounding and subsequent explosion, in October 2003, of a nuclear submarine in the waters of the La Maddalena National Marine Park, fears arose of possible radioactive leakages. However, isotopic analyses on algae showed that the gamma-ray emitting artificial radionuclides that one might expect to leak from a damaged nuclear reactor (such as U-235, I-131, Cs-137) were absent, and that U-238/U-234 activities were in equilibrium with values typical of sea water; this excluded any direct anthropogenic contamination as a result of the accident. We used alpha autoradiographic techniques to detect possible traces of transuranium radionuclides; 160 samples of algae, granites, sea urchins, gastropods, limpets, cuttlefish and jellyfish were collected from the area, as well as from other Mediterranean coastlines and the Baltic Sea. All samples were autoradiographed, and selected samples further analysed by alpha spectrometry. There were no alpha track concentrations above background levels in our control Mediterranean specimens. In the samples from the La Maddalena and Baltic areas two different track distributions were observed: --those homogeneously distributed over the surfaces examined; --groups (10 to over 500) of radially distributed alpha tracks (forming "star" bursts, or "hot spots") emanating from point sources. By comparing radionuclide activities measured by alpha spectroscopy with alpha track densities, we extrapolated Pu activities for all samples. About 74% of algae had Pu activities of less than 1 Bq/kg and 0.25 Bq/kg, 16% had accumulated Pu to levels between 1 and 2 Bq/kg, and a very few specimens had concentrations between 2 and 6 Bq/kg. Plots showed that alpha tracks and stars concentrate around the northern and eastern margins of the Rada (Basin) di Santo Stefano, sites facing the nuclear submarine base on the eastern shore of the island of Santo Stefano. What is the source of these nuclides: last century's atmospheric nuclear testing

  5. Fine-Resolution Voxel S Values for Constructing Absorbed Dose Distributions at Variable Voxel Size

    PubMed Central

    Dieudonné, Arnaud; Hobbs, Robert F.; Bolch, Wesley E.; Sgouros, George; Gardin, Isabelle

    2010-01-01

    This article presents a revised voxel S values (VSVs) approach for dosimetry in targeted radiotherapy, allowing dose calculation for any voxel size and shape of a given SPECT or PET dataset. This approach represents an update to the methodology presented in MIRD pamphlet no. 17. Methods VSVs were generated in soft tissue with a fine spatial sampling using the Monte Carlo (MC) code MCNPX for particle emissions of 9 radionuclides: 18F, 90Y, 99mTc, 111In, 123I, 131I, 177Lu, 186Re, and 201Tl. A specific resampling algorithm was developed to compute VSVs for desired voxel dimensions. The dose calculation was performed by convolution via a fast Hartley transform. The fine VSVs were calculated for cubic voxels of 0.5 mm for electrons and 1.0 mm for photons. Validation studies were done for 90Y and 131I VSV sets by comparing the revised VSV approach to direct MC simulations. The first comparison included 20 spheres with different voxel sizes (3.8–7.7 mm) and radii (4–64 voxels) and the second comparison a hepatic tumor with cubic voxels of 3.8 mm. MC simulations were done with MCNPX for both. The third comparison was performed on 2 clinical patients with the 3D-RD (3-Dimensional Radiobiologic Dosimetry) software using the EGSnrc (Electron Gamma Shower National Research Council Canada)-based MC implementation, assuming a homogeneous tissue-density distribution. Results For the sphere model study, the mean relative difference in the average absorbed dose was 0.20% ± 0.41% for 90Y and −0.36% ± 0.51% for 131I (n = 20). For the hepatic tumor, the difference in the average absorbed dose to tumor was 0.33% for 90Y and −0.61% for 131I and the difference in average absorbed dose to the liver was 0.25% for 90Y and −1.35% for 131I. The comparison with the 3D-RD software showed an average voxel-to-voxel dose ratio between 0.991 and 0.996. The calculation time was below 10 s with the VSV approach and 50 and 15 h with 3D-RD for the 2 clinical patients. Conclusion This new

  6. Radionuclides in the Great Lakes basin.

    PubMed Central

    Ahier, B A; Tracy, B L

    1995-01-01

    The Great Lakes basin is of radiologic interest due to the large population within its boundaries that may be exposed to various sources of ionizing radiation. Specific radionuclides of interest in the basin arising from natural and artificial sources include 3H, 14C, 90Sr, 129I, 131I, 137Cs, 222Rn, 226Ra, 235U, 238U, 239Pu, and 241Am. The greatest contribution to total radiation exposure is the natural background radiation that provides an average dose of about 2.6 mSv/year to all basin residents. Global fallout from atmospheric nuclear weapons tests conducted before 1963 has resulted in the largest input of anthropogenic radioactivity into the lakes. Of increasing importance is the radionuclide input from the various components of the nuclear fuel cycle. Although the dose from these activities is currently very low, it is expected to increase if there is continued growth of the nuclear industry. In spite of strict regulations on design and operation of nuclear power facilities, the potential exists for a serious accident as a result of the large inventories of radionuclides contained in the reactor cores; however, these risks are several orders of magnitude less than the risks from other natural and man-made hazards. An area of major priority over the next few decades will be the management of the substantial amounts of radioactive waste generated by nuclear fuel cycle activities. Based on derived risk coefficients, the theoretical incidence of fatal and weighted nonfatal cancers and hereditary defects in the basin's population, attributable to 50 years of exposure to natural background radiation, is conservatively estimated to be of the order of 3.4 x 10(5) cases. The total number of attributable health effects to the year 2050 from fallout radionuclides in the Great Lakes basin is of the order of 5.0 x 10(3). In contrast, estimates of attributable health effects from 50 years of exposure to current nuclear fuel cycle effluent in the basin are of the order of 2

  7. Gaseous iodine monitoring in Europe after the Fukushima accident

    NASA Astrophysics Data System (ADS)

    Masson, Olivier; de Vismes-Ott, Anne; Manificat, Guillaume; Gurriaran, Rodolfo; Debayle, Christophe

    2014-05-01

    After the Fukushima accident and following the worldwide dispersion of contaminated air masses, many monitoring networks have reported airborne levels of emitted radionuclides, namely and mainly cesium isotopes and iodine 131. Most of the values focused on the particulate fraction (i.e. radionuclide-labeled aerosols) and were dedicated to cesium 137, cesium 134 and iodine 131. Iodine-131 was also found under gaseous form that accounted for most part of the total (gaseous + particulate)I-131 throughout the world. This gaseous predominance was also noticed after the Chernobyl accident despite differences in the type of accident. This predominance is due to the high iodine volatility and also by a rather low transfer from the gaseous form to the particulate one by adsorption on ambient airborne particles. Paradoxically, the number of gaseous determinations was rather low compared to the magnitude of data related to the particulate form (around 10 percent). Routine monitoring of airborne radionuclides species have been extensively based on aerosol sampling for decades as this allows the long term characterization of trace levels of remnant anthropogenic radionuclides. Moreover the capability of gaseous sampler equipped with activated charcoal to allow the quantification of 131I gaseous at trace level is limited by the contact time required for the sorption of iodine on the sorbent and thus by the low acceptable flow rate (usually between 3 and 5 m3/h, exceptionally 12 m3/h). In this context and despite the fact that airborne level outside Japan were of no concern for public health, this contribute to the lack of information on the actual levels of gaseous iodine. Other incidents involving iodine determination in the air have been reported in Europe in 2011 and 2012 without any relation with the Fukushima accident. For the same reason as previously mentioned, mainly, if not only, the particulate form was reported whereas it can be supposed that the predominant form was

  8. Patient-Specific Dosimetry Using Pretherapy [124I]m-iodobenzylguanidine ([124I]mIBG) Dynamic PET/CT Imaging Before [131I]mIBG Targeted Radionuclide Therapy for Neuroblastoma

    PubMed Central

    Huang, Shih-ying; Bolch, Wesley E.; Lee, Choonsik; Van Brocklin, Henry F.; Pampaloni, Miguel H.; Hawkins, Randall A.; Sznewajs, Aimee; DuBois, Steven G.; Matthay, Katherine K.; Seo, Youngho

    2014-01-01

    Purpose Iodine-131-m-iodobenzylguanidine ([131I]mIBG) targeted radionuclide therapy (TRT) is a standard treatment for recurrent or refractory neuroblastoma with response rates of 30–40%. The aim of this study is to demonstrate patient-specific dosimetry using quantitative [124I]mIBG PET/CT imaging with a Geant4-based Monte Carlo method for better treatment planning. Procedures A Monte Carlo dosimetry method was developed using the Geant4 toolkit with voxelized anatomical geometry and source distribution as input. The pre-segmented hybrid computational human phantoms developed by the University of Florida and the National Cancer Institute (UF/NCI) were used as a surrogate to characterize the anatomy of a given patient. S-values for I-131 were estimated by the phantoms coupled with Geant4 and compared with those estimated by OLINDA|EXM and MCNPX for the newborn model. To obtain patient-specific biodistribution of [131I]mIBG, a 10-year-old girl with relapsed neuroblastoma was imaged with [124I]mIBG PET/CT at four time points prior to the planned [131I]mIBG TRT. The organ and tumor absorbed dose of the clinical case were estimated with the Geant4 method using the modified UF/NCI 10-year-old phantom with tumors and the patient-specific residence time. Results For the newborn model, the Geant4 S-values were consistent with the MCNPX S- values. The S-value ratio of the Geant4 method to OLINDA|EXM ranged from 0.08 to 6.5 of all major organs. The [131I]mIBG residence time quantified from the pretherapy [124I]mIBG PET/CT imaging of the 10-year-old patient was mostly comparable to those previously reported. Organ absorbed dose for the salivary glands were 98.0 Gy, heart wall, 36.5 Gy, and liver, 34.3 Gy; while tumor absorbed dose ranged from 143.9 Gy to 1641.3 Gy in different sites. Conclusions Patient-specific dosimetry for [131I]mIBG targeted radionuclide therapy was accomplished using pretherapy [124I]mIBG PET/CT imaging and a Geant4-based Monte Carlo dosimetry method

  9. Thyroid cancer in Luxembourg: a national population-based data report (1983–1999)

    PubMed Central

    Scheiden, René; Keipes, Marc; Bock, Carlo; Dippel, Walter; Kieffer, Nelly; Capesius, Catherine

    2006-01-01

    Background Twenty years after the nuclear accident in Chernobyl (Eastern Europe), there is still a controversial debate concerning a possible effect of the radioactive iodines, especially I-131, on the increase of thyroid carcinomas (TCs) in Western Europe. Time trends in incidence rates of TC in Luxembourg in comparison with other European countries and its descriptive epidemiology were investigated. Methods The population-based data of the national Morphologic Tumour Registry collecting new thyroid cancers diagnosed between 1983 and 1999 at a nation-wide level in the central division of pathology were reviewed and focused on incidence rates of TC. Data from 1990 to 1999 were used to evaluate the distribution by gender, age, histological type, tumour size and the outcome. Results Out of 310 new thyroid carcinomas diagnosed between 1990 and 1999, 304 differentiated carcinomas (A: 80% papillary; B: 14.5% follicular; C: 3.5% medullary) and 6 anaplastic/undifferentiated TCs (D: 2%) were evaluated. The M/F-ratio was 1:3.2, the mean age 48.3 years (range: 13–92). The overall age-standardized (world population) incidence rates over the two 5-year periods 1990–1994 and 1995–1999 increased from 7.4 per 100,000 to 10.1 per 100,000 in females, from 2.3 per 100,000 to 3.6 per 100,000 in males. Only 3 patients were children or adolescents (1%), the majority of the patients (50%) were between 45 and 69 years of age. The percentage of microcarcinomas (<1 cm) was A: 46.4%, (115/248); B: 13.3%, (6/45); C: 27.3%, (3/11). The unexpected increase of TCs in 1997 was mainly due to the rise in the number of microcarcinomas. The observed 5-year survival rates for both genders were A: 96.0+/-2%; B: 88.9%; C: 90.9%; D: 0%. Prognosis was good in younger patients, worse in males and elderly, and extremely poor for undifferentiated TCs. Conclusion The increasing incidence rates of TC, especially of the papillary type, seem mainly due to a rise in diagnosed microcarcinomas due to some

  10. The absorbed dose to blood from blood-borne activity

    NASA Astrophysics Data System (ADS)

    Hänscheid, H.; Fernández, M.; Lassmann, M.

    2015-01-01

    The radiation absorbed dose to blood and organs from activity in the blood is relevant for nuclear medicine dosimetry and for research in biodosimetry. The present study provides coefficients for the average absorbed dose rates to the blood from blood-borne activity for radionuclides frequently used in targeted radiotherapy and in PET diagnostics. The results were deduced from published data for vessel radius-dependent dose rate coefficients and reasonable assumptions on the blood-volume distribution as a function of the vessel radius. Different parts of the circulatory system were analyzed separately. Vessel size information for heart chambers, aorta, vena cava, pulmonary artery, and capillaries was taken from published results of morphometric measurements. The remaining blood not contained in the mentioned vessels was assumed to reside in fractal-like vascular trees, the smallest branches of which are the arterioles or venules. The applied vessel size distribution is consistent with recommendations of the ICRP on the blood-volume distribution in the human. The resulting average absorbed dose rates to the blood per nuclear disintegration per milliliter (ml) of blood are (in 10-11 Gy·s-1·Bq-1·ml) Y-90: 5.58, I-131: 2.49, Lu-177: 1.72, Sm-153: 2.97, Tc-99m: 0.366, C-11: 4.56, F-18: 3.61, Ga-68: 5.94, I-124: 2.55. Photon radiation contributes 1.1-1.2·10-11 Gy·s-1·Bq-1·ml to the total dose rate for positron emitters but significantly less for the other nuclides. Blood self-absorption of the energy emitted by ß-particles in the whole blood ranges from 37% for Y-90 to 80% for Tc-99m. The correspondent values in vascular trees, which are important for the absorbed dose to organs, range from 30% for Y-90 to 82% for Tc-99m.

  11. Gateways to clinical trials.

    PubMed

    Bayes, M; Rabasseda, X; Prous, J R

    2005-01-01

    Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: (-)-Epigallocatechin gallate; ACP-103, Ad.Egr.TNF.11 D, adalimumab, AF-IL 12, AIDSVAX gp120 B/B, alefacept, alemtuzumab, a-Galactosylceramide, ALVAC vCP 1452, alvimopan hydrate, alvocidib hydrochloride, aminolevulinic acid hydrochloride, aminolevulinic acid methyl ester, anakinra, anidulafungin, antarelix, aprepitant, aripiprazole, arsenic sulfide, asoprisnil, atazanavir sulfate, atomoxetine hydrochloride; Bevacizumab, bimatoprost, BMS-184476, bortezomib, bosentan, botulinum toxin type B, BrachySil, brivudine; Caffeine, calcipotriol/betamethasone dipropionate, cannabidiol, capsaicin for injection, caspofungin acetate, CC-4047, cetuximab, CGP-36742, clofazimine, CpG-7909, Cypher; Darbepoetin alfa, dextromethorphan/quinidine sulfate, dimethylfumarate, dronabinol/cannabidiol, drotrecogin alfa (activated), duloxetine hydrochloride, dutasteride; Ecogramostim, efalizumab, eletriptan, emtricitabine, enfuvirtide, eplerenone, esomeprazole magnesium, estradiol acetate, eszopiclone, etoricoxib, exenatide, ezetimibe, ezetimibe/simvastatin; Fampridine, fondaparinux sodium, fosamprenavir calcium; Gefitinib, GPI-0100; hA 20, HTU-PA, human insulin, HuOKT 3 gamma 1(Ala 234-Ala 235), hyaluronic acid; Icatibant, imatinib mesylate, Indiplon, INKP-100, INKP-102, iodine (I131) tositumomab, istradefylline, IV gamma-globulin, ivabradine hydrochloride, ixabepilone; Lacosamide, landiolol, lanthanum carbonate, lasofoxifene tartrate, LB-80380, lenalidomide, lidocaine/tetracaine, linezolid, liposomal doxorubicin, liposomal vincristine sulfate, lopinavir, lopinavir/ritonavir, lumiracoxib, lurtotecan; Maribavir, morphine glucuronide, MVA-5 T

  12. Radiosynthesis of [131I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker — is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?

    PubMed Central

    Suehiro, Makiko; Burgman, Paul; Carlin, Sean; Burke, Sean; Yang, Guangbin; Ouerfelli, Ouathek; Oehler-Janne, Christoph; O’Donoghue, Joseph; Ling, Clifton; Humm, John

    2010-01-01

    Introduction The hypoxia marker IAZGP, 1-(6-deoxy-6-iodo-β-D-galactopyranosyl)-2-nitroimidazole, has been labeled with 123I/124I/125I/131I via iodine–radioiodine exchange, which gives the radiotracer in a specific activity of 10–90 MBq/μmol. We synthesized the same radiotracer possessing several hundred to thousand times higher specific activity (high-SA IAZGP) via nucleophilic substitution and compared its biological behavior with that of conventionally produced IAZGP (low-SA IAZGP) to determine if specific activity is a factor influencing cell uptake kinetics, biodistribution and intratumor microregional localization of the radiotracer. Methods High-SA [131I]IAZGP was prepared by substitution of the tosyl functionality with [131I]iodide. In vitro uptake of high- and low-SA [131I]IAZGP by HCT8 and HT29 cells was assessed in normoxic and hypoxic conditions. Biodistribution and intratumor localization of high- and low-SA [131I]IAZGP were determined by injection into HT29 tumor-bearing mice. Results The nucleophilic substitution reaction proceeded efficiently in acetonitrile at 150°C, giving the final product in an average yield of 42% and an average specific activity of 30 GBq/μmol. In vitro, high-SA [131I]IAZGP was incorporated into the tumor cells with similar kinetics and oxygen dependence to low-SA [131I]IAZGP. In HT29 tumor-bearing mice, biodistributions of high- and low-SA [131I]IAZGP were equivalent. Ex vivo autoradiography revealed heterogeneous intratumor localization of high-SA [131I]IAZGP corresponding closely to distributions of other exogenous and endogenous hypoxia markers. Comparable microregional distribution patterns were observed with low-SA [131I]IAZGP. Conclusions Radiolabeled IAZGP produced via nucleophilic substitution is validated as an exogenous hypoxia marker. Specific activity does not appear to influence the in vivo hypoxia-mapping ability of the radiotracer. PMID:19520288

  13. Calibration of the γ-H2AX DNA Double Strand Break Focus Assay for Internal Radiation Exposure of Blood Lymphocytes

    PubMed Central

    Eberlein, Uta; Peper, Michel; Fernández, Maria; Lassmann, Michael; Scherthan, Harry

    2015-01-01

    DNA double strand break (DSB) formation induced by ionizing radiation exposure is indicated by the DSB biomarkers γ-H2AX and 53BP1. Knowledge about DSB foci formation in-vitro after internal irradiation of whole blood samples with radionuclides in solution will help us to gain detailed insights about dose-response relationships in patients after molecular radiotherapy (MRT). Therefore, we studied the induction of radiation-induced co-localizing γ-H2AX and 53BP1 foci as surrogate markers for DSBs in-vitro, and correlated the obtained foci per cell values with the in-vitro absorbed doses to the blood for the two most frequently used radionuclides in MRT (I-131 and Lu-177). This approach led to an in-vitro calibration curve. Overall, 55 blood samples of three healthy volunteers were analyzed. For each experiment several vials containing a mixture of whole blood and radioactive solutions with different concentrations of isotonic NaCl-diluted radionuclides with known activities were prepared. Leukocytes were recovered by density centrifugation after incubation and constant blending for 1 h at 37°C. After ethanol fixation they were subjected to two-color immunofluorescence staining and the average frequencies of the co-localizing γ-H2AX and 53BP1 foci/nucleus were determined using a fluorescence microscope equipped with a red/green double band pass filter. The exact activity was determined in parallel in each blood sample by calibrated germanium detector measurements. The absorbed dose rates to the blood per nuclear disintegrations occurring in 1 ml of blood were calculated for both isotopes by a Monte Carlo simulation. The measured blood doses in our samples ranged from 6 to 95 mGy. A linear relationship was found between the number of DSB-marking foci/nucleus and the absorbed dose to the blood for both radionuclides studied. There were only minor nuclide-specific intra- and inter-subject deviations. PMID:25853575

  14. Experimental incineration of low level radioactive samples.

    PubMed

    Yumoto, Y; Hanafusa, T; Nagamatsu, T; Okada, S

    2000-08-01

    To determine the volume reduction potential for incineration of radioactivity in low-level radioactive waste, an incineration experiment was performed at the Okayama University Radioisotope Center (OURIC). Solid low-level radioactive samples (LLRS) were prepared for 15 routinely used radionuclides (45Ca, 1251, 32p, 33p, 35S, 59Fe, 123I, 131I, 67Ga, 99mTc, 111In, 3H, 14C, 51Cr, and 201Tl). For each radionuclide, incinerated one at a time, the smoke duct radioisotope concentration was less than 1/10 of the regulatory concentration limit (The Japanese law concerning prevention of radiation hazard due to radioisotopes, etc.). The radionuclide-containing combustible and semi-combustible LLRS were incinerated at the AP-1 50R furnace erected at OURIC, and the distribution of radioactivity inside and outside the furnace was measured. In the experimental incineration of LLRS containing these 15 radionuclides, the fractions released (RF) in the gas phase of the final smoke duct ranged from 0.165 to 0.99. The radioactivities remaining in the incineration residue were 99mTc, 87%; 59Fe, 83.1%; 45Ca, 75%; 51Cr, 62.1%; 33P, 62.0%; 32P, 61.1%; 67Ga, 57.7%; 35S, 26.0%; 111In, 21.1%; 201Tl, 16.6%; 123I, 11.9%; 131I, 8.2%; 125I, 2.4%; 14C, 0.39%; 3H, 0.04%. In the incineration of LLR S containing 35S, the rate of adhesion to the furnace wall was lower at high-temperature (809 degrees C) incineration than at low-temperature (376 degrees C) incineration. For LLRS containing one of the three radioiodines, 123I, 125I, or 131I, no such difference was observed between low (372 degrees C) and high (827 degrees C) temperature incineration (RF varied from 0.82 to 0.94). PMID:10910400

  15. Radionuclides in the Great Lakes basin.

    PubMed

    Ahier, B A; Tracy, B L

    1995-12-01

    The Great Lakes basin is of radiologic interest due to the large population within its boundaries that may be exposed to various sources of ionizing radiation. Specific radionuclides of interest in the basin arising from natural and artificial sources include 3H, 14C, 90Sr, 129I, 131I, 137Cs, 222Rn, 226Ra, 235U, 238U, 239Pu, and 241Am. The greatest contribution to total radiation exposure is the natural background radiation that provides an average dose of about 2.6 mSv/year to all basin residents. Global fallout from atmospheric nuclear weapons tests conducted before 1963 has resulted in the largest input of anthropogenic radioactivity into the lakes. Of increasing importance is the radionuclide input from the various components of the nuclear fuel cycle. Although the dose from these activities is currently very low, it is expected to increase if there is continued growth of the nuclear industry. In spite of strict regulations on design and operation of nuclear power facilities, the potential exists for a serious accident as a result of the large inventories of radionuclides contained in the reactor cores; however, these risks are several orders of magnitude less than the risks from other natural and man-made hazards. An area of major priority over the next few decades will be the management of the substantial amounts of radioactive waste generated by nuclear fuel cycle activities. Based on derived risk coefficients, the theoretical incidence of fatal and weighted nonfatal cancers and hereditary defects in the basin's population, attributable to 50 years of exposure to natural background radiation, is conservatively estimated to be of the order of 3.4 x 10(5) cases. The total number of attributable health effects to the year 2050 from fallout radionuclides in the Great Lakes basin is of the order of 5.0 x 10(3). In contrast, estimates of attributable health effects from 50 years of exposure to current nuclear fuel cycle effluent in the basin are of the order of 2

  16. Preparation of Rh[16aneS4-diol]211 At and Ir[16aneS4-diol]211 At Complexes as Potential Precursors for Astatine Radiopharmaceuticals. Part I: Synthesis

    PubMed Central

    Pruszyński, Marek; Bilewicz, Aleksander; Zalutsky, Michael R.

    2010-01-01

    The goal of this study was to evaluate a new approach that can be applied for labeling biomolecules with 211At. Many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking different 211At labeling strategies. The approach evaluated in this study was to attach astatide anions to soft metal cations, which are also complexed by a bifunctional ligand. Ultimately, this complex could in principle be subsequently conjugated to a biomolecule with the proper selection of ligand functionality. We report here the attachment of 211At− and *I− (*I = 131I or 125I) anions to the soft metal cations Rh(III) and Ir(III), which are complexed by the 1,5,9,13-tetrathiacyclohexadecane-3,11-diol (16aneS4-diol) ligand. Radioactive *I− anions were used for preliminary studies directed at the optimization of reaction conditions and to provide a baseline for comparison of results with 211At. Four complexes Rh[16aneS4-diol]*I/211At and Ir[16aneS4-diol]*I/211 At were synthesized in high yield in a one-step procedure, and the products were characterized mainly by paper electrophoresis and reversed-phase HPLC. The influences of time and temperature of heating and concentrations of metal cations and sulfur ligand 16aneS4-diol, as well as pH on the reaction yields were determined. Yields of about 80% were obtained when the quantities of Rh(III) or Ir(III) cations and 16aneS4-diol ligand in the solutions were 62.5 nmol and 250 nmol, respectively, and the pH ranged 3.0–4.0. Syntheses required heating for 1–1.5 h at 75–80 °C. The influence of microwave heating on the time and completeness of the complexation reaction was evaluated and compared with the conventional method of heating in an oil bath. Microwave synthesis accelerates reactions significantly. With microwave heating, yields of about 75% for Rh[16aneS4-diol]131I and Ir[16aneS4-diol]131I complexes were obtained after only 20 min exposure of the reaction mixtures to microwave

  17. Calibration of the γ-H2AX DNA double strand break focus assay for internal radiation exposure of blood lymphocytes.

    PubMed

    Eberlein, Uta; Peper, Michel; Fernández, Maria; Lassmann, Michael; Scherthan, Harry

    2015-01-01

    DNA double strand break (DSB) formation induced by ionizing radiation exposure is indicated by the DSB biomarkers γ-H2AX and 53BP1. Knowledge about DSB foci formation in-vitro after internal irradiation of whole blood samples with radionuclides in solution will help us to gain detailed insights about dose-response relationships in patients after molecular radiotherapy (MRT). Therefore, we studied the induction of radiation-induced co-localizing γ-H2AX and 53BP1 foci as surrogate markers for DSBs in-vitro, and correlated the obtained foci per cell values with the in-vitro absorbed doses to the blood for the two most frequently used radionuclides in MRT (I-131 and Lu-177). This approach led to an in-vitro calibration curve. Overall, 55 blood samples of three healthy volunteers were analyzed. For each experiment several vials containing a mixture of whole blood and radioactive solutions with different concentrations of isotonic NaCl-diluted radionuclides with known activities were prepared. Leukocytes were recovered by density centrifugation after incubation and constant blending for 1 h at 37°C. After ethanol fixation they were subjected to two-color immunofluorescence staining and the average frequencies of the co-localizing γ-H2AX and 53BP1 foci/nucleus were determined using a fluorescence microscope equipped with a red/green double band pass filter. The exact activity was determined in parallel in each blood sample by calibrated germanium detector measurements. The absorbed dose rates to the blood per nuclear disintegrations occurring in 1 ml of blood were calculated for both isotopes by a Monte Carlo simulation. The measured blood doses in our samples ranged from 6 to 95 mGy. A linear relationship was found between the number of DSB-marking foci/nucleus and the absorbed dose to the blood for both radionuclides studied. There were only minor nuclide-specific intra- and inter-subject deviations. PMID:25853575

  18. Interest of somatostatin receptors scintigraphy for imaging differentiated thyroid carcinoma tumor sites

    SciTech Connect

    Giammarile, F.; Lumbroso, J.; Schlumberger, M.

    1995-05-01

    Despite the fact that differentiated thyroid carcinoma (DTC) is not classified as a neuroendocrine tumor, there is an increasing interest for the use of somatostatin receptors scintigraphy (SRS) in this disease. We evaluated SRS in DTC patients having no or a poor radioiodine uptake at the level of their tumor sites. Nine patients (pts) (7 men, 2 women; aged from 52 to 65 years) were previously treated (surgery of the primary: 9/9pts; followed by cervical radiotherapy: 4/9pts; radioiodine therapy: 8/9pts; surgery or radiotherapy to bone metastases: 2/9 pts) for DTC (papillary form: 6 pts; follicular; 1 pts; insular: 2 pts). They were explored by conventional imaging modalities (CIM) including Tc-99m MDP bone scans. High activity radioiodine scans were obtained 5 days after I-131 therapy. SRS was carried out during thyroxine therapy using Indium-111 pentetreotide (120 MBq) with imaging at 4 and 24 hours after injection (whole body scans and, when necessary, SPECT). Thyroglobulin blood level ranged from 120 to 60,000ng/ml. SRS was positive at the level of all tumor sites in 8/9 pts; radioiodine scans were negative in 4 pts (1pt with an insular DTC, 3 pt with a papillary DTC), slightly positive in 2 pts (papillary DTC), positive only on part of tumor sites in 1 pts (insular DTC), positive in 1 pt (follicular DTC) and not done in 1 pt. SRS demonstrated 3 new tumor sites (1 to bone, 1 to lung and 1 to mediastinal lymph nodes) in 2 pts; in an other pt, SRS clarified out a doubtful Tc-99m bone scan result and led to definitive confirmation of bone metastases. We had only 1 false negative result in 1 pt having pulmonary metastases (slightly positive radioiodine scan) which had been stable in size on CT for 6 years. These results indicate that, when radioiodine scans are ineffective, SRS is a powerful modality for imaging DTC tumor sites.

  19. Preparation of Rh[16aneS4-diol](211)At and Ir[16aneS4-diol](211)At complexes as potential precursors for astatine radiopharmaceuticals. Part I: Synthesis.

    PubMed

    Pruszyński, Marek; Bilewicz, Aleksander; Zalutsky, Michael R

    2008-04-01

    The goal of this study was to evaluate a new approach that can be applied for labeling biomolecules with (211)At. Many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking different (211)At labeling strategies. The approach evaluated in this study was to attach astatide anions to soft metal cations, which are also complexed by a bifunctional ligand. Ultimately, this complex could in principle be subsequently conjugated to a biomolecule with the proper selection of ligand functionality. We report here the attachment of (211)At(-) and *I(-) (*I = (131)I or (125)I) anions to the soft metal cations Rh(III) and Ir(III), which are complexed by the 1,5,9,13-tetrathiacyclohexadecane-3,11-diol (16aneS4-diol) ligand. Radioactive *I(-) anions were used for preliminary studies directed at the optimization of reaction conditions and to provide a baseline for comparison of results with (211)At. Four complexes Rh[16aneS4-diol]*I/(211)At and Ir[16aneS4-diol]*I/(211)At were synthesized in high yield in a one-step procedure, and the products were characterized mainly by paper electrophoresis and reversed-phase HPLC. The influences of time and temperature of heating and concentrations of metal cations and sulfur ligand 16aneS4-diol, as well as pH on the reaction yields were determined. Yields of about 80% were obtained when the quantities of Rh(III) or Ir(III) cations and 16aneS4-diol ligand in the solutions were 62.5 nmol and 250 nmol, respectively, and the pH ranged 3.0-4.0. Syntheses required heating for 1-1.5 h at 75-80 degrees C. The influence of microwave heating on the time and completeness of the complexation reaction was evaluated and compared with the conventional method of heating in an oil bath. Microwave synthesis accelerates reactions significantly. With microwave heating, yields of about 75% for Rh[16aneS4-diol](131)I and Ir[16aneS4-diol](131)I complexes were obtained after only 20 min exposure of the reaction mixtures to

  20. Scenario design and basic analysis of the National Data Centre Preparedness Exercise 2013

    NASA Astrophysics Data System (ADS)

    Ross, Ole; Ceranna, Lars; Hartmann, Gernot; Gestermann, Nicolai; Bönneman, Christian

    2014-05-01

    The Comprehensive Nuclear-Test-Ban Treaty (CTBT) prohibits all kinds of nuclear explosions. For the detection of treaty violations the International Monitoring System (IMS) operates stations observing seismic, hydroacoustic, and infrasound signals as well as radioisotopes in the atmosphere. While the IMS data is collected, processed and technically analyzed in the International Data Center (IDC) of the CTBT-Organization, National Data Centers (NDC) provide interpretation and advice to their government concerning suspicious detections occurring in IMS data. NDC Preparedness Exercises (NPE) are regularly performed dealing with fictitious treaty violations to practice the combined analysis of CTBT verification technologies and for the mutual exchange of information between NDC and also with the IDC. The NPE2010 and NPE2012 trigger scenarios were based on selected seismic events from the Reviewed Event Bulletin (REB) serving as starting point for fictitious Radionuclide dispersion. The main task was the identification of the original REB event and the discrimination between earthquakes and explosions as source. The scenario design of NPE2013 differs from those of previous NPEs. The waveform event selection is not constrained to events in the REB. The exercise trigger is a combination of a tempo-spatial indication pointing to a certain waveform event and simulated radionuclide concentrations generated by forward Atmospheric Transport Modelling based on a fictitious release. For the waveform event the date (4 Sept. 2013) is given and the region is communicated in a map showing the fictitious state of "Frisia" at the Coast of the North Sea in Central Europe. The synthetic radionuclide detections start in Vienna (8 Sept, I-131) and Schauinsland (11 Sept, Xe-133) with rather low activity concentrations and are most prominent in Stockholm and Spitsbergen mid of September 2013. Smaller concentrations in Asia follow later on. The potential connection between the waveform and

  1. Revised series of stylized anthropometric phantoms for internal and external radiation dose assessment

    NASA Astrophysics Data System (ADS)

    Han, Eunyoung

    At present, the dosimetry systems of both the International Commission on Radiological Protection, and the Society of Nuclear Medicine's Medical Internal Radiation Dose Committee utilize a series of stylized or mathematical anthropometric models of patient anatomy developed in 1987 at the Oak Ridge National Laboratory (ORNL). In this study, substantial revisions to the ORNL phantom series are reported with tissue compositions, tissue densities, and organ masses adjusted to match their most recent values in the literature. In addition, both the ICRP and MIRD systems of internal dosimetry implicitly consider that electron and beta-particle energy emitted within the source organs of the patient are fully deposited within these organs. With the development of the revised ORNL phantom series, three additional applications were explored as part of this dissertation research. First, the phantoms were used in combination to assess external radiation exposures to family members caring or interacting with patients released from the hospital following radionuclide therapy with I-131. Values of family member effective dose are then compared to values obtained using NRC guidance and based on a simple point-source methodology which ignores the effects of photon attenuation and scatter within both the source individual (patient) and the target individual (family member). Second, the anatomical structures of the extrathoracic airways and thoracic airways (exclusive of the lungs themselves) have been included in the entire revised ORNL phantom series of pediatric individuals. Values of cross-region photon dose are explored for use in radioactive aerosol inhalation exposures to members of the general public, and comparisons are made to values given by the ICRP in which surrogate organ assignments were made in the absence of explicit models of these airways. Finally, the revised ORNL phantoms of the adult male and adult female are used to determine internal photon exposures to

  2. SU-E-T-256: Optimizing the Combination of Targeted Radionuclide Therapy Agents Using a Multi-Scale Patient-Specific Monte Carlo Dosimetry Platform

    SciTech Connect

    Besemer, A; Bednarz, B; Titz, B; Grudzinski, J; Weichert, J; Hall, L

    2014-06-01

    Purpose: Combination targeted radionuclide therapy (TRT) is appealing because it can potentially exploit different mechanisms of action from multiple radionuclides as well as the variable dose rates due to the different radionuclide half-lives. The work describes the development of a multiobjective optimization algorithm to calculate the optimal ratio of radionuclide injection activities for delivery of combination TRT. Methods: The ‘diapeutic’ (diagnostic and therapeutic) agent, CLR1404, was used as a proof-of-principle compound in this work. Isosteric iodine substitution in CLR1404 creates a molecular imaging agent when labeled with I-124 or a targeted radiotherapeutic agent when labeled with I-125 or I-131. PET/CT images of high grade glioma patients were acquired at 4.5, 24, and 48 hours post injection of 124I-CLR1404. The therapeutic 131I-CLR1404 and 125ICLR1404 absorbed dose (AD) and biological effective dose (BED) were calculated for each patient using a patient-specific Monte Carlo dosimetry platform. The optimal ratio of injection activities for each radionuclide was calculated with a multi-objective optimization algorithm using the weighted sum method. Objective functions such as the tumor dose heterogeneity and the ratio of the normal tissue to tumor doses were minimized and the relative importance weights of each optimization function were varied. Results: For each optimization function, the program outputs a Pareto surface map representing all possible combinations of radionuclide injection activities so that values that minimize the objective function can be visualized. A Pareto surface map of the weighted sum given a set of user-specified importance weights is also displayed. Additionally, the ratio of optimal injection activities as a function of the all possible importance weights is generated so that the user can select the optimal ratio based on the desired weights. Conclusion: Multi-objective optimization of radionuclide injection activities

  3. Identification of duck plague virus by polymerase chain reaction

    USGS Publications Warehouse

    Hansen, W.R.; Brown, Sean E.; Nashold, S.W.; Knudson, D.L.

    1999-01-01

    indefinido y al gen para la proteina de la DNA polimerasa en otros virus herpes. Se encontraron tres o cuatro grupos de iniciadores especificos para el virus vacunal y para el 100% (7/7) de los a??slamientos de campo, pero no amplificaron el DNA del virus de hepatitis por cuerpos de inclusi??n de grullas. Se analiz?? la especificidad de un primer juego de iniciadores con moldes del genoma de otros virus herpes aviares, incluyendo el ?!guila dorada, ?!guila de cabeza blanca, lechuza de cuernos grandes, lechuza blanca, halc??n peregrino, palomas, aves psit?!cidas y pollos (virus de laringotraqueitis infecciosa), pero no se produjeron los productos finales. Por lo tanto, esta prueba de reacci??n en cadena por la polimerasa es altamente especifica para el DNA del virus. Dos grupos de iniciadores fueron capaces de detectar un fragmento de DNA de la cepa vacunal equivalente a cinco copias del genoma. Adem?!s, se determin?? que la proporci??n de la dosis infecciosa en cultivo celular y copias del genoma del virus vacunal de c??lulas de embri??n de pato infectadas era de 10 a 100 respectivamente, haciendo la prueba de la reacci??n en cadena por la polimerasa 20 veces m?!s sensible que el cultivo celular para detectar el virus. La velocidad, sensibilidad y especificidad de la prueba de la reacci??n en cadena por la polimerasa suministra una herramienta de investigaci??n y de diagn??stico altamente mejorada para el estudio de la epizootiolog?-a del virus.

  4. A probabilistic gastrointestinal tract dosimetry model

    NASA Astrophysics Data System (ADS)

    Huh, Chulhaeng

    In internal dosimetry, the tissues of the gastrointestinal (GI) tract represent one of the most radiosensitive organs of the body with the hematopoietic bone marrow. Endoscopic ultrasound is a unique tool to acquire in-vivo data on GI tract wall thicknesses of sufficient resolution needed in radiation dosimetry studies. Through their different echo texture and intensity, five layers of differing echo patterns for superficial mucosa, deep mucosa, submucosa, muscularis propria and serosa exist within the walls of organs composing the alimentary tract. Thicknesses for stomach mucosa ranged from 620 +/- 150 mum to 1320 +/- 80 mum (total stomach wall thicknesses from 2.56 +/- 0.12 to 4.12 +/- 0.11 mm). Measurements made for the rectal images revealed rectal mucosal thicknesses from 150 +/- 90 mum to 670 +/- 110 mum (total rectal wall thicknesses from 2.01 +/- 0.06 to 3.35 +/- 0.46 mm). The mucosa thus accounted for 28 +/- 3% and 16 +/- 6% of the total thickness of the stomach and rectal wall, respectively. Radiation transport simulations were then performed using the Monte Carlo N-particle transport code (MCNP) 4C transport code to calculate S values (Gy/Bq-s) for penetrating and nonpenetrating radiations such as photons, beta particles, conversion electrons and auger electrons of selected nuclides, I123, I131, Tc 99m and Y90 under two source conditions: content and mucosa sources, respectively. The results of this study demonstrate generally good agreement with published data for the stomach mucosa wall. The rectal mucosa data are consistently higher than published data compared with the large intestine due to different radiosensitive cell thicknesses (350 mum vs. a range spanning from 149 mum to 729 mum) and different geometry when a rectal content source is considered. Generally, the ICRP models have been designed to predict the amount of radiation dose in the human body from a "typical" or "reference" individual in a given population. The study has been performed to

  5. Disclosure of the National Data Centre Preparedness Exercise 2013 radionuclide release and atmospheric dispersion scenario

    NASA Astrophysics Data System (ADS)

    Ross, J. Ole; Hartmann, Gernot; Ceranna, Lars; Gestermann, Nicolai

    2015-04-01

    The Comprehensive Nuclear-Test-Ban Treaty (CTBT) prohibits all kinds of nuclear explosions. For the detection of treaty violations the International Monitoring System (IMS) operates stations observing seismic, hydroacoustic, and infrasound signals as well as radioisotopes in the atmosphere. While the IMS data is collected, processed and technically analyzed in the International Data Center (IDC) of the CTBT-Organization, National Data Centers (NDC) provide interpretation and advice to their government concerning suspicious detections occurring in IMS data. NDC Preparedness Exercises (NPE) are regularly performed dealing with fictitious treaty violations to practice the combined analysis of CTBT verification technologies and for the mutual exchange of information between NDC and also with the IDC. The scenario of the NPE2013 was the most complex so far. As exercise trigger, a fictitious accusing State Signatory points to a series of (simulated) radionuclide findings at IMS stations in Europe/Asia and postulates a connection with detections of a supposed seismic event which occurred within the territory of the fictitious state of FRISIA on September 4th, 2013. FRISIA is located at the Coast of the North Sea in Central Europe. The synthetic radionuclide detections start in Vienna (8 Sept, I-131) and Schauinsland (11 Sept, Xe-133) with rather low activity concentrations and are most prominent in Stockholm and Spitsbergen mid of September 2013. Smaller concentrations in Asia follow later on. The potential connection between the waveform and radionuclide evidence remained unclear for the participants. The verification task was to identify the waveform event in the given tempo-spatial domain and to investigate potential sources of the simulated radionuclide findings. Finally the potential conjunction between the sources and the CTBT-relevance of the whole picture has to be evaluated. The overall question is whether requesting an On-Site-Inspection in FRISIA would be

  6. Effect of tree thinning and litter removal on the radiocesium (Cs-134, 137) discharge rates in the Kawauchi forest plantation (Fukushima Prefecture, northern Japan)

    NASA Astrophysics Data System (ADS)

    López-Vicente, Manuel; Onda, Yuichi; Takahashi, Junko; Kato, Hiroaki; Hisadome, Keigo

    2016-04-01

    On 11 March 2011 a 9.0 earthquake and the resulting tsunami occurred in central-eastern Japan triggering, one day after, the Fukushima Dai-ichi nuclear power plant (DNPP) accident. Despite the bulk of radionuclides (ca. 80%) were transported offshore and out over the Pacific Ocean, significant wet and dry deposits of those radionuclides occurred mainly in the Fukushima Prefecture and in a minor way in the Miyagi, Tochigi, Gunma and Ibaraki Prefectures. As a consequence and among other radionuclides, a total of 511,000 TBq of I-131, 13,500 TBq of Cs-134 and 13,600 TBq of Cs-137 were released into the atmosphere and the ocean, contaminating cultivated soils, rivers, settlements and forested areas. This accident caused severe environmental and economic damages. Several decontamination practices have done, including tree thinning and litter removal within the forests and tree plantations. In this study we analysed the effect of eight different management practices on the radiocesium (Cs-134 and Cs-137) discharge rates during 20 months (May'2013 - Dec'2014) in a Japanese cedar (Cryptomeria japonica) plantation (stand age of 57 years), located in a hillslope near the Kawauchi village, Fukushima Prefecture, northern Japan. This study area (37⁰ 20' 04" N, 140⁰ 53' 13.5" E) is located 16 km southwestern from the DNPP and within the evacuation area. The soils are Andosols. Ten runoff plots (5 x 2 meters) were installed and measurements started on May 2013. Two plots remained without any treatment as control plots and the other eight plots represented the following management practices: Mng1) Litter removal + clear-cutting (no sheet); Mng2) Litter removal + clear-cutting (no sheet); Mng3) Litter removal + clear-cutting (no sheet); Mng4) Litter removal; Mng5) Thinning (logged area); Mng6) Thinning (under remnant trees); Mng7) Litter removal + thinning (logged area); Mng8) Litter removal + thinning (under remnant trees). Each plot had a gauging station and sediment samples

  7. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.

    PubMed

    Kassis, A I; Adelstein, S J; Mariani, G

    1996-09-01

    Radiolabeled nucleosides, specifically 5-iodo-2'-deoxyuridine (IUdR) radioiodinated with the Auger-electronemitting 123I or 125I, have been shown to produce extensive DNA damage in mammalian cell systems in vitro. Such nucleosides are cycle-dependent agents that are taken up by mitotically dividing cells in the S phase of the cell cycle. The degree of damage that occurs is related to the fact that these nucleosides bind covalently to DNA bringing the decaying Augerelectron-emitting radionuclide in close proximity to the genome. The use of these radiohalogenated nucleosides in vivo is associated with several problems. The first relates to their extremely short biologic half-life in blood (T1/2 of minutes in humans). The second involves achieving therapeutic ratios in tumor cells in the face of efficient hepatic dehalogenation. The third concerns the uptake of these radiopharmaceuticals by actively proliferating normal cell renewal systems, thus potentially causing toxic side effects. The fourth, one shared with other cycle-dependent drugs, relates to the matter of labeling the whole tumor cell population. To facilitate targeting to tumors, investigators have been examining the direct introduction of these agents into the targeted area or into an arterial blood supply that immediately precedes the target. For example, radiopharmaceutical administration could be intracavitary (bladder, spinal fluid, peritoneum), intralesional (brain tumor, breast mass) or intra-arterial (liver, pancreas). In all these situations, the following conditions must be met: (a) once within the vicinity of the tumor the agent can freely diffuse through the tissues and is selectively taken up by cancerous cells; (b) once the agent has left the target area it is converted quickly into a nontoxic form and/or excreted from the body; and finally, (c) the biologic behavior of the agent is not altered by repeated injections. We report herein our experience and that of others with [123I/125I/131I

  8. Gateways to clinical trials.

    PubMed

    Bayés, M; Rabasseda, X; Prous, J R

    2005-06-01

    , fluvastatin sodium, fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib, gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 HIV-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; Valdecoxib, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride

  9. WE-A-17A-07: Evaluation of a Grid-Based Boltzmann Solver for Nuclear Medicine Voxel-Based Dose Calculations

    SciTech Connect

    Mikell, J; Kappadath, S; Wareing, T; Mourtada, F

    2014-06-15

    Purpose: Grid-based Boltzmann solvers (GBBS) have been successfully implemented in radiation oncology clinics as dose calculations for e×ternal photon beams and 192Ir sealed-source brachytherapy. We report on the evaluation of a GBBS for nuclear medicine vo×el-based absorbed doses. Methods: Vo×el-S-values were calculated for monoenergetic betas and photons (1, 0.1, 0.01 MeV), 90Y, and 131I for 3 mm vo×el sizes using Monte Carlo (DOS×YZnrc) and GBBS (Attila 8.1-beta5, Transpire). The source distribution was uniform throughout a single vo×el. The material was an infinite 1.04 g/cc soft tissue slab. To e×plore convergence properties of the GBBS 3 tetrahedral meshes, 3 energy group structures, 3 different square Chebyschev-Legendre quadrature set orders (Sn), and 4×2013;7 spherical harmonic e×pansion terms (Pn) were investigated for a total of 168 discretizations per source. The mesh, energy group, and quadrature sets are 8×, 3×, and 16×, respectively, finer than the corresponding coarse discretization. GBBS cross sections were generated with full electronphoton-coupling using the vendors e×tended CEP×S code. For accuracy, percent differences (%Δ) in source vo×el absorbed doses between MC and GBBS are reported for the coarsest and finest discretization. For convergence, ratios of the two finest discretization solutions are reported along each variable. Results: For 1 MeV, 0.1 MeV, 0.01 MeV, Y90, and I-131 beta sources the %Δ in the source vo×el for (coarsest,finest) discretization were (+2.0,−6.4), (−8.0, −7.5), (−13.8, −13.4), (+0.9,−5.5), and (− 10.1,−9.0) respectively. The corresponding %Δ for photons were (+33.7,−7.1), (−9.4, −9.8), (−17.4, −15.2), and (−1.7,−7.7), respectively. For betas, the convergence ratio of mesh, energy, Sn, and Pn ranged from 0.991–1.000. For gammas, the convergence ratio of mesh, Sn, and Pn ranged from 0.998–1.003 while the ratio for energy ranged from 0.964–1.001. Conclusions: GBBS is